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Reported Tuberculosis in the United States, 2015, presents summary data for tuberculosis (TB) cases 
verified and counted during 2015. Report of Verified Case of Tuberculosis (RVCT) forms are submit-
ted to the Division of Tuberculosis Elimination (DTBE), National Center for HIV/AIDS, Viral Hepa-
titis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), At-
lanta, Georgia, by 60 reporting areas (the 50 states, the District of Columbia, New York City, Puerto 
Rico, and 7 other U.S.-affiliated jurisdictions in the Pacific Ocean and Caribbean Sea). 
Reported Tuberculosis in the United States, 2015, is similar to previous publications (see page xi, 
#19) and contains an Executive Commentary, Technical Notes, seven major data sections, and ap-
pendixes. The Executive Commentary includes highlights of the 2015 data, and the Technical Notes 
section provides information about how the data were collected and reported; these two sections are 
included to help the reader interpret the data.
Other sections provided in the annual report are described as follows:
• Morbidity Trend Tables — Trends in the overall TB case counts and case rates for the United
States, its insular areas, and freely associated states, by selected demographic, clinical, and geno-
typic characteristics.
• Morbidity Tables, 2015 — Overall case counts and case rates for the United States and other
jurisdictions, by selected demographic and genotypic characteristics.
• Morbidity Tables, 2013 — Overall case counts for the United States, by selected demographic
and clinical characteristics for the most recent year for which data are available for certain
follow-up variables that require a longer data collection period.
• Morbidity Tables, Reporting Areas, 2015 — TB case counts and case rates, by state and other
jurisdictions, with tables of selected demographic and clinical characteristics.
• Morbidity Tables, Reporting Areas, 2013 — Data for the most recent year for which data are
available for selected follow-up variables that require a longer data collection period.
• Morbidity Tables, Metropolitan Statistical Areas, 2015 — TB case counts and case rates, by
metropolitan statistical areas (MSAs: see Technical Notes for further details), with tables of se-
lected demographic and clinical characteristics.
• Surveillance Slide Set, 2015 — Figures from the annual surveillance slide set emphasizing key
recent trends in TB epidemiology in the United States and selected jurisdictions. The slides with
accompanying text can also be viewed and downloaded from
http://www.cdc.gov/tb/.
• Tuberculosis Case Definition for Public Health Surveillance — Appendix A.
• Recommendations for Reporting and Counting Tuberculosis Cases — Appendix B.
• National Surveillance for Severe Adverse Events Associated with Treatment for Latent Tu-
berculosis Infection — Reporting Information — Appendix C.
• Genotyping Background Information and Glossary — Appendix D.
x
xi
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For the first time since 1992, the number of U.S. 
TB cases reported to the National Tuberculosis 
(TB) Surveillance System (NTSS) increased 
over the previous year. In 2015, the 50 United 
States and the District of Columbia reported 
9,557 TB cases to CDC, representing a 1.6% in-
crease from 2014 (Table 1). Twenty-seven states 
and the District of Columbia reported increased 
case counts from 2014 (Table 30), and four 
states (California, Texas, New York, and Florida) 
accounted for 50.6% of the national case total 
(Table 31). Despite this slight increase in case 
count, the TB incidence rate per 100,000 persons 
has remained relatively stable at approximately 
3.0 since 2013 (Table 1). Seven states and the 
District of Columbia reported incidence rates 
above the national average (Table 30). The Na-
tional Center for Health Statistics reported 493 
deaths in 2014 (the most recent year for which 
mortality data are available) that were attribut-
able to TB, an 11.2% decrease from 2013 (Table 
1).
NTSS Description
Since 1953, in cooperation with state and local 
health departments, the United States national 
tuberculosis program has collected informa-
tion on each newly reported case of tuberculosis 
(TB) disease in the United States. In 1985, CDC 
began collecting individual TB case reports us-
ing the Report of Verified Case of Tuberculosis 
(RVCT). The RVCT was expanded in 1993 in 
response to the TB epidemic of the late 1980s 
and early 1990s, and reporting areas began 
submitting the RVCT electronically via the TB 
Information Management System (TIMS). CDC 
has maintained a dynamic TB surveillance case 
registry since 1993. In 2009, CDC expanded the 
RVCT again and reporting areas transitioned 
from TIMS to data collection via the Public 
Health Information Network/National Electronic 
Disease Surveillance System.
In addition to the 50 United States and the Dis-
trict of Columbia, CDC accepts TB case reports 
from four U.S. insular areas (American Samoa, 
Guam, Puerto Rico, and the U.S. Virgin Islands) 
and four sovereign nations that have signed 
compacts of free association with the United 
States (Commonwealth of the Northern Mariana 
Islands, Federated States of Micronesia, Re-
public of the Marshall Islands, and Republic of 
Palau). In this report, these sovereign nations are 
referred to as “freely associated states.”
Each annual TB surveillance report includes 
updated case counts for each year in the dynamic 
surveillance database, starting in 1993 through 
the newly available data. Reporting areas update 
past years’ data as needed and accordingly data 
for past years might not match data published in 
previous annual reports. This annual summary 
contains information through 2015.
Demographics
Overall since 1993, TB incidence rates have 
declined in almost all racial and ethnic groups: 
among American Indian/Alaska Natives, from 
14.4 to 6.1 cases/100,000 persons (–57.6%); 
among Asians, from 42.2 to 18.2 cases/100,000 
(–56.9%); among non-Hispanic blacks/Afri-
can Americans, from 29.1 to 5.0 cases/100,000 
(–82.8%); among non-Hispanic whites, from 3.6 
to 0.6 cases/100,000 (–83.3%); and among His-
panics/Latinos, the decline has been from 20.4 
to 4.8 cases/100,000 (–76.5%). However, since 
2013, TB incidence rates have increased among 
American Indian/Alaska Natives (+12.3%), Na-
tive Hawaiian/Other Pacific Islanders (+59.7%), 
and persons reporting multiple races (+4.8%), 
although these increases should be interpreted 
with caution because of the small sizes of the 
underlying populations. Since 2013, TB inci-
dence rates have continued to gradually decline 
among non-Hispanic blacks/African Americans 
(–6.4%), non-Hispanic whites (–12.1%), and 
Hispanics/Latinos (–4.0%). While the TB inci-
dence rate for Asians also declined from 2013 to 
2015 (–1.0%), in 2015 the overall TB incidence 
rate for Asians remained over three times higher 
than that for Hispanics/Latinos or blacks/African 
Americans (Table 2).
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Although the incidence rates for both the for-
eign-born and the U.S.-born populations have 
declined substantially since 1993, the decline 
has been less among the foreign-born (–55.6%) 
than among the U.S.-born (–83.8%) (Table 5). 
Foreign-born persons are defined as anyone born 
outside of the United States or U.S. insular areas 
and freely associated states (with the excep-
tion of those born abroad to U.S. parents). This 
includes naturalized U.S. citizens, permanent 
residents, visitors, persons with student or work 
visas, refugees, and persons with undocumented 
or unknown immigration status. The burden of 
TB was markedly different between foreign-
born and U.S.-born populations at 15.1 and 1.2 
cases/100,000 persons, respectively, which is 
roughly a 13-fold difference (Table 5). The ma-
jority of these cases progressed from latent TB 
infection acquired years in the past.
Foreign-born persons continued to represent 
the majority of U.S. TB cases (66.4%), roughly 
the same proportion as in 2014 (Table 5), and 
in 36 states and the District of Columbia, ≥50% 
of TB cases occurred among foreign-born per-
sons (Table 34). Asians represented nearly half 
(47.8%) of the reported foreign-born TB cases in 
2015 (Table 19). Hispanics comprised the second 
largest group of foreign-born TB cases (32.0%, 
Table 19). In comparison, among U.S.-born per-
sons, blacks/African Americans represented the 
largest percentage (35.9%) of TB cases, followed 
by whites at 31.1% (Table 18).
Collecting information on country of birth can 
help direct TB prevention efforts, both primary 
prevention efforts around the world, as well as 
secondary prevention efforts in the United States 
to screen and treat individuals for latent TB 
infection. From 2011 through 2015, the top five 
countries of origin of foreign-born persons with 
TB were Mexico, the Philippines, India, Viet-
nam, and China (Table 6). The distribution of 
TB cases among foreign-born persons by world 
region of origin is influenced by the size of the 
total population from those regions living in the 
United States, as well as the prevalence of TB in 
those regions.
Of the 6,350 TB cases reported among foreign-
born persons in 2015, the majority of cases 
occurred among persons born in the Americas 
region (35.7%), and those born in the Western 
Pacific region (32.6%), which is similar to the 
distribution of cases by world region of origin in 
2014 (Table 20). From 1993 through 2015, the 
percentage of cases increased among persons 
born in the Eastern Mediterranean region (2.8% 
in 1993 to 4.6% in 2015), the Southeast Asia 
region (5.6% in 1993 to 15.7% in 2015), and the 
Africa region (2.4% in 1993 to 8.7% in 2015) 
(Table 20). 
In 2015, TB incidence rates continued to decline 
for persons <5 years old and 15–24 years old; 
however the incidence rate for persons 45–64 
years old increased slightly from 3.5 to 3.6 
cases/100,000 persons. Incidence rates for all 
other age groups remained similar to 2014. The 
highest burden of disease continues to be among 
older adults. In 2015, adults ≥65 years old had 
an incidence rate of 4.8 cases/100,000, while 
children 5–14 years old had the lowest rate at 0.5 
cases/100,000 (Table 4). 
HIV Coinfection 
The proportion of TB cases with a reported HIV 
test result who were coinfected with HIV has 
decreased from 48.2% in 1993 to 5.5% in 2015. 
In the past 3 years, this proportion has declined 
from 6.4% in 2013 to 5.5% in 2015 (Table 11). 
TB Treatment Regimens and Drug Resistance
The proportion of TB patients prescribed the rec-
ommended initial treatment regimen including 
isoniazid, rifampin, pyrazinamide, and etham-
butol increased from 40.3% in 1993 to 84.7% in 
2015. The proportion of patients who completed 
therapy within 1 year increased from 63.4% in 
1993 to 89.6% in 2013 (the latest year for which 
complete outcome data are available). The pro-
portion of persons receiving directly observed 
therapy for at least a portion of the treatment 
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duration also increased from 36.1% in 1993 to 
92.1% in 2013 (Table 10).
In 2015, 1.1% of reported TB cases had pri-
mary multidrug resistance (MDR), defined as no 
previous history of TB disease and resistance to 
at least isoniazid and rifampin (Table 9). This 
percentage has remained stable, fluctuating 
between 0.9% and 1.3% since 1996. The propor-
tion of primary MDR TB occurring in foreign-
born persons has increased from 25.3% (103 of 
407) in 1993 to 86.3% (63 of 73) in 2015, which
is similar to the proportion in 2014 (Table 9). In
2015, there was one case reported of extensively
drug-resistant (XDR) TB, defined as resistance
to isoniazid and rifampin, plus resistance to any
fluoroquinolone and at least one of three inject-
able second-line anti-TB drugs (i.e., amikacin,
kanamycin, or capreomycin).
Genotyping
TB genotyping is a laboratory-based analysis of 
the genetic material of the bacteria that cause TB 
disease. TB genotype clusters are defined as two 
or more cases with matching genotypes in the 
same county during a 3-year time period. Cases 
that are clustered may be the consequence of 
recent transmission, while unique cases are more 
likely attributable to reactivation of infection 
that was acquired in the past. Among genotyped 
cases during 2013–2015, 21.5% were clustered 
(Table 23). During this period, the percentage 
of clustered cases among U.S.-born persons 
with TB was 36.0%, compared to 14.4% among 
foreign-born persons diagnosed with TB in the 
United States (Table 22). However, not all clus-
tered cases result from recent transmission. 
In 2015, CDC scientists developed and published 
a new genotype-based method to estimate the 
proportions of cases attributable to recent trans-
mission in defined populations (e.g., geographic 
areas).1 The method, which was validated using 
epidemiologic data, attempts to identify a “plau-
sible-source case” for each genotyped TB case 
using a combination of genotyping and spatial, 
temporal, clinical, and demographic criteria. In 
2016, an estimate was published that approxi-
mately 14% of genotyped cases during 2011–
2014 were attributed to recent transmission.3 The 
method also was refined by distinguishing lim-
ited versus extensive recent transmission based 
on the size of plausible transmission clusters. 
State-level estimates were published.3
Conclusions 
The overall number of TB cases in the United 
States increased in 2015 compared with the 
previous year, after having declined yearly dur-
ing 1993–2014. The increase in the overall case 
count in 2015 and leveling of the U.S. incidence 
rate since 2013 raise concern that current TB 
control practices might no longer be sufficient to 
sustain the previously observed rate of decrease 
in U.S. TB incidence. Statistical modeling has 
shown that decreasing the prevalence of latent 
TB infection will also be key to eliminating TB 
in the United States.2 Resuming and accelerating 
progress toward TB elimination will require an 
intensified, dual approach that includes strength-
ening existing systems to prevent transmission of 
infectious TB disease and increasing efforts to 
detect and treat latent TB infection. 
CDC continues to work with its partners to 
achieve the goal of TB elimination in the United 
States. Current TB control strategies prioritize 
the early diagnosis, isolation, and treatment of 
people with infectious TB disease. This approach 
protects patients’ health, prevents transmission to 
others, and allows for timely contact investi-
gations to detect and prevent additional cases. 
These TB control efforts are essential, but by 
themselves cannot eliminate the disease from the 
United States. More than 85% of U.S. TB cases 
are associated with longstanding, untreated latent 
TB infections, and public sector efforts alone 
will be insufficient to reach all of those who 
need to be tested and treated for latent TB.2 
These efforts must also include public health 
systems and private providers, who are often on 
the front lines of health care in the communities 
most affected by TB. 
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Global TB disease burden and the incidence in 
the United States are closely related, emphasiz-
ing the continued need to strengthen existing 
support for TB control efforts abroad. This is 
particularly true as relates to the countries of 
persons who have lived in countries where TB 
disease is more common. Foreign-born persons 
continue to be disproportionately affected by 
TB; now accounting for 66.4% of total cases. 
To achieve TB elimination, intensified efforts 
continue to be needed to address the persistent 
disparities that exist between U.S.-born and 
foreign-born persons, as well as among U.S.-
born racial and ethnic minorities. 
Ongoing surveillance and improved TB control 
and prevention activities will be essential in light 
of the increase in TB case count in 2015 and 
the leveling of U.S. TB incidence rates in recent 
years. CDC also continues to study available 
data on TB and latent TB infection trends in the 
United States to better inform TB prevention and 
control efforts. Ultimately TB elimination will 
require a sustained focus on domestic TB con-
trol, a strengthened effort to diagnose and treat 
latent TB infection, and continued support of 
global TB control initiatives.
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National Tuberculosis Surveillance System
Reporting areas (i.e., the 50 states, the District of 
Columbia (DC), New York City, Puerto Rico, and 
other U.S. jurisdictions in the Pacific Ocean and 
Caribbean Sea) provide information regarding 
tuberculosis (TB) cases to CDC’s National TB 
Surveillance System (NTSS) by using a standard 
case report form, Report of Verified Case of Tu-
berculosis (RVCT). TB cases are verified accord-
ing to the Tuberculosis Case Definition for Public 
Health Surveillance (Appendix A). TB cases are 
reported and counted according to the Recom-
mendations for Reporting and Counting Tubercu-
losis Cases (Appendix B).
TB Case Definition
In 2009, the TB case definition was modified. 
TB cases are verified according to the following 
specified laboratory and clinical criteria (see Ap-
pendix A).
Laboratory Criteria for Diagnosis
A TB case may be verified by the laboratory case 
definition with at least one of the following crite-
ria: (1) isolation of Mycobacterium tuberculosis 
complex from a clinical specimen; or (2) demon-
stration of M. tuberculosis complex from a clini-
cal specimen by nucleic acid amplification test 
(NAAT), or (3) demonstration of acid-fast bacilli 
(AFB) in a clinical specimen when a culture has 
not been or cannot be obtained or is falsely nega-
tive or contaminated.
Clinical Case Criteria
A TB case may be verified by the clinical case 
definition in the presence of all of the following 
clinical criteria: (1) a positive tuberculin skin test 
(TST) result or positive interferon gamma release 
assay (IGRA) result for M. tuberculosis; and (2) 
other signs and symptoms compatible with TB 
(e.g., abnormal chest radiograph, abnormal chest 
computerized tomography [CT] scan, or other 
chest imaging study or clinical evidence of cur-
rent disease); and (3) treatment with two or more 
anti-TB drugs; and (4) a completed diagnostic 
evaluation.
Provider Diagnosis
Provider diagnosis is not a component of the 
case definition for TB as described in Appendix 
A. However, when cases of TB are diagnosed 
but do not meet either the clinical or laboratory 
case definition, reporting areas have the option 
of verifying TB cases on the basis of provider 
diagnosis as described in Appendix B. Through 
2008, the RVCT did not collect information re-
garding IGRA results. If an IGRA was performed 
in lieu of TST, the RVCT would have indicated 
that TST was not performed. Thus, culture- and 
smear-negative cases without a TST that were 
diagnosed by a positive IGRA result before 
2008 were considered to have been confirmed 
by provider diagnosis. Starting in 2009, positive 
results for an IGRA have been included as part of 
the clinical case definition for TB confirmation. 
Anergic patients with a clinical presentation con-
sistent with TB but without laboratory evidence 
of M. tuberculosis complex would also be an 
example of provider diagnosis and one that has 
not changed over time.
TB Case Verification Criteria Calculation
The software for TB surveillance developed by 
CDC includes a calculated variable for TB case 
verification called “Vercrit,” which was modified 
in 2009. The new variables, Nucleic Acid Ampli-
fication Test (NAAT) Result, Interferon Gamma 
Release Assay (IGRA) for Mycobacterium tuber-
culosis at Diagnosis, and Initial Chest CT Scan 
or Other Chest Imaging Study were added in the 
Vercrit calculation.
Vercrit is calculated by using the following crite-
ria in hierarchical order:
1.   Positive culture.
2.   Positive NAAT.
3.   Positive AFB.
4.   Clinical case confirmation.
5.   Provider diagnosis.
Reporting and Counting of TB Cases
In 2009, the recommendations for reporting and 
counting of TB cases (Appendix B) were modi-
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fied. TB cases that are verified but not countable 
for morbidity statistics are now reported to CDC 
as a measure of programmatic and case manage-
ment burden. However, data for noncountable 
TB cases are incomplete and therefore are not 
included in this report.
The recommendations for counting TB cases 
among immigrants, refugees, and foreign visi-
tors were revised on the basis of the 2007 rec-
ommendations in the Technical Instructions for 
Tuberculosis Screening and Treatment for Panel 
Physicians.1 Regardless of panel physician clas-
sification or citizenship status, immigrants and 
refugees examined after arriving in the United 
States and receiving a diagnosis of clinically ac-
tive TB requiring anti-TB medications should be 
reported and counted by the locality of their resi-
dence at the time of diagnosis. Foreign visitors 
with diagnosed TB receiving anti-TB therapy 
and planning to remain in the United States for 
≥90 days should be reported and counted by the 
locality of current residence.
RVCT Variables
Data regarding demographic characteristics, 
clinical or laboratory diagnosis, initial treatment, 
and treatment outcomes are collected through the 
following three RVCT data collection reports:
1.   Report of Verified Case of Tuberculo-    
      sis — used for all patients with a verified  
      TB case.
2.   Initial Drug Susceptibility Report   
      (Follow-Up Report 1) — used for all 
      patients who had a culture that was posi-   
      tive for M. tuberculosis complex.
3.   Case Completion Report (Follow-Up 
      Report 2) — used for all patients who 
      were alive when TB was diagnosed.
1CDC. Immigration Requirements: Techni-
cal Instructions for Tuberculosis Screen-
ing and Treatment 2007. Atlanta: CDC, 
Division of Global Migration and Quar-
antine, revised September 2007; http://
www.cdc.gov/ immigrantrefugeehealth/ pdf/ 
tuberculosis-ti-2009.pdf.
The instructions for completing the RVCT forms 
and the definitions for all data items are available 
in Centers for Disease Control and Prevention 
(CDC). Report of Verified Case of Tuberculosis 
(RVCT) Instruction Manual. Atlanta, GA: U.S. 
Department of Health and Human Services, 
CDC; 2009. Available at: http://www.cdc.gov/tb/
programs/rvct/InstructionManual.pdf.
Tabulation and Presentation of TB Data
This report presents summary data for TB cases 
counted by reporting areas through the end of 
2015. TB cases are tabulated by year in which 
the reporting area verified that the patient had 
TB and included the patient in its official annual 
TB case count. Since 2004, the published report 
has reflected updated information regarding the 
numbers of cases of confirmed TB for each year 
from 1993 onward. Totals for the United States 
include data from the 50 states and DC.
Trend data are presented in Tables 1–15. Age 
group tabulations are based on the patient’s age 
during the month and year the patient was re-
ported to the health department as having a sus-
pected TB case. State or metropolitan area data 
tabulations are based on the patient’s residence at 
the time of TB diagnosis.
Rates
Rates are expressed as the number of cases 
reported each calendar year per 100,000 per-
sons. Population denominators used in calcu-
lating TB rates were based on official census 
and midyear postcensal estimates from the 
U.S. Census Bureau. In Tables 1, 30, and 31, 
the U.S. total populations for 1990–1999 were 
taken from the Bridged-Race Intercensal Popu-
lation Estimates for July 1, 1990–July 1, 1999 
(http://www.cdc.gov/nchs/nvss/bridged_race/ 
data_documentation.htm); populations for 
2000–2009 were taken from the U.S. Census 
Intercensal Estimates of the Resident Population 
for the United States, Regions, States, and Puerto 
Rico for April 1, 2000–July 1, 2010 (http://
www.census.gov/popest/data/intercensal/state/
state2010.html); and populations for 2010–2015 
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were taken from the U.S. Census Annual Esti-
mates of the Resident Population for the United 
States, Regions, States, and Puerto Rico: April 
1, 2010 to July 1, 2015 (http://www.census.gov/
popest/data/ national/totals/2015/index.html). 
Beginning in 2004, unrounded numbers were ap-
plied to calculate the annual percentage change 
in the TB case rate.
During 2003, two modifications were made 
to the RVCT form: (1) entries for multiple 
race (two or more races reported for a person) 
were allowed, and (2) the previous category 
of “Asian/Pacific Islander” was divided into 
“Asian” and “Native Hawaiian/Other Pacific 
Islander.” To calculate rates for Tables 2 and 4, 
denominators for 1993–1999 were obtained from 
the U.S. Census Monthly Postcensal Resident 
Population, by single year of age, sex, race, and 
Hispanic origin (http://www.census.gov/popest/
data/national/asrh/1990s/nat_monthly_resident.
html); denominators for 2000–2009 were ob-
tained from U.S. Census Intercensal Estimates 
of the Resident Population by Sex, Race, and 
Hispanic Origin for the United States: April 1, 
2000 to July 1, 2010 (http:// www.census.gov/ 
popest/ data/ intercensal/ national/ nat2010.html); 
and denominators for 2010–2015 were obtained 
from the U.S. Census Annual Estimates of the 
Resident Population by Sex, Race, and Hispanic 
Origin: April 1, 2010 to July 1, 2015 (http://
www.census.gov/popest/data/national/asrh/2015/
index.html).
The population source for nativity is the Current 
Population Survey, which is used to calculate 
case rates for U.S.- and foreign-born persons 
with diagnosed TB. U.S.-born populations 
includes persons born in the 50 states and DC, 
those born abroad to U.S. parents, and those born 
in U.S.-affiliated areas. In Table 5, the popula-
tions for U.S.- and foreign-born persons for 1993 
were obtained from Quarterly Estimates of the 
United States Foreign-born and Native Resident 
Populations: April 1, 1990–July 1, 1999 (http://
www.census.gov/population/estimates/nation/
nativity/fbtab001.txt). Denominators for comput-
ing the 1994–2015 rates were based on extrapo-
lations from the U.S. Census Current Population 
Survey (accessed June 2016) through DataFerrett 
at: http://dataferrett.census.gov/). Denominators 
for computing 2015 rates in Table 17 were ob-
tained from U.S. Census Annual Estimates of the 
Resident Population by Sex, Race, and Hispanic 




The annual mortality rate is calculated as the 
number of deaths caused by TB in that year, 
divided by the estimated population for the year, 
multiplied by 100,000 (Table 1). The number of 
deaths was obtained from the CDC’s National 
Center for Health Statistics, Multiple Cause of 
Death Files, 1999–2014, available from CDC’s 
WONDER online database and released in 2016. 
Data were compiled from the 57 vital statistics 
jurisdictions through the Vital Statistics Cooper-
ative Program. Finalized numbers of TB-related 
deaths for 2015 were unavailable at the time of 
this publication.
Drug Resistance
Drug-resistance patterns are displayed in sepa-
rate tables with drug-resistance trend data by 
previous TB status and origin of birth. Isoniazid 
resistance and multidrug resistance are displayed 
in Tables 8 and 9, respectively.
Completion of Tuberculosis Therapy
Tables 10, 59, 60, and 61 present percentages of 
completion of TB therapy (COT). Data collected 
by RVCT Follow Up Report-2 forms regarding 
date and reason therapy was stopped (e.g., the 
patient completed the therapy or the patient died) 
were used to calculate COT percentages. Cases 
were stratified by the indicated length of therapy, 
based on American Thoracic Society, CDC, and 
Infectious Diseases Society of America treatment 
guidelines in effect during the period covered 
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and the patient’s initial drug-susceptibility test 
results, age, and disease site.2
In Table 60, the first column lists the total num-
ber of cases reported during 2013. The remain-
ing columns are grouped under two headings: 
therapy of ≤1 year indicated and therapy of >1 
year indicated. Patients eligible to complete 
therapy in ≤1 year had to have been alive at 
time of diagnosis and initiated therapy with ≥1 
drug. Eligible patients did not have rifampin 
resistance; did not die in ≤1 year after initiating 
therapy; did not move out of the country in ≤1 
year after initiating therapy; and did not have 
meningeal TB, bone or joint TB, or TB of the 
central nervous system, regardless of age. Ad-
ditionally, TB patients aged 0–14 years were 
ineligible to complete therapy in ≤1 year if they 
had disseminated disease (defined as miliary TB, 
a positive TB blood culture, or a positive NAAT 
on a blood specimen). Patients with culture-
negative disease, those with an unknown culture 
status, and those with culture-positive disease 
but unknown initial drug-susceptibility test re-
sults were included under the category of therapy 
of ≤1 year indicated.
COT percentages were only calculated for areas 
reporting the reasons why therapy was stopped 
for ≥90% of cases listed in the overall column. 
For the group with an indicated length of therapy 
of ≤1 year, percentages are displayed for both 
COT in ≤1 year and for COT regardless of 
duration (i.e., duration of therapy ≤1 year or >1 
year). For COT ≤1 year, the numerator included 
only those patients completing therapy in ≤366 
days (based on the dates therapy was started 
and stopped). Patients with missing dates were 
classified as “treatment not completed” for this 
calculation.
COT percentages, regardless of duration, were 
calculated by dividing the number of patients 
2CDC. Treatment of Tuberculosis, American 
Thoracic Society, CDC, and the Infectious 
Diseases Society of America. MMWR 2003; 52 
(No. RR-11): 1–77.
reported as having completed therapy by the 
number of total eligible patients. Patients with 
an outcome other than completed therapy (i.e., 
moved, lost to follow-up, refused treatment, or 
other) were classified as “treatment not com-
pleted.” Patients with an unknown outcome were 
also classified as “treatment not completed.” For 
the group of indicated therapy length >1 year, 
only COT percentages regardless of duration, 
are presented. Table 10 provides percentages for 
COT ≤1 year and for COT regardless of duration 
for the group with an indicated therapy of ≤1 
year only. Table 59 presents COT percentages by 
ethnicity and non-Hispanic race and by state for 
those among whom therapy ≤1 year was indi-
cated.
TB Disease Site
Miliary disease should be reported as a pul-
monary form of TB (Tables 7, 38, and 39). 
Beginning in 2009, miliary disease could not 
be classified as a TB disease site because it is 
a clinical or a radiologic finding and should be 
recorded under Initial Chest Radiograph, Initial 
Chest CT Scan, or Other Chest Imaging Study. 
During 1997–2008, miliary disease was classi-
fied as both an extrapulmonary and a pulmonary 
form of TB. In publications before 1997, miliary 
disease was classified as extrapulmonary TB un-
less pulmonary disease was reported as the major 
TB disease site.
Reporting of HIV Status
Information regarding human immunodeficiency 
virus (HIV) status for persons with TB is dis-
played in Tables 11 and 51 for those persons 
not dead at diagnosis; Table 11 also lists trend 
data for persons aged 25–44 years. Reporting 
completeness for HIV status has significantly 
improved to 95% of TB patients tested among 
persons aged 25–44 years during 2015; however, 
this variable is still underreported across jurisdic-
tions. Data regarding the HIV-infection status of 
persons reported with TB should be interpreted 
with caution because these data are not represen-
tative of all TB patients with HIV infection.
HIV testing is performed after a patient re-
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ceives counseling and gives informed consent. 
TB patients who are tested anonymously might 
choose not to share HIV testing results with their 
health care provider. TB patients managed in 
the private sector can receive confidential HIV 
testing, but results might not be reported to the 
health department’s TB program. Additionally, 
certain factors can influence HIV testing among 
TB patients, including the extent to which testing 
is targeted or routinely offered to specific groups 
(e.g., males aged 25–44 years, injection-drug 
users, or homeless persons) and the availability 
of and access to HIV testing services. These data 
might overrepresent or underrepresent the pro-
portion of TB patients known to be HIV-infected 
in a reporting area.
Primary Occupation for the Past Year
Table 48 reflects the modified 2009 RVCT vari-
able, Primary Occupation Within the Past Year, 
which replaces the Occupation Within Past 24 
Months of TB Diagnosis in previous reports. 
After the 2009 RVCT revision, Multiple Occupa-
tion was removed and the Retired and Not Seek-
ing Employment categories were added.
Reason Therapy Was Stopped
Tables 12 and 57 now include a patient’s adverse 
reaction to anti-TB drug therapy as an option 
for the reason therapy was stopped. The 2009 
RVCT revision removed the option of Moved as 
a valid response to the variable Reason Therapy 
Stopped, and this option is therefore not reported 
after 2009. Those cases entered as Moved as 
reason therapy was stopped after 2009 are now 
included in the Unknown category.
Metropolitan Statistical Areas
Tables 62 through 66 present data by metro-
politan statistical areas (MSAs) having an es-
timated 2015 population of ≥500,000 persons. 
MSAs are defined by the White House Office 
of Management and Budget (OMB), and the 
definitions were based on the application of the  
2010 OMB standards for delineating MSAs to 
Census Bureau population estimates for 2012–
2013 announced as of July 2015 (https://www.
whitehouse.gov/sites/default/files/omb/bulle-
tins/2015/15-01.pdf).
The MSA definitions apply to all areas except the 
six New England states; for those states, the New 
England County Metropolitan Areas (NECMAs) 
are used. MSAs are named for a central city in 
the MSA or NECMA, can include multiple cities 
and counties, and can cross state boundaries. For 
example, the TB cases and case rates presented 
for DC in Table 30 include only persons residing 
within DC’s geographic boundaries. However, 
the TB cases and case rates for the Washington, 
DC-MSA (Table 62) include persons residing 
within the multiple counties in the metropolitan 
area, including counties in Maryland, Virginia, 
and West Virginia. Cities or MSAs with incom-
plete or unavailable data were not included in the 
tables, and certain cities’ or MSAs’ total num-
bers might be underreported because of missing 
information.
National Tuberculosis Genotyping Service
National Tuberculosis Genotyping Service labo-
ratories primarily use two genotyping methods: 
spoligotyping and MIRU–VNTR (mycobacterial 
interspersed repetitive units–variable number of 
tandem repeats). Both methods require only a 
minor amount of culture material, provide digital 
results, and are relatively quick. Retrospective 
24-locus MIRU–VNTR for older isolates can be 
performed, if requested, and can help in further 
differentiating genotype clusters. All isolates are 
prepared for long-term storage at genotyping 
laboratories or CDC.
Tuberculosis Genotyping Information Man-
agement System
In March 2010, the Tuberculosis Genotyping 
Information Management System (TB GIMS) 
was launched by CDC as a secure Internet-based 
system to support ongoing use of TB genotyping 
data in TB control activities. TB GIMS facili-
tates systematic data collection of TB genotyping 
results, and it integrates genotyping results with 
epidemiologic data collected by NTSS to form a 
national and centralized database. Primary users 
of TB GIMS include TB laboratories that submit 
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isolates for genotyping, national CDC-contracted 
genotyping laboratories, state and local TB con-
trol programs, and CDC programs that apply this 
information for TB control activities.
Genotyping results from the national genotyp-
ing laboratories or CDC are uploaded into TB 
GIMS as they become available. Line-listed data 
from the NTSS are also uploaded into TB GIMS 
weekly. After genotyping results have been 
linked to individual patient surveillance data in 
TB GIMS, the record is considered complete. 
These complete records are essential for the 
majority of the applications of TB genotyping, 
including all reports and maps as well as for 
using the outbreak detection system to identify 
potential chains of transmission and outbreaks. 
Twenty-one system updates have occurred for 
adding new reports, data management functions, 
and other tools since TB GIMS was released 
in March 2010. As of July 2016, a total of 537 
local, state, and federal users have accessed the 
system.
Genotype Clustering
A genotype cluster comprises two or more cases 
in a jurisdiction during a specified period having 
M. tuberculosis isolates that share matching gen-
otypes. The jurisdiction and period used vary on
the basis of the specific application. Cases that
are part of the same genotype cluster are likely
to be related by TB transmission in some way;
however, the cases might not be directly related
(i.e., one person did not necessarily give TB to
another person in the cluster) or recently related
(i.e., both persons might have contracted TB
from the same person, but the exposure might
have happened years ago). Therefore, although
we use genotype clustering to identify likely TB
transmission, transmission must be confirmed by
using field data from contact investigations or
other sources. In TB GIMS, clustering is defined
as ≥2 cases with matching genotypes (spoligo-
type and 24-locus MIRU-VNTR) in a single
county within a 3-year period.
Mycobacterium bovis
For culture-confirmed TB cases that have been 
genotyped, Mycobacterium bovis can be defined 
primarily on the basis of spoligotyping results. 
The genotype-based definition for M. bovis 
required either (1) the absence of spoligotyping 
spacers 3, 9, 16, and 39–43; the presence of ≥1 
of the spacers 29–32; and the presence of ≥1 of 
the spacers 33–36; or (2) the absence of spacers 
3, 9, 16, and 39–43 and ≥2 copies of the repeated 
sequence at MIRU locus 24; or (3) determina-
tion based on microbiologic expertise. Data 
reported for 2004–2015 exclude cases of bacillus 
Calmette-Guérin M. bovis, which were defined 
as spoligotype 676773777777600 with x, y, or 
z in the second MIRU position. Although cases 
of bacillus Calmette-Guérin M. bovis (defined as 
spoligotype 676773777777600 with x, y, or z in 
the second MIRU position) were reported during 




1Official tuberculosis mortality statistics were compiled by the National Center for Health Statistics, CDC (http://wonder.cdc.gov/mcd-icd10.html); accessed Aug 9, 2016. 
2Case data after 1974 are not comparable to prior years due to changes in the surveillance case definition that became effective in 1975. 
3The large decrease in death rate in 1979 occurred because late effects of tuberculosis (e.g., bronchiectasis or fibrosis) and pleurisy with effusion (without mention of cause) are 
no longer included in tuberculosis deaths.
Percent change in tuberculosis death rates is calculated with unrounded figures. See Technical Notes. 
Note: The 1993 to 2015 tuberculosis case counts and rates were updated using the following sources: Bridged-Race 1990–1999 Intercensal Population Estimates for 
1990–1999 (ftp://ftp.cdc.gov/pub/health_statistics/nchs/datasets/nvss/bridgepop/documentationbridgedintercena1.doc), Intercensal Estimates of the Resident Population for the 
United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2010 (http://www.census.gov/popest/data/intercensal/state/state2010.html) and Annual Estimates of the 
Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2015 (http://www.census.gov/popest/data/national/totals/2015/index.html); 
accessed Aug 9, 2016. 
Percentage change results reported to one decimal. See Surveillance Slides #2 and #3.
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Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates 
per 100,000 Population, and Percent Change: United States, 1953–2015
Tuberculosis cases Tuberculosis deaths
Percent changePercent change
Number Rate Number RateNumber Number1Rate Rate1Year
1953 84,304 52.6 — — 19,707 12.4 —              —
1954 79,775 48.9 –5.4 –7.0 16,527 10.2 –16.1 –17.7
1955 77,368 46.6 –3.0 –4.7 15,016 9.1 –9.1 –10.8
1956 69,895 41.4 –9.7 –11.1 14,137 8.4 –5.9 –7.7
1957 67,149 39.0 –3.9 –5.8 13,390 7.8 –5.3 –7.1
1958 63,534 36.3 –5.4 –6.9 12,417 7.1 –7.3 –9.0
1959 57,535 32.4 –9.4 –10.7 11,474 6.5 –7.6 –8.5
1960 55,494 30.7 –3.5 –5.2 10,866 6.0 –5.3 –7.7
1961 53,726 29.2 –3.2 –4.9 9,938 5.4 –8.5 –10.0
1962 53,315 28.6 –0.8 –2.1 9,506 5.1 –4.3 –5.6
1963 54,042 28.6 1.4 0.0 9,311 4.9 –2.1 –3.9
1964 50,874 26.5 –5.9 –7.3 8,303 4.3 –10.8 –12.2
1965 49,016 25.2 –3.7 –4.9 7,934 4.1 –4.4 –4.7
1966 47,767 24.3 –2.5 –3.6 7,625 3.9 –3.9 –4.9
1967 45,647 23.0 –4.4 –5.3 6,901 3.5 –9.5 –10.3
1968 42,623 21.2 –6.6 –7.8 6,292 3.1 –8.8 –11.4
1969 39,120 19.3 –8.2 –9.0 5,567 2.8 –11.5 –9.7
1970 37,137 18.1 –5.1 –6.2 5,217 2.6 –6.3 –7.1
1971 35,217 17.0 –5.2 –6.1 4,501 2.2 –13.7 –15.4
1972 32,882 15.7 –6.6 –7.6 4,376 2.1 –2.8 –4.5
1973 30,998 14.6 –5.7 –7.0 3,875 1.8 –11.4 –14.5
19742 30,122 14.1 –2.8 –3.4 3,513 1.7 –9.3 –5.6
1975 33,989 15.7 — — 3,333 1.6 –5.1 –5.9
1976 32,105 14.7 –5.5 –6.4 3,130 1.5 –6.1 –6.3
1977 30,145 13.7 –6.1 –6.8 2,968 1.4 –5.2 –6.7
1978 28,521 12.8 –5.4 –6.6 2,914 1.3 –1.8 –7.1
19793 27,669 12.3 –3.0 –3.9 2,007 0.9 –31.1 –30.8
1980 27,749 12.2 0.3 –0.7 1,978 0.9 –1.4 –3.3
1981 27,373 11.9 –1.4 –2.3 1,937 0.8 –2.1 –3.0
1982 25,520 11.0 –6.8 –7.7 1,807 0.8 –6.7 –7.6
1983 23,846 10.2 –6.6 –7.4 1,779 0.8 –1.5 –2.4
1984 22,255 9.4 –6.7 –7.5 1,729 0.7 –2.8 –3.6
1985 22,201 9.3 –0.2 –1.1 1,752 0.7 1.3 0.4
1986 22,768 9.5 2.6 1.6 1,782 0.7 1.7 0.8
1987 22,517 9.3 –1.1 –2.0 1,755 0.7 –1.5 –2.4
1988 22,436 9.2 –0.4 –1.3 1,921 0.8 9.5 8.5
1989 23,495 9.5 4.7 3.7 1,970 0.8 2.6 1.6
1990 25,701 10.3 9.4 8.2 1,810 0.7 –8.1 –9.2
1991 26,283 10.4 2.3 0.9 1,713 0.7 –5.4 –6.6
1992 26,673 10.4 1.5 0.1 1,705 0.7 –0.5 –1.8
1993 25,102 9.7 –5.9 –7.1 1,631 0.6 –4.3 –5.6
1994 24,206 9.2 –3.6 –4.7 1,478 0.6 –9.4 –10.5
1995 22,726 8.5 –6.1 –7.2 1,336 0.5 –9.6 –10.7
1996 21,210 7.9 –6.7 –7.8 1,202 0.4 –10.0 –11.1
1997 19,751 7.2 –6.9 –8.0 1,166 0.4 -3.0 –4.2
1998 18,286 6.6 –7.4 –8.5 1,112 0.4 –4.6 –5.7
1999 17,499 6.3 –4.3 –5.4 930 0.3 –16.4 –17.3
2000 16,308 5.8 –6.8 –7.8 776 0.3 –16.6 –17.5
2001 15,945 5.6 –2.2 –3.2 764 0.3 –1.5 –2.5
2002 15,055 5.2 –5.6 –6.5 784 0.3 2.6 1.7
2003 14,835 5.1 –1.5 –2.3 711 0.2 –9.3 –10.1
2004 14,499 5.0 –2.3 –3.2 657 0.2 –7.6 –8.4
2005 14,060 4.8 –3.0 –3.9 648 0.2 –1.4 –2.3
2006 13,728 4.6 –2.4 –3.3 652 0.2 0.6 –0.3
2007 13,282 4.4 –3.2 –4.2 554 0.2 –15.0 –15.8
2008 12,893 4.2 –2.9 –3.8 585 0.2 5.6 4.6
2009 11,520 3.8 –10.6 –11.4 529 0.2 –9.6 –10.4
2010 11,159 3.6 –3.1 –3.9 569 0.2 7.6 6.7
2011 10,510 3.4 –5.8 –6.5 539 0.2 –5.3 –6.0
2012 9,942 3.2 –5.4 –6.1 510 0.2 –5.4 –6.1
2013 9,550 3.0 –3.9 –4.6 555 0.2 8.8 8.0
2014 9,406 2.9 –1.5 –2.3 493 0.2 –11.2 –11.9
2015 9,557 3.0 1.6 0.8 — — — —
18
1993 25,102 272 (1.1) 14.4 3,454 (13.8) 42.2 8,947 (35.6) 29.1       —      —      — 6,903 (27.5) 3.6        —    —    — 5,137 (20.5) 20.4 389 (1.5)
1994 24,206 327 (1.4) 17.1 3,639 (15.0) 42.8 8,383 (34.6) 26.9       —      —      — 6,572 (27.2) 3.4        —    —    — 5,019 (20.7) 19.2 266 (1.1)
1995 22,726 319 (1.4) 16.5 3,840 (16.9) 43.4 7,554 (33.2) 23.9       —      —      — 5,972 (26.3) 3.1        —    —    — 4,834 (21.3) 17.8 207 (0.9)
1996 21,210 287 (1.4) 14.7 3,666 (17.3) 39.9 7,097 (33.5) 22.2       —      —      — 5,487 (25.9) 2.8        —    —    — 4,492 (21.2) 16.0 181 (0.9)
1997 19,751 264 (1.3) 13.3 3,683 (18.6) 38.6 6,604 (33.4) 20.4       —      —      — 4,824 (24.4) 2.5        —    —    — 4,217 (21.4) 14.5 159 (0.8)
1998 18,286 254 (1.4) 12.7 3,516 (19.2) 35.6 5,823 (31.8) 17.8       —      —      — 4,475 (24.5) 2.3        —    —    — 4,089 (22.4) 13.5 129 (0.7)
1999 17,499 242 (1.4) 11.9 3,519 (20.1) 34.5 5,549 (31.7) 16.8       —      —      — 4,227 (24.2) 2.2        —    —    — 3,864 (22.1) 12.3 98 (0.6)
2000 16,308 232 (1.4) 11.0 3,392 (20.8) 31.3 5,148 (31.6) 15.0       —      —      — 3,638 (22.3) 1.9        —    —    — 3,803 (23.3) 10.7 95 (0.6)
2001 15,945 226 (1.4) 10.7 3,499 (21.9) 30.9 4,782 (30.0) 13.7       —      —      — 3,346 (21.0) 1.7        —    —    — 4,009 (25.1) 10.8 83 (0.5)
2002 15,055 185 (1.2) 8.7 3,322 (22.1) 28.2 4,467 (29.7) 12.7       —      —      — 3,042 (20.2) 1.6        —    —    — 3,973 (26.4) 10.3 66 (0.4)
2003 14,835 179 (1.2) 8.3 3,460 (23.3) 29.3 4,159 (28.0) 11.7 64 (0.4) 15.7 2,792 (18.8) 1.4 37 (0.2) 0.9 4,105 (27.7) 10.2 39 (0.3)
2004 14,499 157 (1.1) 7.2 3,335 (23.0) 27.3 4,070 (28.1) 11.4 63 (0.4) 15.0 2,631 (18.1) 1.3 34 (0.2) 0.8 4,181 (28.8) 10.1 28 (0.2)
2005 14,060 153 (1.1) 7.0 3,201 (22.8) 25.3 3,954 (28.1) 10.9 54 (0.4) 12.4 2,567 (18.3) 1.3 45 (0.3) 1.0 4,044 (28.8) 9.4 42 (0.3)
2006 13,728 165 (1.2) 7.5 3,297 (24.0) 25.2 3,730 (27.2) 10.2 52 (0.4) 11.6 2,387 (17.4) 1.2 39 (0.3) 0.8 4,049 (29.5) 9.1 9 (0.1)
2007 13,282 133 (1.0) 6.0 3,447 (26.0) 25.5 3,477 (26.2) 9.4 95 (0.7) 20.6 2,207 (16.6) 1.1 24 (0.2) 0.5 3,875 (29.2) 8.4 24 (0.2)
2008 12,893 137 (1.1) 6.1 3,395 (26.3) 24.3 3,280 (25.4) 8.8 69 (0.5) 14.5 2,143 (16.6) 1.1 43 (0.3) 0.8 3,801 (29.5) 8.0 25 (0.2)
2009 11,520 102 (0.9) 4.5 3,204 (27.8) 22.3 2,871 (24.9) 7.6 73 (0.6) 15.0 1,817 (15.8) 0.9 49 (0.4) 0.9 3,372 (29.3) 6.8 32 (0.3)
2010 11,159 151 (1.4) 6.7 3,080 (27.6) 20.8 2,675 (24.0) 7.0 96 (0.9) 19.2 1,759 (15.8) 0.9 152 (1.4) 2.7 3,231 (29.0) 6.4 15 (0.1)
2011 10,510 132 (1.3) 5.8 3,073 (29.2) 20.2 2,411 (22.9) 6.3 82 (0.8) 16.1 1,646 (15.7) 0.8 143 (1.4) 2.5 3,006 (28.6) 5.8 17 (0.2)
2012 9,942 146 (1.5) 6.3 2,964 (29.8) 18.8 2,247 (22.6) 5.8 64 (0.6) 12.3 1,570 (15.8) 0.8 141 (1.4) 2.3 2,789 (28.1) 5.3 21 (0.2)
2013 9,550 127 (1.3) 5.5 2,999 (31.4) 18.4 2,089 (21.9) 5.3 61 (0.6) 11.4 1,422 (14.9) 0.7 150 (1.6) 2.4 2,687 (28.1) 5.0 15 (0.2)
2014 9,406 117 (1.2) 5.0 2,990 (31.8) 17.7 2,013 (21.4) 5.1 91 (1.0) 16.6 1,253 (13.3) 0.6 176 (1.9) 2.8 2,747 (29.2) 5.0 19 (0.2)
2015 9,557 145 (1.5) 6.1 3,177 (33.2) 18.2 1,995 (20.9) 5.0 102 (1.1) 18.2 1,251 (13.1) 0.6 167 (1.7) 2.5 2,694 (28.2) 4.8 26 (0.3)
Year
 Table 2. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Hispanic Ethnicity and Non-Hispanic Race: 
United States, 1993–2015
White
1Asian race category reporting includes  Pacific Islander from 1993–2002.
2Native Hawaiian/Other Pacific Islander race first reported separately in 2003. 
 3Indicates two or more races reported for a person. Category first reported in 2003 and does not include persons of Hispanic/Latino origin.
4Persons of Hispanic ethnicity may be of any or multiple race.
 5The higher count for unknown or missing race results for 1993–2001 reflect the impact of the transitional period of incorporating new race definitions for Asian, Native Hawaiian, and multiple race in 
2003.
 Note: Rates for 1993–1999 have been updated using Resident Population: Monthly Postcensal Resident Population, by single year of age, sex, race, and Hispanic origin (http://www.census.gov/
popest/data/national/asrh/1990s/nat_monthly_resident.html); accessed July 26, 2016. Denominators for computing 2000–2009 case rates were obtained from the Intercensal Estimates of the 
Resident Population by Sex, Race, and Hispanic Origin for the United States: April 1, 2000 to July 1, 2010 (http://www.census.gov/popest/data/intercensal/national/nat2010.html); accessed August 
8, 2016. Denominators for computing 2010–2015 case rates were obtained from the Annual Estimates of the Resident Population by Sex, Race, and Hispanic Origin: April 1, 2010 to July 1, 2015 
(http://www.census.gov/popest/data/national/asrh/2015/index.html); accessed July 22, 2016.  
Case counts for race categories (American Indian or Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) do not include persons of Hispanic ethnicity or 
multiple race.
Data for all years updated through June 9, 2016.
 See Technical Notes.
















1993 263 (97.0) 8 (3.0) 131 (3.8) 3315 (96.2) 8,250 (92.9) 630 (7.1)    —   —     —   — 6,317 (92.3) 528 (7.7)    —   —     —   — 2,235 (44.0) 2849 (56.0) 239 (77.1) 71 (22.9)
1994 322 (98.5) 5 (1.5) 173 (4.8) 3456 (95.2) 7,576 (91.1) 738 (8.9)    —   —     —   — 6,009 (92.4) 494 (7.6)    —   —     —   — 1,989 (40.1) 2967 (59.9) 122 (57.3) 91 (42.7)
1995 313 (98.1) 6 (1.9) 159 (4.1) 3678 (95.9) 6,750 (89.4) 797 (10.6)    —   —     —   — 5,427 (91.1) 529 (8.9)    —   —     —   — 1,907 (39.6) 2911 (60.4) 119 (60.7) 77 (39.3)
1996 281 (97.9) 6 (2.1) 169 (4.6) 3490 (95.4) 6,301 (88.8) 793 (11.2)    —   —     —   — 4,968 (90.8) 503 (9.2)    —   —     —   — 1,603 (35.9) 2859 (64.1) 76 (46.3) 88 (53.7)
1997 259 (98.5) 4 (1.5) 166 (4.5) 3511 (95.5) 5,718 (86.7) 875 (13.3)    —   —     —   — 4,255 (88.6) 546 (11.4)    —   —     —   — 1,464 (34.9) 2727 (65.1) 73 (48.0) 79 (52.0)
1998 249 (98.0) 5 (2.0) 163 (4.6) 3347 (95.4) 4,972 (85.5) 845 (14.5)    —   —     —   — 3,914 (87.6) 553 (12.4)    —   —     —   — 1,280 (31.5) 2785 (68.5) 55 (46.2) 64 (53.8)
1999 237 (97.9) 5 (2.1) 161 (4.6) 3346 (95.4) 4,607 (83.3) 924 (16.7)    —   —     —   — 3,637 (86.3) 575 (13.7)    —   —     —   — 1,119 (29.2) 2717 (70.8) 44 (55.7) 35 (44.3)
2000 226 (97.4) 6 (2.6) 154 (4.6) 3228 (95.4) 4,106 (79.8) 1038 (20.2)    —   —     —   — 3,102 (85.3) 534 (14.7)    —   —     —   — 1,015 (26.8) 2770 (73.2) 44 (50.6) 43 (49.4)
2001 214 (95.1) 11 (4.9) 147 (4.2) 3332 (95.8) 3,664 (76.7) 1,114 (23.3)    —   —     —   — 2,787 (83.6) 547 (16.4)    —   —     —   — 1,025 (25.7) 2965 (74.3) 35 (46.1) 41 (53.9)
2002 183 (98.9) 2 (1.1) 143 (4.3) 3169 (95.7) 3,401 (76.4) 1,051 (23.6)    —   —     —   — 2,547 (83.9) 490 (16.1)    —   —     —   — 980 (24.8) 2973 (75.2) 28 (45.9) 33 (54.1)
2003 176 (98.3) 3 (1.7) 152 (4.4) 3297 (95.6) 3,087 (74.4) 1,064 (25.6) 50 (78.1) 14 (21.9) 2,369 (85.0) 418 (15.0) 9 (24.3) 28 (75.7) 1,000 (24.5) 3088 (75.5) 18 (52.9) 16 (47.1)
2004 154 (98.1) 3 (1.9) 146 (4.4) 3181 (95.6) 2,972 (73.1) 1,096 (26.9) 55 (87.3) 8 (12.7) 2,211 (84.1) 418 (15.9) 15 (44.1) 19 (55.9) 1,064 (25.5) 3107 (74.5) 15 (55.6) 12 (44.4)
2005 147 (96.1) 6 (3.9) 121 (3.8) 3077 (96.2) 2,874 (72.8) 1,075 (27.2) 41 (75.9) 13 (24.1) 2,131 (83.1) 434 (16.9) 23 (51.1) 22 (48.9) 955 (23.7) 3073 (76.3) 13 (35.1) 24 (64.9)
2006 162 (98.2) 3 (1.8) 133 (4.0) 3161 (96.0) 2,595 (69.6) 1,132 (30.4) 38 (73.1) 14 (26.9) 1,959 (82.1) 426 (17.9) 16 (41.0) 23 (59.0) 983 (24.4) 3051 (75.6) 3 (37.5) 5 (62.5)
2007 129 (97.0) 4 (3.0) 135 (3.9) 3302 (96.1) 2,460 (71.0) 1,003 (29.0) 72 (75.8) 23 (24.2) 1,785 (81.2) 412 (18.8) 9 (37.5) 15 (62.5) 877 (22.8) 2968 (77.2) 14 (77.8) 4 (22.2)
2008 134 (97.8) 3 (2.2) 153 (4.5) 3238 (95.5) 2,239 (68.3) 1,041 (31.7) 52 (75.4) 17 (24.6) 1,755 (81.9) 387 (18.1) 16 (37.2) 27 (62.8) 921 (24.3) 2876 (75.7) 12 (48.0) 13 (52.0)
2009 98 (96.1) 4 (3.9) 149 (4.7) 3051 (95.3) 1,923 (67.0) 947 (33.0) 66 (90.4) 7 (9.6) 1,439 (79.2) 378 (20.8) 15 (30.6) 34 (69.4) 847 (25.2) 2514 (74.8) 7 (22.6) 24 (77.4)
2010 149 (98.7) 2 (1.3) 123 (4.0) 2957 (96.0) 1,770 (66.2) 903 (33.8) 79 (83.2) 16 (16.8) 1,423 (80.9) 335 (19.1) 22 (14.5) 130 (85.5) 806 (25.0) 2420 (75.0) 0 (0) 15 (100.0)
2011 130 (98.5) 2 (1.5) 128 (4.2) 2944 (95.8) 1,541 (63.9) 869 (36.1) 60 (73.2) 22 (26.8) 1,319 (80.1) 327 (19.9) 26 (18.3) 116 (81.7) 765 (25.5) 2238 (74.5) 4 (23.5) 13 (76.5)
2012 145 (99.3) 1 (0.7) 119 (4.0) 2843 (96.0) 1,348 (60.0) 899 (40.0) 52 (81.3) 12 (18.8) 1,272 (81.1) 297 (18.9) 27 (19.1) 114 (80.9) 692 (24.8) 2096 (75.2) 6 (28.6) 15 (71.4)
2013 125 (98.4) 2 (1.6) 151 (5.0) 2847 (95.0) 1,251 (59.9) 837 (40.1) 44 (72.1) 17 (27.9) 1,098 (77.3) 323 (22.7) 32 (21.6) 116 (78.4) 650 (24.2) 2034 (75.8) 4 (28.6) 10 (71.4)
2014 117 (100.0) 0 (0) 137 (4.6) 2852 (95.4) 1,185 (58.9) 828 (41.1) 83 (91.2) 8 (8.8) 970 (77.5) 282 (22.5) 30 (17.0) 146 (83.0) 651 (23.7) 2093 (76.3) 4 (22.2) 14 (77.8)
2015 140 (99.3) 1 (0.7) 137 (4.3) 3033 (95.7) 1,143 (57.3) 851 (42.7) 88 (86.3) 14 (13.7) 990 (79.3) 259 (20.7) 25 (15.1) 141 (84.9) 658 (24.5) 2030 (75.5) 5 (19.2) 21 (80.8)
 Table 3. Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race, and by Origin of Birth:






























1Asian race category reporting includes  Pacific Islander from 1993–2002.
2Native Hawaiian/Other Pacific Islander race first reported separately in 2003. 
 3Indicates two or more races reported for a person. Category first reported in 2003 and does not include persons of Hispanic/Latino origin.
4Persons of Hispanic ethnicity may be of any or multiple race.
 5The higher count for unknown or missing race results for 1993–2001 reflect the impact of the transitional period of incorporating new race definitions for Asian, Native Hawaiian, and multiple race 
in 2003.
 Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) do not include persons of 
Hispanic/Latino origin or multiple race.
Data for all years updated through June 9, 2016.
 See Technical Notes.
 See Surveillance Slide #15.
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 Table 4. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age Group: United States, 1993–2015 
Note: Previously published rates for 1993–1999 have been updated using Resident Population: Monthly Postcensal Resident Population, by single year of age, sex, race, and Hispanic origin 
(http://www.census.gov/popest/data/national/asrh/1990s/nat_monthly_resident.html); accessed July 26, 2016). Denominators for computing 2000–2015 case rates were obtained from the 
Intercensal Estimates of the Resident Population by Sex and Age for the United States: April 1, 2000 to July 1, 2010 (http://www.census.gov/popest/data/intercensal/national/nat2010.html), and 
Annual Estimates of the Resident Population for Selected Age Groups by Sex: April 1, 2010 to July 1, 2015 (http://www.census.gov/popest/data/national/asrh/2015/index.html); accessed July 
22, 2016. 
Data for all years updated through June 9, 2016.
See Technical Notes.
Zero % (0) denotes <0.05%.






1993 25,102 1,014 (4.0) 5.2 646 (2.6) 1.7 1,821 (7.3) 5.0 9,589 (38.2) 11.6 6,195 (24.7) 12.5 5,820 (23.2) 17.7 17 (0.1)
1994 24,206 995 (4.1) 5.1 664 (2.7) 1.8 1,832 (7.6) 5.1 9,043 (37.4) 10.9 6,126 (25.3) 12.0 5,540 (22.9) 16.7 6 (0)
1995 22,726 894 (3.9) 4.6 642 (2.8) 1.7 1,697 (7.5) 4.7 8,200 (36.1) 9.8 5,960 (26.2) 11.4 5,328 (23.4) 15.8 5 (0)
1996 21,210 770 (3.6) 4.0 586 (2.8) 1.5 1,637 (7.7) 4.5 7,564 (35.7) 9.0 5,572 (26.3) 10.4 5,076 (23.9) 14.9 5 (0)
1997 19,751 734 (3.7) 3.8 517 (2.6) 1.3 1,674 (8.5) 4.6 6,884 (34.9) 8.2 5,278 (26.7) 9.5 4,663 (23.6) 13.6 1 (0)
1998 18,286 638 (3.5) 3.4 439 (2.4) 1.1 1,543 (8.4) 4.1 6,335 (34.6) 7.6 4,954 (27.1) 8.7 4,377 (23.9) 12.7 0 (0)
1999 17,499 602 (3.4) 3.2 436 (2.5) 1.1 1,518 (8.7) 4.0 6,062 (34.6) 7.3 4,860 (27.8) 8.2 4,019 (23.0) 11.6 2 (0)
2000 16,308 544 (3.3) 2.8 420 (2.6) 1.0 1,618 (9.9) 4.1 5,576 (34.2) 6.6 4,635 (28.4) 7.4 3,515 (21.6) 10.0 0 (0)
2001 15,945 543 (3.4) 2.8 386 (2.4) 0.9 1,597 (10.0) 4.0 5,610 (35.2) 6.6 4,515 (28.3) 7.0 3,293 (20.7) 9.3 1 (0)
2002 15,055 556 (3.7) 2.9 388 (2.6) 0.9 1,498 (10.0) 3.7 5,288 (35.1) 6.3 4,182 (27.8) 6.3 3,142 (20.9) 8.8 1 (0)
2003 14,835 547 (3.7) 2.8 364 (2.5) 0.9 1,573 (10.6) 3.8 5,074 (34.2) 6.1 4,283 (28.9) 6.2 2,994 (20.2) 8.3 0 (0)
2004 14,499 549 (3.8) 2.8 403 (2.8) 1.0 1,603 (11.1) 3.8 4,940 (34.1) 5.9 4,192 (28.9) 5.9 2,811 (19.4) 7.8 1 (0)
2005 14,060 474 (3.4) 2.4 377 (2.7) 0.9 1,540 (11.0) 3.6 4,737 (33.7) 5.7 4,123 (29.3) 5.6 2,809 (20.0) 7.7 0 (0)
2006 13,728 482 (3.5) 2.4 321 (2.3) 0.8 1,532 (11.2) 3.6 4,690 (34.2) 5.7 4,039 (29.4) 5.4 2,663 (19.4) 7.2 1 (0)
2007 13,282 467 (3.5) 2.3 310 (2.3) 0.8 1,580 (11.9) 3.7 4,313 (32.5) 5.2 4,037 (30.4) 5.2 2,574 (19.4) 6.8 1 (0)
2008 12,893 497 (3.9) 2.5 289 (2.2) 0.7 1,444 (11.2) 3.3 4,238 (32.9) 5.1 3,929 (30.5) 5.0 2,496 (19.4) 6.4 0 (0)
2009 11,520 403 (3.5) 2.0 244 (2.1) 0.6 1,279 (11.1) 2.9 3,885 (33.7) 4.7 3,425 (29.7) 4.3 2,283 (19.8) 5.8 1 (0)
2010 11,159 365 (3.3) 1.8 271 (2.4) 0.7 1,199 (10.7) 2.7 3,669 (32.9) 4.5 3,429 (30.7) 4.2 2,226 (19.9) 5.5 0 (0)
2011 10,510 351 (3.3) 1.7 227 (2.2) 0.6 1,030 (9.8) 2.3 3,365 (32.0) 4.1 3,292 (31.3) 4.0 2,245 (21.4) 5.4 0 (0)
2012 9,942 261 (2.6) 1.3 226 (2.3) 0.5 1,019 (10.2) 2.3 3,119 (31.4) 3.8 3,115 (31.3) 3.8 2,200 (22.1) 5.1 2 (0)
2013 9,550 295 (3.1) 1.5 188 (2.0) 0.5 976 (10.2) 2.2 2,959 (31.0) 3.5 2,952 (30.9) 3.5 2,180 (22.8) 4.9 0 (0)
2014 9,406 263 (2.8) 1.3 195 (2.1) 0.5 962 (10.2) 2.2 2,822 (30.0) 3.4 2,957 (31.4) 3.5 2,207 (23.5) 4.8 0 (0)
2015 9,557 244 (2.6) 1.2 196 (2.1) 0.5 935 (9.8) 2.1 2,858 (29.9) 3.4 3,028 (31.7) 3.6 2,294 (24.0) 4.8 2 (0)
Rate
15–24 25–44 45–64 ≥65 Unknown/missing5–14
No. (%) Rate No. (%) Rate No. (%) Rate No. (%) Rate No. (%) Rate No. (%)
21
1993 25,102 17,435 (69.5) 7.4 7,401 (29.5) 34.0 266 (1.1)
1994 24,206 16,191 (66.9) 6.8 7,751 (32.0) 36.0 264 (1.1)
1995 22,726 14,675 (64.6) 6.1 7,998 (35.2) 38.0 53 (0.2)
1996 21,210 13,398 (63.2) 5.6 7,739 (36.5) 32.0 73 (0.3)
1997 19,751 11,935 (60.4) 4.9 7,742 (39.2) 30.8 74 (0.4)
1998 18,286 10,633 (58.1) 4.4 7,599 (41.6) 28.8 54 (0.3)
1999 17,499 9,805 (56.0) 4.0 7,602 (43.4) 28.1 92 (0.5)
2000 16,308 8,647 (53.0) 3.5 7,619 (46.7) 26.4 42 (0.3)
2001 15,945 7,872 (49.4) 3.2 8,010 (50.2) 27.6 63 (0.4)
2002 15,055 7,282 (48.4) 2.9 7,718 (51.3) 25.5 55 (0.4)
2003 14,835 6,861 (46.2) 2.7 7,928 (53.4) 23.8 46 (0.3)
2004 14,499 6,632 (45.7) 2.6 7,844 (54.1) 23.1 23 (0.2)
2005 14,060 6,305 (44.8) 2.5 7,724 (54.9) 22.2 31 (0.2)
2006 13,728 5,889 (42.9) 2.3 7,815 (56.9) 21.6 24 (0.2)
2007 13,282 5,481 (41.3) 2.1 7,731 (58.2) 20.8 70 (0.5)
2008 12,893 5,282 (41.0) 2.0 7,602 (59.0) 20.1 9 (0.1)
2009 11,520 4,544 (39.4) 1.7 6,959 (60.4) 18.7 17 (0.1)
2010 11,159 4,372 (39.2) 1.6 6,778 (60.7) 17.7 9 (0.1)
2011 10,510 3,973 (37.8) 1.5 6,531 (62.1) 17.0 6 (0.1)
2012 9,942 3,661 (36.8) 1.4 6,277 (63.1) 15.9 4 (0)
2013 9,550 3,355 (35.1) 1.2 6,186 (64.8) 15.6 9 (0.1)
2014 9,406 3,177 (33.8) 1.2 6,223 (66.2) 15.4 6 (0.1)
2015 9,557 3,186 (33.3) 1.2 6,350 (66.4) 15.1 21 (0.2)




U.S.-born persons Foreign-born persons1 Unknown/missing
No. (%) RateNo. (%) Rate
1Includes persons born outside the United States (including the U.S. insular areas) and the sovereign freely associated states (the Federated States of Micronesia, the Republic of the Marshall 
Islands, and the Republic of Palau).
Note: Denominators  for computing rates for years 1993–1994 were obtained from Quarterly Estimates of the United States Foreign-born and Native Resident Populations: April 1, 1990–July 1, 
1999 (http://www.census.gov/population/estimates/nation/nativity/fbtab001.txt); accessed June, 2016. Denominators for computing the 1994–2015 rates are based on the U.S. Census Bureau, 
Current Population Survey via Data Ferrett (http://dataferrett.census.gov/); accessed June, 2016.  
Data for all years updated through June 9, 2016.
 See Technical Notes.
Zero % (0) denotes <0.05%.
See Surveillance Slides #13, #14, #17, and #18.
No. (%)
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
2The top 30 countries were selected based on their ranked 5-year average number of TB cases.
3Includes Not Specified for Country of Origin. 
Note: Data for all years updated through June 9, 2016.
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Table 6. Tuberculosis Cases and Percentages Among Foreign-Born Persons1 by the Top 30 
Countries2 of Birth: United States, 2011–2015
Country of Origin
2015 2014 2013 2012 2011
Year
No. No. No. No. No.(%) (%) (%) (%) (%)
Total Cases 6,350 (100.0) 6,223 (100.0) 6,186 (100.0) 6,277 (100.0) 6,531 (100.0)
Mexico 1,254 (19.7) 1,282 (20.6) 1,243 (20.1) 1,312 (20.9) 1,445 (22.1)
Philippines 820 (12.9) 755 (12.1) 781 (12.6) 772 (12.3) 759 (11.6)
India 579 (9.1) 479 (7.7) 495 (8.0) 531 (8.5) 509 (7.8)
Vietnam 519 (8.2) 502 (8.1) 457 (7.4) 453 (7.2) 551 (8.4)
China 426 (6.7) 420 (6.7) 376 (6.1) 354 (5.6) 377 (5.8)
Guatemala 189 (3.0) 180 (2.9) 214 (3.5) 194 (3.1) 172 (2.6)
Haiti 166 (2.6) 165 (2.7) 171 (2.8) 199 (3.2) 189 (2.9)
Ethiopia 143 (2.3) 142 (2.3) 159 (2.6) 162 (2.6) 155 (2.4)
Honduras 140 (2.2) 142 (2.3) 121 (2.0) 125 (2.0) 129 (2.0)
Myanmar 120 (1.9) 102 (1.6) 105 (1.7) 116 (1.8) 93 (1.4)
Korea, Republic of 94 (1.5) 92 (1.5) 99 (1.6) 109 (1.7) 131 (2.0)
El Salvador 109 (1.7) 97 (1.6) 96 (1.6) 116 (1.8) 104 (1.6)
Somalia 85 (1.3) 105 (1.7) 87 (1.4) 101 (1.6) 116 (1.8)
Peru 80 (1.3) 91 (1.5) 91 (1.5) 79 (1.3) 93 (1.4)
Pakistan 85 (1.3) 89 (1.4) 78 (1.3) 68 (1.1) 88 (1.3)
Cambodia 86 (1.4) 74 (1.2) 71 (1.1) 78 (1.2) 91 (1.4)
Nepal 79 (1.2) 78 (1.3) 72 (1.2) 81 (1.3) 78 (1.2)
Ecuador 70 (1.1) 74 (1.2) 80 (1.3) 65 (1.0) 78 (1.2)
Laos 66 (1.0) 70 (1.1) 89 (1.4) 64 (1.0) 62 (0.9)
Dominican Republic 65 (1.0) 68 (1.1) 62 (1.0) 74 (1.2) 75 (1.1)
Nigeria 74 (1.2) 51 (0.8) 68 (1.1) 58 (0.9) 52 (0.8)
Bangladesh 67 (1.1) 42 (0.7) 71 (1.1) 54 (0.9) 66 (1.0)
Kenya 50 (0.8) 49 (0.8) 48 (0.8) 58 (0.9) 75 (1.1)
Bhutan 46 (0.7) 63 (1.0) 57 (0.9) 58 (0.9) 39 (0.6)
Thailand 39 (0.6) 48 (0.8) 38 (0.6) 33 (0.5) 36 (0.6)
Korea, Dem. People’s Republic 27 (0.4) 30 (0.5) 37 (0.6) 47 (0.7) 38 (0.6)
Colombia 45 (0.7) 36 (0.6) 37 (0.6) 25 (0.4) 33 (0.5)
Indonesia 39 (0.6) 29 (0.5) 34 (0.5) 41 (0.7) 32 (0.5)
Cuba 32 (0.5) 44 (0.7) 25 (0.4) 30 (0.5) 40 (0.6)
Liberia 40 (0.6) 28 (0.4) 29 (0.5) 33 (0.5) 28 (0.4)
All Others3 716 (11.3) 796 (12.8) 795 (12.9) 787 (12.5) 797 (12.2)
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No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1Based on the public health surveillance case definition for tuberculosis; see Appendix A.
2Nucleic Acid Amplification test. Information not collected before 2008.
3Includes all cases among persons with pulmonary as the only site of disease, and persons with both pulmonary and extrapulmonary sites of disease.
4Includes cases among persons with extrapulmonary TB disease only.
5Excludes missing and unknowns.
Note: See Technical Notes.
Data for all years updated through June 9, 2016.
1993 25,102 20,306 (80.9)               —           — 185 (0.7) 3,088 (12.3) 1,523 (6.1) 21,153 (84.3) 3,940 (15.7)
1994 24,206 19,507 (80.6)               —           — 189 (0.8) 2,917 (12.1) 1,593 (6.6) 20,318 (83.9) 3,886 (16.1)
1995 22,726 18,265 (80.4)               —           — 189 (0.8) 2,749 (12.1) 1,523 (6.7) 18,887 (83.1) 3,834 (16.9)
1996 21,210 17,154 (80.9)               —           — 131 (0.6) 2,607 (12.3) 1,318 (6.2) 17,387 (82.0) 3,814 (18.0)
1997 19,751 15,979 (80.9)               —           — 155 (0.8) 2,411 (12.2) 1,206 (6.1) 16,239 (82.2) 3,509 (17.8)
1998 18,286 14,789 (80.9)               —           — 155 (0.8) 2,253 (12.3) 1,089 (6.0) 14,801 (81.0) 3,483 (19.0)
1999 17,499 13,994 (80.0)               —           — 172 (1.0) 2,103 (12.0) 1,230 (7.0) 14,065 (80.4) 3,431 (19.6)
2000 16,308 13,013 (79.8)               —           — 148 (0.9) 1,950 (12.0) 1,197 (7.3) 13,085 (80.3) 3,211 (19.7)
2001 15,945 12,750 (80.0)               —           — 123 (0.8) 1,886 (11.8) 1,186 (7.4) 12,724 (79.8) 3,217 (20.2)
2002 15,055 11,974 (79.5)               —           — 104 (0.7) 1,822 (12.1) 1,155 (7.7) 11,901 (79.1) 3,148 (20.9)
2003 14,835 11,683 (78.8)               —           — 116 (0.8) 1,783 (12.0) 1,253 (8.4) 11,805 (79.6) 3,020 (20.4)
2004 14,499 11,327 (78.1)               —           — 80 (0.6) 1,824 (12.6) 1,268 (8.7) 11,524 (79.5) 2,971 (20.5)
2005 14,060 10,954 (77.9)               —           — 96 (0.7) 1,797 (12.8) 1,213 (8.6) 11,121 (79.1) 2,933 (20.9)
2006 13,728 10,745 (78.3)               —           — 93 (0.7) 1,629 (11.9) 1,261 (9.2) 10,853 (79.1) 2,872 (20.9)
2007 13,282 10,426 (78.5)               —           — 69 (0.5) 1,496 (11.3) 1,291 (9.7) 10,592 (79.8) 2,687 (20.2)
2008 12,893 10,022 (77.7) 18 (0.1) 60 (0.5) 1,549 (12.0) 1,244 (9.6) 10,236 (79.4) 2,653 (20.6)
2009 11,520 8,883 (77.1) 57 (0.5) 74 (0.6) 1,779 (15.4) 727 (6.3) 9,009 (78.3) 2,497 (21.7)
2010 11,159 8,458 (75.8) 105 (0.9) 69 (0.6) 1,879 (16.8) 648 (5.8) 8,721 (78.2) 2,433 (21.8)
2011 10,510 8,084 (76.9) 123 (1.2) 61 (0.6) 1,680 (16.0) 562 (5.3) 8,328 (79.3) 2,179 (20.7)
2012 9,942 7,630 (76.7) 119 (1.2) 38 (0.4) 1,640 (16.5) 515 (5.2) 7,845 (79.0) 2,087 (21.0)
2013 9,550 7,360 (77.1) 149 (1.6) 47 (0.5) 1,506 (15.8) 488 (5.1) 7,574 (79.4) 1,971 (20.6)
2014 9,406 7,235 (76.9) 163 (1.7) 45 (0.5) 1,496 (15.9) 467 (5.0) 7,462 (79.4) 1,935 (20.6)





Table 8. Tuberculosis Cases and Percentages, by Resistance to Isoniazid (INH)1, Origin of Birth, and Previous History of TB: 
United States, 1993–2015
1993 1,534 982 161 (16.4) 16,600 1,367 (8.2) 668 83 (12.4) 11,809 789 (6.7) 301 75 (24.9) 4,663 564 (12.1)
1994 1,543 1,033 175 (16.9) 16,417 1,352 (8.2) 693 81 (11.7) 11,019 709 (6.4) 336 93 (27.7) 5,281 631 (11.9)
1995 1,350 958 168 (17.5) 16,021 1,172 (7.3) 593 77 (13.0) 10,350 555 (5.4) 363 91 (25.1) 5,640 616 (10.9)
1996 1,284 862 142 (16.5) 15,358 1,133 (7.4) 559 68 (12.2) 9,646 496 (5.1) 303 74 (24.4) 5,665 636 (11.2)
1997 1,195 742 109 (14.7) 14,448 1,078 (7.5) 455 35 (7.7) 8,705 435 (5.0) 286 74 (25.9) 5,698 640 (11.2)
1998 1,120 749 98 (13.1) 13,418 1,011 (7.5) 485 38 (7.8) 7,711 366 (4.7) 262 60 (22.9) 5,674 643 (11.3)
1999 999 669 82 (12.3) 12,655 899 (7.1) 383 25 (6.5) 7,020 283 (4.0) 283 55 (19.4) 5,583 614 (11.0)
2000 981 632 84 (13.3) 11,825 889 (7.5) 360 22 (6.1) 6,144 269 (4.4) 272 62 (22.8) 5,652 617 (10.9)
2001 897 629 87 (13.8) 11,510 800 (7.0) 324 28 (8.6) 5,583 242 (4.3) 302 59 (19.5) 5,891 557 (9.5)
2002 912 569 80 (14.1) 10,813 826 (7.6) 303 23 (7.6) 5,069 206 (4.1) 264 57 (21.6) 5,703 619 (10.9)
2003 903 524 65 (12.4) 10,751 822 (7.6) 253 16 (6.3) 4,864 214 (4.4) 271 49 (18.1) 5,857 604 (10.3)
2004 872 537 64 (11.9) 10,481 801 (7.6) 274 15 (5.5) 4,698 214 (4.6) 263 49 (18.6) 5,773 587 (10.2)
2005 842 506 70 (13.8) 10,063 761 (7.6) 239 18 (7.5) 4,411 188 (4.3) 267 52 (19.5) 5,635 567 (10.1)
2006 845 493 67 (13.6) 9,906 770 (7.8) 203 9 (4.4) 4,145 173 (4.2) 289 57 (19.7) 5,745 596 (10.4)
2007 798 496 71 (14.3) 9,647 715 (7.4) 206 14 (6.8) 3,878 164 (4.2) 288 57 (19.8) 5,716 547 (9.6)
2008 835 429 57 (13.3) 9,305 774 (8.3) 170 13 (7.6) 3,677 189 (5.1) 259 44 (17.0) 5,622 584 (10.4)
2009 763 341 52 (15.2) 7,740 652 (8.4) 116 6 (5.2) 3,042 186 (6.1) 224 46 (20.5) 4,690 466 (9.9)
2010 699 359 62 (17.3) 7,812 628 (8.0) 128 12 (9.4) 2,970 165 (5.6) 231 50 (21.6) 4,836 463 (9.6)
2011 752 345 59 (17.1) 7,545 686 (9.1) 137 9 (6.6) 2,719 172 (6.3) 208 50 (24.0) 4,823 514 (10.7)
2012 693 356 56 (15.7) 7,084 637 (9.0) 126 8 (6.3) 2,548 153 (6.0) 230 48 (20.9) 4,536 484 (10.7)
2013 675 299 48 (16.1) 6,848 620 (9.1) 97 8 (8.2) 2,303 131 (5.7) 202 40 (19.8) 4,540 489 (10.8)
2014 689 336 63 (18.8) 6,715 620 (9.2) 96 5 (5.2) 2,205 164 (7.4) 240 58 (24.2) 4,506 456 (10.1)
2015 666 319 48 (15.0) 6,846 613 (9.0) 104 7 (6.7) 2,173 140 (6.4) 215 41 (19.1) 4,659 468 (10.0)
Total INH-resistant
Isoniazid resistant TB cases
1Resistance to at least isoniazid. Isolates may be resistant to other drugs. Eligible cases are culture positive with initial drug susceptibility testing done. Excludes cases with susceptibility testing not done or unknown for isoniazid. 
Cases have been susceptibility tested to at least isoniazid and rifampin.
2This column provides an overall total of all INH-resistant cases, including those where previous history of TB is unknown and origin or birth is unknown. 
3Excludes cases where previous history of TB is unknown and cases where origin of birth is unknown.  
4Includes persons born outside the United States (including the U.S. insular areas) and the sovereign freely associated states (the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
























Table 9. Tuberculosis Cases and Percentages, by Multidrug Resistance (MDR)1, Origin of Birth, and Previous History of TB: 
United States, 1993–2015
1993 484 982 76 (7.7) 16,600 407 (2.5) 668 30 (4.5) 11,809 301 (2.5) 301 46 (15.3) 4,663 103 (2.2)
1994 431 1,033 74 (7.2) 16,417 353 (2.2) 693 35 (5.1) 11,019 238 (2.2) 336 38 (11.3) 5,281 110 (2.1)
1995 327 958 70 (7.3) 16,021 254 (1.6) 593 28 (4.7) 10,350 169 (1.6) 363 42 (11.6) 5,640 85 (1.5)
1996 250 862 43 (5.0) 15,358 207 (1.3) 559 21 (3.8) 9,646 105 (1.1) 303 22 (7.3) 5,665 101 (1.8)
1997 201 742 44 (5.9) 14,448 155 (1.1) 455 12 (2.6) 8,705 76 (0.9) 286 32 (11.2) 5,698 79 (1.4)
1998 155 749 23 (3.1) 13,418 132 (1.0) 485 6 (1.2) 7,711 55 (0.7) 262 17 (6.5) 5,674 76 (1.3)
1999 157 669 28 (4.2) 12,655 127 (1.0) 383 6 (1.6) 7,020 39 (0.6) 283 22 (7.8) 5,583 88 (1.6)
2000 146 632 26 (4.1) 11,825 120 (1.0) 360 2 (0.6) 6,144 40 (0.7) 272 24 (8.8) 5,652 80 (1.4)
2001 151 629 33 (5.2) 11,510 115 (1.0) 324 7 (2.2) 5,583 34 (0.6) 302 26 (8.6) 5,891 81 (1.4)
2002 158 569 26 (4.6) 10,813 132 (1.2) 303 3 (1.0) 5,069 35 (0.7) 264 23 (8.7) 5,703 97 (1.7)
2003 119 524 21 (4.0) 10,751 94 (0.9) 253 2 (0.8) 4,864 24 (0.5) 271 19 (7.0) 5,857 69 (1.2)
2004 128 537 27 (5.0) 10,481 100 (1.0) 274 4 (1.5) 4,698 26 (0.6) 263 23 (8.7) 5,773 74 (1.3)
2005 125 506 23 (4.5) 10,063 98 (1.0) 239 2 (0.8) 4,411 20 (0.5) 267 21 (7.9) 5,635 77 (1.4)
2006 124 493 20 (4.1) 9,906 103 (1.0) 203 1 (0.5) 4,145 19 (0.5) 289 19 (6.6) 5,745 84 (1.5)
2007 124 496 19 (3.8) 9,647 101 (1.0) 206 3 (1.5) 3,878 19 (0.5) 288 16 (5.6) 5,716 82 (1.4)
2008 107 429 19 (4.4) 9,305 88 (0.9) 170 3 (1.8) 3,677 21 (0.6) 259 16 (6.2) 5,622 67 (1.2)
2009 115 341 19 (5.6) 7,740 90 (1.2) 116 1 (0.9) 3,042 11 (0.4) 224 18 (8.0) 4,690 79 (1.7)
2010 105 359 16 (4.5) 7,812 87 (1.1) 128 2 (1.6) 2,970 14 (0.5) 231 14 (6.1) 4,836 73 (1.5)
2011 127 345 27 (7.8) 7,545 100 (1.3) 137 1 (0.7) 2,719 16 (0.6) 208 26 (12.5) 4,823 84 (1.7)
2012 89 356 13 (3.7) 7,084 76 (1.1) 126 0 (0) 2,548 13 (0.5) 230 13 (5.7) 4,536 63 (1.4)
2013 96 299 12 (4.0) 6,848 83 (1.2) 97 2 (2.1) 2,303 7 (0.3) 202 10 (5.0) 4,540 76 (1.7)
2014 94 336 24 (7.1) 6,715 70 (1.0) 96 0 (0) 2,205 10 (0.5) 240 24 (10.0) 4,506 60 (1.3)
2015 89 319 16 (5.0) 6,846 73 (1.1) 104 3 (2.9) 2,173 10 (0.5) 215 13 (6.0) 4,659 63 (1.4)
1Resistance to at least isoniazid and rifampin. Isolates may be resistant to other drugs. Eligible cases are culture positive with initial drug susceptibility testing done. Excludes cases with susceptibility testing not done or unknown 
for isoniazid and rifampin. Cases have been susceptibility tested to at least isoniazid and rifampin.
2This column provides an overall total of all MDR cases, including those where previous history of TB is unknown and origin or birth is unknown. 
3Excludes cases where previous history of TB is unknown and cases where origin of birth is unknown.  
4Includes persons born outside the United States (including the U.S. insular areas) and the sovereign freely associated states (the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).






U.S.-born MDR3 Foreign-born3,4 MDR
Eligible (%)


















1993 (13.0) (31.2) (40.3) (21.7) (14.4) (63.4) (86.0)
1994 (7.0) (23.3) (55.7) (28.1) (20.5) (68.6) (86.8)
1995 (5.2) (20.3) (62.7) (37.3) (21.5) (74.1) (89.2)
1996 (4.2) (17.5) (67.3) (42.5) (22.4) (76.8) (90.2)
1997 (3.2) (15.1) (71.9) (47.0) (23.8) (78.7) (91.0)
1998 (2.6) (12.9) (74.3) (47.7) (26.6) (81.2) (92.2)
1999 (2.2) (11.2) (76.9) (49.4) (27.6) (81.4) (92.2)
2000 (2.0) (10.4) (78.5) (52.5) (25.8) (82.2) (92.5)
2001 (1.7) (9.6) (79.8) (53.6) (27.5) (82.5) (92.7)
2002 (1.8) (8.9) (80.3) (55.4) (27.8) (83.0) (92.5)
2003 (1.4) (8.1) (81.3) (56.5) (28.5) (83.6) (92.8)
2004 (1.5) (6.4) (82.4) (58.9) (27.7) (84.3) (92.6)
2005 (1.3) (5.5) (83.7) (57.9) (29.6) (84.0) (92.5)
2006 (1.2) (4.8) (83.3) (57.5) (30.4) (84.8) (93.2)
2007 (1.1) (4.6) (83.8) (56.3) (32.9) (85.6) (93.9)
2008 (1.0) (3.5) (84.3) (56.3) (33.5) (86.0) (93.3)
2009 (0.9) (3.1) (84.3) (59.6) (30.3) (88.8) (95.6)
2010 (0.8) (2.8) (84.5) (59.3) (31.1) (89.7) (96.1)
20115 (0.7) (2.6) (85.2) (62.2) (29.2) (89.6) (96.3)
20125 (0.6) (2.0) (85.4) (61.8) (29.2) (90.0) (96.2)
20135 (0.5) (2.3) (84.4) (63.2) (28.9) (89.6) (95.9)
20145 (0.3) (2.1) (84.9)                —                      —                           —                   —
20155 (0.5) (2.0) (84.7)                —                      —                           —                   —
 Table 10. Percentages of Tuberculosis Cases, by Initial Drug Regimen, Use of Directly  
Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2015
Year
Initial drug regimen1,2 Directly observed therapy3 Therapy <1 year indicated4
IRZ DOT only
Both DOT and self-
administered COT <1 Year COT everIR
 1Includes persons alive at diagnosis.
2I, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol. Excludes cases with no information on initial drug regimen. In 2015, 0.48% 
received no initial drug therapy, 0.12% were started on one drug, and 12.3% had an initial drug regimen other than IR, IRZ, or IRZE.
3Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.
4Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, and who did not die 
within one year of initiating therapy. Persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal 
disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive 
nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment were 
excluded.
5Begining in 2011, those who moved out of country during treatment are excluded from the denominator of those eligible for COT.
Note: Data as of June 9, 2016.
See Technical Notes for details and for description of COT calculation.
See Surveillance Slides #30 and #31.
IRZE
27
1993 9,329 4,211 (45.1) 2,633 (62.5) 24,052 7,185 (29.9) 3,466 (48.2)
1994 8,805 4,288 (48.7) 2,524 (58.9) 23,273 7,644 (32.8) 3,403 (44.5)
1995 8,016 4,156 (51.8) 2,063 (49.6) 21,882 7,940 (36.3) 2,869 (36.1)
1996 7,400 4,246 (57.4) 1,757 (41.4) 20,441 8,595 (42.0) 2,461 (28.6)
1997 6,757 4,058 (60.1) 1,407 (34.7) 19,082 8,593 (45.0) 1,999 (23.3)
1998 6,261 3,810 (60.9) 1,194 (31.3) 17,745 8,158 (46.0) 1,755 (21.5)
1999 5,983 3,752 (62.7) 1,125 (30.0) 16,968 8,295 (48.9) 1,658 (20.0)
2000 5,499 3,476 (63.2) 917 (26.4) 15,888 7,990 (50.3) 1,398 (17.5)
2001 5,550 3,544 (63.9) 892 (25.2) 15,567 8,007 (51.4) 1,369 (17.1)
2002 5,237 3,475 (66.4) 822 (23.7) 14,725 7,924 (53.8) 1,344 (17.0)
2003 5,028 3,396 (67.5) 786 (23.1) 14,509 8,037 (55.4) 1,280 (15.9)
2004 4,886 3,399 (69.6) 655 (19.3) 14,208 8,415 (59.2) 1,150 (13.7)
2005 4,696 3,253 (69.3) 598 (18.4) 13,767 8,150 (59.2) 1,017 (12.5)
2006 4,648 3,270 (70.4) 546 (16.7) 13,412 8,231 (61.4) 927 (11.3)
2007 4,266 3,133 (73.4) 468 (14.9) 12,993 8,266 (63.6) 846 (10.2)
2008 4,203 3,089 (73.5) 399 (12.9) 12,642 8,166 (64.6) 792 (9.7)
2009 3,853 2,834 (73.6) 384 (13.5) 11,269 7,337 (65.1) 688 (9.4)
2010 3,632 2,759 (76.0) 310 (11.2) 10,912 7,436 (68.1) 595 (8.0)
20112 3,332 3,047 (91.4) 331 (10.9) 10,268 8,711 (84.8) 649 (7.5)
2012 3,098 2,882 (93.0) 328 (11.4) 9,726 8,433 (86.7) 611 (7.2)
2013 2,935 2,779 (94.7) 257 (9.2) 9,339 8,343 (89.3) 535 (6.4)
2014 2,804 2,649 (94.5) 229 (8.6) 9,212 8,269 (89.8) 493 (6.0)
2015 2,843 2,698 (94.9) 204 (7.6) 9,349 8,366 (89.5) 459 (5.5)
 Table 11. Tuberculosis Cases and Percentages Among Persons with HIV Test Results1 and with HIV Coinfection by Age Group: 
United States, 1993–2015
Year
25–44 Years Old All Ages
HIV test results HIV positive
No. No.(%) (%)
1Includes persons with positive, negative, or indeterminate HIV test results and persons from California with co-diagnosis of TB and AIDS for the period 1993–2004, and those persons not 
dead at diagnosis. Rhode Island did not report HIV test results for years 1993–1997. HIV test results for Vermont are not included for years 2007–present. HIV test results for California are not 
included for years 2005–2010.
2California began reporting HIV test results to CDC in 2011.
Note: Data as of June 9, 2016.
See Surveillance Slides #26 and #27. 





HIV test results HIV positive
No. No.(%) (%)
28
1993 23,740 18,043 (76.0) 0 (0) 1,120 (4.7) 1,086 (4.6) 223 (0.9) 3,053 (12.9) 215 (0.9)
1994 23,052 17,764 (77.1) 0 (0) 1,194 (5.2) 740 (3.2) 183 (0.8) 2,743 (11.9) 428 (1.9)
1995 21,705 17,306 (79.7) 0 (0) 969 (4.5) 570 (2.6) 155 (0.7) 2,396 (11.0) 309 (1.4)
1996 20,298 16,528 (81.4) 0 (0) 783 (3.9) 525 (2.6) 156 (0.8) 1,998 (9.8) 308 (1.5)
1997 18,930 15,673 (82.8) 0 (0) 667 (3.5) 444 (2.3) 119 (0.6) 1,755 (9.3) 272 (1.4)
1998 17,583 14,766 (84.0) 0 (0) 533 (3.0) 411 (2.3) 104 (0.6) 1,579 (9.0) 190 (1.1)
1999 16,861 14,234 (84.4) 0 (0) 456 (2.7) 359 (2.1) 104 (0.6) 1,437 (8.5) 271 (1.6)
2000 15,784 13,407 (84.9) 0 (0) 406 (2.6) 397 (2.5) 112 (0.7) 1,294 (8.2) 168 (1.1)
2001 15,409 13,242 (85.9) 0 (0) 378 (2.5) 402 (2.6) 99 (0.6) 1,121 (7.3) 167 (1.1)
2002 14,564 12,482 (85.7) 0 (0) 336 (2.3) 412 (2.8) 87 (0.6) 1,080 (7.4) 167 (1.1)
2003 14,379 12,418 (86.4) 0 (0) 313 (2.2) 390 (2.7) 84 (0.6) 994 (6.9) 180 (1.3)
2004 14,080 12,118 (86.1) 0 (0) 337 (2.4) 370 (2.6) 82 (0.6) 975 (6.9) 198 (1.4)
2005 13,673 11,727 (85.8) 1 (0) 323 (2.4) 338 (2.5) 90 (0.7) 985 (7.2) 209 (1.5)
2006 13,317 11,541 (86.7) 0 (0) 292 (2.2) 358 (2.7) 79 (0.6) 939 (7.1) 108 (0.8)
2007 12,907 11,348 (87.9) 0 (0) 241 (1.9) 327 (2.5) 73 (0.6) 819 (6.3) 99 (0.8)
2008 12,552 10,887 (86.7) 7 (0.1) 256 (2.0) 329 (2.6) 78 (0.6) 843 (6.7) 152 (1.2)
2009 11,185 9,832 (87.9) 22 (0.2) 96 (0.9) 165 (1.5) 82 (0.7) 682 (6.1) 306 (2.7)
2010 10,835 9,543 (88.1) 29 (0.3) — — 159 (1.5) 64 (0.6) 657 (6.1) 383 (3.5)
2011 10,209 8,982 (88.0) 28 (0.3) — — 127 (1.2) 69 (0.7) 688 (6.7) 315 (3.1)
2012 9,674 8,502 (87.9) 31 (0.3) — — 123 (1.3) 57 (0.6) 607 (6.3) 354 (3.7)
2013 9,266 8,127 (87.7) 40 (0.4) — — 97 (1.0) 66 (0.7) 579 (6.2) 357 (3.9)
Table 12. Tuberculosis Cases and Percentages, by Reason Tuberculosis Therapy Was 






Moved2 Lost Refused Died3 Unknown4
1Includes all cases in persons reported as alive at diagnosis and taking one or more TB drugs.
2In 2009 the “moved” response option was removed from the RVCT’s reason therapy was stopped variable; see Technical Notes for 
details.
3Died = died of any cause (not only TB).
4Includes cases in persons reporting reason therapy stopped = other, missing, unknown, or moved (from 2010). 
Note: Data for all years are updated through June 9, 2016.
Data complete to 2013. See Technical Notes for details.




2004 14,499 11,327 5,954 (52.6)
2005 14,060 10,954 7,500 (68.5)
2006 13,728 10,745 7,529 (70.1)
2007 13,282 10,426 8,427 (80.8)
2008 12,893 10,022 8,179 (81.6)
2009 11,520 8,883 7,718 (86.9)
2010 11,159 8,458 7,749 (91.6)
2011 10,510 8,084 7,617 (94.2)
2012 9,942 7,630 7,234 (94.8)
2013 9,550 7,360 7,049 (95.8)
2014 9,406 7,235 6,981 (96.5)
2015 9,557 7,410 7,123 (96.1)




1Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate.
Note: This table reflects genotyping surveillance coverage for the 50 states and the District of Columbia; for genotyping surveillance 
coverage of the U.S.-affiliated areas, please see Table 14.











2004 288 213 19 (8.9)
2005 388 237 95 (40.1)
2006 344 211 84 (39.8)
2007 527 181 85 (47.0)
2008 553 240 72 (30.0)
2009 534 237 206 (86.9)
2010 618 309 279 (90.3)
2011 462 229 191 (83.4)
2012 493 247 225 (91.1)
2013 420 230 207 (90.0)
2014 462 234 219 (93.6)
2015 413 149 127 (85.2)
Table 14. National Tuberculosis Genotyping Surveillance Coverage1: 
United States’-Affiliated Areas2, 2004–2015
Genotype surveillance 
coverage 
1Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate 
2The U.S.-affiliated areas include: American Samoa, Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands, 










1M. bovis cases were defined predominantly by spoligotyping results with missing spacers 3, 9, 16, and 39–43. Data exclude cases of 
Bacillus Calmette-Guérin (BCG) M. bovis, which have x, y or z in the second MIRU position.
2This column reports all genotyped M. bovis cases, including those where origin of birth is unknown.
3Denominator is all M. bovis cases.
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(%) No. (%)3 No. (%)3
2004 5,954 73 (1.2) 23 (31.5) 50 (68.5)
2005 7,500 81 (1.1) 23 (28.4) 58 (71.6)
2006 7,529 116 (1.5) 25 (21.6) 90 (77.6)
2007 8,427 113 (1.3) 17 (15.0) 95 (84.1)
2008 8,179 129 (1.6) 29 (22.5) 100 (77.5)
2009 7,718 113 (1.5) 27 (23.9) 86 (76.1)
2010 7,749 108 (1.4) 20 (18.5) 88 (81.5)
2011 7,617 117 (1.5) 30 (25.6) 87 (74.4)
2012 7,234 109 (1.5) 18 (16.5) 91 (83.5)
2013 7,049 86 (1.2) 17 (19.8) 69 (80.2)
2014 6,981 107 (1.5) 24 (22.4) 83 (77.6)







Total  6,350 1,062 (16.7) 1,003 (15.8)  776 (12.2) 1,240 (19.5) 1,682 (26.5) 587 (9.2)
Mexico  1,254 115 (9.2) 84 (6.7)  115 (9.2) 300 (23.9) 488 (38.9) 152 (12.1)
Philippines  820 110 (13.4) 81 (9.9)  100 (12.2) 167 (20.4) 277 (33.8) 85 (10.4)
India  579 122 (21.1) 125 (21.6)  86 (14.9) 113 (19.5) 94 (16.2) 39 (6.7)
Vietnam  519 53 (10.2) 60 (11.6)  69 (13.3) 80 (15.4) 185 (35.6) 72 (13.9)
China  426 48 (11.3) 70 (16.4)  52 (12.2) 100 (23.5) 118 (27.7) 38 (8.9)
Guatemala  189 41 (21.7) 52 (27.5)  31 (16.4) 25 (13.2) 22 (11.6) 18 (9.5)
Haiti  166 26 (15.7) 34 (20.5)  24 (14.5) 36 (21.7) 32 (19.3) 14 (8.4)
Ethiopia  143 36 (25.2) 44 (30.8)  29 (20.3) 24 (16.8) 6 (4.2) 4 (2.8)
Honduras  140 42 (30.0) 37 (26.4)  19 (13.6) 25 (17.9) 13 (9.3) 4 (2.9)
Myanmar  120 42 (35.0) 46 (38.3)  21 (17.5) 5 (4.2) 4 (3.3) 2 (1.7)
El Salvador  109 16 (14.7) 17 (15.6)  14 (12.8) 23 (21.1) 28 (25.7) 11 (10.1)
Korea, Republic of  94 3 (3.2) 6 (6.4)  6 (6.4) 25 (26.6) 50 (53.2) 4 (4.3)
Cambodia  86 3 (3.5) 4 (4.7)  5 (5.8) 8 (9.3) 44 (51.2) 22 (25.6)
Pakistan  85 23 (27.1) 18 (21.2)  12 (14.1) 11 (12.9) 15 (17.6) 6 (7.1)
Somalia  85 29 (34.1) 18 (21.2)  11 (12.9) 21 (24.7) 2 (2.4) 4 (4.7)
Peru  80 10 (12.5) 11 (13.8)  5 (6.3) 33 (41.3) 20 (25.0) 1 (1.3)
Nepal  79 18 (22.8) 30 (38.0)  23 (29.1) 7 (8.9) 1 (1.3) 0 (0)
Nigeria  74 24 (32.4) 23 (31.1)  11 (14.9) 7 (9.5) 5 (6.8) 4 (5.4)
Ecuador  70 14 (20.0) 6 (8.6)  13 (18.6) 20 (28.6) 8 (11.4) 9 (12.9)
Bangladesh  67 16 (23.9) 22 (32.8)  8 (11.9) 12 (17.9) 6 (9.0) 3 (4.5)
Laos  66 3 (4.5) 1 (1.5) 0 (0) 8 (12.1) 46 (69.7) 8 (12.1)
Dominican Republic  65 6 (9.2) 15 (23.1)  6 (9.2) 10 (15.4) 23 (35.4) 5 (7.7)
Kenya  50 16 (32.0) 14 (28.0)  7 (14.0) 9 (18.0) 2 (4.0) 2 (4.0)
Bhutan  46 17 (37.0) 19 (41.3)  9 (19.6) 0 (0) 0 (0) 1 (2.2)
Colombia  45 8 (17.8) 6 (13.3)  3 (6.7) 11 (24.4) 15 (33.3) 2 (4.4)
Liberia  40 11 (27.5) 10 (25.0)  10 (25.0) 6 (15.0) 2 (5.0) 1 (2.5)
Indonesia  39 9 (23.1) 7 (17.9)  4 (10.3) 9 (23.1) 6 (15.4) 4 (10.3)
Thailand  39 8 (20.5) 10 (25.6)  4 (10.3) 3 (7.7) 11 (28.2) 3 (7.7)
Congo  37 25 (67.6) 7 (18.9) 0 (0) 1 (2.7) 0 (0) 4 (10.8)
Cuba  32 9 (28.1) 1 (3.1)  3 (9.4) 7 (21.9) 10 (31.3) 2 (6.3)
All others4  706 159 (22.5) 125 (17.7)  76 (10.8) 134 (19.0) 149 (21.1) 63 (8.9)
 Table 16. Tuberculosis Cases and Percentages Among Foreign-Born Persons1, by the Top 30 





1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
2Ranked by total case count.
3Among foreign-born persons, the number of years since arrival in the United States before diagnosis with tuberculosis.
4Includes not specified for country of origin. 
See Surveillance Slide #20.
<1 Year 1–4 5–9 10–19 >20 Unknown/ 
missing
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
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Age group
Table 17. Tuberculosis Cases and Rates per 100,000 Population, by Hispanic Ethnicity and Non-Hispanic Race, Sex, and 
Age Group: United States, 2015
Total cases 9,557 3.0 244 1.2 196 0.5 935 2.1 2,858 3.4 3,028 3.6 2,294 4.8 2        —
Male 5,724 3.6 122 1.2 95 0.5 518 2.3 1,592 3.7 1,992 4.9 1,405 6.7 0        —
Female 3,827 2.3 122 1.3 101 0.5 416 1.9 1,264 3.0 1,035 2.4 889 3.3 0        —
Unknown 6       —  0         — 0           —  1          — 2        — 1        — 0        — 2        —
Hispanic/Latino1 2,694 4.8 106 2.1 70 0.7 305 3.2 926 5.4 802 7.4 484 12.8 1        —
Male 1,677 5.9 49 1.9 31 0.6 187 3.8 593 6.7 540 10.0 277 17.0 0        —
Female 1,016 3.6 57 2.3 39 0.8 118 2.6 333 4.0 262 4.8 207 9.7 0        —
Unknown 1       —  0         — 0           — 0          — 0        — 0        — 0        — 1        —
American Indian/Alaska Native 145 6.1 5 3.0 11 3.1 11 2.9 35 5.5 57 9.7 26 10.6 0        —
Male 88 7.5 2 2.3 9 5.1 6 3.1 21 6.6 36 12.9 14 12.7 0        —
Female 57 4.7 3 3.7 2 1.2 5 2.7 14 4.4 21 6.9 12 8.9 0        —
Unknown 0       —  0         — 0           — 0          — 0        — 0        — 0        — 0        —
Asian 3,177 18.2 38 3.9 44 2.2 301 13.2 887 15.3 961 22.2 945 47.0 1        —
Male 1,776 21.5 20 4.0 24 2.4 155 13.4 422 15.3 577 29.0 578 66.4 0        —
Female 1,399 15.3 18 3.8 20 2.0 146 12.9 465 15.2 383 16.4 367 32.2 0        —
Unknown 2       —  0         — 0           — 0          — 0        — 1        — 0        — 1        —
Black/African American 1,995 5.0 57 2.1 52 0.9 222 3.5 659 6.0 695 7.0 310 7.4 0        —
Male 1,195 6.3 29 2.1 22 0.8 118 3.6 360 6.8 474 10.3 192 11.4 0        —
Female 798 3.8 28 2.1 30 1.1 103 3.3 298 5.2 221 4.2 118 4.7 0        —
Unknown 2       —  0         — 0           — 1          — 1        — 0        — 0        — 0        —
Race/ethnicity and sex
All ages
Under 5 5–14 15–24 25–44 45–64 >65 Unknown
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
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Native Hawaiian/Other Pacific Islander 102 18.2 14 34.7 6 7.4 20 22.9 41 22.7 13 10.5 8 17.4 0        —
Male 46 16.3 4 19.1 3 7.2 11 24.5 19 20.6 7 11.4 2 9.4 0        —
Female 56 20.2 10 51.5 3 7.5 9 21.2 22 25.0 6 9.6 6 24.4 0        —
Unknown 0       —  0         — 0           — 0          — 0        — 0        — 0        — 0        —
White 1,251 0.6 19 0.2 10 0.0 53 0.2 228 0.5 467 0.8 474 1.3 0        —
Male 831 0.9 13 0.3 6 0.1 28 0.2 126 0.5 339 1.2 319 1.9 0        —
Female 420 0.4 6 0.1 4 0.0 25 0.2 102 0.4 128 0.4 155 0.8 0        —
Unknown 0       —  0         — 0           — 0          — 0        — 0        — 0        — 0        —
Multiple race2 167 2.5 5 0.5 1 0.1 19 1.5 74 5.1 28 3.2 40 11.6 0        —
Male 98 3.0 5 1.0 0 0.0 10 1.5 47 6.8 15 3.6 21 13.8 0        —
Female 68 2.0 0 0.0 1 0.1 9 1.4 26 3.4 13 2.8 19 9.9 0        —
Unknown 1       —  0         — 0           — 0          — 1        — 0        — 0        — 0        —
Unknown 26       —  0         — 2           — 4          — 8        — 5        — 7        — 0        —
Male 13       —  0         — 0           — 3          — 4        — 4        — 2        — 0        —
Female 13       —  0         — 2           — 1          — 4        — 1        — 5        — 0        —
Unknown 0       —  0         — 0           — 0          — 0        — 0        — 0        — 0        —
1Persons of Hispanic/Latino origin may be of any or multiple race.
2Indicates two or more races reported for a person, and does not include persons of Hispanic/Latino origin.         
Note: Denominators for computing 2015 case rates were obtained from the U.S. Census Annual Estimates of the Resident Population by Sex, Age, Race, and Hispanic Origin: April 1, 2010 to 
July 1, 2015 (http://www.census.gov/popest/data/national/asrh/2015/index.html); accessed July 20, 2016. 
Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) are mutually exclusive and do not include 
persons of Hispanic/Latino origin or multiple race.
See Technical Notes.                 
See Surveillance Slides #9 and #11.                 
Table 17. (Con’t) Tuberculosis Cases and Rates per 100,000 Population, by Hispanic Ethnicity and Non-Hispanic Race, Sex, and 




Under 5 5–14 15–24 25–44 45–64 >65 Unknown
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
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Total cases 3,186 212 132 296 666 1,133 747 0
Male 2,044 104 61 147 400 827 505 0
Female 1,141 108 71 148 266 306 242 0
Unknown 1 0 0 1 0 0 0 0
Hispanic/Latino1 658 100 55 105 167 142 89 0
Male 388 44 24 50 115 100 55 0
Female 270 56 31 55 52 42 34 0
Unknown 0 0 0 0 0 0 0 0
American Indian/Alaska Native 140 5 10 11 32 56 26 0
Male 85 2 8 6 19 36 14 0
Female 55 3 2 5 13 20 12 0
Unknown 0 0 0 0 0 0 0 0
Asian 137 26 20 36 28 18 9 0
Male 73 15 9 19 13 11 6 0
Female 64 11 11 17 15 7 3 0
Unknown 0 0 0 0 0 0 0 0
Black/African American 1,143 46 31 84 250 490 242 0
Male 753 24 12 43 148 367 159 0
Female 389 22 19 40 102 123 83 0
Unknown 1 0 0 1 0 0 0 0
Native Hawaiian/Other Pacific Islander 88 14 6 19 35 10 4 0
Male 42 4 3 10 19 5 1 0
Female 46 10 3 9 16 5 3 0
Unknown 0 0 0 0 0 0 0 0
White 990 17 9 36 147 409 372 0
Male 685 11 5 17 83 303 266 0
Female 305 6 4 19 64 106 106 0
Unknown 0 0 0 0 0 0 0 0
Multiple race2 25 4 1 5 6 5 4 0
Male 14 4 0 2 3 2 3 0
Female 11 0 1 3 3 3 1 0
Unknown 0 0 0 0 0 0 0 0
Unknown 5 0 0 0 1 3 1 0
Male 4 0 0 0 0 3 1 0
Female 1 0 0 0 1 0 0 0
Unknown 0 0 0 0 0 0 0 0
Age group
Race/ethnicity and sex All ages Under 5 5–14 15–24 25–44 45–64 >65 Unknown
Table 18. Tuberculosis Cases Among U.S.-Born Persons, by Hispanic Ethnicity and 
Non-Hispanic Race, Sex, and Age Group: United States, 2015
1Persons of Hispanic/Latino origin may be of any or multiple race.          
2Indicates two or more races reported for a person and does not include persons of Hispanic/Latino origin.
Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific 
Islander, and white) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. 
See Technical Notes.
See Surveillance Slide #15.
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).          
2Persons of Hispanic ethnicity may be of any race or multiple race.             
3Indicates two or more races reported for a person and does not include persons of Hispanic/Latino origin.
Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific 
Islander, and white) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. 
See Technical Notes.
See Surveillance Slide #15.
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Age group
Table 19. Tuberculosis Cases Among Foreign-Born Persons1, by Hispanic Ethnicity and 
Non-Hispanic Race, Sex, and Age Group: United States, 2015
Race/ethnicity and sex All ages Under 5 5–14 15–24 25–44 45–64 >65 Unknown
Total cases 6,350 32 63 639 2,182 1,890 1,542 2
Male 3,665 18 33 371 1,185 1,162 896 0
Female 2,680 14 30 268 995 727 646 0
Unknown 5 0 0 0 2 1 0 2
Hispanic/Latino2 2,030 6 15 200 756 659 393 1
Male 1,284 5 7 137 475 440 220 0
Female 745 1 8 63 281 219 173 0
Unknown 1 0 0 0 0 0 0 1
American Indian/Alaska Native 1 0 0 0 1 0 0 0
Male 0 0 0 0 0 0 0 0
Female 1 0 0 0 1 0 0 0
Unknown 0 0 0 0 0 0 0 0
Asian 3,033 12 24 265 857 941 933 1
Male 1,698 5 15 136 408 564 570 0
Female 1,333 7 9 129 449 376 363 0
Unknown 2 0 0 0 0 1 0 1
Black/African American 851 11 21 138 408 205 68 0
Male 442 5 10 75 212 107 33 0
Female 408 6 11 63 195 98 35 0
Unknown 1 0 0 0 1 0 0 0
Native Hawaiian/Other Pacific Islander 14 0 0 1 6 3 4 0
Male 4 0 0 1 0 2 1 0
Female 10 0 0 0 6 1 3 0
Unknown 0 0 0 0 0 0 0 0
White 259 2 1 17 80 57 102 0
Male 144 2 1 11 42 35 53 0
Female 115 0 0 6 38 22 49 0
Unknown 0 0 0 0 0 0 0 0
Multiple race3 141 1 0 14 67 23 36 0
Male 84 1 0 8 44 13 18 0
Female 56 0 0 6 22 10 18 0
Unknown 1 0 0 0 1 0 0 0
Unknown 21 0 2 4 7 2 6 0
Male 9 0 0 3 4 1 1 0
Female 12 0 2 1 3 1 5 0
Unknown 0 0 0 0 0 0 0 0
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Algeria 2 Ethiopia 143 Niger 1
Angola 6 Gabon 0 Nigeria 74
Benin 1 Gambia 7 Rwanda 5
Botswana 0 Ghana 14 Sao Tome and Principe 0
Burkina Faso 4 Guinea 11 Senegal 10
Burundi 5 Guinea-Bissau 0 Seychelles 0
Cameroon 24 Kenya 50 Sierra Leone 18
Cape Verde 0 Lesotho 0 South Africa 12
Central African Republic 3 Liberia 40 Swaziland 0
Chad 1 Madagascar 2 Tanzania, United Republic of 3
Comoros 1 Malawi 4 Togo 5
Congo, Republic of 37 Mali 1 Uganda 12
Côte d'Ivoire 5 Mauritania 1 Zambia 8
Congo, Dem. Republic of 6 Mauritius 1 Zimbabwe 10
Equatorial Guinea 2 Mozambique 4   
Eritrea 19 Namibia 0
Anguilla 0 Costa Rica 1 Netherland Antilles 0
Antigua and Barbuda 0 Cuba 32 Nicaragua 16
Argentina 1 Dominica 0 Panama 1
Bahamas 0 Dominican Republic 65 Paraguay 0
Barbados 0 Ecuador 70 Peru 80
Belize 1 El Salvador 109 St. Kitts and Nevis 2
Bermuda 0 Grenada 1 St. Lucia 1
Bolivia 14 Guatemala 189 St. Vincent & Grenadines 2
Brazil 20 Guyana 23 Suriname 0
British Virgin Islands 0 Haiti 166 Trinidad and Tobago 6
Canada 2 Honduras 140 Turks and Caicos Islands 0
Cayman Islands 0 Jamaica 13 Uruguay 1
Chile 2 Mexico 1,254 Venezuela 13
Colombia 45 Montserrat 0
  
 
Afghanistan 27 Lebanon 2 Sudan 12
Bahrain 0 Libyan Arab Jamahiriya 0 Syrian Arab Republic 2
Djibouti 3 Morocco 10 Tunisia 0
Egypt 3 Oman 0 United Arab Emirates 3
Iran, Islamic Republic of 20 Pakistan 85 West Bank and Gaza 0
Iraq 11 Qatar 1 Yemen 7
Jordan 1 Saudi Arabia 11
Kuwait 5 Somalia 85
Eastern Mediterranean Region
Total cases = 288
Table 20. Tuberculosis Cases Among Foreign-Born Persons1, by WHO Region and Country 
of Birth2: United States, 2015
African Region
Total cases = 552
Americas Region
Total cases = 2,270
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
2Country as reported by patient.
3Includes country codes currently reported via the National Tuberculosis Surveillance System that are not represented by WHO member 
states.
Note: Regional composition of countries based on WHO Report Global Tuberculosis Report 2015, World Health Organization  
(http://www.who.int/tb/publications/global_report/en/).
Korea, DPR, Democratic People’s Republic of Korea.
Lao PDR, Lao People’s Democratic Republic.
Macedonia TFYR, the former Yugoslav Republic of Macedonia.
WHO, World Health Organization.
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Albania 8  Greece 2 Poland 7
Andorra 0 Hungary 1  Portugal 4
Armenia 0 Iceland 0 Romania 10
Austria 0 Ireland 1 Russian Federation 20
Azerbaijan 2 Israel 0 San Marino 0
Belarus 1 Italy 6 Serbia 2
Belgium 1 Kazakhstan 1 Slovakia 0
Bosnia and Herzegovina 14 Kyrgyzstan 1 Slovenia 0
Bulgaria 0 Latvia 0 Spain 1
Croatia 2 Lithuania 0 Sweden 0
Cyprus 0 Luxembourg 0 Switzerland 0
Czech Republic 1 Macedonia, TFYR 1 Tajikistan 0
Denmark 1 Malta 0 Turkey 6
Estonia 0 Moldova, Republic of 3 Turkmenistan 0
Finland 2 Monaco 0 Ukraine 13
France 3 Montenegro 1 United Kingdom 2
Georgia 2 Netherlands 0 Uzbekistan 2
Germany 6 Norway 1
Bangladesh 67 Korea, DPR 27 Sri Lanka 4
Bhutan 46 Maldives 0 Thailand 39
India 579 Myanmar 120 Timor-Leste 0
Indonesia 39 Nepal 79
Australia 0 Kiribati 1 Philippines 820
Brunei Darussalam 0 Korea, Republic of 94 Samoa 0
Cambodia 86 Lao PDR 66 Singapore 0
China 426 Malaysia 8 Solomon Islands 0
China, Hong Kong SAR 22 Mongolia 11 Tokelau 0
China, Macao SAR 1 Nauru 0 Tonga 4
Cook Islands 0 New Caledonia 0 Tuvalu 0
Fiji 2 New Zealand 0 Vanuatu 1
French Polynesia 0 Niue 0 Vietnam 519
Japan 4 Papua New Guinea 2 Wallis and Futuna 0
Table 20. (Cont’d) Tuberculosis Cases Among Foreign-Born Persons1, by WHO Region and 
Country of Birth2: United States, 2015
European Region
Total cases = 128
Other3
Total Cases = 28
Unknown
Total cases = 17
Southeast Asia Region
Total cases = 1,000
Western Pacific Region
Total cases = 2,067
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Table 21. Tuberculosis Risk Factors1, by Origin and Race/Ethnicity: United States, 2015
United States 9,536 13 (0.1) 66 (0.7) 701 (7.4) 202 (2.1) 52 (0.5) 39 (0.4) 1,485 (15.6) 199 (2.1) 406 (4.3) 2,186 (22.9) 4,246 (44.5) 681 (7.1)
U.S.-born total 3,186 7 (0.2) 53 (1.7) 472 (14.8) 91 (2.9) 20 (0.6) 16 (0.5) 374 (11.7) 63 (2.0) 164 (5.1) 844 (26.5) 1,267 (39.8) 135 (4.2)
American Indian/
Alaska Native 140 0 (0) 8 (5.7) 46 (32.9) 9 (6.4) 1 (0.7) 0 (0) 19 (13.6) 3 (2.1) 4 (2.9) 21 (15.0) 56 (40.0) 6 (4.3)
Asian 137 0 (0) 0 (0) 32 (23.4) 3 (2.2) 0 (0) 0 (0) 6 (4.4) 0 (0) 2 (1.5) 22 (16.1) 66 (48.2) 9 (6.6)
Black/African 
American 1,143 1 (0.1) 26 (2.3) 156 (13.6) 46 (4.0) 4 (0.3) 5 (0.4) 139 (12.2) 33 (2.9) 45 (3.9) 325 (28.4) 443 (38.8) 54 (4.7)
Hispanic/Latino3 658 4 (0.6) 7 (1.1) 122 (18.5) 9 (1.4) 3 (0.5) 3 (0.5) 84 (12.8) 7 (1.1) 19 (2.9) 155 (23.6) 264 (40.1) 33 (5.0)




88 0 (0) 0 (0) 34 (38.6) 0 (0) 0 (0) 0 (0) 17 (19.3) 0 (0) 1 (1.1) 12 (13.6) 28 (31.8) 0 (0)
White 990 2 (0.2) 12 (1.2) 79 (8.0) 22 (2.2) 12 (1.2) 8 (0.8) 104 (10.5) 19 (1.9) 92 (9.3) 302 (30.5) 398 (40.2) 32 (3.2)






























No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1Includes the number of risk factors reported (which may be more than one per case) and the number of cases with no information on additional risk factors. The sum of risk factors is greater 
than the total number of cases because more than one risk factor may be selected per case.
2Excludes TB risk factor information for 21 cases with unknown origin.
3Persons of Hispanic/Latino origin may be of any or multiple race.
4Indicates two or more races reported for a person, and does not include persons of Hispanic/Latino origin.         
Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) are mutually exclusive and do not 









total 6,350 6 (0.1) 13 (0.2) 229 (3.6) 111 (1.7) 32 (0.5) 23 (0.4) 1111 (17.5) 136 (2.1) 242 (3.8) 1342 (21.1) 2979 (46.9) 546 (8.6)
American Indian/
Alaska Native 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0.0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
Asian 3,033 3 (0.1) 6 (0.2) 100 (3.3) 52 (1.7) 18 (0.6) 15 (0.5) 569 (18.8) 86 (2.8) 124 (4.1) 654 (21.6) 1358 (44.8) 291 (9.6)
Black/African 
American 851 0 (0) 2 (0.2) 29 (3.4) 33 (3.9) 2 (0.2) 2 (0.2) 55 (6.5) 7 (0.8) 24 (2.8) 160 (18.8) 484 (56.9) 86 (10.1)
Hispanic/Latino3 2,030 3 (0.1) 4 (0.2) 86 (4.2) 21 (1.0) 9 (0.4) 5 (0.2) 430 (21.2) 41 (2.0) 78 (3.8) 414 (20.4) 937 (46.2) 127 (6.3)
Multiple races4 141 0 (0) 0 (0) 3 (2.1) 0 (0) 1 (0.7) 0 (0) 22 (15.6) 0 (0) 3 (2.1) 51 (36.2) 61 (43.3) 8 (5.7)
Native Hawaiian/
 Other Pacific 
Islander
14 0 (0) 0 (0) 2 (14.3) 0 (0) 0 (0) 0 (0) 1 (7.1) 0 (0) 0 (0) 3 (21.4) 7 (50.0) 1 (7.1)
White 259 0 (0) 1 (0.4) 8 (3.1) 4 (1.5) 2 (0.8) 1 (0.4) 32 (12.4) 2 (0.8) 13 (5.0) 57 (22.0) 123 (47.5) 27 (10.4)
Unknown 21 0 (0) 0 (0) 1 (4.8) 1 (4.8) 0 (0) 0 (0) 2 (9.5) 0 (0) 0 (0) 3 (14.3) 8 (38.1) 6 (28.6)

























No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
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Table 22. Epidemiologic Characteristics of Cases in GENType Clusters1, by Alert Levels Based on Log-Likelihood Ratios (LLR)2: 
United States, 2013–2015
Total 16,540 (78.5) 4,529 (21.5) 2,524 (55.7) 1,117 (24.7) 888 (19.6)
Race and ethnicity
Hispanic/Latino 4,546 (76.4) 1,402 (23.6) 860 (61.3) 373 (26.6) 169 (12.1)
American Indian/Alaska Native 148 (46.7) 169 (53.3) 16 (9.5) 32 (18.9) 121 (71.6)
Asian 6,070 (86.5) 947 (13.5) 797 (84.2) 91 (9.6) 59 (6.2)
Black/African American 2,985 (69.6) 1,303 (30.4) 541 (41.5) 364 (27.9) 398 (30.5)
Native Hawaiian/Other Pacific Islander 88 (52.4) 80 (47.6) 24 (30.0) 35 (43.8) 21 (26.3)
White 2,347 (80.2) 579 (19.8) 253 (43.7) 212 (36.6) 114 (19.7)
Multiple race 318 (88.1) 43 (11.9) 30 (69.8) 8 (18.6) 5 (11.6)
Unknown or missing 38 (86.4) 6 (13.6) 3 (50.0) 2 (33.3) 1 (16.7)
Age group (years)
0–4 78 (38.6) 124 (61.4) 56 (45.2) 41 (33.1) 27 (21.8)
5–14 108 (59.3) 74 (40.7) 30 (40.5) 19 (25.7) 25 (33.8)
15–24 1,589 (73.8) 564 (26.2) 317 (56.2) 139 (24.7) 108 (19.2)
25–44 5,042 (78.0) 1,420 (22.0) 778 (54.8) 375 (26.4) 267 (18.8)
45–64 5,005 (74.7) 1,692 (25.3) 869 (51.4) 432 (25.5) 391 (23.1)
≥65  4,717 (87.8) 655 (12.2) 474 (72.4) 111 (17.0) 70 (10.7)
Unknown 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
Origin of birth
U.S-born 4,415 (64.0) 2,485 (36.0) 956 (38.5) 773 (31.1) 756 (30.4)
Foreign-born 12,107 (85.6) 2,030 (14.4) 1,562 (77.0) 343 (16.9) 125 (6.2)
Unknown or missing 18 (56.3) 14 (43.8) 6 (42.9) 1 (7.1) 7 (50.0)
Disease site
Pulmonary only 11,764 (76.5) 3,611 (23.5) 1,966 (54.4) 915 (25.3) 730 (20.2)
Extrapulmonary 2,939 (86.8) 449 (13.3) 300 (66.8) 87 (19.4) 62 (13.8)
Both 1,832 (79.7) 467 (20.3) 256 (54.8) 115 (24.6) 96 (20.6)
Unknown 5 (71.4) 2 (28.6) 2 (100.0) 0 (0) 0 (0)
Sputum smear 
Positive 7,773 (75.6) 2,503 (24.4) 1,363 (54.5) 651 (26.0) 489 (19.5)
Negative 6,669 (80.7) 1,600 (19.4) 923 (57.7) 359 (22.4) 318 (19.9)
Not done 2,087 (83.1) 425 (16.9) 237 (55.8) 107 (25.2) 81 (19.1)
Unknown or missing 11 (91.7) 1 (8.3) 1 (100.0) 0 (0) 0 (0)
Cavitary disease
Yes 174 (80.2) 43 (19.8) 25 (58.1) 12 (27.9) 6 (14.0)
No 1,289 (78.4) 356 (21.6) 191 (53.7) 90 (25.3) 75 (21.1)









No. (%) No. (%) No. (%)
Alert levels for clustered cases3
No. (%) No. (%)
1GENType clusters have two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat type within a county during the 
specified 3-year time period.
2Alert levels are based on a log-likelihood ratio (LLR), which calculates the geographic concentration of a genotype in a county compared to the rest of the country during a 3-year period. 
3There were 4,529 cases in 1,464 alerted clusters: 888 cases were in 83 (5.7%) high alert clusters; 1,117 cases were in 345 (23.6%) medium alert clusters, and 2,524 cases were in 1,036 
(70.8%) nonalert clusters. 
Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) are mutually exclusive and do not 
include persons of Hispanic ethnicity or multiple race. Multiple race does not include persons of Hispanic ethnicity.
See Surveillance Slide #36
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Homeless within past year
Yes 626 (50.2) 620 (49.8) 213 (34.4) 154 (24.8) 253 (40.8)
No 15,806 (80.3) 3,889 (19.8) 2,299 (59.1) 957 (24.6) 633 (16.3)
Unknown or missing 108 (84.4) 20 (15.6) 12 (60.0) 6 (30.0) 2 (10.0)
Excess alcohol use within the past year
Yes 1,472 (60.7) 955 (39.4) 377 (39.5) 280 (29.3) 298 (31.2)
No 14,857 (80.9) 3,516 (19.1) 2,113 (60.1) 822 (23.4) 581 (16.5)
Unknown or missing 211 (78.4) 58 (21.6) 34 (58.6) 15 (25.9) 9 (15.5)
Injecting illicit drug use within past year
Yes 184 (55.6) 147 (44.4) 67 (45.6) 40 (27.2) 40 (27.2)
No 16,188 (78.9) 4,323 (21.1) 2,423 (56.1)  1,062 (24.6) 838 (19.4)
Unknown or missing 168 (74.0) 59 (26.0) 34 (57.6) 15 (25.4) 10 (16.9)
Noninjecting illicit drug use Within past year
Yes 883 (55.4) 711 (44.6) 277 (39.0) 205 (28.8) 229 (32.2)
No 15,485 (80.5) 3,762 (19.6) 2,217 (58.9) 895 (23.8) 650 (17.3)
Unknown or missing 172 (75.4) 56 (24.6) 30 (53.6) 17 (30.4) 9 (16.1)
Resident of a correctional facility at the time of diagnosis
Yes 524 (70.2) 222 (29.8) 103 (46.4) 56 (25.2) 63 (28.4)
No 15,975 (78.8) 4,298 (21.2) 2,416 (56.2) 1,059 (24.6) 823 (19.2)
Unknown or missing 41 (82.0) 9 (18.0) 5 (55.6) 2 (22.2) 2 (22.2)
HIV status
Positive 832 (71.6) 330 (28.4) 170 (51.5) 78 (23.6) 82 (24.9)
Negative 13,787 (78.3) 3,814 (21.7) 2,110 (55.3) 956 (25.1) 748 (19.6)
Refused testing 562 (84.3) 105 (15.7) 70 (66.7) 20 (19.1) 15 (14.3)
Testing not offered 1,003 (81.2) 232 (18.8) 140 (60.3) 56 (24.1) 36 (15.5)
Unknown, missing or indeterminate 356 (88.1) 48 (11.9) 34 (70.8) 7 (14.6) 7 (14.6)
Multidrug-resistant TB
Yes 237 (87.5) 34 (12.6) 30 (88.2) 2 (5.9) 2 (5.9)
No 15,954 (78.3) 4,410 (21.7) 2,453 (55.6) 1,088 (24.7) 869 (19.7)
Unknown or missing 349 (80.4) 85 (19.6) 41 (48.2) 27 (31.8) 17 (20.0)
Table 22. (Con’t) Epidemiologic Characteristics of Cases in GENType Clusters1, by Alert Levels Based on Log-Likelihood Ratios 









No. (%) No. (%) No. (%)
Alert levels for clustered cases3





Table 23. Tuberculosis Cases, by Cluster Status1: United States, 2013–2015
1Cluster status indicates whether a case is unique or clustered within a county for cases with a valid GENType. 
2A unique case is a case with a GENType (spoligotype and 24 locus mycobacterial interspersed repetitive unit-variable number tandem 
repeat type) that does not match any other case in that county during the specified three-year time period.
3Clustered cases are defined as two or more cases with same GENType within a county during the specified 3-year time period.






Total 1,464 (100.0) 4,529 (100.0)
2-case cluster 958 (65.4) 1,916 (42.3)
3-case cluster 233 (15.9) 699 (15.4)
4-case cluster 115 (7.9) 460 (10.2)
5-case cluster 48 (3.3) 240 (5.3)
6-case cluster 31 (2.1) 186 (4.1)
7-case cluster 14 (1.0) 98 (2.2)
8-case cluster 17 (1.2) 136 (3.0)
9-case cluster 10 (0.7) 90 (2.0)
≥10-case cluster 38 (2.6) 704 (15.5)
Table 24. Tuberculosis Cases and Clusters, by Cluster Size1: United States, 2013–2015
1Clusters have two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat type (GENType) within a county during the specified 3-year time period.
2Cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat type (GEN-
Type) are members of a cluster within a county during the specified 3-year time period.
3Denominator is total number of clusters.
4Denominator is total number of cases.






1GENType is defined as a unique combination of spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat (MIRU-VNTR) type.
2PCRType is defined as a unique combination of spoligotype and 12-locus MIRU-VNTR; every GENType has a corresponding PCRType.
3Among 21,153 cases with GENTypes during 2013–2015.
4This table reflects common GENTypes for the 50 states and the District of Columbia; for common GENTypes in the U.S.-affiliated areas, 
please see Table 26.
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G00010 PCR00002 000000000003771 223325173533 444534423428 177 (0.8) 21
G00012 PCR00002 000000000003771 223325173533 445644423328 164 (0.8) 26
G00016 PCR00041 677777477413771 254326223432 14a843263217 136 (0.6) 23
G05056 PCR00041 677777477413771 254326223432 14a943263217 121 (0.6) 27
G00013 PCR00016 700036777760731 222325143223 434534412334 87 (0.4) 20
G00017 PCR00803 000000000003771 222325173533 445644423328 73 (0.3) 17
G00011 PCR00015 777776777760601 224325153323 444234423337 71 (0.3) 21
G10345 PCR00160 777776777760601 224325143323 244234423337 66 (0.3) 7
G00019 PCR00309 000000000003771 222325173543 445644423328 65 (0.3) 18
G05625 PCR00231 700036777760771  222325133223  234634413334 64 (0.3) 6
G00015 PCR11884 000000000003771 223326171531 445544423228 63 (0.3) 11
G12500 PCR00617 777777607760771 224226153321 543424115228 63 (0.3) 11
G11610 PCR08263 777777377560771 223425153322 242524223324 57 (0.3) 4
G00617 PCR00001 000000000003771 223321153643 344334233339 52 (0.2) 13
G01521 PCR01201 000000000003771 223325173534 244544423239 51 (0.2) 5
G10508 PCR00015 777776777760601 224325153323 43-234422333 49 (0.2) 6
G00020 PCR01328 776377777760751 333325153222 351544223229 48 (0.2) 7
G00846 PCR00093 000000000003771 223325163533 445644423328 48 (0.2) 16
G00018 PCR00036 000000000003771 223425173563 344644623337 47 (0.2) 13
G00769 PCR00224 000000000003771 223325163333 444344223437 46 (0.2) 9
G08735 PCR00143 777000377760771 225125113322 143134423337 46 (0.2) 19
G00014 PCR00051 776037777760771 223125163324 242434223525 44 (0.2) 10
G01363 PCR00002 000000000003771 223325173533 445544423328 43 (0.2) 15
G00734 PCR00091 000000000003771 223325153533 445644423328 38 (0.2) 16
G05637 PCR00769 700036777760771 222325143223 234634413334 36 (0.2) 10
 Table 25. Twenty-Five Most Frequently Reported GENTypes1 Among Genotyped Tuberculosis 
Cases: United States, 2013–2015
PCRType2 Spoligotype 24-locus MIRU-VNTR








G00017 PCR00803 000000000003771 222325173533  445644423328 124 (21.9) 4
G01284 PCR00002 000000000003771 223325173533  44474442334A 12 (2.1) 3
G01967 PCR03284 000000007720771 225413153223 133532423434 12 (2.1) 1
G04942 PCR00041 677777477413771  254326223432  149843263217 12 (2.1) 3
G04701 PCR00117 677777477413771 254326223422 147843263217 10 (1.7) 2
 Table 26. Five Most Frequently Reported GENTypes1 Among Genotyped Tuberculosis Cases: 
United States’-Affiliated Areas2, 2013–2015
PCRType3 Spoligotype 24-locus MIRU-VNTR






1GENType is defined as a unique combination of spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number 
tandem repeat (MIRU-VNTR) type. 
2The U.S.-affiliated areas include: American Samoa, Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands, 
Palau, Puerto Rico, and U.S. Virgin Islands.
3PCRType is defined as a unique combination of spoligotype and 12-locus MIRU-VNTR; every GENType has a corresponding PCRType.







1Includes patients who were alive at diagnosis, started on treatment, and moved in state.
2Includes patients who were alive at diagnosis, started on treatment, and moved out of state.
3Includes patients who were alive at diagnosis, started on treatment, and moved out of the country; transnational referrals were provided 
for 230 (62.7%) TB patients who moved out of the country.
4Therapy was discontinued for a known reason other than those listed (e.g., patient moved outside the United States, or patient moved 
from state A to state B, and although state A notified state B, state B never followed up).
Note: There may be differences in the way jurisdictions determine treatment completion for patients who moved out of the country; some 
reporting jurisdictions may be classifying all patients who moved out of the country as ‘other’ for reason therapy stopped.
Moving in and out of state or country is not mutually exclusive. Two patients moved twice, and one patient moved but did not indicate 
moving in state, out of state or out of country.
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Moved in state1 320 268 (83.8) 1 (0.3) 8 (2.5) 1 (0.3) 14 (4.4) 27 (8.4) 1 (0.3)
Moved out of 
state2 293 239 (81.6) 0 (0) 17 (5.8) 3 (1.0) 5 (1.7) 25 (8.5) 4 (1.4)
Moved out of 
country3 367 147 (40.1) 3 (0.8) 21 (5.7) 4 (1.1) 7 (1.9) 167 (45.5) 17 (4.6)
Did not move 8,033 7,310 (91.0) 35 (0.4) 52 (0.6) 54 (0.7) 536 (6.7) 26 (0.3) 20 (0.2)
Unknown if 
moved 273 168 (61.5) 1 (0.4) 1 (0.4) 4 (1.5) 18 (6.6) 6 (2.2) 75 (27.5)
Table 27. Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Was 






Lost Refused Died Other4 Unknown




Total 807 285 (35.3) 211 60 (28.4) 111 (52.6) 40 (19.0) 596 225 (37.8) 288 (48.3) 83 (13.9)
0–4 5 4 (80.0) 3 2 (66.7) 1 (33.3) 0 (0) 2 2 (100.0) 0 (0) 0 (0)
5–14 0 0            … 0 0      … 0      … 0      … 0 0    … 0       … 0          …
15–24 8 5 (62.5) 2 2 (100.0) 0 (0) 0 (0) 6 3 (50.0) 2 (33.3) 1 (16.7)
25–44 61 30 (49.2) 24 13 (54.2) 5 (20.8) 6 (25.0) 37 17 (45.9) 15 (40.5) 5 (13.5)
45–64 234 91 (38.9) 71 23 (32.4) 38 (53.5) 10 (14.1) 163 68 (41.7) 79 (48.5) 16 (9.8)
≥65 499 155 (31.1) 111 20 (18.0) 67 (60.4) 24 (21.6) 388 135 (34.8) 192 (49.5) 61 (15.7)
 Table 28. Deaths Among Reported Tuberculosis Cases, by Age Group: United States, 2013
Age group
Total Died after diagnosis
Deaths related to TB 
disease or therapy1
Total dead at 
TB diagnosis 
No. No.(%) (%)
1Includes patients who were dead at diagnosis or died during therapy, for which TB or TB therapy was indicated as a cause of death.
2Eight patient deaths during therapy were related to TB therapy.






TB a cause of 
death
TB not a cause of 
death






Related to TB 
therapy/disease2
Unrelated to TB 
therapy/disease
Cause of death 
unknown/missing
(%)No. (%) No. (%) No. (%) No. (%)
1Among persons who were alive at diagnosis and had positive sputum culture.
2Among persons who  had sputum culture conversion documented at any time.
3Among persons who were alive at diagnosis, had positive culture, and did not have documented culture conversion (excludes patients with unknown culture conversion).
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Total 5,230 4,598 (87.9) 569 (10.9) 63 (1.2) 45 (7.9) 114 (20.0) 225 (39.5) 11 (1.9) 22 (3.9) 134 (23.6) 18 (3.2)
0-4 9 4 (44.4) 5 (55.6) 0 (0) 1 (20.0) 0 (0) 2 (40.0) 0 (0) 0 (0) 2 (40.0) 0 (0)
5-14 42 34 (81.0) 8 (19.0) 0 (0) 3 (37.5) 4 (50.0) 0 (0) 0 (0) 0 (0) 1 (12.5) 0 (0)
15-24 615 553 (89.9) 56 (9.1) 6 (1.0) 3 (5.4) 22 (39.3) 3 (5.4) 1 (1.8) 4 (7.1) 18 (32.1) 5 (8.9)
25-44 1,657 1,506 (90.9) 127 (7.7) 24 (1.4) 9 (7.1) 34 (26.8) 17 (13.4) 3 (2.4) 7 (5.5) 51 (40.2) 6 (4.7)
45-64 1,661 1,496 (90.1) 147 (8.9) 18 (1.1) 14 (9.5) 24 (16.3) 67 (45.6) 3 (2.0) 8 (5.4) 28 (19.0) 3 (2.0)
≥65 1,246 1,005 (80.7) 226 (18.1) 15 (1.2) 15 (6.6) 30 (13.3) 136 (60.2) 4 (1.8) 3 (1.3) 34 (15.0) 4 (1.8)
 Table 29. Sputum Culture Conversion, by Age Group: United States, 2013
Age group


































1Not ranked with the states. See Table 31 for District of Columbia ranking among states.
2Not included in U.S. totals. 
Note: Denominators for computing 2014 and 2015 rates for states, the District of Columbia, and Puerto Rico were obtained from U.S. 
Census Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico (April 1, 2010 to July 1, 
2015) (http://www.census.gov/popest/data/national/totals/2015/index.html) and totals for other U.S.-affiliated areas were obtained from 
the International Data Base (http://www.census.gov/population/international/data/idb/informationGateway.php); accessed July 20, 2016.
See Technical Notes.
See Surveillance Slide #4.
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United States 9,557 9,406 3.0 2.9              —               — 321,418,820   
Alabama 119 133 2.4 2.7 21 14 4,858,979
Alaska 68 62 9.2 8.4 1 2 738,432
Arizona 198 193 2.9 2.9 13 12 6,828,065
Arkansas 90 93 3.0 3.1 8 9 2,978,204
California 2,133 2,134 5.4 5.5 3 3 39,144,818
Colorado 73 64 1.3 1.2 37 39 5,456,574
Connecticut 70 60 1.9 1.7 28 31 3,590,886
Delaware 22 22 2.3 2.4 22 22 945,934
District of Columbia1 33 32 4.9 4.8              —               — 672,228
Florida 602 595 3.0 3.0 9 10 20,271,272
Georgia 324 335 3.2 3.3 7 7 10,214,860
Hawaii 127 136 8.9 9.6 2 1 1,431,603
Idaho 11 11 0.7 0.7 49 47 1,654,930
Illinois 343 320 2.7 2.5 17 18 12,859,995
Indiana 116 108 1.8 1.6 30 32 6,619,680
Iowa 38 54 1.2 1.7 42 30 3,123,899
Kansas 36 40 1.2 1.4 39 36 2,911,641
Kentucky 67 80 1.5 1.8 34 29 4,425,092
Louisiana 119 121 2.5 2.6 18 17 4,670,724
Maine 18 14 1.4 1.1 36 42 1,329,328
Maryland 176 198 2.9 3.3 11 8 6,006,401
Massachusetts 192 199 2.8 2.9 15 11 6,794,422
Michigan 131 105 1.3 1.1 38 40 9,922,576
Minnesota 150 147 2.7 2.7 16 15 5,489,594
Mississippi 74 74 2.5 2.5 20 19 2,992,333
Missouri 92 80 1.5 1.3 35 38 6,083,672
Montana 9 6 0.9 0.6 47 48 1,032,949
Nebraska 33 38 1.7 2.0 31 25 1,896,190
Nevada 85 74 2.9 2.6 10 16 2,890,845
New Hampshire 13 11 1.0 0.8 46 45 1,330,608
New Jersey 326 307 3.6 3.4 6 6 8,958,013
New Mexico 47 50 2.3 2.4 23 20 2,085,109
New York 765 784 3.9 4.0 5 5 19,795,791
North Carolina 199 195 2.0 2.0 26 27 10,042,802
North Dakota 9 15 1.2 2.0 44 24 756,927
Ohio 143 156 1.2 1.3 41 37 11,613,423
Oklahoma 67 59 1.7 1.5 32 35 3,911,338
Oregon 76 77 1.9 1.9 29 28 4,028,977
Pennsylvania 200 208 1.6 1.6 33 34 12,802,503
Rhode Island 30 21 2.8 2.0 14 26 1,056,298
South Carolina 104 79 2.1 1.6 24 33 4,896,146
South Dakota 17 8 2.0 0.9 27 43 858,469
Tennessee 131 151 2.0 2.3 25 23 6,600,299
Texas 1,334 1,269 4.9 4.7 4 4 27,469,114
Utah 37 31 1.2 1.1 40 41 2,995,919
Vermont 7 2 1.1 0.3 45 50 626,042
Virginia 212 198 2.5 2.4 19 21 8,382,993
Washington 208 194 2.9 2.7 12 13 7,170,351
West Virginia 10 13 0.5 0.7 50 46 1,844,128
Wisconsin 69 48 1.2 0.8 43 44 5,771,337
Wyoming 4 2 0.7 0.3 48 49 586,107
American Samoa1,2 4 1 7.4 1.8              —               — 54,343
Fed. States of Micronesia1,2 103 170 97.9 160.9              —               — 105,216
Guam1,2 76 56 47.0 34.8              —               — 161,785
Marshall Islands1,2 137 152 189.8 214.1              —               — 72,191
N. Mariana Islands1,2 27 25 51.6 48.6              —               — 52,344
Puerto Rico1,2 52 44 1.4 1.2              —               — 3,598,357
Republic of Palau1,2 14 14 65.8 66.1              —               — 21,265
U.S. Virgin Islands1,2         —             —           —              —              —               — 103,574
Table 30. Tuberculosis Cases and Case Rates per 100,000 Population: 
Reporting Areas, 2015 and 2014
Reporting Area
Cases Case rates Rank according to rate Population estimates
July 1, 20152015 2014 2015 2014 2015 2014
60
Total 9,557 3.0 9,406 2.9 1.6 3.4 —
≥500 cases in 2015
California 2,133 5.4 2,134 5.5 –0.0 –1.8 3
Texas 1,334 4.9 1,269 4.7 5.1 4.3 4
New York1 765 3.9 784 4.0 –2.4 –2.5 5
Florida 602 3.0 595 3.0 1.2 0.0 9
100–499 cases in 2015
Illinois 343 2.7 320 2.5 7.2 8.0 17
New Jersey 326 3.6 307 3.4 6.2 5.9 6
Georgia 324 3.2 335 3.3 –3.3 –3.0 7
Virginia 212 2.5 198 2.4 7.1 4.2 19
Washington 208 2.9 194 2.7 7.2 7.4 12
Pennsylvania 200 1.6 208 1.6 –3.8 0.0 33
North Carolina 199 2.0 195 2.0 2.1 0.0 26
Arizona 198 2.9 193 2.9 2.6 0.0 13
Massachusetts 192 2.8 199 2.9 –3.5 –3.4 15
Maryland 176 2.9 198 3.3 –11.1 –12.1 11
Minnesota 150 2.7 147 2.7 2.0 0.0 16
Ohio 143 1.2 156 1.3 –8.3 –7.7 41
Michigan 131 1.3 105 1.1 24.8 18.2 38
Tennessee 131 2.0 151 2.3 –13.2 –13.0 25
Hawaii 127 8.9 136 9.6 –6.6 –7.3 2
Alabama 119 2.4 133 2.7 –10.5 –11.1 21
Louisiana 119 2.5 121 2.6 –1.7 –3.8 18
Indiana 116 1.8 108 1.6 7.4 12.5 30
South Carolina 104 2.1 79 1.6 31.6 31.3 24
<100 cases in 2015
Missouri 92 1.5 80 1.3 15.0 15.4 35
Arkansas 90 3.0 93 3.1 –3.2 –3.2 8
Nevada 85 2.9 74 2.6 14.9 11.5 10
Oregon 76 1.9 77 1.9 –1.3 0.0 29
Mississippi 74 2.5 74 2.5 0.0 0.0 20
Colorado 73 1.3 64 1.2 14.1 8.3 37
Connecticut 70 1.9 60 1.7 16.7 11.8 28
Wisconsin 69 1.2 48 0.8 43.8 50.0 43
Alaska 68 9.2 62 8.4 9.7 9.5 1
Kentucky 67 1.5 80 1.8 –16.3 –16.7 34
Oklahoma 67 1.7 59 1.5 13.6 13.3 32
New Mexico 47 2.3 50 2.4 –6.0 –4.2 23
Iowa 38 1.2 54 1.7 –29.6 –29.4 42
Utah 37 1.2 31 1.1 19.4 9.1 40
Kansas 36 1.2 40 1.4 –10.0 –14.3 39
District of Columbia 33 4.9 32 4.8 3.1 2.1 —
Nebraska 33 1.7 38 2.0 –13.2 –15.0 31
Rhode Island 30 2.8 21 2.0 42.9 40.0 14
Delaware 22 2.3 22 2.4 0.0 –4.2 22
Maine 18 1.4 14 1.1 28.6 27.3 36
South Dakota 17 2.0 8 0.9 112.5 122.2 27
New Hampshire 13 1.0 11 0.8 18.2 25.0 46
Idaho 11 0.7 11 0.7 0.0 0.0 49
West Virginia 10 0.5 13 0.7 –23.1 –28.6 50
Montana 9 0.9 6 0.6 50.0 50.0 47
North Dakota 9 1.2 15 2.0 –40.0 –40.0 44
Vermont 7 1.1 2 0.3 250.0 266.7 45
Wyoming 4 0.7 2 0.3 100.0 133.3 48
Table 31. Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and Grouped 
by Number of Cases: United States and the District of Columbia, 2015 and 2014
Reporting area
2015 2014 2014–2015 % change




1Includes New York City.
Note: Denominators for computing 2014 and 2015 rates for states and the District of Columbia were obtained from U.S. Census Annual 
Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico (April 1, 2010 to July 1, 2015) (http://www.
census.gov/popest/data/national/totals/2015/index.html); accessed July 25, 2016.
See Table 30 for ranking of states without the District of Columbia.
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United States 9,557 244 (2.6) 196 (2.1) 935 (9.8) 2,858 (29.9) 3,028 (31.7) 2,294 (24.0) 2 (0)
Alabama 119 1 (0.8) 2 (1.7) 8 (6.7) 32 (26.9) 46 (38.7) 30 (25.2) 0 (0)
Alaska 68 4 (5.9) 9 (13.2) 4 (5.9) 14 (20.6) 26 (38.2) 11 (16.2) 0 (0)
Arizona 198 8 (4.0) 6 (3.0) 24 (12.1) 56 (28.3) 57 (28.8) 47 (23.7) 0 (0)
Arkansas 90 12 (13.3) 0 (0) 10 (11.1) 24 (26.7) 25 (27.8) 19 (21.1) 0 (0)
California 2,133 36 (1.7) 32 (1.5) 186 (8.7) 507 (23.8) 692 (32.4) 680 (31.9) 0 (0)
Colorado 73 5 (6.8) 2 (2.7) 5 (6.8) 20 (27.4) 21 (28.8) 20 (27.4) 0 (0)
Connecticut 70 0 (0) 0 (0) 6 (8.6) 31 (44.3) 22 (31.4) 11 (15.7) 0 (0)
Delaware 22 2 (9.1) 0 (0) 2 (9.1) 9 (40.9) 5 (22.7) 3 (13.6) 1 (4.5)
District of Columbia 33 2 (6.1) 0 (0) 3 (9.1) 12 (36.4) 6 (18.2) 10 (30.3) 0 (0)
Florida 602 10 (1.7) 11 (1.8) 54 (9.0) 172 (28.6) 245 (40.7) 110 (18.3) 0 (0)
Georgia 324 15 (4.6) 3 (0.9) 26 (8.0) 110 (34.0) 124 (38.3) 46 (14.2) 0 (0)
Hawaii 127 4 (3.1) 4 (3.1) 22 (17.3) 26 (20.5) 37 (29.1) 34 (26.8) 0 (0)
Idaho 11 1 (9.1) 1 (9.1) 0 (0) 6 (54.5) 0 (0) 3 (27.3) 0 (0)
Illinois 343 9 (2.6) 4 (1.2) 27 (7.9) 101 (29.4) 105 (30.6) 97 (28.3) 0 (0)
Indiana 116 3 (2.6) 1 (0.9) 26 (22.4) 41 (35.3) 26 (22.4) 19 (16.4) 0 (0)
Iowa 38 2 (5.3) 0 (0) 7 (18.4) 18 (47.4) 8 (21.1) 3 (7.9) 0 (0)
Kansas 36 0 (0) 1 (2.8) 5 (13.9) 12 (33.3) 14 (38.9) 4 (11.1) 0 (0)
Kentucky 67 1 (1.5) 2 (3.0) 7 (10.4) 21 (31.3) 24 (35.8) 12 (17.9) 0 (0)
Louisiana 119 3 (2.5) 2 (1.7) 11 (9.2) 37 (31.1) 50 (42.0) 16 (13.4) 0 (0)
Maine 18 1 (5.6) 1 (5.6) 4 (22.2) 5 (27.8) 3 (16.7) 4 (22.2) 0 (0)
Maryland 176 3 (1.7) 4 (2.3) 23 (13.1) 66 (37.5) 46 (26.1) 34 (19.3) 0 (0)
Massachusetts 192 2 (1.0) 5 (2.6) 14 (7.3) 61 (31.8) 59 (30.7) 51 (26.6) 0 (0)
Michigan 131 2 (1.5) 1 (0.8) 17 (13.0) 43 (32.8) 35 (26.7) 33 (25.2) 0 (0)
Minnesota 150 1 (0.7) 9 (6.0) 14 (9.3) 67 (44.7) 38 (25.3) 21 (14.0) 0 (0)
Mississippi 74 2 (2.7) 1 (1.4) 4 (5.4) 20 (27.0) 29 (39.2) 18 (24.3) 0 (0)
Missouri 92 3 (3.3) 5 (5.4) 14 (15.2) 32 (34.8) 21 (22.8) 17 (18.5) 0 (0)
Montana 9 0 (0) 0 (0) 1 (11.1) 2 (22.2) 2 (22.2) 4 (44.4) 0 (0)
Nebraska 33 1 (3.0) 1 (3.0) 4 (12.1) 16 (48.5) 6 (18.2) 5 (15.2) 0 (0)
Nevada 85 0 (0) 1 (1.2) 6 (7.1) 28 (32.9) 25 (29.4) 25 (29.4) 0 (0)
New Hampshire 13 0 (0) 1 (7.7) 2 (15.4) 4 (30.8) 2 (15.4) 4 (30.8) 0 (0)
New Jersey 326 8 (2.5) 2 (0.6) 32 (9.8) 109 (33.4) 87 (26.7) 88 (27.0) 0 (0)




missingUnder 5 5–14 15–24
25–44 45–64 >65
No. (%)Reporting Area No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
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New Mexico 47 1 (2.1) 0 (0) 2 (4.3) 9 (19.1) 17 (36.2) 18 (38.3) 0 (0)
New York 765 18 (2.4) 14 (1.8) 83 (10.8) 249 (32.5) 230 (30.1) 171 (22.4) 0 (0)
North Carolina 199 7 (3.5) 3 (1.5) 19 (9.5) 67 (33.7) 57 (28.6) 46 (23.1) 0 (0)
North Dakota 9 0 (0) 0 (0) 2 (22.2) 2 (22.2) 3 (33.3) 2 (22.2) 0 (0)
Ohio 143 3 (2.1) 2 (1.4) 22 (15.4) 46 (32.2) 35 (24.5) 35 (24.5) 0 (0)
Oklahoma 67 2 (3.0) 3 (4.5) 3 (4.5) 12 (17.9) 23 (34.3) 24 (35.8) 0 (0)
Oregon 76 1 (1.3) 3 (3.9) 12 (15.8) 22 (28.9) 21 (27.6) 17 (22.4) 0 (0)
Pennsylvania 200 1 (0.5) 3 (1.5) 12 (6.0) 58 (29.0) 80 (40.0) 46 (23.0) 0 (0)
Rhode Island 30 0 (0) 0 (0) 2 (6.7) 8 (26.7) 8 (26.7) 12 (40.0) 0 (0)
South Carolina 104 3 (2.9) 3 (2.9) 10 (9.6) 25 (24.0) 39 (37.5) 24 (23.1) 0 (0)
South Dakota 17 0 (0) 1 (5.9) 3 (17.6) 5 (29.4) 6 (35.3) 2 (11.8) 0 (0)
Tennessee 131 6 (4.6) 0 (0) 13 (9.9) 39 (29.8) 33 (25.2) 40 (30.5) 0 (0)
Texas 1,334 47 (3.5) 37 (2.8) 135 (10.1) 443 (33.2) 446 (33.4) 226 (16.9) 0 (0)
Utah 37 4 (10.8) 3 (8.1) 5 (13.5) 11 (29.7) 11 (29.7) 3 (8.1) 0 (0)
Vermont 7 0 (0) 0 (0) 0 (0) 5 (71.4) 1 (14.3) 1 (14.3) 0 (0)
Virginia 212 5 (2.4) 5 (2.4) 14 (6.6) 68 (32.1) 56 (26.4) 64 (30.2) 0 (0)
Washington 208 5 (2.4) 6 (2.9) 28 (13.5) 64 (30.8) 48 (23.1) 56 (26.9) 1 (0.5)
West Virginia 10 0 (0) 1 (10.0) 1 (10.0) 0 (0) 4 (40.0) 4 (40.0) 0 (0)
Wisconsin 69 0 (0) 1 (1.4) 1 (1.4) 22 (31.9) 23 (33.3) 22 (31.9) 0 (0)
Wyoming 4 0 (0) 0 (0) 0 (0) 1 (25.0) 1 (25.0) 2 (50.0) 0 (0)
American Samoa1 4 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 3 (75.0) 0 (0)
Fed. States of Micronesia1 103 7 (6.8) 14 (13.6) 21 (20.4) 28 (27.2) 26 (25.2) 7 (6.8) 0 (0)
Guam1 76 9 (11.8) 7 (9.2) 9 (11.8) 15 (19.7) 22 (28.9) 14 (18.4) 0 (0)
Marshall Islands1 137 7 (5.1) 22 (16.1) 21 (15.3) 44 (32.1) 33 (24.1) 10 (7.3) 0 (0)
N. Mariana Islands1 27 2 (7.4) 1 (3.7) 2 (7.4) 7 (25.9) 12 (44.4) 3 (11.1) 0 (0)
Puerto Rico1 52 0 (0) 0 (0) 3 (5.8) 14 (26.9) 19 (36.5) 16 (30.8) 0 (0)
Republic of Palau1 14 0 (0) 1 (7.1) 2 (14.3) 2 (14.3) 5 (35.7) 4 (28.6) 0 (0)
U.S. Virgin Islands1 0 0 … 0 … 0 … 0 … 0 … 0 … 0 …
Table 32. (Cont’d) Tuberculosis Cases and Percentages, by Age Group: Reporting Areas, 2015
1Not included in U.S. totals.




missingUnder 5 5–14 15–24
25–44 45–64 >65
No. (%)Reporting Area No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
64
United States 9,557 2,694 (28.2) 145 (1.5) 3,177 (33.2) 1,995 (20.9) 102 (1.1) 1,251 (13.1) 167 (1.7) 26 (0.3)
Alabama 119 21 (17.6) 0 (0) 6 (5.0) 63 (52.9) 0 (0) 26 (21.8) 3 (2.5) 0 (0)
Alaska 68 0 (0) 56 (82.4) 9 (13.2) 0 (0) 0 (0) 3 (4.4) 0 (0) 0 (0)
Arizona 198 97 (49.0) 14 (7.1) 42 (21.2) 19 (9.6) 1 (0.5) 25 (12.6) 0 (0) 0 (0)
Arkansas 90 10 (11.1) 0 (0) 8 (8.9) 29 (32.2) 17 (18.9) 26 (28.9) 0 (0) 0 (0)
California 2,133 760 (35.6) 1 (0) 1,013 (47.5) 98 (4.6) 10 (0.5) 133 (6.2) 116 (5.4) 2 (0.1)
Colorado 73 22 (30.1) 0 (0) 24 (32.9) 14 (19.2) 0 (0) 11 (15.1) 1 (1.4) 1 (1.4)
Connecticut 70 20 (28.6) 0 (0) 25 (35.7) 17 (24.3) 0 (0) 8 (11.4) 0 (0) 0 (0)
Delaware 22 5 (22.7) 0 (0) 7 (31.8) 4 (18.2) 0 (0) 4 (18.2) 2 (9.1) 0 (0)
District of Columbia 33 5 (15.2) 0 (0) 3 (9.1) 21 (63.6) 0 (0) 4 (12.1) 0 (0) 0 (0)
Florida 602 169 (28.1) 0 (0) 85 (14.1) 221 (36.7) 1 (0.2) 125 (20.8) 1 (0.2) 0 (0)
Georgia 324 40 (12.3) 1 (0.3) 81 (25.0) 157 (48.5) 0 (0) 44 (13.6) 1 (0.3) 0 (0)
Hawaii 127 0 (0) 0 (0) 87 (68.5) 1 (0.8) 33 (26.0) 3 (2.4) 2 (1.6) 1 (0.8)
Idaho 11 2 (18.2) 0 (0) 3 (27.3) 1 (9.1) 0 (0) 3 (27.3) 0 (0) 2 (18.2)
Illinois 343 91 (26.5) 0 (0) 139 (40.5) 57 (16.6) 1 (0.3) 55 (16.0) 0 (0) 0 (0)
Indiana 116 23 (19.8) 0 (0) 38 (32.8) 24 (20.7) 0 (0) 31 (26.7) 0 (0) 0 (0)
Iowa 38 6 (15.8) 1 (2.6) 12 (31.6) 9 (23.7) 1 (2.6) 9 (23.7) 0 (0) 0 (0)
Kansas 36 6 (16.7) 0 (0) 13 (36.1) 8 (22.2) 1 (2.8) 8 (22.2) 0 (0) 0 (0)
Kentucky 67 12 (17.9) 0 (0) 13 (19.4) 13 (19.4) 1 (1.5) 28 (41.8) 0 (0) 0 (0)
Louisiana 119 20 (16.8) 0 (0) 17 (14.3) 39 (32.8) 0 (0) 36 (30.3) 6 (5.0) 1 (0.8)
Maine 18 0 (0) 0 (0) 2 (11.1) 12 (66.7) 0 (0) 4 (22.2) 0 (0) 0 (0)
Maryland 176 39 (22.2) 0 (0) 50 (28.4) 71 (40.3) 1 (0.6) 13 (7.4) 2 (1.1) 0 (0)
Massachusetts 192 35 (18.2) 0 (0) 80 (41.7) 45 (23.4) 0 (0) 20 (10.4) 8 (4.2) 4 (2.1)
Michigan 131 10 (7.6) 1 (0.8) 50 (38.2) 36 (27.5) 0 (0) 34 (26.0) 0 (0) 0 (0)
Minnesota 150 9 (6.0) 4 (2.7) 40 (26.7) 84 (56.0) 1 (0.7) 12 (8.0) 0 (0) 0 (0)
Mississippi 74 4 (5.4) 0 (0) 5 (6.8) 51 (68.9) 0 (0) 14 (18.9) 0 (0) 0 (0)
Missouri 92 11 (12.0) 0 (0) 34 (37.0) 15 (16.3) 10 (10.9) 22 (23.9) 0 (0) 0 (0)
Montana 9 0 (0) 3 (33.3) 1 (11.1) 1 (11.1) 0 (0) 4 (44.4) 0 (0) 0 (0)
Nebraska 33 10 (30.3) 0 (0) 9 (27.3) 5 (15.2) 0 (0) 5 (15.2) 4 (12.1) 0 (0)
Nevada 85 19 (22.4) 0 (0) 36 (42.4) 16 (18.8) 1 (1.2) 12 (14.1) 1 (1.2) 0 (0)
New Hampshire 13 2 (15.4) 0 (0) 4 (30.8) 4 (30.8) 0 (0) 3 (23.1) 0 (0) 0 (0)
New Jersey 326 104 (31.9) 0 (0) 146 (44.8) 49 (15.0) 0 (0) 27 (8.3) 0 (0) 0 (0)











White Multiple race2 Unknown/ missing
No. No. No. No. No. No. No. No. (%)(%)(%)(%)(%)(%)(%)(%)Reporting area
65
New Mexico 47 27 (57.4) 7 (14.9) 3 (6.4) 1 (2.1) 0 (0) 9 (19.1) 0 (0) 0 (0)
New York 765 194 (25.4) 0 (0) 332 (43.4) 157 (20.5) 1 (0.1) 64 (8.4) 7 (0.9) 10 (1.3)
North Carolina 199 41 (20.6) 23 (11.6) 40 (20.1) 61 (30.7) 0 (0) 31 (15.6) 3 (1.5) 0 (0)
North Dakota 9 0 (0) 0 (0) 3 (33.3) 2 (22.2) 0 (0) 2 (22.2) 0 (0) 2 (22.2)
Ohio 143 7 (4.9) 0 (0) 49 (34.3) 49 (34.3) 1 (0.7) 37 (25.9) 0 (0) 0 (0)
Oklahoma 67 11 (16.4) 10 (14.9) 14 (20.9) 7 (10.4) 1 (1.5) 18 (26.9) 6 (9.0) 0 (0)
Oregon 76 10 (13.2) 1 (1.3) 35 (46.1) 7 (9.2) 2 (2.6) 21 (27.6) 0 (0) 0 (0)
Pennsylvania 200 26 (13.0) 0 (0) 78 (39.0) 60 (30.0) 1 (0.5) 34 (17.0) 1 (0.5) 0 (0)
Rhode Island 30 12 (40.0) 0 (0) 9 (30.0) 3 (10.0) 0 (0) 6 (20.0) 0 (0) 0 (0)
South Carolina 104 12 (11.5) 0 (0) 12 (11.5) 60 (57.7) 1 (1.0) 19 (18.3) 0 (0) 0 (0)
South Dakota 17 1 (5.9) 11 (64.7) 1 (5.9) 2 (11.8) 0 (0) 2 (11.8) 0 (0) 0 (0)
Tennessee 131 18 (13.7) 1 (0.8) 20 (15.3) 50 (38.2) 0 (0) 41 (31.3) 1 (0.8) 0 (0)
Texas 1,334 675 (50.6) 2 (0.1) 258 (19.3) 250 (18.7) 6 (0.4) 140 (10.5) 2 (0.1) 1 (0.1)
Utah 37 18 (48.6) 0 (0) 10 (27.0) 4 (10.8) 1 (2.7) 4 (10.8) 0 (0) 0 (0)
Vermont 7 1 (14.3) 0 (0) 2 (28.6) 1 (14.3) 0 (0) 3 (42.9) 0 (0) 0 (0)
Virginia 212 41 (19.3) 0 (0) 94 (44.3) 53 (25.0) 0 (0) 24 (11.3) 0 (0) 0 (0)
Washington 208 31 (14.9) 7 (3.4) 102 (49.0) 35 (16.8) 9 (4.3) 22 (10.6) 0 (0) 2 (1.0)
West Virginia 10 1 (10.0) 0 (0) 1 (10.0) 0 (0) 0 (0) 8 (80.0) 0 (0) 0 (0)
Wisconsin 69 15 (21.7) 1 (1.4) 30 (43.5) 9 (13.0) 0 (0) 14 (20.3) 0 (0) 0 (0)
Wyoming 4 1 (25.0) 1 (25.0) 2 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
American Samoa3 4 0 (0) 0 (0) 2 (50.0) 0 (0) 2 (50.0) 0 (0) 0 (0) 0 (0)
Fed. States of Micronesia3 103 0 (0) 0 (0) 0 (0) 0 (0) 102 (99.0) 0 (0) 1 (1.0) 0 (0)
Guam3 76 0 (0) 0 (0) 36 (47.4) 1 (1.3) 38 (50.0) 1 (1.3) 0 (0) 0 (0)
Marshall Islands3 137 1 (0.7) 0 (0) 0 (0) 0 (0) 133 (97.1) 0 (0) 3 (2.2) 0 (0)
N. Mariana Islands3 27 2 (7.4) 0 (0) 14 (51.9) 0 (0) 10 (37.0) 0 (0) 0 (0) 1 (3.7)
Puerto Rico3 52 51 (98.1) 0 (0) 1 (1.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Republic of Palau3 14 0 (0) 0 (0) 3 (21.4) 0 (0) 11 (78.6) 0 (0) 0 (0) 0 (0)
U.S. Virgin Islands3 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Table 33. (Cont’d) Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race: Reporting Areas, 2015
1Persons of Hispanic/Latino origin may be of any or multiple race.
2Indicates two or more races reported for a person and does not include persons of Hispanic/Latino origin. 
3Not included in U.S. totals. 
 Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) are mutually exclusive and do 
not include persons of Hispanic ethnicity or multiple race.










 Other Pacific 
Islander
White Multiple race2 Unknown/ missing
No. No. No. No. No. No. No. No. (%)(%)(%)(%)(%)(%)(%)(%)Reporting area
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
Note: See Surveillance Slide #16.
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United States 9,557 3,186 (33.3) 6,350 (66.4) 21 (0.2)
Alabama 119 90 (75.6) 29 (24.4) 0 (0)
Alaska 68 55 (80.9) 8 (11.8) 5 (7.4)
Arizona 198 57 (28.8) 141 (71.2) 0 (0)
Arkansas 90 72 (80.0) 18 (20.0) 0 (0)
California 2,133 406 (19.0) 1,718 (80.5) 9 (0.4)
Colorado 73 15 (20.5) 58 (79.5) 0 (0)
Connecticut 70 13 (18.6) 57 (81.4) 0 (0)
Delaware 22 8 (36.4) 13 (59.1) 1 (4.5)
District of Columbia 33 15 (45.5) 18 (54.5) 0 (0)
Florida 602 260 (43.2) 342 (56.8) 0 (0)
Georgia 324 176 (54.3) 148 (45.7) 0 (0)
Hawaii 127 45 (35.4) 82 (64.6) 0 (0)
Idaho 11 1 (9.1) 9 (81.8) 1 (9.1)
Illinois 343 100 (29.2) 243 (70.8) 0 (0)
Indiana 116 49 (42.2) 67 (57.8) 0 (0)
Iowa 38 7 (18.4) 31 (81.6) 0 (0)
Kansas 36 10 (27.8) 26 (72.2) 0 (0)
Kentucky 67 34 (50.7) 33 (49.3) 0 (0)
Louisiana 119 80 (67.2) 39 (32.8) 0 (0)
Maine 18 4 (22.2) 14 (77.8) 0 (0)
Maryland 176 42 (23.9) 134 (76.1) 0 (0)
Massachusetts 192 25 (13.0) 163 (84.9) 4 (2.1)
Michigan 131 47 (35.9) 84 (64.1) 0 (0)
Minnesota 150 22 (14.7) 128 (85.3) 0 (0)
Mississippi 74 64 (86.5) 10 (13.5) 0 (0)
Missouri 92 37 (40.2) 55 (59.8) 0 (0)
Montana 9 7 (77.8) 2 (22.2) 0 (0)
Nebraska 33 8 (24.2) 25 (75.8) 0 (0)
Nevada 85 26 (30.6) 59 (69.4) 0 (0)
New Hampshire 13 2 (15.4) 11 (84.6) 0 (0)
New Jersey 326 61 (18.7) 265 (81.3) 0 (0)
New Mexico 47 23 (48.9) 24 (51.1) 0 (0)
New York 765 148 (19.3) 616 (80.5) 1 (0.1)
North Carolina 199 107 (53.8) 92 (46.2) 0 (0)
North Dakota 9 1 (11.1) 8 (88.9) 0 (0)
Ohio 143 54 (37.8) 89 (62.2) 0 (0)
Oklahoma 67 42 (62.7) 25 (37.3) 0 (0)
Oregon 76 24 (31.6) 52 (68.4) 0 (0)
Pennsylvania 200 79 (39.5) 121 (60.5) 0 (0)
Rhode Island 30 4 (13.3) 26 (86.7) 0 (0)
South Carolina 104 79 (76.0) 25 (24.0) 0 (0)
South Dakota 17 12 (70.6) 5 (29.4) 0 (0)
Tennessee 131 72 (55.0) 59 (45.0) 0 (0)
Texas 1,334 570 (42.7) 764 (57.3) 0 (0)
Utah 37 9 (24.3) 28 (75.7) 0 (0)
Vermont 7 3 (42.9) 4 (57.1) 0 (0)
Virginia 212 44 (20.8) 168 (79.2) 0 (0)
Washington 208 48 (23.1) 160 (76.9) 0 (0)
West Virginia 10 7 (70.0) 3 (30.0) 0 (0)
Wisconsin 69 20 (29.0) 49 (71.0) 0 (0)
Wyoming 4 2 (50.0) 2 (50.0) 0 (0)
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United States 6,350 1,254 (19.7) 820 (12.9) 579 (9.1) 519 (8.2) 426 (6.7) 189 (3.0) 166 (2.6) 2,387 (37.6) 10 (0.2)
Alabama 29 8 (27.6) 2 (6.9) 1 (3.4) 1 (3.4) 0 (0) 11 (37.9) 1 (3.4) 5 (17.2) 0 (0)
Alaska 8 0 (0) 5 (62.5) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 2 (25.0) 0 (0)
Arizona 141 70 (49.6) 14 (9.9) 9 (6.4) 3 (2.1) 6 (4.3) 4 (2.8) 0 (0) 35 (24.8) 0 (0)
Arkansas 18 3 (16.7) 1 (5.6) 0 (0) 3 (16.7) 1 (5.6) 4 (22.2) 0 (0) 6 (33.3) 0 (0)
California 1,718 447 (26.0) 409 (23.8) 113 (6.6) 218 (12.7) 130 (7.6) 36 (2.1) 0 (0) 365 (21.2) 0 (0)
Colorado 58 14 (24.1) 5 (8.6) 4 (6.9) 3 (5.2) 3 (5.2) 0 (0) 0 (0) 29 (50.0) 0 (0)
Connecticut 57 4 (7.0) 7 (12.3) 10 (17.5) 2 (3.5) 0 (0) 2 (3.5) 2 (3.5) 30 (52.6) 0 (0)
Delaware 13 2 (15.4) 0 (0) 3 (23.1) 1 (7.7) 0 (0) 0 (0) 0 (0) 7 (53.8) 0 (0)
District of Columbia 18 0 (0) 1 (5.6) 1 (5.6) 1 (5.6) 0 (0) 1 (5.6) 0 (0) 14 (77.8) 0 (0)
Florida 342 31 (9.1) 31 (9.1) 13 (3.8) 13 (3.8) 7 (2.0) 24 (7.0) 94 (27.5) 128 (37.4) 1 (0.3)
Georgia 148 21 (14.2) 8 (5.4) 21 (14.2) 16 (10.8) 4 (2.7) 4 (2.7) 2 (1.4) 70 (47.3) 2 (1.4)
Hawaii 82 0 (0) 66 (80.5) 0 (0) 6 (7.3) 2 (2.4) 0 (0) 0 (0) 8 (9.8) 0 (0)
Idaho 9 0 (0) 0 (0) 0 (0) 1 (11.1) 0 (0) 0 (0) 0 (0) 8 (88.9) 0 (0)
Illinois 243 70 (28.8) 29 (11.9) 46 (18.9) 8 (3.3) 23 (9.5) 5 (2.1) 0 (0) 62 (25.5) 0 (0)
Indiana 67 14 (20.9) 1 (1.5) 9 (13.4) 4 (6.0) 4 (6.0) 0 (0) 2 (3.0) 33 (49.3) 0 (0)
Iowa 31 2 (6.5) 0 (0) 5 (16.1) 3 (9.7) 2 (6.5) 2 (6.5) 0 (0) 17 (54.8) 0 (0)
Kansas 26 3 (11.5) 0 (0) 3 (11.5) 2 (7.7) 0 (0) 1 (3.8) 0 (0) 17 (65.4) 0 (0)
Kentucky 33 4 (12.1) 2 (6.1) 4 (12.1) 2 (6.1) 0 (0) 1 (3.0) 0 (0) 20 (60.6) 0 (0)
Louisiana 39 4 (10.3) 3 (7.7) 2 (5.1) 12 (30.8) 1 (2.6) 3 (7.7) 0 (0) 14 (35.9) 0 (0)
Maine 14 0 (0) 0 (0) 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 12 (85.7) 0 (0)
Maryland 134 6 (4.5) 5 (3.7) 11 (8.2) 8 (6.0) 6 (4.5) 5 (3.7) 4 (3.0) 88 (65.7) 1 (0.7)
Massachusetts 163 2 (1.2) 7 (4.3) 14 (8.6) 15 (9.2) 15 (9.2) 3 (1.8) 12 (7.4) 95 (58.3) 0 (0)
Michigan 84 3 (3.6) 5 (6.0) 13 (15.5) 6 (7.1) 5 (6.0) 3 (3.6) 0 (0) 49 (58.3) 0 (0)
Minnesota 128 8 (6.3) 4 (3.1) 5 (3.9) 8 (6.3) 6 (4.7) 0 (0) 0 (0) 97 (75.8) 0 (0)
Mississippi 10 0 (0) 0 (0) 4 (40.0) 2 (20.0) 0 (0) 2 (20.0) 0 (0) 2 (20.0) 0 (0)
Missouri 55 4 (7.3) 4 (7.3) 14 (25.5) 7 (12.7) 1 (1.8) 3 (5.5) 1 (1.8) 21 (38.2) 0 (0)
Montana 2 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0) 0 (0)





Mexico Philippines  IndiaVietnam China GuatemalaHaiti All others2
Unknown/
missing
No. No. No. No. No. No. No. No.(%) (%) (%) (%) (%) (%) (%) (%) No. (%)
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the Federated States of Micronesia, the Republic of the 
Marshall Islands, and the Republic of Palau).
2Includes 136 countries.
Note: See Surveillance Slide #19.69
Nebraska 25 3 (12.0) 0 (0) 0 (0) 3 (12.0) 1 (4.0) 2 (8.0) 0 (0) 16 (64.0) 0 (0)
Nevada 59 13 (22.0) 20 (33.9) 5 (8.5) 3 (5.1) 5 (8.5) 0 (0) 0 (0) 12 (20.3) 1 (1.7)
New Hampshire 11 0 (0) 0 (0) 1 (9.1) 0 (0) 0 (0) 0 (0) 0 (0) 10 (90.9) 0 (0)
New Jersey 265 15 (5.7) 29 (10.9) 75 (28.3) 12 (4.5) 9 (3.4) 9 (3.4) 15 (5.7) 101 (38.1) 0 (0)
New  Mexico 24 20 (83.3) 1 (4.2) 0 (0) 1 (4.2) 0 (0) 0 (0) 0 (0) 2 (8.3) 0 (0)
New York 616 45 (7.3) 37 (6.0) 36 (5.8) 1 (0.2) 134 (21.8) 7 (1.1) 27 (4.4) 329 (53.4) 0 (0)
North Carolina 92 24 (26.1) 6 (6.5) 14 (15.2) 8 (8.7) 2 (2.2) 6 (6.5) 1 (1.1) 28 (30.4) 3 (3.3)
North Dakota 8 0 (0) 0 (0) 1 (12.5) 1 (12.5) 1 (12.5) 0 (0) 0 (0) 5 (62.5) 0 (0)
Ohio 89 3 (3.4) 7 (7.9) 15 (16.9) 4 (4.5) 7 (7.9) 2 (2.2) 1 (1.1) 50 (56.2) 0 (0)
Oklahoma 25 8 (32.0) 1 (4.0) 3 (12.0) 5 (20.0) 0 (0) 0 (0) 0 (0) 8 (32.0) 0 (0)
Oregon 52 5 (9.6) 7 (13.5) 3 (5.8) 9 (17.3) 7 (13.5) 1 (1.9) 0 (0) 19 (36.5) 1 (1.9)
Pennsylvania 121 2 (1.7) 9 (7.4) 22 (18.2) 10 (8.3) 9 (7.4) 0 (0) 3 (2.5) 66 (54.5) 0 (0)
Rhode Island 26 1 (3.8) 0 (0) 0 (0) 1 (3.8) 3 (11.5) 3 (11.5) 0 (0) 18 (69.2) 0 (0)
South Carolina 25 8 (32.0) 2 (8.0) 6 (24.0) 2 (8.0) 1 (4.0) 2 (8.0) 0 (0) 4 (16.0) 0 (0)
South Dakota 5 0 (0) 1 (20.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (80.0) 0 (0)
Tennessee 59 12 (20.3) 4 (6.8) 5 (8.5) 6 (10.2) 0 (0) 3 (5.1) 0 (0) 29 (49.2) 0 (0)
Texas 764 324 (42.4) 25 (3.3) 40 (5.2) 71 (9.3) 18 (2.4) 30 (3.9) 1 (0.1) 255 (33.4) 0 (0)
Utah 28 10 (35.7) 0 (0) 5 (17.9) 0 (0) 0 (0) 0 (0) 0 (0) 13 (46.4) 0 (0)
Vermont 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100.0) 0 (0)
Virginia 168 5 (3.0) 23 (13.7) 17 (10.1) 17 (10.1) 1 (0.6) 7 (4.2) 0 (0) 98 (58.3) 0 (0)
Washington 160 25 (15.6) 33 (20.6) 16 (10.0) 18 (11.3) 9 (5.6) 2 (1.3) 0 (0) 56 (35.0) 1 (0.6)
West Virginia 3 1 (33.3) 0 (0) 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0)
Wisconsin 49 10 (20.4) 4 (8.2) 6 (12.2) 2 (4.1) 2 (4.1) 1 (2.0) 0 (0) 24 (49.0) 0 (0)
Wyoming 2 0 (0) 1 (50.0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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United States 6,350 24 (0.4) 122 (1.9) 171 (2.7) 1,670 (26.3) 409 (6.4) 191 (3.0) 113 (1.8) 1,408 (22.2) 2,242 (35.3)
Alabama 29 1 (3.4) 2 (6.9) 3 (10.3) 2 (6.9) 0 (0) 1 (3.4) 0 (0) 19 (65.5) 1 (3.4)
Alaska 8 0 (0) 0 (0) 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 7 (87.5)
Arizona 141 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 141 (100.0)
Arkansas 18 0 (0) 0 (0) 2 (11.1) 8 (44.4) 0 (0) 2 (11.1) 0 (0) 1 (5.6) 5 (27.8)
California 1,718 5 (0.3) 39 (2.3) 63 (3.7) 751 (43.7) 63 (3.7) 53 (3.1) 42 (2.4) 324 (18.9) 378 (22.0)
Colorado 58 0 (0) 2 (3.4) 9 (15.5) 23 (39.7) 7 (12.1) 1 (1.7) 1 (1.7) 6 (10.3) 9 (15.5)
Connecticut 57 0 (0) 4 (7.0) 7 (12.3) 16 (28.1) 5 (8.8) 6 (10.5) 4 (7.0) 11 (19.3) 4 (7.0)
Delaware 13 0 (0) 1 (7.7) 3 (23.1) 1 (7.7) 0 (0) 1 (7.7) 0 (0) 2 (15.4) 5 (38.5)
District of Columbia 18 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 18 (100.0)
Florida 342 6 (1.8) 15 (4.4) 6 (1.8) 112 (32.7) 3 (0.9) 3 (0.9) 2 (0.6) 67 (19.6) 128 (37.4)
Georgia 148 1 (0.7) 6 (4.1) 13 (8.8) 50 (33.8) 18 (12.2) 5 (3.4) 3 (2.0) 28 (18.9) 24 (16.2)
Hawaii 82 0 (0) 0 (0) 0 (0) 46 (56.1) 0 (0) 2 (2.4) 0 (0) 0 (0) 34 (41.5)
Idaho 9 0 (0) 0 (0) 0 (0) 2 (22.2) 7 (77.8) 0 (0) 0 (0) 0 (0) 0 (0.0)
Illinois 243 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 243 (100.0)
Indiana 67 0 (0) 0 (0) 0 (0) 22 (32.8) 20 (29.9) 2 (3.0) 0 (0) 3 (4.5) 20 (29.9)
Iowa 31 0 (0) 2 (6.5) 2 (6.5) 11 (35.5) 8 (25.8) 5 (16.1) 0 (0) 3 (9.7) 0 (0.0)
Kansas 26 0 (0) 4 (15.4) 1 (3.8) 9 (34.6) 9 (34.6) 0 (0) 0 (0) 3 (11.5) 0 (0.0)
Kentucky 33 0 (0) 0 (0) 0 (0) 5 (15.2) 13 (39.4) 3 (9.1) 0 (0) 11 (33.3) 1 (3.0)
Louisiana 39 0 (0) 1 (2.6) 0 (0) 14 (35.9) 3 (7.7) 1 (2.6) 0 (0) 6 (15.4) 14 (35.9)
Maine 14 3 (21.4) 0 (0) 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0) 9 (64.3)
Maryland 134 1 (0.7) 1 (0.7) 6 (4.5) 52 (38.8) 9 (6.7) 13 (9.7) 3 (2.2) 38 (28.4) 11 (8.2)
Massachusetts 163 0 (0) 1 (0.6) 3 (1.8) 19 (11.7) 11 (6.7) 2 (1.2) 4 (2.5) 5 (3.1) 118 (72.4)
Michigan 84 0 (0) 4 (4.8) 3 (3.6) 49 (58.3) 3 (3.6) 10 (11.9) 3 (3.6) 4 (4.8) 8 (9.5)
Minnesota 128 2 (1.6) 4 (3.1) 11 (8.6) 31 (24.2) 52 (40.6) 6 (4.7) 10 (7.8) 5 (3.9) 7 (5.5)
Mississippi 10 0 (0) 1 (10.0) 1 (10.0) 0 (0) 0 (0) 1 (10.0) 0 (0) 2 (20.0) 5 (50.0)
Missouri 55 0 (0) 2 (3.6) 0 (0) 4 (7.3) 2 (3.6) 17 (30.9) 2 (3.6) 0 (0) 28 (50.9)
Montana 2 0 (0) 0 (0) 0 (0) 1 (50.0) 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0.0)
Nebraska 25 0 (0) 0 (0) 0 (0) 2 (8.0) 8 (32.0) 2 (8.0) 0 (0) 0 (0) 13 (52.0)
No. (%)No. (%)No. (%)No. (%) No. (%) No. (%) No. (%) No. (%)
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the Federated States of Micronesia, the Republic of the 
Marshall Islands, and the Republic of Palau).
2Other immigration status includes (but is not limited to) foreign-born persons who were not required to obtain a visa or persons with no official immigration status (i.e., undocumented).
3Excludes New York City.
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Table 36. (Con’t) Tuberculosis Cases and Percentages Among Foreign-Born Persons1, by Immigration Status at First Entry: 
Reporting Areas, 2015
Nevada 59 0 (0) 0 (0) 0 (0) 50 (84.7) 2 (3.4) 0 (0) 1 (1.7) 2 (3.4) 4 (6.8)
New Hampshire 11 1 (9.1) 1 (9.1) 0 (0) 3 (27.3) 3 (27.3) 1 (9.1) 0 (0) 0 (0) 2 (18.2)
New Jersey 265 1 (0.4) 7 (2.6) 2 (0.8) 139 (52.5) 2 (0.8) 7 (2.6) 10 (3.8) 96 (36.2) 1 (0.4)
New Mexico 24 0 (0) 4 (16.7) 1 (4.2) 11 (45.8) 0 (0) 0 (0) 0 (0) 4 (16.7) 4 (16.7)
New York State3 145 0 (0) 1 (0.7) 0 (0) 30 (20.7) 21 (14.5) 8 (5.5) 9 (6.2) 76 (52.4) 0 (0.0)
New York City 471 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 471 (100.0)
North Carolina 92 0 (0) 3 (3.3) 4 (4.3) 8 (8.7) 7 (7.6) 2 (2.2) 0 (0) 64 (69.6) 4 (4.3)
North Dakota 8 0 (0) 0 (0) 0 (0) 2 (25.0) 3 (37.5) 1 (12.5) 1 (12.5) 0 (0) 1 (12.5)
Ohio 89 0 (0) 1 (1.1) 5 (5.6) 5 (5.6) 12 (13.5) 3 (3.4) 4 (4.5) 0 (0) 59 (66.3)
Oklahoma 25 0 (0) 0 (0) 0 (0) 4 (16.0) 4 (16.0) 4 (16.0) 0 (0) 3 (12.0) 10 (40.0)
Oregon 52 0 (0) 0 (0) 5 (9.6) 14 (26.9) 8 (15.4) 4 (7.7) 2 (3.8) 5 (9.6) 14 (26.9)
Pennsylvania 121 0 (0) 3 (2.5) 5 (4.1) 56 (46.3) 19 (15.7) 5 (4.1) 6 (5.0) 10 (8.3) 17 (14.0)
Rhode Island 26 0 (0) 0 (0) 0 (0) 5 (19.2) 1 (3.8) 0 (0) 0 (0) 5 (19.2) 15 (57.7)
South Carolina 25 0 (0) 2 (8.0) 0 (0) 2 (8.0) 1 (4.0) 0 (0) 0 (0) 5 (20.0) 15 (60.0)
South Dakota 5 0 (0) 0 (0) 0 (0) 2 (40.0) 1 (20.0) 0 (0) 0 (0) 1 (20.0) 1 (20.0)
Tennessee 59 0 (0) 0 (0) 0 (0) 0 (0) 3 (5.1) 1 (1.7) 0 (0) 0 (0) 55 (93.2)
Texas 764 3 (0.4) 8 (1.0) 12 (1.6) 91 (11.9) 57 (7.5) 16 (2.1) 5 (0.7) 568 (74.3) 4 (0.5)
Utah 28 0 (0) 1 (3.6) 0 (0) 9 (32.1) 6 (21.4) 1 (3.6) 0 (0) 10 (35.7) 1 (3.6)
Vermont 4 0 (0) 0 (0) 0 (0) 2 (50.0) 1 (25.0) 0 (0) 1 (25.0) 0 (0) 0 (0.0)
Virginia 168 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 168 (100.0)
Washington 160 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 160 (100.0)
West Virginia 3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 0 (0) 2 (66.7)
Wisconsin 49 0 (0) 1 (2.0) 3 (6.1) 6 (12.2) 16 (32.7) 0 (0) 0 (0) 21 (42.9) 2 (4.1)
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United States 6,350 1,062 (16.7) 1,003 (15.8) 776 (12.2) 1,240 (19.5) 1,682 (26.5) 587 (9.2)
Alabama 29 2 (6.9) 3 (10.3) 9 (31.0) 12 (41.4) 3 (10.3) 0 (0)
Alaska 8 1 (12.5) 1 (12.5) 2 (25.0) 0 (0) 3 (37.5) 1 (12.5)
Arizona 141 43 (30.5) 18 (12.8) 9 (6.4) 21 (14.9) 46 (32.6) 4 (2.8)
Arkansas 18 6 (33.3) 4 (22.2) 4 (22.2) 3 (16.7) 1 (5.6) 0 (0)
California 1,718 154 (9.0) 162 (9.4) 161 (9.4) 320 (18.6) 613 (35.7) 308 (17.9)
Colorado 58 12 (20.7) 10 (17.2) 5 (8.6) 8 (13.8) 11 (19.0) 12 (20.7)
Connecticut 57 12 (21.1) 16 (28.1) 6 (10.5) 11 (19.3) 12 (21.1) 0 (0)
Delaware 13 3 (23.1) 3 (23.1) 1 (7.7) 6 (46.2) 0 (0) 0 (0)
District of Columbia 18 5 (27.8) 3 (16.7) 5 (27.8) 0 (0) 5 (27.8) 0 (0)
Florida 342 54 (15.8) 68 (19.9) 45 (13.2) 79 (23.1) 82 (24.0) 14 (4.1)
Georgia 148 38 (25.7) 23 (15.5) 21 (14.2) 29 (19.6) 29 (19.6) 8 (5.4)
Hawaii 82 20 (24.4) 6 (7.3) 9 (11.0) 15 (18.3) 25 (30.5) 7 (8.5)
Idaho 9 4 (44.4) 4 (44.4) 0 (0) 1 (11.1) 0 (0) 0 (0)
Illinois 243 43 (17.7) 41 (16.9) 32 (13.2) 64 (26.3) 57 (23.5) 6 (2.5)
Indiana 67 21 (31.3) 9 (13.4) 7 (10.4) 16 (23.9) 5 (7.5) 9 (13.4)
Iowa 31 0 (0) 0 (0) 2 (6.5) 0 (0) 0 (0) 29 (93.5)
Kansas 26 4 (15.4) 6 (23.1) 6 (23.1) 5 (19.2) 5 (19.2) 0 (0)
Kentucky 33 7 (21.2) 11 (33.3) 4 (12.1) 9 (27.3) 2 (6.1) 0 (0)
Louisiana 39 10 (25.6) 5 (12.8) 9 (23.1) 7 (17.9) 8 (20.5) 0 (0)
Maine 14 9 (64.3) 2 (14.3) 0 (0) 1 (7.1) 2 (14.3) 0 (0)
Maryland 134 25 (18.7) 36 (26.9) 21 (15.7) 18 (13.4) 33 (24.6) 1 (0.7)
Massachusetts 163 42 (25.8) 26 (16.0) 21 (12.9) 30 (18.4) 34 (20.9) 10 (6.1)
Michigan 84 16 (19.0) 16 (19.0) 15 (17.9) 16 (19.0) 16 (19.0) 5 (6.0)
Minnesota 128 28 (21.9) 24 (18.8) 21 (16.4) 34 (26.6) 20 (15.6) 1 (0.8)
Mississippi 10 0 (0) 3 (30.0) 2 (20.0) 3 (30.0) 2 (20.0) 0 (0)
Missouri 55 20 (36.4) 10 (18.2) 2 (3.6) 14 (25.5) 9 (16.4) 0 (0)
Montana 2 0 (0) 2 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
Nebraska 25 6 (24.0) 5 (20.0) 4 (16.0) 5 (20.0) 4 (16.0) 1 (4.0)
Nevada 59 6 (10.2) 8 (13.6) 9 (15.3) 13 (22.0) 22 (37.3) 1 (1.7)
New Hampshire 11 3 (27.3) 3 (27.3) 1 (9.1) 3 (27.3) 1 (9.1) 0 (0)
New Jersey 265 41 (15.5) 44 (16.6) 29 (10.9) 54 (20.4) 49 (18.5) 48 (18.1)
New Mexico 24 4 (16.7) 1 (4.2) 1 (4.2) 3 (12.5) 15 (62.5) 0 (0)
New York 616 80 (13.0) 127 (20.6) 93 (15.1) 119 (19.3) 151 (24.5) 46 (7.5)
North Carolina 92 14 (15.2) 13 (14.1) 9 (9.8) 15 (16.3) 8 (8.7) 33 (35.9)
North Dakota 8 1 (12.5) 2 (25.0) 0 (0) 3 (37.5) 1 (12.5) 1 (12.5)
Ohio 89 25 (28.1) 30 (33.7) 16 (18.0) 9 (10.1) 9 (10.1) 0 (0)
Oklahoma 25 4 (16.0) 5 (20.0) 3 (12.0) 3 (12.0) 8 (32.0) 2 (8.0)
Oregon 52 12 (23.1) 5 (9.6) 5 (9.6) 5 (9.6) 3 (5.8) 22 (42.3)
Pennsylvania 121 16 (13.2) 27 (22.3) 18 (14.9) 31 (25.6) 29 (24.0) 0 (0)
Rhode Island 26 2 (7.7) 6 (23.1) 4 (15.4) 3 (11.5) 9 (34.6) 2 (7.7)
South Carolina 25 2 (8.0) 6 (24.0) 8 (32.0) 5 (20.0) 4 (16.0) 0 (0)
South Dakota 5 2 (40.0) 0 (0) 0 (0) 3 (60.0) 0 (0) 0 (0)
Tennessee 59 15 (25.4) 8 (13.6) 9 (15.3) 16 (27.1) 11 (18.6) 0 (0)
Texas 764 179 (23.4) 121 (15.8) 83 (10.9) 152 (19.9) 229 (30.0) 0 (0)
Utah 28 10 (35.7) 3 (10.7) 4 (14.3) 6 (21.4) 4 (14.3) 1 (3.6)
Vermont 4 1 (25.0) 1 (25.0) 1 (25.0) 1 (25.0) 0 (0) 0 (0)
Virginia 168 24 (14.3) 42 (25.0) 26 (15.5) 37 (22.0) 39 (23.2) 0 (0)
Washington 160 25 (15.6) 26 (16.3) 24 (15.0) 25 (15.6) 47 (29.4) 13 (8.1)
West Virginia 3 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 0 (0) 0 (0)
Wisconsin 49 9 (18.4) 7 (14.3) 10 (20.4) 5 (10.2) 16 (32.7) 2 (4.1)
Wyoming 2 1 (50.0) 0 (0) 0 (0) 1 (50.0) 0 (0) 0 (0)
Table 37. Tuberculosis Cases and Percentages Among Foreign-Born Persons1, by Number of 




1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
                 
<1 Year 1–4 5–9 10–19 >20 Unknown/
missing
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
1Includes cases with pulmonary listed as the only site of disease.
2Includes cases with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmonary, listed as site of disease.
3Not included in U.S. totals.
Note: Six cases had missing and/or unknown site of disease.
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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United States 9,557 6,668 (69.8) 1,933 (20.2) 950 (9.9)
Alabama 119 97 (81.5) 20 (16.8) 2 (1.7)
Alaska 68 60 (88.2) 5 (7.4) 3 (4.4)
Arizona 198 154 (77.8) 31 (15.7) 13 (6.6)
Arkansas 90 65 (72.2) 16 (17.8) 9 (10.0)
California 2,133 1,500 (70.3) 418 (19.6) 215 (10.1)
Colorado 73 34 (46.6) 24 (32.9) 15 (20.5)
Connecticut 70 40 (57.1) 22 (31.4) 8 (11.4)
Delaware 22 10 (45.5) 12 (54.5) 0 (0)
District of Columbia 33 18 (54.5) 8 (24.2) 7 (21.2)
Florida 602 462 (76.7) 80 (13.3) 60 (10.0)
Georgia 324 240 (74.1) 59 (18.2) 25 (7.7)
Hawaii 127 93 (73.2) 13 (10.2) 21 (16.5)
Idaho 11 7 (63.6) 2 (18.2) 1 (9.1)
Illinois 343 235 (68.5) 81 (23.6) 27 (7.9)
Indiana 116 75 (64.7) 28 (24.1) 13 (11.2)
Iowa 38 26 (68.4) 9 (23.7) 3 (7.9)
Kansas 36 26 (72.2) 8 (22.2) 2 (5.6)
Kentucky 67 49 (73.1) 14 (20.9) 4 (6.0)
Louisiana 119 99 (83.2) 17 (14.3) 3 (2.5)
Maine 18 9 (50.0) 9 (50.0) 0 (0)
Maryland 176 104 (59.1) 51 (29.0) 21 (11.9)
Massachusetts 192 120 (62.5) 48 (25.0) 22 (11.5)
Michigan 131 74 (56.5) 44 (33.6) 13 (9.9)
Minnesota 150 79 (52.7) 53 (35.3) 18 (12.0)
Mississippi 74 61 (82.4) 8 (10.8) 5 (6.8)
Missouri 92 60 (65.2) 15 (16.3) 17 (18.5)
Montana 9 9 (100.0) 0 (0) 0 (0)
Nebraska 33 19 (57.6) 13 (39.4) 0 (0)
Nevada 85 61 (71.8) 19 (22.4) 5 (5.9)
New Hampshire 13 8 (61.5) 3 (23.1) 2 (15.4)
New Jersey 326 224 (68.7) 70 (21.5) 32 (9.8)
New Mexico 47 35 (74.5) 10 (21.3) 2 (4.3)
New York 765 499 (65.2) 152 (19.9) 114 (14.9)
North Carolina 199 141 (70.9) 31 (15.6) 27 (13.6)
North Dakota 9 7 (77.8) 2 (22.2) 0 (0)
Ohio 143 98 (68.5) 45 (31.5) 0 (0)
Oklahoma 67 50 (74.6) 16 (23.9) 1 (1.5)
Oregon 76 51 (67.1) 14 (18.4) 11 (14.5)
Pennsylvania 200 138 (69.0) 49 (24.5) 13 (6.5)
Rhode Island 30 16 (53.3) 11 (36.7) 3 (10.0)
South Carolina 104 68 (65.4) 22 (21.2) 14 (13.5)
South Dakota 17 12 (70.6) 2 (11.8) 3 (17.6)
Tennessee 131 88 (67.2) 27 (20.6) 16 (12.2)
Texas 1,334 1,014 (76.0) 211 (15.8) 109 (8.2)
Utah 37 23 (62.2) 10 (27.0) 4 (10.8)
Vermont 7 6 (85.7) 1 (14.3) 0 (0)
Virginia 212 139 (65.6) 45 (21.2) 28 (13.2)
Washington 208 114 (54.8) 59 (28.4) 33 (15.9)
West Virginia 10 7 (70.0) 3 (30.0) 0 (0)
Wisconsin 69 41 (59.4) 22 (31.9) 6 (8.7)
Wyoming 4 3 (75.0) 1 (25.0) 0 (0)
American Samoa3 4 4 (100.0) 0 (0) 0 (0)
Fed. States of Micronesia3 103 90 (87.4) 13 (12.6) 0 (0)
Guam3 76 73 (96.1) 2 (2.6) 1 (1.3)
Marshall Islands3 137 98 (71.5) 28 (20.4) 11 (8.0)
N. Mariana Islands3 27 25 (92.6) 1 (3.7) 0 (0)
Puerto Rico3 52 49 (94.2) 2 (3.8) 1 (1.9)
Republic of Palau3 14 10 (71.4) 3 (21.4) 1 (7.1)
U.S. Virgin Islands3 0 0 ... 0 ... 0 ...










United States 1,933 2,032 349 (17.2) 715 (35.2) 196 (9.6) 91 (4.5) 92 (4.5) 126 (6.2) 4 (0.2) 459 (22.6)
Alabama 20 20 6 (30.0) 3 (15.0) 0 (0) 0 (0) 2 (10.0) 3 (15.0) 0 (0) 6 (30.0)
Alaska 5 5 0 (0) 0 (0) 1 (20.0) 0 (0) 2 (40.0) 0 (0) 0 (0) 2 (40.0)
Arizona 31 32 7 (21.9) 11 (34.4) 5 (15.6) 2 (6.3) 1 (3.1) 1 (3.1) 0 (0) 5 (15.6)
Arkansas 16 17 5 (29.4) 3 (17.6) 1 (5.9) 0 (0) 1 (5.9) 1 (5.9) 0 (0) 6 (35.3)
California 418 435 82 (18.9) 133 (30.6) 38 (8.7) 28 (6.4) 20 (4.6) 33 (7.6) 0 (0) 101 (23.2)
Colorado 24 27 2 (7.4) 9 (33.3) 3 (11.1) 1 (3.7) 1 (3.7) 1 (3.7) 0 (0) 10 (37.0)
Connecticut 22 24 3 (12.5) 13 (54.2) 4 (16.7) 2 (8.3) 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Delaware 12 12 4 (33.3) 2 (16.7) 2 (16.7) 0 (0) 0 (0) 1 (8.3) 0 (0) 3 (25.0)
District of Columbia 8 8 1 (12.5) 2 (25.0) 0 (0) 0 (0) 2 (25.0) 0 (0) 0 (0) 3 (37.5)
Florida 80 84 14 (16.7) 28 (33.3) 12 (14.3) 2 (2.4) 6 (7.1) 2 (2.4) 0 (0) 20 (23.8)
Georgia 59 60 8 (13.3) 20 (33.3) 2 (3.3) 5 (8.3) 4 (6.7) 2 (3.3) 0 (0) 19 (31.7)
Hawaii 13 14 1 (7.1) 4 (28.6) 1 (7.1) 3 (21.4) 0 (0) 0 (0) 1 (7.1) 4 (28.6)
Idaho 2 2 0 (0) 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0)
Illinois 81 86 11 (12.8) 34 (39.5) 10 (11.6) 3 (3.5) 1 (1.2) 10 (11.6) 0 (0) 17 (19.8)
Indiana 28 30 7 (23.3) 9 (30.0) 3 (10.0) 5 (16.7) 0 (0) 2 (6.7) 0 (0) 4 (13.3)
Iowa 9 11 2 (18.2) 5 (45.5) 0 (0) 1 (9.1) 0 (0) 0 (0) 0 (0) 3 (27.3)
Kansas 8 8 2 (25.0) 3 (37.5) 2 (25.0) 0 (0) 0 (0) 1 (12.5) 0 (0) 0 (0)
Kentucky 14 17 3 (17.6) 4 (23.5) 2 (11.8) 2 (11.8) 1 (5.9) 1 (5.9) 0 (0) 4 (23.5)
Louisiana 17 17 4 (23.5) 7 (41.2) 0 (0) 0 (0) 2 (11.8) 0 (0) 0 (0) 4 (23.5)
Maine 9 11 2 (18.2) 4 (36.4) 0 (0) 0 (0) 0 (0) 1 (9.1) 0 (0) 4 (36.4)
Maryland 51 54 14 (25.9) 17 (31.5) 4 (7.4) 1 (1.9) 3 (5.6) 1 (1.9) 0 (0) 14 (25.9)
Massachusetts 48 48 7 (14.6) 14 (29.2) 2 (4.2) 1 (2.1) 3 (6.3) 3 (6.3) 0 (0) 18 (37.5)
Michigan 44 44 9 (20.5) 12 (27.3) 3 (6.8) 0 (0) 0 (0) 2 (4.5) 1 (2.3) 17 (38.6)
Minnesota 53 55 2 (3.6) 33 (60.0) 11 (20.0) 3 (5.5) 0 (0) 3 (5.5) 0 (0) 3 (5.5)
Mississippi 8 8 1 (12.5) 2 (25.0) 2 (25.0) 0 (0) 1 (12.5) 0 (0) 0 (0) 2 (25.0)
Missouri 15 15 2 (13.3) 7 (46.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 5 (33.3)
Nebraska 13 13 0 (0) 2 (15.4) 1 (7.7) 1 (7.7) 1 (7.7) 0 (0) 0 (0) 8 (61.5)
Nevada 19 19 3 (15.8) 8 (42.1) 1 (5.3) 0 (0) 3 (15.8) 2 (10.5) 0 (0) 2 (10.5)
New Hampshire 3 3 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 0 (0) 2 (66.7)
New Jersey 70 74 12 (16.2) 27 (36.5) 7 (9.5) 5 (6.8) 3 (4.1) 8 (10.8) 0 (0) 12 (16.2)
New Mexico 10 11 4 (36.4) 0 (0) 1 (9.1) 1 (9.1) 1 (9.1) 0 (0) 0 (0) 4 (36.4)




OtherPleural Lymphatic Bone or joint Genitourinary Meningeal Peritoneal








1Excludes cases with pulmonary site of disease and cases with site not stated.
2Patient may have more than one extrapulmonary site of disease.
3Not included in U.S. totals. 
Note:Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes.
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New York 152 173 35 (20.2) 69 (39.9) 16 (9.2) 10 (5.8) 9 (5.2) 8 (4.6) 0 (0) 26 (15.0)
North Carolina 31 36 11 (30.6) 7 (19.4) 5 (13.9) 2 (5.6) 2 (5.6) 2 (5.6) 0 (0) 7 (19.4)
North Dakota 2 2 0 (0) 2 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ohio 45 45 6 (13.3) 15 (33.3) 4 (8.9) 2 (4.4) 4 (8.9) 4 (8.9) 0 (0) 10 (22.2)
Oklahoma 16 16 5 (31.3) 10 (62.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (6.3)
Oregon 14 14 1 (7.1) 4 (28.6) 1 (7.1) 0 (0) 0 (0) 2 (14.3) 0 (0) 6 (42.9)
Pennyslvania 49 49 7 (14.3) 19 (38.8) 2 (4.1) 2 (4.1) 0 (0) 7 (14.3) 0 (0) 12 (24.5)
Rhode Island 11 12 3 (25.0) 3 (25.0) 1 (8.3) 2 (16.7) 2 (16.7) 1 (8.3) 0 (0) 0 (0)
South Carolina 22 25 6 (24.0) 9 (36.0) 4 (16.0) 0 (0) 1 (4.0) 3 (12.0) 0 (0) 2 (8.0)
South Dakota 2 2 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0)
Tennessee 27 27 2 (7.4) 15 (55.6) 3 (11.1) 0 (0) 1 (3.7) 1 (3.7) 0 (0) 5 (18.5)
Texas 211 222 36 (16.2) 77 (34.7) 31 (14.0) 3 (1.4) 11 (5.0) 8 (3.6) 1 (0.5) 55 (24.8)
Utah 10 10 0 (0) 3 (30.0) 2 (20.0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (50.0)
Vermont 1 1 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Virginia 45 47 3 (6.4) 25 (53.2) 3 (6.4) 1 (2.1) 0 (0) 3 (6.4) 0 (0) 12 (25.5)
Washington 59 61 12 (19.7) 27 (44.3) 3 (4.9) 1 (1.6) 2 (3.3) 7 (11.5) 0 (0) 9 (14.8)
West Virginia 3 3 0 (0) 1 (33.3) 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3)
Wisconsin 22 22 4 (18.2) 11 (50.0) 0 (0) 2 (9.1) 0 (0) 1 (4.5) 1 (4.5) 3 (13.6)
Wyoming 1 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
American Samoa3 0 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Fed. States of Micronesia3 13 14 4 (28.6) 9 (64.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1)
Guam3 2 2 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0)
Marshall Islands3 28 28 10 (35.7) 8 (28.6) 1 (3.6) 0 (0) 0 (0) 8 (28.6) 0 (0) 1 (3.6)
N. Mariana Islands3 1 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
Puerto Rico3 2 3 2 (66.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3)
Republic of Palau3 3 3 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (66.7)
U.S. Virgin Islands3 0 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
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76 Table 40. Tuberculosis Risk Factors1: Reporting Areas, 2015
United States 9,557 13 (0.1) 66 (0.7) 705 (7.4) 202 (2.1) 1,488 (15.6) 199 (2.1) 52 (0.5) 39 (0.4) 406 (4.2) 2,191 (22.9) 4,251 (44.5) 686 (7.2)
Alabama 119 1 (0.8) 1 (0.8) 23 (19.3) 6 (5.0) 9 (7.6) 2 (1.7) 1 (0.8) 2 (1.7) 6 (5.0) 5 (4.2) 68 (57.1) 0 (0)
Alaska 68 0 (0) 0 (0) 28 (41.2) 2 (2.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (5.9) 34 (50.0) 0 (0)
Arizona 198 1 (0.5) 2 (1.0) 16 (8.1) 4 (2.0) 26 (13.1) 2 (1.0) 2 (1.0) 2 (1.0) 3 (1.5) 35 (17.7) 120 (60.6) 0 (0)
Arkansas 90 0 (0) 5 (5.6) 30 (33.3) 7 (7.8) 12 (13.3) 1 (1.1) 0 (0) 0 (0) 4 (4.4) 6 (6.7) 38 (42.2) 1 (1.1)
California 2,133 2 (0.1) 5 (0.2) 87 (4.1) 16 (0.8) 491 (23.0) 71 (3.3) 12 (0.6) 7 (0.3) 92 (4.3) 633 (29.7) 883 (41.4) 39 (1.8)
Colorado 73 0 (0) 0 (0) 4 (5.5) 1 (1.4) 12 (16.4) 2 (2.7) 4 (5.5) 0 (0) 3 (4.1) 0 (0) 51 (69.9) 0 (0)
Connecticut 70 0 (0) 0 (0) 0 (0) 0 (0) 8 (11.4) 1 (1.4) 1 (1.4) 0 (0) 0 (0) 16 (22.9) 45 (64.3) 0 (0)
Delaware 22 0 (0) 0 (0) 2 (9.1) 0 (0) 2 (9.1) 1 (4.5) 0 (0) 0 (0) 2 (9.1) 12 (54.5) 5 (22.7) 0 (0)
District of Columbia 33 0 (0) 0 (0) 0 (0) 1 (3.0) 1 (3.0) 1 (3.0) 0 (0) 0 (0) 1 (3.0) 5 (15.2) 25 (75.8) 0 (0)
Florida 602 0 (0) 9 (1.5) 56 (9.3) 14 (2.3) 84 (14.0) 9 (1.5) 1 (0.2) 2 (0.3) 75 (12.5) 113 (18.8) 280 (46.5) 0 (0)
Georgia 324 2 (0.6) 6 (1.9) 37 (11.4) 13 (4.0) 53 (16.4) 7 (2.2) 1 (0.3) 1 (0.3) 16 (4.9) 76 (23.5) 160 (49.4) 2 (0.6)
Hawaii 127 0 (0) 0 (0) 12 (9.4) 5 (3.9) 41 (32.3) 0 (0) 0 (0) 0 (0) 3 (2.4) 12 (9.4) 62 (48.8) 0 (0)
Idaho 11 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (18.2) 3 (27.3) 6 (54.5)
Illinois 343 0 (0) 4 (1.2) 33 (9.6) 4 (1.2) 62 (18.1) 3 (0.9) 0 (0) 1 (0.3) 21 (6.1) 49 (14.3) 192 (56.0) 1 (0.3)
Indiana 116 0 (0) 1 (0.9) 17 (14.7) 4 (3.4) 9 (7.8) 3 (2.6) 0 (0) 1 (0.9) 8 (6.9) 21 (18.1) 59 (50.9) 0 (0)
Iowa 38 0 (0) 0 (0) 3 (7.9) 4 (10.5) 1 (2.6) 0 (0) 0 (0) 0 (0) 2 (5.3) 0 (0) 26 (68.4) 3 (7.9)
Kansas 36 0 (0) 0 (0) 1 (2.8) 0 (0) 7 (19.4) 0 (0) 1 (2.8) 0 (0) 0 (0) 3 (8.3) 23 (63.9) 1 (2.8)
Kentucky 67 0 (0) 0 (0) 4 (6.0) 2 (3.0) 1 (1.5) 1 (1.5) 0 (0) 0 (0) 7 (10.4) 23 (34.3) 32 (47.8) 0 (0)
Louisiana 119 1 (0.8) 3 (2.5) 10 (8.4) 3 (2.5) 15 (12.6) 2 (1.7) 0 (0) 0 (0) 6 (5.0) 11 (9.2) 67 (56.3) 3 (2.5)
Maine 18 0 (0) 0 (0) 5 (27.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5.6) 1 (5.6) 12 (66.7) 0 (0)
Maryland 176 0 (0) 0 (0) 17 (9.7) 3 (1.7) 27 (15.3) 2 (1.1) 0 (0) 1 (0.6) 7 (4.0) 17 (9.7) 99 (56.3) 8 (4.5)
Massachusetts 192 2 (1.0) 2 (1.0) 8 (4.2) 8 (4.2) 13 (6.8) 8 (4.2) 3 (1.6) 1 (0.5) 0 (0) 57 (29.7) 95 (49.5) 17 (8.9)
Michigan 131 0 (0) 1 (0.8) 9 (6.9) 8 (6.1) 18 (13.7) 1 (0.8) 0 (0) 0 (0) 3 (2.3) 97 (74.0) 0 (0) 1 (0.8)
Minnesota 150 0 (0) 0 (0) 5 (3.3) 14 (9.3) 12 (8.0) 3 (2.0) 0 (0) 0 (0) 13 (8.7) 82 (54.7) 43 (28.7) 1 (0.7)
Mississippi 74 0 (0) 1 (1.4) 4 (5.4) 4 (5.4) 5 (6.8) 0 (0) 0 (0) 0 (0) 0 (0) 61 (82.4) 8 (10.8) 1 (1.4)
Missouri 92 0 (0) 1 (1.1) 18 (19.6) 0 (0) 13 (14.1) 3 (3.3) 1 (1.1) 0 (0) 11 (12.0) 12 (13.0) 49 (53.3) 0 (0)
Montana 9 0 (0) 0 (0) 1 (11.1) 0 (0) 1 (11.1) 0 (0) 0 (0) 0 (0) 1 (11.1) 8 (88.9) 0 (0) 0 (0)
Nebraska 33 0 (0) 1 (3.0) 3 (9.1) 1 (3.0) 2 (6.1) 0 (0) 0 (0) 0 (0) 1 (3.0) 12 (36.4) 3 (9.1) 12 (36.4)
Nevada 85 0 (0) 0 (0) 0 (0) 2 (2.4) 17 (20.0) 0 (0) 2 (2.4) 0 (0) 3 (3.5) 1 (1.2) 60 (70.6) 0 (0)
New Hampshire 13 0 (0) 0 (0) 0 (0) 1 (7.7) 1 (7.7) 0 (0) 1 (7.7) 0 (0) 0 (0) 2 (15.4) 8 (61.5) 0 (0)
New Jersey 326 1 (0.3) 0 (0) 20 (6.1) 1 (0.3) 68 (20.9) 11 (3.4) 1 (0.3) 3 (0.9) 13 (4.0) 41 (12.6) 184 (56.4) 1 (0.3)























No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Total
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New York State3 188 0 (0) 2 (1.1) 21 (11.2) 8 (4.3) 33 (17.6) 3 (1.6) 1 (0.5) 3 (1.6) 6 (3.2) 26 (13.8) 102 (54.3) 0 (0)
New York City 577 1 (0.2) 1 (0.2) 28 (4.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 0 (0) 547 (94.8)
North Carolina 199 0 (0) 3 (1.5) 25 (12.6) 15 (7.5) 19 (9.5) 3 (1.5) 2 (1.0) 1 (0.5) 8 (4.0) 45 (22.6) 103 (51.8) 21 (10.6)
North Dakota 9 0 (0) 0 (0) 0 (0) 0 (0) 1 (11.1) 0 (0) 0 (0) 0 (0) 0 (0) 4 (44.4) 5 (55.6) 0 (0)
Ohio 143 0 (0) 1 (0.7) 6 (4.2) 10 (7.0) 19 (13.3) 2 (1.4) 0 (0) 1 (0.7) 5 (3.5) 16 (11.2) 83 (58.0) 0 (0)
Oklahoma 67 0 (0) 3 (4.5) 14 (20.9) 6 (9.0) 18 (26.9) 2 (3.0) 0 (0) 0 (0) 3 (4.5) 4 (6.0) 30 (44.8) 0 (0)
Oregon 76 0 (0) 1 (1.3) 6 (7.9) 0 (0) 11 (14.5) 0 (0) 1 (1.3) 0 (0) 4 (5.3) 15 (19.7) 46 (60.5) 0 (0)
Pennsylvania 200 0 (0) 0 (0) 5 (2.5) 7 (3.5) 20 (10.0) 6 (3.0) 2 (1.0) 1 (0.5) 11 (5.5) 48 (24.0) 106 (53.0) 2 (1.0)
Rhode Island 30 0 (0) 0 (0) 1 (3.3) 3 (10.0) 8 (26.7) 2 (6.7) 0 (0) 0 (0) 2 (6.7) 4 (13.3) 15 (50.0) 0 (0)
South Carolina 104 0 (0) 1 (1.0) 11 (10.6) 1 (1.0) 15 (14.4) 5 (4.8) 2 (1.9) 1 (1.0) 5 (4.8) 11 (10.6) 60 (57.7) 0 (0)
South Dakota 17 0 (0) 3 (17.6) 6 (35.3) 1 (5.9) 4 (23.5) 1 (5.9) 0 (0) 0 (0) 1 (5.9) 3 (17.6) 5 (29.4) 0 (0)
Tennessee 131 0 (0) 3 (2.3) 11 (8.4) 7 (5.3) 17 (13.0) 3 (2.3) 0 (0) 0 (0) 6 (4.6) 24 (18.3) 67 (51.1) 0 (0)
Texas 1,334 0 (0) 4 (0.3) 87 (6.5) 8 (0.6) 207 (15.5) 16 (1.2) 5 (0.4) 6 (0.4) 21 (1.6) 445 (33.4) 613 (46.0) 2 (0.1)
Utah 37 1 (2.7) 0 (0) 5 (13.5) 0 (0) 8 (21.6) 0 (0) 1 (2.7) 0 (0) 1 (2.7) 2 (5.4) 19 (51.4) 0 (0)
Vermont 7 0 (0) 0 (0) 1 (14.3) 1 (14.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (85.7) 1 (14.3) 0 (0)
Virginia 212 0 (0) 1 (0.5) 7 (3.3) 0 (0) 44 (20.8) 11 (5.2) 4 (1.9) 3 (1.4) 7 (3.3) 25 (11.8) 124 (58.5) 0 (0)
Washington 208 0 (0) 1 (0.5) 13 (6.3) 3 (1.4) 31 (14.9) 10 (4.8) 1 (0.5) 1 (0.5) 12 (5.8) 49 (23.6) 97 (46.6) 11 (5.3)
West Virginia 10 0 (0) 0 (0) 0 (0) 0 (0) 1 (10.0) 0 (0) 0 (0) 0 (0) 1 (10.0) 5 (50.0) 4 (40.0) 0 (0)
Wisconsin 69 1 (1.4) 0 (0) 4 (5.8) 3 (4.3) 8 (11.6) 1 (1.4) 1 (1.4) 0 (0) 7 (10.1) 34 (49.3) 19 (27.5) 0 (0)
Wyoming 4 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 2 (50.0)
American Samoa4 4 0 (0) 0 (0) 0 (0) 2 (50.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 1 (25.0) 0 (0)
Fed. States of Micronesia4 103 1 (1.0) 2 (1.9) 38 (36.9) 1 (1.0) 13 (12.6) 0 (0) 0 (0) 0 (0) 0 (0) 32 (31.1) 17 (16.5) 1 (1.0)
Guam4 76 0 (0) 0 (0) 14 (18.4) 1 (1.3) 14 (18.4) 1 (1.3) 0 (0) 0 (0) 0 (0) 2 (2.6) 39 (51.3) 6 (7.9)
Marshall Islands4 137 2 (1.5) 0 (0) 23 (16.8) 0 (0) 35 (25.5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.7) 74 (54.0) 2 (1.5)
N. Mariana Islands4 27 0 (0) 0 (0) 2 (7.4) 0 (0) 13 (48.1) 1 (3.7) 0 (0) 0 (0) 0 (0) 1 (3.7) 4 (14.8) 7 (25.9)
Puerto Rico4 52 0 (0) 0 (0) 3 (5.8) 0 (0) 13 (25.0) 1 (1.9) 0 (0) 1 (1.9) 1 (1.9) 5 (9.6) 33 (63.5) 0 (0)
Republic of Palau4 14 0 (0) 0 (0) 0 (0) 0 (0) 4 (28.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 9 (64.3) 1 (7.1)
U.S. Virgin Islands4 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1Includes the number of risk factors reported (which may be more than one per case) and the number of cases with no information on additional risk factors. The sum of risk factors is greater 
than the total number of cases because more than one risk factor may be selected per case.
2None of the options for additional risk factors was selected.
3Excludes New York City.
4Not included in U.S. totals.
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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Table 41. Primary Reason for Tuberculosis Evaluation1: Reporting Areas, 2015
United States 9,557 5,341 (55.9) 1,977 (20.7) 430 (4.5) 390 (4.1) 22 (0.2) 67 (0.7) 188 (2.0) 1,087 (11.4) 55 (0.6)
Alabama 119 35 (29.4) 48 (40.3) 18 (15.1) 1 (0.8) 0 (0) 0 (0) 0 (0) 17 (14.3) 0 (0)
Alaska 68 25 (36.8) 11 (16.2) 18 (26.5) 10 (14.7) 0 (0) 0 (0) 0 (0) 4 (5.9) 0 (0)
Arizona 198 98 (49.5) 28 (14.1) 8 (4.0) 32 (16.2) 0 (0) 0 (0) 9 (4.5) 23 (11.6) 0 (0)
Arkansas 90 51 (56.7) 23 (25.6) 9 (10.0) 1 (1.1) 0 (0) 1 (1.1) 1 (1.1) 4 (4.4) 0 (0)
California 2,133 1,260 (59.1) 459 (21.5) 58 (2.7) 53 (2.5) 4 (0.2) 7 (0.3) 39 (1.8) 240 (11.3) 13 (0.6)
Colorado 73 66 (90.4) 2 (2.7) 3 (4.1) 2 (2.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Connecticut 70 57 (81.4) 4 (5.7) 0 (0) 5 (7.1) 0 (0) 0 (0) 0 (0) 4 (5.7) 0 (0)
Delaware 22 16 (72.7) 1 (4.5) 0 (0) 1 (4.5) 0 (0) 0 (0) 1 (4.5) 2 (9.1) 1 (4.5)
District of Columbia 33 27 (81.8) 1 (3.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (15.2) 0 (0)
Florida 602 216 (35.9) 251 (41.7) 21 (3.5) 5 (0.8) 1 (0.2) 1 (0.2) 7 (1.2) 99 (16.4) 1 (0.2)
Georgia 324 181 (55.9) 76 (23.5) 10 (3.1) 9 (2.8) 2 (0.6) 2 (0.6) 10 (3.1) 31 (9.6) 3 (0.9)
Hawaii 127 64 (50.4) 11 (8.7) 9 (7.1) 1 (0.8) 1 (0.8) 13 (10.2) 16 (12.6) 12 (9.4) 0 (0)
Idaho 11 5 (45.5) 4 (36.4) 0 (0) 1 (9.1) 0 (0) 0 (0) 0 (0) 1 (9.1) 0 (0)
Illinois 343 209 (60.9) 48 (14.0) 11 (3.2) 12 (3.5) 1 (0.3) 2 (0.6) 13 (3.8) 47 (13.7) 0 (0)
Indiana 116 49 (42.2) 23 (19.8) 13 (11.2) 1 (0.9) 0 (0) 5 (4.3) 8 (6.9) 17 (14.7) 0 (0)
Iowa 38 26 (68.4) 5 (13.2) 2 (5.3) 0 (0) 0 (0) 4 (10.5) 1 (2.6) 0 (0) 0 (0)
Kansas 36 22 (61.1) 3 (8.3) 0 (0) 0 (0) 0 (0) 1 (2.8) 0 (0) 9 (25.0) 1 (2.8)
Kentucky 67 25 (37.3) 21 (31.3) 6 (9.0) 2 (3.0) 0 (0) 1 (1.5) 6 (9.0) 6 (9.0) 0 (0)
Louisiana 119 78 (65.5) 24 (20.2) 6 (5.0) 3 (2.5) 0 (0) 0 (0) 3 (2.5) 5 (4.2) 0 (0)
Maine 18 9 (50.0) 2 (11.1) 2 (11.1) 0 (0) 0 (0) 0 (0) 1 (5.6) 4 (22.2) 0 (0)
Maryland 176 107 (60.8) 43 (24.4) 5 (2.8) 2 (1.1) 2 (1.1) 2 (1.1) 1 (0.6) 14 (8.0) 0 (0)
Massachusetts 192 134 (69.8) 45 (23.4) 2 (1.0) 0 (0) 1 (0.5) 2 (1.0) 0 (0) 8 (4.2) 0 (0)
Michigan 131 64 (48.9) 39 (29.8) 3 (2.3) 4 (3.1) 0 (0) 0 (0) 0 (0) 21 (16.0) 0 (0)
Minnesota 150 130 (86.7) 3 (2.0) 4 (2.7) 1 (0.7) 1 (0.7) 1 (0.7) 8 (5.3) 2 (1.3) 0 (0)
Mississippi 74 14 (18.9) 28 (37.8) 3 (4.1) 6 (8.1) 0 (0) 1 (1.4) 1 (1.4) 20 (27.0) 1 (1.4)
Missouri 92 43 (46.7) 5 (5.4) 5 (5.4) 8 (8.7) 2 (2.2) 0 (0) 1 (1.1) 3 (3.3) 25 (27.2)
Montana 9 6 (66.7) 2 (22.2) 1 (11.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nebraska 33 24 (72.7) 1 (3.0) 3 (9.1) 1 (3.0) 0 (0) 0 (0) 1 (3.0) 3 (9.1) 0 (0)
Nevada 85 57 (67.1) 10 (11.8) 1 (1.2) 1 (1.2) 0 (0) 2 (2.4) 3 (3.5) 11 (12.9) 0 (0)
New Hampshire 13 3 (23.1) 6 (46.2) 0 (0) 1 (7.7) 0 (0) 0 (0) 1 (7.7) 1 (7.7) 1 (7.7)
New Jersey 326 177 (54.3) 79 (24.2) 12 (3.7) 2 (0.6) 1 (0.3) 0 (0) 3 (0.9) 52 (16.0) 0 (0)
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New York State2 188 89 (47.3) 43 (22.9) 14 (7.4) 4 (2.1) 0 (0) 0 (0) 0 (0) 35 (18.6) 3 (1.6)
New York City 577 305 (52.9) 124 (21.5) 15 (2.6) 8 (1.4) 1 (0.2) 8 (1.4) 8 (1.4) 107 (18.5) 1 (0.2)
North Carolina 199 53 (26.6) 60 (30.2) 29 (14.6) 0 (0) 1 (0.5) 1 (0.5) 0 (0) 55 (27.6) 0 (0)
North Dakota 9 6 (66.7) 0 (0) 0 (0) 2 (22.2) 0 (0) 0 (0) 0 (0) 1 (11.1) 0 (0)
Ohio 143 66 (46.2) 44 (30.8) 3 (2.1) 3 (2.1) 0 (0) 1 (0.7) 1 (0.7) 25 (17.5) 0 (0)
Oklahoma 67 35 (52.2) 12 (17.9) 3 (4.5) 4 (6.0) 0 (0) 1 (1.5) 3 (4.5) 9 (13.4) 0 (0)
Oregon 76 65 (85.5) 1 (1.3) 2 (2.6) 2 (2.6) 0 (0) 0 (0) 4 (5.3) 2 (2.6) 0 (0)
Pennsylvania 200 111 (55.5) 55 (27.5) 3 (1.5) 10 (5.0) 0 (0) 3 (1.5) 4 (2.0) 14 (7.0) 0 (0)
Rhode Island 30 14 (46.7) 11 (36.7) 1 (3.3) 1 (3.3) 0 (0) 0 (0) 0 (0) 3 (10.0) 0 (0)
South Carolina 104 41 (39.4) 34 (32.7) 10 (9.6) 2 (1.9) 0 (0) 0 (0) 0 (0) 17 (16.3) 0 (0)
South Dakota 17 5 (29.4) 4 (23.5) 5 (29.4) 0 (0) 0 (0) 0 (0) 0 (0) 3 (17.6) 0 (0)
Tennessee 131 49 (37.4) 44 (33.6) 3 (2.3) 3 (2.3) 0 (0) 2 (1.5) 4 (3.1) 26 (19.8) 0 (0)
Texas 1,334 841 (63.0) 147 (11.0) 88 (6.6) 178 (13.3) 4 (0.3) 1 (0.1) 16 (1.2) 59 (4.4) 0 (0)
Utah 37 25 (67.6) 1 (2.7) 6 (16.2) 0 (0) 0 (0) 2 (5.4) 3 (8.1) 0 (0) 0 (0)
Vermont 7 5 (71.4) 2 (28.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Virginia 212 163 (76.9) 31 (14.6) 4 (1.9) 3 (1.4) 0 (0) 1 (0.5) 0 (0) 10 (4.7) 0 (0)
Washington 208 113 (54.3) 39 (18.8) 8 (3.8) 0 (0) 0 (0) 2 (1.0) 7 (3.4) 34 (16.3) 5 (2.4)
West Virginia 10 5 (50.0) 2 (20.0) 0 (0) 1 (10.0) 0 (0) 0 (0) 0 (0) 2 (20.0) 0 (0)
Wisconsin 69 34 (49.3) 10 (14.5) 3 (4.3) 1 (1.4) 0 (0) 0 (0) 3 (4.3) 18 (26.1) 0 (0)
Wyoming 4 4 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
American Samoa3 4 3 (75.0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 0 (0) 0 (0) 0 (0)
Fed. States of Micronesia3 103 87 (84.5) 6 (5.8) 9 (8.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
Guam3 76 30 (39.5) 10 (13.2) 15 (19.7) 0 (0) 0 (0) 0 (0) 8 (10.5) 13 (17.1) 0 (0)
Marshall Islands3 137 108 (78.8) 24 (17.5) 3 (2.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (1.5)
N. Mariana Islands3 27 15 (55.6) 10 (37.0) 2 (7.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Puerto Rico3 52 24 (46.2) 26 (50.0) 1 (1.9) 0 (0) 0 (0) 1 (1.9) 0 (0) 0 (0) 0 (0)
Republic of Palau3 14 9 (64.3) 2 (14.3) 1 (7.1) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
U.S. Virgin Islands3 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1Each TB patient has only one primary reason for TB evaluation.
2Excludes New York City.
3Not included in U.S. totals.
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.






















No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)
80
United States 9,115 9,095 (99.8) 330 (3.6)
Alabama 116 116 (100.0) 8 (6.9)
Alaska 55 55 (100.0) 2 (3.6)
Arizona 184 184 (100.0) 37 (20.1)
Arkansas 78 78 (100.0) 0 (0)
California 2,065 2,063 (99.9) 41 (2.0)
Colorado 66 66 (100.0) 0 (0)
Connecticut 70 70 (100.0) 0 (0)
Delaware 19 19 (100.0) 0 (0)
District of Columbia 31 31 (100.0) 0 (0)
Florida 581 581 (100.0) 11 (1.9)
Georgia 306 305 (99.7) 8 (2.6)
Hawaii 119 119 (100.0) 0 (0)
Idaho 9 8 (88.9) 0 (0)
Illinois 330 330 (100.0) 3 (0.9)
Indiana 112 112 (100.0) 5 (4.5)
Iowa 36 36 (100.0) 0 (0)
Kansas 35 35 (100.0) 1 (2.9)
Kentucky 64 64 (100.0) 3 (4.7)
Louisiana 114 113 (99.1) 4 (3.5)
Maine 16 16 (100.0) 0 (0)
Maryland 169 167 (98.8) 0 (0)
Massachusetts 185 184 (99.5) 1 (0.5)
Michigan 128 128 (100.0) 2 (1.6)
Minnesota 140 140 (100.0) 3 (2.1)
Mississippi 71 71 (100.0) 1 (1.4)
Missouri 84 83 (98.8) 0 (0)
Montana 9 9 (100.0) 0 (0)
Nebraska 31 29 (93.5) 0 (0)
Nevada 84 84 (100.0) 2 (2.4)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 316 (100.0) 4 (1.3)
New Mexico 46 46 (100.0) 4 (8.7)
New York State5 173 173 (100.0) 2 (1.2)
New York City 560 554 (98.9) 5 (0.9)
North Carolina 189 189 (100.0) 5 (2.6)
North Dakota 9 9 (100.0) 1 (11.1)
Ohio 138 138 (100.0) 1 (0.7)
Oklahoma 62 62 (100.0) 5 (8.1)
Oregon 72 72 (100.0) 1 (1.4)
Pennsylvania 196 195 (99.5) 3 (1.5)
Rhode Island 30 30 (100.0) 0 (0)
South Carolina 98 98 (100.0) 7 (7.1)
South Dakota 16 16 (100.0) 0 (0)
Tennessee 125 124 (99.2) 4 (3.2)
Texas 1,250 1,250 (100.0) 150 (12.0)
Utah 30 30 (100.0) 0 (0)
Vermont 7 7 (100.0) 0 (0)
Virginia 202 202 (100.0) 1 (0.5)
Washington 196 195 (99.5) 5 (2.6)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 0 (0)
Wyoming 4 4 (100.0) 0 (0)
American Samoa6 4 4 (100.0) 0 (0)
Fed. States of Micronesia6 82 82 (100.0) 0 (0)
Guam6 60 60 (100.0) 1 (1.7)
Marshall Islands6 108 108 (100.0) 0 (0)
N. Mariana Islands6 24 24 (100.0) 0 (0)
Puerto Rico6 52 52 (100.0) 0 (0)
Republic of Palau6 13 13 (100.0) 0 (0)
U.S. Virgin Islands6 0 0 ... 0 ...
Table 42. Tuberculosis Cases and Percentages, by Residence in and Type of 




Cases with information on residence
 in correctional facilities
Cases reported as residents
 of correctional facilities2
No. No.(%) (%)
81
59 (17.9) 67 (20.3) 101 (30.6) 1 (0.3) 99 (30.0) 3 (0.9) 329 (99.7) 120 (36.5)
0 (0) 6 (75.0) 2 (25.0) 0 (0) 0 (0) 0 (0) 8 (100.0) 0 (0)
0 (0) 1 (50.0) 1 (50.0) 0 (0) 0 (0) 0 (0) 2 (100.0) 0 (0)
17 (45.9) 3 (8.1) 10 (27.0) 1 (2.7) 6 (16.2) 0 (0) 37 (100.0) 14 (37.8)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
11 (26.8) 5 (12.2) 15 (36.6) 0 (0) 10 (24.4) 0 (0) 41 (100.0) 13 (31.7)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
2 (18.2) 5 (45.5) 2 (18.2) 0 (0) 2 (18.2) 0 (0) 11 (100.0) 2 (18.2)
0 (0) 3 (37.5) 5 (62.5) 0 (0) 0 (0) 0 (0) 8 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 2 (66.7) 1 (33.3) 0 (0) 0 (0) 0 (0) 3 (100.0) 0 (0)
0 (0) 2 (40.0) 3 (60.0) 0 (0) 0 (0) 0 (0) 5 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
1 (33.3) 0 (0) 2 (66.7) 0 (0) 0 (0) 0 (0) 3 (100.0) 2 (66.7)
1 (25.0) 0 (0) 3 (75.0) 0 (0) 0 (0) 0 (0) 4 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0) 1 (100.0) 1 (100.0)
0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0) 0 (0) 2 (100.0) 1 (50.0)
2 (66.7) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 3 (100.0) 1 (33.3)
0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 1 (50.0) 1 (50.0) 0 (0) 0 (0) 0 (0) 2 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
2 (50.0) 1 (25.0) 0 (0) 0 (0) 1 (25.0) 0 (0) 4 (100.0) 2 (50.0)
0 (0) 0 (0) 0 (0) 0 (0) 4 (100.0) 0 (0) 4 (100.0) 4 (100.0)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0) 2 (100.0) 1 (50.0)
0 (0) 1 (20.0) 3 (60.0) 0 (0) 0 (0) 1 (20.0) 5 (100.0) 0 (0)
3 (60.0) 1 (20.0) 1 (20.0) 0 (0) 0 (0) 0 (0) 5 (100.0) 2 (40.0)
0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 1 (100.0) 1 (100.0)
0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0) 1 (100.0) 0 (0)
0 (0) 3 (60.0) 2 (40.0) 0 (0) 0 (0) 0 (0) 5 (100.0) 0 (0)
0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
0 (0) 0 (0) 3 (100.0) 0 (0) 0 (0) 0 (0) 3 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
1 (14.3) 3 (42.9) 3 (42.9) 0 (0) 0 (0) 0 (0) 7 (100.0) 1 (14.3)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 1 (25.0) 3 (75.0) 0 (0) 0 (0) 0 (0) 4 (100.0) 1 (25.0)
19 (12.7) 28 (18.7) 38 (25.3) 0 (0) 65 (43.3) 0 (0) 150 (100.0) 68 (45.3)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0) 1 (100.0) 1 (100.0)
0 (0) 0 (0) 0 (0) 0 (0) 5 (100.0) 0 (0) 5 (100.0) 5 (100.0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Table 42. (Con’t) Tuberculosis Cases and Percentages, by Residence in and Type of 




1Resident of correctional facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). 
Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Percent of those with known status.
3Excludes youth who are <15 years of age.
4Immigration and Customs Enforcement (ICE) detainment among cases who were residents in correctional facilities.
5Excludes New York City.
6Not included in U.S. totals.
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
























United States 9,115 9,065 (99.5) 495 (5.5)
Alabama 116 116 (100.0) 7 (6.0)
Alaska 55 55 (100.0) 9 (16.4)
Arizona 184 173 (94.0) 11 (6.4)
Arkansas 78 78 (100.0) 4 (5.1)
California 2,065 2,058 (99.7) 115 (5.6)
Colorado 66 66 (100.0) 1 (1.5)
Connecticut 70 70 (100.0) 1 (1.4)
Delaware 19 19 (100.0) 1 (5.3)
District of Columbia 31 31 (100.0) 0 (0)
Florida 581 573 (98.6) 46 (8.0)
Georgia 306 303 (99.0) 26 (8.6)
Hawaii 119 119 (100.0) 2 (1.7)
Idaho 9 9 (100.0) 0 (0)
Illinois 330 328 (99.4) 12 (3.7)
Indiana 112 112 (100.0) 7 (6.3)
Iowa 36 36 (100.0) 0 (0)
Kansas 35 35 (100.0) 6 (17.1)
Kentucky 64 64 (100.0) 7 (10.9)
Louisiana 114 113 (99.1) 6 (5.3)
Maine 16 16 (100.0) 1 (6.3)
Maryland 169 168 (99.4) 7 (4.2)
Massachusetts 185 184 (99.5) 7 (3.8)
Michigan 128 128 (100.0) 7 (5.5)
Minnesota 140 140 (100.0) 5 (3.6)
Mississippi 71 71 (100.0) 9 (12.7)
Missouri 84 83 (98.8) 1 (1.2)
Montana 9 9 (100.0) 0 (0)
Nebraska 31 29 (93.5) 0 (0)
Nevada 84 84 (100.0) 7 (8.3)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 316 (100.0) 10 (3.2)
New Mexico 46 44 (95.7) 5 (11.4)
New York State3 173 173 (100.0) 5 (2.9)
New York City 560 558 (99.6) 19 (3.4)
North Carolina 189 189 (100.0) 11 (5.8)
North Dakota 9 9 (100.0) 0 (0)
Ohio 138 138 (100.0) 6 (4.3)
Oklahoma 62 62 (100.0) 2 (3.2)
Oregon 72 72 (100.0) 8 (11.1)
Pennsylvania 196 195 (99.5) 5 (2.6)
Rhode Island 30 29 (96.7) 0 (0)
South Carolina 98 96 (98.0) 4 (4.2)
South Dakota 16 16 (100.0) 3 (18.8)
Tennessee 125 125 (100.0) 10 (8.0)
Texas 1,250 1,250 (100.0) 90 (7.2)
Utah 30 30 (100.0) 2 (6.7)
Vermont 7 7 (100.0) 1 (14.3)
Virginia 202 202 (100.0) 2 (1.0)
Washington 196 191 (97.4) 6 (3.1)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 1 (1.5)
Wyoming 4 4 (100.0) 0 (0)
American Samoa4 4 4 (100.0) 0 (0)
Fed. States of Micronesia4 82 82 (100.0) 1 (1.2)
Guam4 60 60 (100.0) 0 (0)
Marshall Islands4 108 108 (100.0) 0 (0)
N. Mariana Islands4 24 24 (100.0) 1 (4.2)
Puerto Rico4 52 52 (100.0) 4 (7.7)
Republic of Palau4 13 13 (100.0) 0 (0)









Table 43. Tuberculosis Cases and Percentages, by Homeless Status,1 Ages >15 Years: 
Reporting Areas, 2015
1Homeless within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Percent of those with known status. 
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
See Surveillance Slide #29
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United States 9,115 9,099 (99.8) 171 (1.9)
Alabama 116 116 (100.0) 2 (1.7)
Alaska 55 55 (100.0) 1 (1.8)
Arizona 184 184 (100.0) 3 (1.6)
Arkansas 78 78 (100.0) 1 (1.3)
California 2,065 2,065 (100.0) 58 (2.8)
Colorado 66 66 (100.0) 1 (1.5)
Connecticut 70 70 (100.0) 1 (1.4)
Delaware 19 19 (100.0) 1 (5.3)
District of Columbia 31 31 (100.0) 2 (6.5)
Florida 581 581 (100.0) 0 (0)
Georgia 306 305 (99.7) 4 (1.3)
Hawaii 119 119 (100.0) 3 (2.5)
Idaho 9 9 (100.0) 0 (0)
Illinois 330 330 (100.0) 7 (2.1)
Indiana 112 112 (100.0) 2 (1.8)
Iowa 36 36 (100.0) 0 (0)
Kansas 35 35 (100.0) 0 (0)
Kentucky 64 64 (100.0) 7 (10.9)
Louisiana 114 113 (99.1) 4 (3.5)
Maine 16 16 (100.0) 0 (0)
Maryland 169 168 (99.4) 5 (3.0)
Massachusetts 185 184 (99.5) 1 (0.5)
Michigan 128 128 (100.0) 2 (1.6)
Minnesota 140 140 (100.0) 0 (0)
Mississippi 71 71 (100.0) 1 (1.4)
Missouri 84 83 (98.8) 3 (3.6)
Montana 9 9 (100.0) 0 (0)
Nebraska 31 29 (93.5) 0 (0)
Nevada 84 84 (100.0) 1 (1.2)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 316 (100.0) 5 (1.6)
New Mexico 46 46 (100.0) 0 (0)
New York State3 173 173 (100.0) 2 (1.2)
New York City 560 554 (98.9) 10 (1.8)
North Carolina 189 189 (100.0) 5 (2.6)
North Dakota 9 9 (100.0) 0 (0)
Ohio 138 138 (100.0) 5 (3.6)
Oklahoma 62 62 (100.0) 1 (1.6)
Oregon 72 72 (100.0) 2 (2.8)
Pennsylvania 196 195 (99.5) 3 (1.5)
Rhode Island 30 30 (100.0) 4 (13.3)
South Carolina 98 98 (100.0) 1 (1.0)
South Dakota 16 16 (100.0) 0 (0)
Tennessee 125 125 (100.0) 2 (1.6)
Texas 1,250 1,250 (100.0) 19 (1.5)
Utah 30 30 (100.0) 0 (0)
Vermont 7 7 (100.0) 0 (0)
Virginia 202 202 (100.0) 2 (1.0)
Washington 196 194 (99.0) 0 (0)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 0 (0)
Wyoming 4 4 (100.0) 0 (0)
American Samoa4 4 4 (100.0) 0 (0)
Fed. States of Micronesia4 82 82 (100.0) 1 (1.2)
Guam4 60 60 (100.0) 0 (0)
Marshall Islands4 108 108 (100.0) 0 (0)
N. Mariana Islands4 24 24 (100.0) 0 (0)
Puerto Rico4 52 52 (100.0) 1 (1.9)
Republic of Palau4 13 13 (100.0) 0 (0)




Cases with information on
residence in long-term care facilities
Cases reported as residents of
long-term care facilities2
No. No.(%) (%)
Table 44. Tuberculosis Cases and Percentages, by Residence in Long-Term Care Facilities,1 
Ages >15 Years: Reporting Areas, 2015
1Resident of long-term care facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Percent of those with known status.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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United States 9,115 9,016 (98.9) 146 (1.6)
Alabama 116 116 (100.0) 1 (0.9)
Alaska 55 52 (94.5) 2 (3.8)
Arizona 184 180 (97.8) 8 (4.4)
Arkansas 78 78 (100.0) 1 (1.3)
California 2,065 2,037 (98.6) 27 (1.3)
Colorado 66 66 (100.0) 0 (0)
Connecticut 70 70 (100.0) 0 (0)
Delaware 19 18 (94.7) 0 (0)
District of Columbia 31 31 (100.0) 2 (6.5)
Florida 581 574 (98.8) 16 (2.8)
Georgia 306 300 (98.0) 2 (0.7)
Hawaii 119 119 (100.0) 0 (0)
Idaho 9 9 (100.0) 0 (0)
Illinois 330 330 (100.0) 7 (2.1)
Indiana 112 112 (100.0) 6 (5.4)
Iowa 36 36 (100.0) 0 (0)
Kansas 35 35 (100.0) 1 (2.9)
Kentucky 64 64 (100.0) 1 (1.6)
Louisiana 114 111 (97.4) 5 (4.5)
Maine 16 16 (100.0) 0 (0)
Maryland 169 168 (99.4) 1 (0.6)
Massachusetts 185 184 (99.5) 2 (1.1)
Michigan 128 125 (97.7) 3 (2.4)
Minnesota 140 140 (100.0) 0 (0)
Mississippi 71 70 (98.6) 2 (2.9)
Missouri 84 83 (98.8) 1 (1.2)
Montana 9 8 (88.9) 0 (0)
Nebraska 31 29 (93.5) 0 (0)
Nevada 84 84 (100.0) 1 (1.2)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 313 (99.1) 3 (1.0)
New Mexico 46 44 (95.7) 1 (2.3)
New York State2 173 169 (97.7) 0 (0)
New York City 560 558 (99.6) 0 (0)
North Carolina 189 189 (100.0) 3 (1.6)
North Dakota 9 9 (100.0) 0 (0)
Ohio 138 138 (100.0) 1 (0.7)
Oklahoma 62 61 (98.4) 2 (3.3)
Oregon 72 70 (97.2) 0 (0)
Pennsylvania 196 194 (99.0) 2 (1.0)
Rhode Island 30 27 (90.0) 0 (0)
South Carolina 98 95 (96.9) 1 (1.1)
South Dakota 16 15 (93.8) 0 (0)
Tennessee 125 124 (99.2) 3 (2.4)
Texas 1,250 1,250 (100.0) 37 (3.0)
Utah 30 30 (100.0) 0 (0)
Vermont 7 7 (100.0) 0 (0)
Virginia 202 202 (100.0) 2 (1.0)
Washington 196 183 (93.4) 0 (0)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 2 (2.9)
Wyoming 4 4 (100.0) 0 (0)
American Samoa3 4 4 (100.0) 0 (0)
Fed. States of Micronesia3 82 82 (100.0) 0 (0)
Guam3 60 58 (96.7) 0 (0)
Marshall Islands3 108 108 (100.0) 0 (0)
N. Mariana Islands3 24 24 (100.0) 0 (0)
Puerto Rico3 52 52 (100.0) 7 (13.5)
Republic of Palau3 13 13 (100.0) 0 (0)




Cases with information on
injecting drug use
Cases reporting injecting drug use
No. No.(%) (%)
Table 45.  Tuberculosis Cases and Percentages, by Injecting Drug Use,1 Ages >15 Years: 
Reporting Areas, 2015
1Injecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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United States 9,115 9,015 (98.9) 653 (7.2)
Alabama 116 116 (100.0) 17 (14.7)
Alaska 55 52 (94.5) 12 (23.1)
Arizona 184 181 (98.4) 23 (12.7)
Arkansas 78 78 (100.0) 8 (10.3)
California 2,065 2,033 (98.5) 111 (5.5)
Colorado 66 66 (100.0) 1 (1.5)
Connecticut 70 70 (100.0) 2 (2.9)
Delaware 19 19 (100.0) 0 (0)
District of Columbia 31 31 (100.0) 1 (3.2)
Florida 581 574 (98.8) 53 (9.2)
Georgia 306 300 (98.0) 28 (9.3)
Hawaii 119 119 (100.0) 3 (2.5)
Idaho 9 9 (100.0) 0 (0)
Illinois 330 329 (99.7) 24 (7.3)
Indiana 112 112 (100.0) 14 (12.5)
Iowa 36 36 (100.0) 0 (0)
Kansas 35 35 (100.0) 4 (11.4)
Kentucky 64 64 (100.0) 9 (14.1)
Louisiana 114 111 (97.4) 14 (12.6)
Maine 16 16 (100.0) 0 (0)
Maryland 169 168 (99.4) 5 (3.0)
Massachusetts 185 184 (99.5) 5 (2.7)
Michigan 128 127 (99.2) 11 (8.7)
Minnesota 140 140 (100.0) 2 (1.4)
Mississippi 71 70 (98.6) 14 (20.0)
Missouri 84 83 (98.8) 4 (4.8)
Montana 9 9 (100.0) 1 (11.1)
Nebraska 31 27 (87.1) 1 (3.7)
Nevada 84 84 (100.0) 4 (4.8)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 313 (99.1) 9 (2.9)
New Mexico 46 43 (93.5) 4 (9.3)
New York State2 173 169 (97.7) 2 (1.2)
New York City 560 557 (99.5) 31 (5.6)
North Carolina 189 189 (100.0) 33 (17.5)
North Dakota 9 8 (88.9) 0 (0)
Ohio 138 138 (100.0) 7 (5.1)
Oklahoma 62 61 (98.4) 7 (11.5)
Oregon 72 71 (98.6) 7 (9.9)
Pennsylvania 196 194 (99.0) 9 (4.6)
Rhode Island 30 27 (90.0) 2 (7.4)
South Carolina 98 96 (98.0) 10 (10.4)
South Dakota 16 15 (93.8) 2 (13.3)
Tennessee 125 124 (99.2) 14 (11.3)
Texas 1,250 1,250 (100.0) 131 (10.5)
Utah 30 30 (100.0) 0 (0)
Vermont 7 7 (100.0) 1 (14.3)
Virginia 202 202 (100.0) 4 (2.0)
Washington 196 185 (94.4) 4 (2.2)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 5 (7.4)
Wyoming 4 4 (100.0) 0 (0)
American Samoa3 4 4 (100.0) 0 (0)
Fed. States of Micronesia3 82 82 (100.0) 3 (3.7)
Guam3 60 58 (96.7) 0 (0)
Marshall Islands3 108 108 (100.0) 0 (0)
N. Mariana Islands3 24 24 (100.0) 0 (0)
Puerto Rico3 52 52 (100.0) 12 (23.1)
Republic of Palau3 13 13 (100.0) 0 (0)




Cases with information on
noninjecting drug use
Cases reporting noninjecting drug use
No. No.(%) (%)
Table 46.  Tuberculosis Cases and Percentages, by Noninjecting Drug Use,1 Ages >15 Years: 
Reporting Areas, 2015
1Noninjecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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United States 9,115 9,000 (98.7) 977 (10.9)
Alabama 116 116 (100.0) 12 (10.3)
Alaska 55 52 (94.5) 21 (40.4)
Arizona 184 179 (97.3) 17 (9.5)
Arkansas 78 78 (100.0) 8 (10.3)
California 2,065 2,036 (98.6) 158 (7.8)
Colorado 66 66 (100.0) 3 (4.5)
Connecticut 70 70 (100.0) 3 (4.3)
Delaware 19 19 (100.0) 2 (10.5)
District of Columbia 31 31 (100.0) 4 (12.9)
Florida 581 574 (98.8) 95 (16.6)
Georgia 306 300 (98.0) 41 (13.7)
Hawaii 119 119 (100.0) 14 (11.8)
Idaho 9 9 (100.0) 0 (0)
Illinois 330 329 (99.7) 39 (11.9)
Indiana 112 112 (100.0) 10 (8.9)
Iowa 36 36 (100.0) 2 (5.6)
Kansas 35 35 (100.0) 6 (17.1)
Kentucky 64 64 (100.0) 10 (15.6)
Louisiana 114 110 (96.5) 20 (18.2)
Maine 16 16 (100.0) 0 (0)
Maryland 169 168 (99.4) 9 (5.4)
Massachusetts 185 184 (99.5) 11 (6.0)
Michigan 128 127 (99.2) 17 (13.4)
Minnesota 140 140 (100.0) 9 (6.4)
Mississippi 71 70 (98.6) 15 (21.4)
Missouri 84 83 (98.8) 7 (8.4)
Montana 9 9 (100.0) 4 (44.4)
Nebraska 31 28 (90.3) 2 (7.1)
Nevada 84 84 (100.0) 8 (9.5)
New Hampshire 12 12 (100.0) 1 (8.3)
New Jersey 316 313 (99.1) 17 (5.4)
New Mexico 46 44 (95.7) 6 (13.6)
New York State2 173 166 (96.0) 14 (8.4)
New York City 560 543 (97.0) 5 (0.9)
North Carolina 189 189 (100.0) 27 (14.3)
North Dakota 9 9 (100.0) 1 (11.1)
Ohio 138 138 (100.0) 9 (6.5)
Oklahoma 62 59 (95.2) 10 (16.9)
Oregon 72 72 (100.0) 11 (15.3)
Pennsylvania 196 194 (99.0) 15 (7.7)
Rhode Island 30 28 (93.3) 6 (21.4)
South Carolina 98 95 (96.9) 25 (26.3)
South Dakota 16 15 (93.8) 1 (6.7)
Tennessee 125 125 (100.0) 14 (11.2)
Texas 1,250 1,250 (100.0) 221 (17.7)
Utah 30 30 (100.0) 4 (13.3)
Vermont 7 7 (100.0) 0 (0)
Virginia 202 202 (100.0) 17 (8.4)
Washington 196 184 (93.9) 13 (7.1)
West Virginia 9 9 (100.0) 0 (0)
Wisconsin 68 68 (100.0) 13 (19.1)
Wyoming 4 4 (100.0) 0 (0)
American Samoa3 4 3 (75.0) 0 (0)
Fed. States of Micronesia3 82 82 (100.0) 2 (2.4)
Guam3 60 59 (98.3) 2 (3.4)
Marshall Islands3 108 107 (99.1) 23 (21.5)
N. Mariana Islands3 24 24 (100.0) 1 (4.2)
Puerto Rico3 52 52 (100.0) 10 (19.2)
Republic of Palau3 13 13 (100.0) 0 (0)









Table 47. Tuberculosis Cases and Percentages, by Excess Alcohol Use,1 Ages >15 Years: 
Reporting Areas, 2015
1Excess alcohol use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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United States 9,115 8,953 (98.2) (24.4) (3.9) (0.1) (1.2) (17.1) (16.3) (37.1)
Alabama 116 116 (100.0) (16.4) (1.7) (0.9) (0.9) (22.4) (22.4) (35.3)
Alaska 55 50 (90.9) (32.0) (2.0) (0) (8.0) (16.0) (24.0) (18.0)
Arizona 184 164 (89.1) (13.4) (4.3) (0.6) (4.9) (27.4) (11.6) (37.8)
Arkansas 78 78 (100.0) (10.3) (2.6) (0) (2.6) (24.4) (17.9) (42.3)
California 2,065 2,035 (98.5) (18.8) (4.5) (0.1) (1.5) (23.7) (17.7) (33.6)
Colorado 66 66 (100.0) (6.1) (4.5) (0) (1.5) (25.8) (19.7) (42.4)
Connecticut 70 70 (100.0) (14.3) (5.7) (0) (0) (12.9) (17.1) (50.0)
Delaware 19 19 (100.0) (26.3) (0) (0) (0) (10.5) (10.5) (52.6)
District of Columbia 31 31 (100.0) (61.3) (0) (0) (0) (9.7) (0) (29.0)
Florida 581 573 (98.6) (57.1) (4.0) (0) (1.6) (4.5) (1.9) (30.9)
Georgia 306 291 (95.1) (37.5) (3.4) (0) (0.3) (8.6) (14.8) (35.4)
Hawaii 119 114 (95.8) (19.3) (1.8) (0) (0.9) (14.0) (15.8) (48.2)
Idaho 9 7 (77.8) (0) (0) (0) (14.3) (14.3) (28.6) (42.9)
Illinois 330 328 (99.4) (15.9) (4.6) (0) (0) (21.3) (17.1) (41.2)
Indiana 112 111 (99.1) (15.3) (5.4) (0) (0.9) (13.5) (29.7) (35.1)
Iowa 36 36 (100.0) (5.6) (2.8) (0) (0) (5.6) (27.8) (58.3)
Kansas 35 35 (100.0) (14.3) (5.7) (0) (0) (5.7) (20.0) (54.3)
Kentucky 64 64 (100.0) (25.0) (3.1) (0) (3.1) (9.4) (20.3) (39.1)
Louisiana 114 101 (88.6) (15.8) (1.0) (0) (4.0) (12.9) (17.8) (48.5)
Maine 16 16 (100.0) (12.5) (6.3) (0) (0) (25.0) (18.8) (37.5)
Maryland 169 166 (98.2) (12.7) (9.0) (0) (1.2) (13.3) (20.5) (43.4)
Massachusetts 185 182 (98.4) (28.6) (6.0) (0) (0) (22.5) (7.1) (35.7)
Michigan 128 128 (100.0) (61.7) (0.8) (0) (1.6) (0) (0) (35.9)
Minnesota 140 139 (99.3) (12.2) (11.5) (0) (0) (10.8) (23.0) (42.4)
Mississippi 71 69 (97.2) (40.6) (1.4) (1.4) (0) (26.1) (1.4) (29.0)
Missouri 84 74 (88.1) (13.5) (5.4) (0) (0) (20.3) (28.4) (32.4)
Montana 9 9 (100.0) (22.2) (0) (0) (0) (55.6) (0) (22.2)
Nebraska 31 30 (96.8) (16.7) (0) (0) (3.3) (13.3) (13.3) (53.3)
Nevada 84 84 (100.0) (14.3) (3.6) (0) (0) (25.0) (25.0) (32.1)
New Hampshire 12 12 (100.0) (16.7) (8.3) (0) (0) (33.3) (16.7) (25.0)
New Jersey 316 314 (99.4) (17.8) (2.2) (0) (1.0) (17.2) (14.3) (47.5)
New Mexico 46 43 (93.5) (11.6) (0) (0) (0) (11.6) (48.8) (27.9)
New York State2 173 164 (94.8) (23.2) (3.0) (0) (0) (22.0) (11.6) (40.2)
New York City 560 553 (98.8) (28.2) (5.8) (0) (1.1) (16.5) (5.6) (42.9)
North Carolina 189 189 (100.0) (26.5) (2.1) (0) (2.1) (18.5) (7.9) (42.9)
North Dakota 9 0 (0) — — — — — — —
Ohio 138 138 (100.0) (21.7) (2.9) (0) (0) (20.3) (20.3) (34.8)
Oklahoma 62 61 (98.4) (31.1) (3.3) (0) (3.3) (14.8) (8.2) (39.3)
Oregon 72 72 (100.0) (16.7) (2.8) (0) (0) (26.4) (20.8) (33.3)
Pennsylvania 196 195 (99.5) (20.5) (5.1) (0) (0.5) (23.6) (13.3) (36.9)
Rhode Island 30 29 (96.7) (13.8) (0) (0) (3.4) (24.1) (17.2) (41.4)
South Carolina 98 97 (99.0) (33.0) (1.0) (0) (0) (18.6) (9.3) (38.1)
South Dakota 16 16 (100.0) (0) (0) (0) (0) (0) (56.3) (43.8)
Tennessee 125 124 (99.2) (21.0) (1.6) (0) (3.2) (21.8) (19.4) (33.1)
Texas 1,250 1,250 (100.0) (31.8) (2.9) (0) (0.2) (9.9) (21.7) (33.5)
Utah 30 30 (100.0) (23.3) (6.7) (0) (0) (3.3) (26.7) (40.0)
Vermont 7 7 (100.0) (0) (0) (0) (0) (0) (28.6) (71.4)
Virginia 202 202 (100.0) (8.4) (3.5) (0) (0) (22.3) (17.8) (48.0)
Washington 196 190 (96.9) (4.2) (4.2) (0) (4.7) (15.8) (34.2) (36.8)
West Virginia 9 9 (100.0) (33.3) (0) (0) (0) (33.3) (11.1) (22.2)
Wisconsin 68 68 (100.0) (1.5) (0) (0) (2.9) (14.7) (33.8) (47.1)
Wyoming 4 4 (100.0) (0) (0) (0) (0) (50.0) (25.0) (25.0)
American Samoa3 4 4 (100.0) (0) (0) (0) (0) (0) (0) (100.0)
Fed. States of Micronesia3 82 81 (98.8) (43.2) (1.2) (0) (0) (0) (42.0) (13.6)
Guam3 60 60 (100.0) (43.3) (1.7) (0) (0) (13.3) (5.0) (36.7)
Marshall Islands3 108 107 (99.1) (40.2) (0.9) (0.9) (0) (5.6) (29.0) (23.4)
N. Mariana Islands3 24 24 (100.0) (0) (4.2) (4.2) (29.2) (0) (45.8) (16.7)
Puerto Rico3 52 52 (100.0) (30.8) (1.9) (0) (0) (9.6) (42.3) (15.4)
Republic of Palau3 13 13 (100.0) (7.7) (0) (0) (23.1) (38.5) (15.4) (15.4)
U.S. Virgin Islands3 0 0 ... ... ... ... ... ... ... ...
Table 48. Tuberculosis Cases and Percentages, by Primary Occupation, Ages >15 Years: 
Reporting Areas, 2015
1Occupation within past 12 months of TB diagnosis. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 



















United States 9,557 9,344 9,274 (99.3) (0.5) (2.0) (85.1)
Alabama 119 117 116 (99.1) (0) (2.6) (81.0)
Alaska 68 63 61 (96.8) (1.6) (6.6) (73.8)
Arizona 198 193 193 (100.0) (0.5) (1.6) (93.8)
Arkansas 90 87 87 (100.0) (0) (4.6) (87.4)
California 2,133 2,091 2,068 (98.9) (0.1) (0.9) (90.2)
Colorado 73 72 72 (100.0) (0) (8.3) (66.7)
Connecticut 70 70 70 (100.0) (0) (0) (18.6)
Delaware 22 21 20 (95.2) (0) (0) (90.0)
District of Columbia 33 30 30 (100.0) (0) (0) (93.3)
Florida 602 583 583 (100.0) (0.2) (2.9) (88.7)
Georgia 324 316 314 (99.4) (0) (1.3) (33.8)
Hawaii 127 126 126 (100.0) (0) (3.2) (92.9)
Idaho 11 11 11 (100.0) (0) (0) (90.9)
Illinois 343 336 333 (99.1) (1.2) (3.9) (86.2)
Indiana 116 114 114 (100.0) (0) (0.9) (94.7)
Iowa 38 38 38 (100.0) (0) (2.6) (97.4)
Kansas 36 35 35 (100.0) (0) (0) (85.7)
Kentucky 67 67 67 (100.0) (0) (0) (89.6)
Louisiana 119 117 115 (98.3) (0) (2.6) (93.9)
Maine 18 17 17 (100.0) (5.9) (5.9) (76.5)
Maryland 176 174 171 (98.3) (0.6) (4.1) (88.3)
Massachusetts 192 190 187 (98.4) (2.7) (0.5) (70.1)
Michigan 131 130 129 (99.2) (0.8) (3.9) (58.1)
Minnesota 150 148 146 (98.6) (0) (4.8) (87.0)
Mississippi 74 72 70 (97.2) (2.9) (5.7) (78.6)
Missouri 92 90 90 (100.0) (0) (1.1) (81.1)
Montana 9 9 8 (88.9) (0) (0) (87.5)
Nebraska 33 33 32 (97.0) (0) (3.1) (71.9)
Nevada 85 82 82 (100.0) (1.2) (0) (98.8)
New Hampshire 13 12 12 (100.0) (0) (8.3) (83.3)
New Jersey 326 316 312 (98.7) (2.6) (2.6) (80.1)
New  Mexico 47 42 41 (97.6) (0) (4.9) (90.2)
New York State4 188 186 184 (98.9) (0) (5.4) (84.8)
New York City 577 566 566 (100.0) (0.4) (1.6) (85.3)
North Carolina 199 193 192 (99.5) (0) (0.5) (82.3)
North Dakota 9 9 9 (100.0) (0) (11.1) (77.8)
Ohio 143 139 139 (100.0) (1.4) (3.6) (86.3)
Oklahoma 67 64 63 (98.4) (6.3) (3.2) (77.8)
Oregon 76 75 75 (100.0) (0) (1.3) (90.7)
Pennsylvania 200 197 195 (99.0) (0) (0) (84.1)
Rhode Island 30 29 28 (96.6) (0) (0) (89.3)
South Carolina 104 100 100 (100.0) (1.0) (1.0) (88.0)
South Dakota 17 17 17 (100.0) (0) (5.9) (70.6)
Tennessee 131 128 128 (100.0) (0) (1.6) (86.7)
Texas 1,334 1,311 1,304 (99.5) (0.4) (1.6) (92.6)
Utah 37 37 37 (100.0) (0) (5.4) (83.8)
Vermont 7 7 7 (100.0) (0) (14.3) (71.4)
Virginia 212 208 208 (100.0) (0.5) (0) (97.1)
Washington 208 198 194 (98.0) (0) (1.0) (80.4)
West Virginia 10 8 8 (100.0) (0) (12.5) (75.0)
Wisconsin 69 66 66 (100.0) (0) (7.6) (84.8)
Wyoming 4 4 4 (100.0) (0) (0) (100.0)
American Samoa5 4 4 4 (100.0) (0) (0) (50.0)
Fed. States of Micronesia5 103 103 101 (98.1) (0) (1.0) (96.0)
Guam5 76 74 73 (98.6) (0) (0) (91.8)
Marshall Islands5 137 132 132 (100.0) (0) (0) (94.7)
N. Mariana Islands5 27 27 27 (100.0) (0) (0) (18.5)
Puerto Rico5 52 49 48 (98.0) (0) (0) (100.0)
Republic of Palau5 14 14 14 (100.0) (0) (0) (100.0)
U.S. Virgin Islands5 0 0 0 ... ... ... ...
Table 49. Tuberculosis Cases and Percentages, by Initial Drug Regimen: 
Reporting Areas, 2015
1Includes persons who were alive at diagnosis and started on one or more drug.
2Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages 
shown only for reporting areas with information reported for >75% of cases.
3I, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol. Cases with other drugs prescribed in addition to these regimens are excluded.
4Excludes New York City.
5Not included in U.S. totals.
Note: Excluding cases with no information on drug regimen, 45 (0.48%) persons were not started on any drugs, 11 (0.12%) were started 
on one drug, and 1,146 (12.30%) had an initial multiple drug regimen other than IR, IRZ, or IRZE.




Cases with information on
initial drug regimen1








United States 7,410 7,209 (97.3) 666 (9.2) 89 (1.2)
Alabama 91 82 (90.1) 1 (1.2) 0 (0)
Alaska 58 58 (100.0) 11 (19.0) 0 (0)
Arizona 147 147 (100.0) 16 (10.9) 2 (1.4)
Arkansas 64 64 (100.0) 1 (1.6) 0 (0)
California 1,765 1,736 (98.4) 186 (10.7) 23 (1.3)
Colorado 49 49 (100.0) 4 (8.2) 0 (0)
Connecticut 55 52 (94.5) 9 (17.3) 2 (3.8)
Delaware 15 13 (86.7) 0 (0) 0 (0)
District of Columbia 27 27 (100.0) 2 (7.4) 0 (0)
Florida 463 431 (93.1) 30 (7.0) 5 (1.2)
Georgia 235 226 (96.2) 29 (12.8) 0 (0)
Hawaii 96 94 (97.9) 4 (4.3) 0 (0)
Idaho 8 6 (75.0) 0 (0) 0 (0)
Illinois 260 246 (94.6) 21 (8.5) 2 (0.8)
Indiana 89 88 (98.9) 6 (6.8) 1 (1.1)
Iowa 23 23 (100.0) 1 (4.3) 0 (0)
Kansas 35 33 (94.3) 6 (18.2) 1 (3.0)
Kentucky 44 44 (100.0) 5 (11.4) 2 (4.5)
Louisiana 99 81 (81.8) 4 (4.9) 0 (0)
Maine 13 13 (100.0) 1 (7.7) 1 (7.7)
Maryland 134 131 (97.8) 12 (9.2) 1 (0.8)
Massachusetts 141 137 (97.2) 22 (16.1) 7 (5.1)
Michigan 92 92 (100.0) 5 (5.4) 0 (0)
Minnesota 115 115 (100.0) 9 (7.8) 0 (0)
Mississippi 44 41 (93.2) 2 (4.9) 0 (0)
Missouri 65 62 (95.4) 5 (8.1) 3 (4.8)
Montana 7 7 (100.0) 2 (28.6) 1 (14.3)
Nebraska 25 24 (96.0) 4 (16.7) 0 (0)
Nevada 65 65 (100.0) 12 (18.5) 0 (0)
New Hampshire 8 8 (100.0) 1 (12.5) 1 (12.5)
New Jersey 263 254 (96.6) 23 (9.1) 4 (1.6)
New Mexico 36 36 (100.0) 3 (8.3) 0 (0)
New York State3 150 150 (100.0) 17 (11.3) 1 (0.7)
New York City 446 432 (96.9) 44 (10.2) 5 (1.2)
North Carolina 171 169 (98.8) 8 (4.7) 1 (0.6)
North Dakota 8 8 (100.0) 0 (0) 0 (0)
Ohio 97 94 (96.9) 4 (4.3) 0 (0)
Oklahoma 48 46 (95.8) 2 (4.3) 0 (0)
Oregon 60 60 (100.0) 6 (10.0) 0 (0)
Pennsylvania 150 147 (98.0) 11 (7.5) 3 (2.0)
Rhode Island 18 18 (100.0) 0 (0) 0 (0)
South Carolina 79 78 (98.7) 5 (6.4) 1 (1.3)
South Dakota 13 13 (100.0) 2 (15.4) 1 (7.7)
Tennessee 89 85 (95.5) 9 (10.6) 2 (2.4)
Texas 1,003 984 (98.1) 83 (8.4) 9 (0.9)
Utah 25 25 (100.0) 4 (16.0) 1 (4.0)
Vermont 7 7 (100.0) 1 (14.3) 0 (0)
Virginia 171 168 (98.2) 9 (5.4) 1 (0.6)
Washington 173 170 (98.3) 14 (8.2) 4 (2.4)
West Virginia 8 8 (100.0) 1 (12.5) 0 (0)
Wisconsin 59 58 (98.3) 8 (13.8) 4 (6.9)
Wyoming 4 4 (100.0) 1 (25.0) 0 (0)
American Samoa4 3 0 (0) — — — —
Fed. States of Micronesia4 30 25 (83.3) 2 (8.0) 1 (4.0)
Guam4 39 35 (89.7) 4 (11.4) 1 (2.9)
Marshall Islands4 26 24 (92.3) 0 (0) 0 (0)
N. Mariana Islands4 14 13 (92.9) 1 (7.7) 0 (0)
Puerto Rico4 32 31 (96.9) 2 (6.5) 1 (3.2)
Republic of Palau4 5 5 (100.0) 0 (0) 0 (0)
U.S. Virgin Islands4 0 0 ... 0 ... 0 ...
1Patients tested to at least isoniazid and rifampin.
2Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District 
of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
Table 50. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility 











Isoniazid1 Isoniazid and rifampin1
No. No.(%) (%)
90
United States 9,349 8,366 (89.5) 459 (5.5)
Alabama 117 114 (97.4) 2 (1.8)
Alaska 67 55 (82.1) 0 (0)
Arizona 193 181 (93.8) 11 (6.1)
Arkansas 87 87 (100.0) 3 (3.4)
California 2,091 1,861 (89.0) 60 (3.2)
Colorado 72 69 (95.8) 3 (4.3)
Connecticut 70 67 (95.7) 5 (7.5)
Delaware 21 18 (85.7) 1 (5.6)
District of Columbia 30 27 (90.0) 4 (14.8)
Florida 583 527 (90.4) 59 (11.2)
Georgia 316 296 (93.7) 27 (9.1)
Hawaii 126 122 (96.8) 1 (0.8)
Idaho 11 10 (90.9) 0 (0)
Illinois 336 301 (89.6) 13 (4.3)
Indiana 114 102 (89.5) 1 (1.0)
Iowa 38 34 (89.5) 0 (0)
Kansas 35 33 (94.3) 5 (15.2)
Kentucky 67 66 (98.5) 5 (7.6)
Louisiana 117 101 (86.3) 9 (8.9)
Maine 17 16 (94.1) 1 (6.3)
Maryland 174 162 (93.1) 16 (9.9)
Massachusetts 190 97 (51.1) 12 (12.4)
Michigan 130 118 (90.8) 3 (2.5)
Minnesota 148 136 (91.9) 9 (6.6)
Mississippi 72 70 (97.2) 2 (2.9)
Missouri 90 78 (86.7) 1 (1.3)
Montana 9 8 (88.9) 0 (0)
Nebraska 33 28 (84.8) 0 (0)
Nevada 82 79 (96.3) 4 (5.1)
New Hampshire 12 12 (100.0) 0 (0)
New Jersey 316 260 (82.3) 16 (6.2)
New Mexico 42 41 (97.6) 1 (2.4)
New York State3 186 155 (83.3) 5 (3.2)
New York City 566 480 (84.8) 34 (7.1)
North Carolina 193 189 (97.9) 16 (8.5)
North Dakota 9 9 (100.0) 2 (22.2)
Ohio 139 121 (87.1) 7 (5.8)
Oklahoma 64 59 (92.2) 0 (0)
Oregon 75 74 (98.7) 2 (2.7)
Pennsylvania 197 169 (85.8) 15 (8.9)
Rhode Island 29 26 (89.7) 1 (3.8)
South Carolina 100 93 (93.0) 6 (6.5)
South Dakota 17 13 (76.5) 1 (7.7)
Tennessee 128 126 (98.4) 7 (5.6)
Texas 1,311 1,192 (90.9) 76 (6.4)
Utah 37 37 (100.0) 1 (2.7)
Vermont 7 7 (100.0) 0 (0)
Virginia 208 204 (98.1) 7 (3.4)
Washington 199 178 (89.4) 5 (2.8)
West Virginia 8 6 (75.0) 0 (0)
Wisconsin 66 52 (78.8) 0 (0)
Wyoming 4 0 (0) 0 …
American Samoa4 4 4 (100.0) 0 (0)
Fed. States of Micronesia4 103 60 (58.3) — —
Guam4 74 70 (94.6) 0 (0)
Marshall Islands4 132 124 (93.9) 0 (0)
N. Mariana Islands4 27 24 (88.9) 0 (0)
Puerto Rico4 49 48 (98.0) 7 (14.6)
Republic of Palau4 14 13 (92.9) 0 (0)
U.S. Virgin Islands4 0 0 ... 0 ...
Table 51. Tuberculosis Cases and Percentages, by HIV Status: Reporting Areas, 2015
1Includes only those cases in persons with negative, positive, or indeterminate HIV test results and those persons not dead at diagnosis.
2Counts and percentages shown only for reporting areas with information reported for >75% of cases. 
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.





Cases with information on HIV status1 Cases in persons with HIV-positive results2
No. (%) No. (%)
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Table 52. Tuberculosis Diagnostic Tests, by Type of Laboratory: Reporting Areas, 2015
United States 5,707 (30.2) (53.2) (12.9) (3.7) 7,898 (28.0) (52.2) (14.9) (5.0) 4,359 (46.5) (23.9) (24.8) (4.8)
Alabama 65 (7.7) (89.2) (1.5) (1.5) 114 (7.9) (90.4) (0.9) (0.9) 39 (30.8) (59.0) (10.3) (0)
Alaska 39 (5.1) (94.9) (0) (0) 64 (4.7) (93.8) (1.6) (0) 12 (16.7) (83.3) (0) (0)
Arizona 96 (24.0) (50.0) (25.0) (1.0) 165 (17.0) (73.3) (9.7) (0) 91 (25.3) (29.7) (45.1) (0)
Arkansas 73 (4.1) (89.0) (6.8) (0) 74 (6.8) (89.2) (2.7) (1.4) 49 (32.7) (26.5) (40.8) (0)
California 1,319 (38.6) (49.7) (10.5) (1.3) 1,791 (43.9) (40.7) (13.8) (1.6) 929 (56.1) (22.5) (19.6) (1.8)
Colorado 30 (20.0) (30.0) (36.7) (13.3) 57 (7.0) (35.1) (14.0) (43.9) 41 (17.1) (14.6) (39.0) (29.3)
Connecticut 20 (50.0) (50.0) (0) (0) 52 (38.5) (59.6) (1.9) (0) 43 (46.5) (53.5) (0) (0)
Delaware 10 (20.0) (60.0) (20.0) (0) 6 (33.3) (50.0) (0) (16.7) 11 (18.2) (18.2) (45.5) (18.2)
District of Columbia 18 (61.1) (0) (33.3) (5.6) 28 (42.9) (0) (57.1) (0) 22 (45.5) (0) (54.5) (0)
Florida 487 (14.6) (80.1) (5.3) (0) 528 (16.3) (81.1) (2.7) (0) 266 (42.9) (49.2) (7.9) (0)
Georgia 196 (44.9) (44.4) (5.6) (5.1) 263 (24.0) (57.4) (18.6) (0) 155 (72.3) (18.1) (0) (9.7)
Hawaii 104 (98.1) (0) (1.0) (1.0) 114 (95.6) (0) (3.5) (0.9) 34 (88.2) (0) (8.8) (2.9)
Idaho 10 (10.0) (70.0) (10.0) (10.0) 9 (0) (88.9) (0) (11.1) 4 (0) (75.0) (25.0) (0)
Illinois 136 (45.6) (37.5) (16.9) (0) 251 (32.7) (39.0) (27.1) (1.2) 186 (63.4) (9.1) (27.4) (0)
Indiana 74 (35.1) (51.4) (13.5) (0) 82 (8.5) (78.0) (13.4) (0) 45 (42.2) (26.7) (31.1) (0)
Iowa 23 (21.7) (78.3) (0) (0) 29 (10.3) (89.7) (0) (0) 16 (18.8) (81.3) (0) (0)
Kansas 16 (31.3) (68.8) (0) (0) 34 (32.4) (67.6) (0) (0) 22 (72.7) (27.3) (0) (0)
Kentucky 51 (21.6) (68.6) (9.8) (0) 64 (28.1) (64.1) (7.8) (0) 27 (48.1) (40.7) (11.1) (0)
Louisiana 68 (36.8) (58.8) (1.5) (2.9) 92 (46.7) (38.0) (12.0) (3.3) 32 (81.3) (9.4) (6.3) (3.1)
Maine 6 (0) (100.0) (0) (0) 9 (11.1) (88.9) (0) (0) 10 (0) (100.0) (0) (0)
Maryland 124 (34.7) (62.1) (3.2) (0) 165 (17.0) (81.2) (1.8) (0) 87 (49.4) (41.4) (8.0) (1.1)
Massachusetts 106 (9.4) (39.6) (0) (50.9) 126 (29.4) (39.7) (0) (31.0) 114 (48.2) (35.1) (0) (16.7)
Michigan 81 (18.5) (54.3) (23.5) (3.7) 97 (0) (100.0) (0) (0) 62 (16.1) (50.0) (33.9) (0)
Minnesota 71 (77.5) (22.5) (0) (0) 97 (56.7) (43.3) (0) (0) 80 (48.8) (51.3) (0) (0)
Mississippi 55 (3.6) (0) (50.9) (45.5) 68 (5.9) (0) (47.1) (47.1) 39 (2.6) (0) (48.7) (48.7)
Missouri 40 (47.5) (40.0) (0) (12.5) 76 (17.1) (78.9) (0) (3.9) 50 (48.0) (46.0) (0) (6.0)
Montana 8 (0) (87.5) (0) (12.5) 7 (14.3) (85.7) (0) (0) 3 (0) (100.0) (0) (0)
Nebraska 15 (13.3) (53.3) (6.7) (26.7) 21 (4.8) (47.6) (14.3) (33.3) 16 (25.0) (50.0) (12.5) (12.5)
Nevada 42 (33.3) (64.3) (2.4) (0) 78 (35.9) (64.1) (0) (0) 28 (71.4) (28.6) (0) (0)
New Hampshire 10 (20.0) (60.0) (10.0) (10.0) 10 (20.0) (80.0) (0) (0) 3 (33.3) (66.7) (0) (0)
New Jersey 125 (63.2) (8.8) (25.6) (2.4) 243 (44.9) (27.6) (27.6) (0) 177 (42.9) (4.5) (51.4) (1.1)





































1Nunber of patients with positive or negative NAA test results.
2Number of patients with positive or negative sputum culture test results.
3Number of patients with positive or negative culture of tissue and other body fluid test results.
4Excludes New York City.
5Not included in U.S. totals.
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
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New York State4 115 (14.8) (34.8) (20.9) (29.6) 161 (20.5) (24.2) (26.7) (28.6) 101 (22.8) (30.7) (26.7) (19.8)
New York City 444 (7.7) (61.0) (24.8) (6.5) 505 (8.7) (10.1) (45.9) (35.2) 271 (5.2) (3.7) (59.0) (32.1)
North Carolina 106 (41.5) (58.5) (0) (0) 173 (13.9) (73.4) (12.7) (0) 104 (63.5) (8.7) (27.9) (0)
North Dakota 4 (100.0) (0) (0) (0) 8 (50.0) (50.0) (0) (0) 4 (75.0) (25.0) (0) (0)
Ohio 77 (85.7) (14.3) (0) (0) 110 (89.1) (10.9) (0) (0) 90 (95.6) (4.4) (0) (0)
Oklahoma 41 (22.0) (75.6) (2.4) (0) 49 (6.1) (91.8) (2.0) (0) 21 (33.3) (66.7) (0) (0)
Oregon 57 (7.0) (38.6) (50.9) (3.5) 69 (5.8) (63.8) (24.6) (5.8) 28 (7.1) (14.3) (78.6) (0)
Pennsylvania 87 (13.8) (67.8) (10.3) (8.0) 146 (26.7) (62.3) (6.8) (4.1) 107 (44.9) (25.2) (26.2) (3.7)
Rhode Island 14 (28.6) (71.4) (0) (0) 24 (29.2) (70.8) (0) (0) 22 (54.5) (45.5) (0) (0)
South Carolina 66 (16.7) (78.8) (4.5) (0) 84 (14.3) (77.4) (8.3) (0) 45 (51.1) (17.8) (31.1) (0)
South Dakota 13 (0) (100.0) (0) (0) 15 (6.7) (93.3) (0) (0) 8 (0) (100.0) (0) (0)
Tennessee 59 (44.1) (45.8) (10.2) (0) 117 (27.4) (70.1) (1.7) (0.9) 65 (70.8) (15.4) (13.8) (0)
Texas 783 (21.5) (55.7) (22.5) (0.4) 1136 (16.8) (59.8) (23.3) (0.1) 508 (34.8) (16.9) (48.0) (0.2)
Utah 16 (75.0) (25.0) (0) (0) 24 (58.3) (41.7) (0) (0) 14 (100.0) (0) (0) (0)
Vermont 4 (25.0) (50.0) (25.0) (0) 6 (66.7) (16.7) (16.7) (0) 2 (100.0) (0) (0) (0)
Virginia 81 (19.8) (51.9) (28.4) (0) 192 (7.8) (85.4) (6.8) (0) 109 (33.9) (34.9) (29.4) (1.8)
Washington 148 (44.6) (53.4) (0) (2.0) 167 (50.3) (42.5) (0) (7.2) 110 (91.8) (6.4) (0.9) (0.9)
West Virginia 2 (0) (100.0) (0) (0) 7 (14.3) (85.7) (0) (0) 1 (0) (100.0) (0) (0)
Wisconsin 39 (7.7) (89.7) (2.6) (0) 51 (21.6) (76.5) (0) (2.0) 37 (45.9) (54.1) (0) (0)
Wyoming 4 (25.0) (75.0) (0) (0) 2 (0) (100.0) (0) (0) 3 (33.3) (66.7) (0) (0)
American Samoa5 0 ... ... ... ... 3 (0) (0) (100.0) (0) 0 ... ... ... ...
Fed. States of Micronesia5 36 (83.3) (0) (16.7) (0) 59 (100.0) (0) (0) (0) 3 (100.0) (0) (0) (0)
Guam5 64 (12.5) (87.5) (0) (0) 59 (91.5) (8.5) (0) (0) 3 (100.0) (0) (0) (0)
Marshall Islands5 56 (16.1) (78.6) (1.8) (3.6) 53 (98.1) (1.9) (0) (0) 0 ... ... ... ...
N. Mariana Islands5 18 (0) (100.0) (0) (0) 18 (88.9) (0) (0) (11.1) 0 ... ... ... ...
Puerto Rico5 21 (0) (100.0) (0) (0) 49 (8.2) (91.8) (0) (0) 10 (30.0) (70.0) (0) (0)
Republic of Palau5 12 (0) (83.3) (0) (16.7) 10 (100.0) (0) (0) (0) 1 (100.0) (0) (0) (0)
U.S. Virgin Islands5 0 ... ... ... ... 0 ... ... ... ... 0 ... ... ... ...






































United States 9,557 7,410 7,123 (96.1)
Alabama 119 91 90 (98.9) 
Alaska 68 58 57 (98.3) 
Arizona 198 147 146 (99.3) 
Arkansas 90 64 62 (96.9) 
California 2,133 1,765 1,675 (94.9) 
Colorado 73 49 49 (100.0) 
Connecticut 70 55 55 (100.0)
District of Columbia 33 27 26 (96.3) 
Delaware 22 15 14 (93.3) 
Florida 602 463 460 (99.4) 
Georgia 324 235 229 (97.4) 
Hawaii 127 96 93 (96.9) 
Idaho 11 8 8 (100.0) 
Illinois 343 260 231 (88.8) 
Indiana 116 89 89 (100.0) 
Iowa 38 23 20 (87.0) 
Kansas 36 35 34 (97.1) 
Kentucky 67 44 42 (95.5) 
Louisiana 119 99 69 (69.7) 
Maine 18 13 13 (100.0) 
Maryland 176 134 127 (94.8) 
Massachusetts 192 141 135 (95.7) 
Michigan 131 92 92 (100.0)
Minnesota 150 115 115 (100.0) 
Mississippi 74 44 44 (100.0) 
Missouri 92 65 63 (96.9) 
Montana 9 7 6 (85.7) 
Nebraska 33 25 20 (80.0) 
Nevada 85 65 62 (95.4) 
New Hampshire 13 8 7 (87.5) 
New Jersey 326 263 250 (95.1) 
New Mexico 47 36 35 (97.2) 
New York3 765 596 580 (97.3) 
North Carolina 199 171 171 (100.0) 
North Dakota 9 8 8 (100.0) 
Ohio 143 97 96 (99.0) 
Oklahoma 67 48 45 (93.8) 
Oregon 76 60 60 (100.0) 
Pennsylvania 200 150 146 (97.3) 
Rhode Island 30 18 18 (100.0) 
South Carolina 104 79 79 (100.0) 
South Dakota 17 13 13 (100.0) 
Tennessee 131 89 84 (94.4) 
Texas 1,334 1003 963 (96.0) 
Utah 37 25 24 (96.0) 
Vermont 7 7 7 (100.0) 
Virginia 212 171 169 (98.8) 
Washington 208 173 171 (98.8) 
West Virginia 10 8 8 (100.0) 
Wisconsin 69 59 59 (100.0)
Wyoming 4 4 4 (100.0) 
American Samoa4 4 3 2 (66.7) 
Fed State of Micronesia4 103 30 25 (83.3) 
Guam4 76 39 36 (92.3) 
Marshall Islands4 137 26 19 (73.1) 
N. Mariana Islands4 27 14 8 (57.1) 
Puerto Rico4 52 32 32 (100.0) 
Republic of Palau4 14 5 5 (100.0) 
U.S. Virgin Islands4 0 0 0 ...
Table 53. Tuberculosis Genotyping Surveillance Coverage1: Reporting Areas, 2015
1Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a 
genotyped isolate.
2National TB Performance Indicator goal for national TB genotyping surveillance coverage is 94.0%.
3Includes New York City.
4Not included in U.S. totals.



















United States 21,153 (96.1) 1,464 4,529 2 (2-60)
Alabama 271 (97.1) 28 85 2 (2-9)
Alaska 160 (95.8) 15 107 5 (2-22)
Arizona 449 (99.1) 38 85 2 (2-4)
Arkansas 169 (96.6) 13 45 2 (2-15)
California 5,032 (95.8) 393 1,277 2 (2-52)
Colorado 140 (100.0) 1 2 2 (2-2)
Connecticut 153 (100.0) 6 15 3 (2-3)
District of Columbia 73 (91.3) 4 11 3 (2-4)
Delaware 34 (85.0) 2 4 2 (2-2)
Florida 1,446 (99.4) 109 332 2 (2-42)
Georgia 696 (97.2) 48 175 2 (2-39)
Hawaii 279 (97.9) 18 67 3 (2-10)
Idaho 23 (100.0) -- -- -- --
Illinois 617 (81.6) 34 99 2 (2-8)
Indiana 245 (99.2) 11 33 2 (2-10)
Iowa 92 (93.9) 5 10 2 (2-2)
Kansas 96 (97.0) 4 8 2 (2-2)
Kentucky 149 (98.7) 11 29 2 (2-4)
Louisiana 233 (74.9) 29 78 2 (2-6)
Maine 31 (96.9) 3 6 2 (2-2)
Maryland 398 (96.8) 22 52 2 (2-5)
Massachusetts 421 (95.0) 18 43 2 (2-8)
Michigan 265 (99.3) 10 29 2 (2-9)
Minnesota 337 (100.0) 13 35 2 (2-4)
Mississippi 147 (98.0) 11 28 2 (2-6)
Missouri 186 (94.9) 14 35 2 (2-4)
Montana 17 (89.5) -- -- -- --
Nebraska 63 (88.7) 2 4 2 (2-2)
Nevada 166 (96.0) 9 22 2 (2-4)
New Hampshire 30 (96.8) -- -- -- --
New Jersey 748 (97.9) 40 101 2 (2-5)
New Mexico 111 (98.2) 3 6 2 (2-2)
New York 1,768 (96.3) 120 306 2 (2-13)
North Carolina 488 (100.0) 33 113 2 (2-20)
North Dakota 24 (100.0) 1 3 3 (3-3)
Ohio 329 (98.8) 12 45 2 (2-12)
Oklahoma 129 (93.5) 10 25 2 (2-5)
Oregon 178 (100.0) 10 30 3 (2-5)
Pennsylvania 460 (95.8) 23 59 2 (2-8)
Rhode Island 46 (100.0) 2 4 2 (2-2)
South Carolina 211 (99.1) 19 55 2 (2-8)
South Dakota 26 (100.0) 2 5 3 (2-3)
Tennessee 282 (96.2) 20 74 2 (2-21)
Texas 2742 (96.4) 242 845 2 (2-60)
Utah 67 (98.5) -- -- -- --
Vermont 12 (100.0) -- -- -- --
Virginia 449 (97.4) 19 40 2 (2-4)
Washington 490 (98.0) 30 80 2 (2-8)
West Virginia 30 (93.8) 1 2 2 (2-2)
Wisconsin 139 (97.9) 6 20 3 (2-8)
Wyoming 6 (100.0) -- -- -- --
Table 54. County-Based Tuberculosis Genotype Clusters1 Based on GENType: 
Reporting Areas, 2013–2015
1Clusters are two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tan-
dem repeat type (GENType) within a county during the specified 3-year time period (Total number of clusters from 2013–2015 = 1,464).
2Genotype surveillance coverage is defined as the percentage of all culture positive tuberculosis (TB) cases for which there was a geno-
typed isolate.
Note: Dashes (--) indicate no clustered cases.
See Technical Notes.








United States 9,550 9,334 8,770 (94.0) (65.7) (22.3) (12.0)
Alabama 108 103 86 (83.5) (64.0) (16.3) (19.8)
Alaska 71 71 71 (100.0) (12.7) (7.0) (80.3)
Arizona 184 179 178 (99.4) (57.9) (25.3) (16.9)
Arkansas 72 71 70 (98.6) (88.6) (5.7) (5.7)
California 2,164 2,118 2,089 (98.6) (54.2) (35.4) (10.4)
Colorado 74 73 72 (98.6) (87.5) (12.5) (0)
Connecticut 62 59 59 (100.0) (23.7) (22.0) (54.2)
Delaware 18 18 9 (50.0) — — —
District of Columbia 37 37 37 (100.0) (70.3) (21.6) (8.1)
Florida 651 632 612 (96.8) (63.4) (25.7) (10.9)
Georgia 339 327 310 (94.8) (84.5) (3.5) (11.9)
Hawaii 115 114 114 (100.0) (65.8) (10.5) (23.7)
Idaho 11 11 10 (90.9) (20.0) (60.0) (20.0)
Illinois 327 321 316 (98.4) (42.4) (21.5) (36.1)
Indiana 94 90 90 (100.0) (60.0) (12.2) (27.8)
Iowa 47 47 47 (100.0) (0) (100.0) (0)
Kansas 36 36 35 (97.2) (88.6) (8.6) (2.9)
Kentucky 59 58 58 (100.0) (87.9) (12.1) (0)
Louisiana 139 135 124 (91.9) (77.4) (10.5) (12.1)
Maine 15 14 14 (100.0) (7.1) (21.4) (71.4)
Maryland 175 174 172 (98.9) (91.9) (3.5) (4.7)
Massachusetts 201 198 177 (89.4) (72.3) (23.7) (4.0)
Michigan 141 139 133 (95.7) (75.9) (24.1) (0)
Minnesota 151 150 150 (100.0) (54.7) (38.0) (7.3)
Mississippi 65 60 60 (100.0) (96.7) (3.3) (0)
Missouri 104 102 53 (52.0) — — —
Montana 6 6 5 (83.3) (0) (60.0) (40.0)
Nebraska 21 21 18 (85.7) (27.8) (50.0) (22.2)
Nevada 91 88 88 (100.0) (88.6) (8.0) (3.4)
New Hampshire 15 15 15 (100.0) (20.0) (73.3) (6.7)
New Jersey 319 314 314 (100.0) (76.4) (13.1) (10.5)
New Mexico 50 46 38 (82.6) (71.1) (23.7) (5.3)
New York State3 215 215 211 (98.1) (64.9) (23.7) (11.4)
New York City 650 644 366 (56.8) — — —
North Carolina 216 206 206 (100.0) (80.1) (3.9) (16.0)
North Dakota 12 9 9 (100.0) (0) (100.0) (0)
Ohio 148 145 142 (97.9) (83.8) (16.2) (0)
Oklahoma 70 68 68 (100.0) (73.5) (2.9) (23.5)
Oregon 73 73 71 (97.3) (47.9) (38.0) (14.1)
Pennsylvania 214 212 210 (99.1) (73.3) (19.5) (7.1)
Rhode Island 27 26 26 (100.0) (96.2) (3.8) (0)
South Carolina 112 107 107 (100.0) (84.1) (8.4) (7.5)
South Dakota 9 9 9 (100.0) (33.3) (66.7) (0)
Tennessee 143 141 100 (70.9) — — —
Texas 1,209 1,173 1,172 (99.9) (78.9) (15.6) (5.5)
Utah 33 33 33 (100.0) (97.0) (3.0) (0)
Vermont 5 5 5 (100.0) (0) (0) (100.0)
Virginia 179 172 166 (96.5) (80.1) (7.8) (12.0)
Washington 210 206 195 (94.7) (62.1) (15.4) (22.6)
West Virginia 13 13 0 (0) — — —
Wisconsin 50 50 50 (100.0) (0) (2.0) (98.0)
Wyoming 0 0 0 ... ... ... ...
American Samoa4 2 2 0 (0) — — —
Fed. States of Micronesia4 128 125 122 (97.6) (99.2) (0.8) (0)
Guam4 48 47 47 (100.0) (97.9) (2.1) (0)
Marshall Islands4 153 153 152 (99.3) (100.0) (0) (0)
N. Mariana Islands4 31 31 26 (83.9) (100.0) (0) (0)
Puerto Rico4 49 46 46 (100.0) (67.4) (28.3) (4.3)
Republic of Palau4 7 7 7 (100.0) (85.7) (14.3) (0)
U.S. Virgin Islands4 2 2 1 (50.0) — — —
1Most recent year for which data are available.
2Health department: all outpatient care provided by the state or local health department; private/other: all care (except contact investiga-
tion and dispensing of medication) provided by non-health department providers; both health department and private/other: both sectors 
involved in the care of the patient. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Colum-
bia). Percentages shown only for reporting areas with information reported for >75% of cases.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
Table 55. Tuberculosis Cases and Percentages, by Type of Health Care Provider: 
Reporting Areas, 20131
Reporting area Total cases
Percentage of cases by











Cases with information on
type of health care provider
100
United States 9,550 9,266 9,065 (97.8) (63.2) (28.9)
Alabama 108 103 102 (99.0) (46.1) (52.9)
Alaska 71 71 71 (100.0) (95.8) (2.8)
Arizona 184 176 176 (100.0) (85.2) (14.8)
Arkansas 72 70 70 (100.0) (38.6) (34.3)
California 2,164 2,105 2,076 (98.6) (53.0) (36.7)
Colorado 74 72 72 (100.0) (81.9) (11.1)
Connecticut 62 59 59 (100.0) (10.2) (69.5)
Delaware 18 18 9 (50.0) — —
District of Columbia 37 35 35 (100.0) (85.7) (0)
Florida 651 631 619 (98.1) (20.4) (77.2)
Georgia 339 327 310 (94.8) (86.8) (10.3)
Hawaii 115 113 113 (100.0) (90.3) (2.7)
Idaho 11 11 11 (100.0) (45.5) (36.4)
Illinois 327 316 306 (96.8) (51.6) (33.0)
Indiana 94 90 90 (100.0) (85.6) (12.2)
Iowa 47 47 47 (100.0) (61.7) (27.7)
Kansas 36 36 35 (97.2) (100.0) (0)
Kentucky 59 58 58 (100.0) (96.6) (1.7)
Louisiana 139 135 124 (91.9) (66.9) (16.9)
Maine 15 14 14 (100.0) (57.1) (21.4)
Maryland 175 174 174 (100.0) (79.9) (19.0)
Massachusetts 201 189 185 (97.9) (45.4) (40.5)
Michigan 141 136 121 (89.0) (62.0) (38.0)
Minnesota 151 150 150 (100.0) (79.3) (20.0)
Mississippi 65 60 60 (100.0) (75.0) (25.0)
Missouri 104 102 96 (94.1) (34.4) (62.5)
Montana 6 6 5 (83.3) (80.0) (20.0)
Nebraska 21 21 21 (100.0) (9.5) (85.7)
Nevada 91 88 86 (97.7) (91.9) (8.1)
New Hampshire 15 15 15 (100.0) (46.7) (40.0)
New Jersey 319 314 312 (99.4) (59.0) (24.7)
New Mexico 50 45 45 (100.0) (95.6) (2.2)
New York State4 215 214 213 (99.5) (34.3) (60.6)
New York City 650 640 576 (90.0) (60.6) (10.8)
North Carolina 216 205 205 (100.0) (99.0) (1.0)
North Dakota 12 9 9 (100.0) (77.8) (22.2)
Ohio 148 145 145 (100.0) (66.2) (25.5)
Oklahoma 70 67 66 (98.5) (9.1) (90.9)
Oregon 73 72 72 (100.0) (88.9) (8.3)
Pennsylvania 214 209 209 (100.0) (73.2) (17.7)
Rhode Island 27 26 26 (100.0) (19.2) (73.1)
South Carolina 112 106 106 (100.0) (76.4) (19.8)
South Dakota 9 9 9 (100.0) (44.4) (55.6)
Tennessee 143 141 140 (99.3) (99.3) (0.7)
Texas 1,209 1,160 1,159 (99.9) (79.6) (18.7)
Utah 33 32 32 (100.0) (93.8) (3.1)
Vermont 5 5 5 (100.0) (40.0) (20.0)
Virginia 179 172 167 (97.1) (88.6) (7.8)
Washington 210 204 198 (97.1) (68.7) (20.2)
West Virginia 13 13 12 (92.3) (100.0) (0)
Wisconsin 50 50 49 (98.0) (89.8) (8.2)
Wyoming 0 0 0 … — —
American Samoa5 2 2 2 (100.0) (0) (100.0)
Fed. States of Micronesia5 128 125 125 (100.0) (98.4) (1.6)
Guam5 48 47 46 (97.9) (100.0) (0)
Marshall Islands5 153 153 152 (99.3) (88.2) (11.8)
N. Mariana Islands5 31 0 0 (0) — —
Puerto Rico5 49 46 46 (100.0) (63.0) (4.3)
Republic of Palau5 7 7 7 (100.0) (42.9) (57.1)
U.S. Virgin Islands5 2 2 1 (50.0) — —
Table 56. Tuberculosis Cases and Percentages, by Directly Observed Therapy (DOT): 
Reporting Areas, 20131
1Most recent year for which data are available.
2Includes persons alive at diagnosis with an initial drug regimen of one or more drugs prescribed.
3Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for 
reporting areas with information reported for >75% of cases.
4Excludes New York City.
5Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
Reporting area Total cases
Percentage of Cases by
directly observed therapy3
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United States 9,266 8,127 (87.7) 40 (0.4) 97 (1.0) 66 (0.7) 579 (6.2) 357 (3.9)
Alabama 103 94 (91.3) 1 (1.0) 0 (0) 0 (0) 8 (7.8) 0 (0)
Alaska 71 68 (95.8) 0 (0) 0 (0) 1 (1.4) 2 (2.8) 0 (0)
Arizona 176 147 (83.5) 0 (0) 2 (1.1) 2 (1.1) 10 (5.7) 15 (8.5)
Arkansas 70 54 (77.1) 1 (1.4) 2 (2.9) 3 (4.3) 4 (5.7) 6 (8.6)
California 2,105 1,803 (85.7) 13 (0.6) 15 (0.7) 13 (0.6) 164 (7.8) 97 (4.6)
Colorado 72 63 (87.5) 0 (0) 0 (0) 1 (1.4) 8 (11.1) 0 (0)
Connecticut 59 51 (86.4) 1 (1.7) 2 (3.4) 0 (0) 3 (5.1) 2 (3.4)
Delaware 18 8 (44.4) 0 (0) 0 (0) 1 (5.6) 0 (0) 9 (50.0)
District of Columbia 35 32 (91.4) 0 (0) 0 (0) 0 (0) 1 (2.9) 2 (5.7)
Florida 631 572 (90.6) 0 (0) 3 (0.5) 0 (0) 27 (4.3) 29 (4.6)
Georgia 327 295 (90.2) 1 (0.3) 3 (0.9) 0 (0) 12 (3.7) 16 (4.9)
Hawaii 113 109 (96.5) 0 (0) 0 (0) 0 (0) 4 (3.5) 0 (0)
Idaho 11 10 (90.9) 0 (0) 0 (0) 0 (0) 1 (9.1) 0 (0)
Illinois 316 278 (88.0) 1 (0.3) 3 (0.9) 4 (1.3) 25 (7.9) 5 (1.6)
Indiana 90 83 (92.2) 0 (0) 0 (0) 1 (1.1) 4 (4.4) 2 (2.2)
Iowa 47 44 (93.6) 0 (0) 0 (0) 1 (2.1) 1 (2.1) 1 (2.1)
Kansas 36 31 (86.1) 0 (0) 0 (0) 0 (0) 4 (11.1) 1 (2.8)
Kentucky 58 49 (84.5) 0 (0) 0 (0) 1 (1.7) 6 (10.3) 2 (3.4)
Louisiana 135 112 (83.0) 0 (0) 4 (3.0) 4 (3.0) 4 (3.0) 11 (8.1)
Maine 14 13 (92.9) 0 (0) 0 (0) 0 (0) 1 (7.1) 0 (0)
Maryland 174 161 (92.5) 0 (0) 0 (0) 0 (0) 7 (4.0) 6 (3.4)
Massachusetts 189 161 (85.2) 1 (0.5) 1 (0.5) 0 (0) 6 (3.2) 20 (10.6)
Michigan 136 124 (91.2) 0 (0) 0 (0) 2 (1.5) 8 (5.9) 2 (1.5)
Minnesota 150 141 (94.0) 0 (0) 1 (0.7) 1 (0.7) 5 (3.3) 2 (1.3)
Mississippi 60 45 (75.0) 0 (0) 1 (1.7) 0 (0) 11 (18.3) 3 (5.0)
Missouri 102 75 (73.5) 2 (2.0) 0 (0) 2 (2.0) 9 (8.8) 14 (13.7)
Montana 6 3 (50.0) 0 (0) 0 (0) 0 (0) 2 (33.3) 1 (16.7)
Nebraska 21 19 (90.5) 0 (0) 0 (0) 0 (0) 1 (4.8) 1 (4.8)
Nevada 88 84 (95.5) 0 (0) 0 (0) 0 (0) 4 (4.5) 0 (0)
New Hampshire 15 12 (80.0) 0 (0) 0 (0) 0 (0) 1 (6.7) 2 (13.3)
New Jersey 314 275 (87.6) 1 (0.3) 6 (1.9) 3 (1.0) 20 (6.4) 9 (2.9)
New Mexico 45 36 (80.0) 0 (0) 3 (6.7) 1 (2.2) 3 (6.7) 2 (4.4)
Table 57. Tuberculosis Cases and Percentages, by Reason Therapy Was Stopped: Reporting Areas, 20131
Reporting area
Completed
therapy Lost Refused Died3 Unknown4







Did not complete therapy
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New York State5 214 194 (90.7) 0 (0) 1 (0.5) 3 (1.4) 10 (4.7) 6 (2.8)
New York City 640 589 (92.0) 4 (0.6) 7 (1.1) 4 (0.6) 29 (4.5) 7 (1.1)
North Carolina 205 195 (95.1) 0 (0) 2 (1.0) 0 (0) 7 (3.4) 1 (0.5)
North Dakota 9 9 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ohio 145 124 (85.5) 1 (0.7) 1 (0.7) 2 (1.4) 12 (8.3) 5 (3.4)
Oklahoma 67 61 (91.0) 0 (0) 1 (1.5) 0 (0) 4 (6.0) 1 (1.5)
Oregon 72 64 (88.9) 1 (1.4) 0 (0) 2 (2.8) 5 (6.9) 0 (0)
Pennsylvania 209 177 (84.7) 0 (0) 2 (1.0) 1 (0.5) 17 (8.1) 12 (5.7)
Rhode Island 26 24 (92.3) 1 (3.8) 0 (0) 0 (0) 1 (3.8) 0 (0)
South Carolina 106 93 (87.7) 3 (2.8) 3 (2.8) 1 (0.9) 5 (4.7) 1 (0.9)
South Dakota 9 6 (66.7) 0 (0) 0 (0) 0 (0) 2 (22.2) 1 (11.1)
Tennessee 141 123 (87.2) 0 (0) 0 (0) 0 (0) 16 (11.3) 2 (1.4)
Texas 1,160 992 (85.5) 4 (0.3) 29 (2.5) 11 (0.9) 84 (7.2) 40 (3.4)
Utah 32 31 (96.9) 0 (0) 0 (0) 0 (0) 1 (3.1) 0 (0)
Vermont 5 4 (80.0) 1 (20.0) 0 (0) 0 (0) 0 (0) 0 (0)
Virginia 172 157 (91.3) 0 (0) 1 (0.6) 1 (0.6) 8 (4.7) 5 (2.9)
Washington 204 176 (86.3) 3 (1.5) 3 (1.5) 0 (0) 10 (4.9) 12 (5.9)
West Virginia 13 9 (69.2) 0 (0) 0 (0) 0 (0) 2 (15.4) 2 (15.4)
Wisconsin 50 47 (94.0) 0 (0) 1 (2.0) 0 (0) 0 (0) 2 (4.0)
Wyoming 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
American Samoa6 2 2 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fed. States of Micronesia6 125 114 (91.2) 0 (0) 0 (0) 3 (2.4) 4 (3.2) 4 (3.2)
Guam6 47 45 (95.7) 0 (0) 0 (0) 0 (0) 2 (4.3) 0 (0)
Marshall Islands6 153 131 (85.6) 0 (0) 8 (5.2) 0 (0) 11 (7.2) 3 (2.0)
N. Mariana Islands6 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Puerto Rico6 46 37 (80.4) 0 (0) 1 (2.2) 0 (0) 8 (17.4) 0 (0)
Republic of Palau6 7 7 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
U.S. Virgin Islands6 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0)
1Most recent year for which data are available.
2Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the 
District of Columbia).
3Died = died of any cause.
4Includes cases reported as other, missing, and unknown.
5Excludes New York City.
6Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
Table 57. (Con’t) Tuberculosis Cases and Percentages, by Reason Therapy Was Stopped: Reporting Areas, 20131
Reporting area
Completed
therapy Lost Refused Died3 Unknown4







Did not complete therapy
104 Table 58. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20131
Reasons therapy was extended
United States 798 59 (7.4) 146 (18.3) 100 (12.5) 10 (1.3) 319 (40.0) 273 (34.2)
Alabama 4 0 (0) 0 (0) 1 (25.0) 0 (0) 2 (50.0) 1 (25.0)
Alaska 5 0 (0) 0 (0) 3 (60.0) 0 (0) 2 (40.0) 2 (40.0)
Arizona 22 1 (4.5) 4 (18.2) 5 (22.7) 1 (4.5) 13 (59.1) 5 (22.7)
Arkansas 6 0 (0) 1 (16.7) 2 (33.3) 1 (16.7) 1 (16.7) 1 (16.7)
California 192 17 (8.9) 57 (29.7) 19 (9.9) 0 (0) 86 (44.8) 51 (26.6)
Colorado 5 0 (0) 1 (20.0) 0 (0) 0 (0) 3 (60.0) 1 (20.0)
Connecticut 6 1 (16.7) 3 (50.0) 0 (0) 0 (0) 3 (50.0) 3 (50.0)
Delaware 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
District of Columbia 8 1 (12.5) 0 (0) 3 (37.5) 0 (0) 3 (37.5) 3 (37.5)
Florida 45 6 (13.3) 4 (8.9) 7 (15.6) 0 (0) 21 (46.7) 8 (17.8)
Georgia 24 1 (4.2) 1 (4.2) 3 (12.5) 0 (0) 6 (25.0) 13 (54.2)
Hawaii 14 0 (0) 3 (21.4) 1 (7.1) 0 (0) 3 (21.4) 9 (64.3)
Idaho 2 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0) 1 (50.0)
Illinois 24 1 (4.2) 4 (16.7) 3 (12.5) 0 (0) 7 (29.2) 10 (41.7)
Indiana 5 0 (0) 0 (0) 0 (0) 0 (0) 4 (80.0) 1 (20.0)
Iowa 4 0 (0) 0 (0) 1 (25.0) 0 (0) 0 (0) 3 (75.0)
Kansas 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Kentucky 4 0 (0) 1 (25.0) 1 (25.0) 0 (0) 1 (25.0) 1 (25.0)
Louisiana 20 0 (0) 1 (5.0) 1 (5.0) 1 (5.0) 3 (15.0) 14 (70.0)
Maine 1 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0)
Maryland 20 1 (5.0) 2 (10.0) 1 (5.0) 0 (0) 9 (45.0) 9 (45.0)
Massachusetts 20 2 (10.0) 1 (5.0) 0 (0) 0 (0) 8 (40.0) 9 (45.0)
Michigan 5 0 (0) 0 (0) 1 (20.0) 0 (0) 1 (20.0) 3 (60.0)
Minnesota 10 0 (0) 3 (30.0) 0 (0) 0 (0) 7 (70.0) 0 (0)
Mississippi 5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (100.0)
Missouri 4 0 (0) 1 (25.0) 0 (0) 0 (0) 0 (0) 3 (75.0)
Montana 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Nebraska 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Nevada 4 1 (25.0) 1 (25.0) 0 (0) 0 (0) 2 (50.0) 0 (0)
New Hampshire 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
New Jersey 31 3 (9.7) 8 (25.8) 3 (9.7) 0 (0) 13 (41.9) 9 (29.0)
New Mexico 2 0 (0) 1 (50.0) 0 (0) 0 (0) 0 (0) 1 (50.0)
Reporting area






No. (%) No. (%) No. (%) No. (%) No. (%)
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1Most recent year for which data are available.
2Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.
3Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).
4Excludes New York City. 
5Not included in U.S. totals.
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
New York State4 31 0 (0) 5 (16.1) 4 (12.9) 0 (0) 8 (25.8) 16 (51.6)
New York City 26 2 (7.7) 4 (15.4) 2 (7.7) 2 (7.7) 7 (26.9) 9 (34.6)
North Carolina 12 4 (33.3) 2 (16.7) 3 (25.0) 0 (0) 1 (8.3) 7 (58.3)
North Dakota 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0)
Ohio 20 3 (15.0) 2 (10.0) 3 (15.0) 0 (0) 9 (45.0) 3 (15.0)
Oklahoma 5 0 (0) 0 (0) 0 (0) 0 (0) 1 (20.0) 4 (80.0)
Oregon 9 2 (22.2) 4 (44.4) 0 (0) 0 (0) 1 (11.1) 2 (22.2)
Pennsylvania 37 3 (8.1) 24 (64.9) 7 (18.9) 4 (10.8) 21 (56.8) 6 (16.2)
Rhode Island 1 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
South Carolina 10 0 (0) 2 (20.0) 0 (0) 0 (0) 2 (20.0) 6 (60.0)
South Dakota 1 0 (0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0)
Tennessee 6 1 (16.7) 0 (0) 1 (16.7) 0 (0) 5 (83.3) 2 (33.3)
Texas 104 4 (3.8) 3 (2.9) 19 (18.3) 0 (0) 54 (51.9) 29 (27.9)
Utah 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Vermont 1 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0) 0 (0)
Virginia 12 2 (16.7) 2 (16.7) 0 (0) 0 (0) 5 (41.7) 4 (33.3)
Washington 20 1 (5.0) 0 (0) 3 (15.0) 0 (0) 2 (10.0) 14 (70.0)
West Virginia 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Wisconsin 7 2 (28.6) 1 (14.3) 1 (14.3) 1 (14.3) 2 (28.6) 1 (14.3)
Wyoming 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
American Samoa5 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Fed. States of Micronesia5 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
Guam5 3 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 2 (66.7)
Marshall Islands5 6 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 5 (83.3)
N. Mariana Islands5 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Puerto Rico5 3 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 2 (66.7)
Republic of Palau5 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
U.S. Virgin Islands5 0 0 ... 0 ... 0 ... 0 ... 0 ... 0 ...
Table 58. (Con’t) Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20131
Reasons therapy was extended
Reporting area






No. (%) No. (%) No. (%) No. (%) No. (%)
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United States 7,774 2,175 (90.1) 109 (89.9) 2,473 (90.4) 1,716 (89.0) 52 (78.8) 1,123 (88.2) 115 (91.3) 11 (81.8)
Alabama 94 18 (83.3) 0 ... 5 (100.0) 43 (97.7) 0 ... 28 (100.0) 0 ... 0 ...
Alaska 67 1 (100.0) 52 (94.2) 12 (83.3) 0 ... 0 ... 2 (100.0) 0 ... 0 ...
Arizona 131 67 (88.1) 15 (80.0) 22 (86.4) 8 (62.5) 0 ... 19 (94.7) 0 ... 0 ...
Arkansas 61 11 (90.9) 0 ... 6 (100.0) 15 (60.0) 5 (60.0) 24 (66.7) 0 ... 0 ...
California 1,758 637 (90.0) 3 (100.0) 784 (88.9) 114 (80.7) 7 (57.1) 132 (86.4) 81 (90.1) 0 ...
Colorado 58 17 (94.1) 0 ... 18 (94.4) 18 (94.4) 0 ... 5 (100.0) 0 ... 0 ...
Connecticut 49 16 (93.8) 0 ... 18 (83.3) 7 (100.0) 0 ... 8 (62.5) 0 ... 0 ...
Delaware 17 — — — — — — — — — — — — — — — —
District of Columbia 27 2 (100.0) 0 ... 1 (0) 22 (86.4) 0 ... 2 (100.0) 0 ... 0 ...
Florida 547 149 (93.3) 2 (50.0) 72 (94.4) 204 (94.1) 1 (100.0) 118 (93.2) 1 (100.0) 0 ...
Georgia 290 49 (89.8) 2 (100.0) 56 (89.3) 147 (90.5) 0 ... 32 (78.1) 2 (50.0) 2 (100.0)
Hawaii 102 0 ... 1 (0) 81 (91.4) 1 (100.0) 11 (90.9) 2 (100.0) 6 (83.3) 0 ...
Idaho 9 3 (100.0) 1 (100.0) 2 (100.0) 0 ... 0 ... 3 (66.7) 0 ... 0 ...
Illinois 267 84 (86.9) 0 ... 96 (93.8) 61 (83.6) 0 ... 26 (96.2) 0 ... 0 ...
Indiana 77 8 (100.0) 0 ... 31 (96.8) 16 (93.8) 0 ... 22 (95.5) 0 ... 0 ...
Iowa 41 5 (80.0) 0 ... 15 (80.0) 8 (87.5) 1 (100.0) 10 (100.0) 2 (100.0) 0 ...
Kansas 30 8 (100.0) 0 ... 14 (100.0) 2 (100.0) 1 (100.0) 5 (100.0) 0 ... 0 ...
Kentucky 47 6 (100.0) 0 ... 8 (100.0) 10 (90.0) 0 ... 23 (87.0) 0 ... 0 ...
Louisiana 120 12 (83.3) 0 ... 13 (69.2) 50 (78.0) 0 ... 45 (68.9) 0 ... 0 ...
Maine 12 1 (100.0) 0 ... 1 (100.0) 5 (100.0) 0 ... 5 (80.0) 0 ... 0 ...
Maryland 149 20 (95.0) 0 ... 42 (85.7) 64 (92.2) 2 (100.0) 21 (95.2) 0 ... 0 ...
Massachusetts 149 23 (87.0) 0 ... 51 (90.2) 40 (95.0) 0 ... 34 (94.1) 1 (100.0) 0 ...
Michigan 107 13 (92.3) 0 ... 38 (94.7) 27 (92.6) 3 (100.0) 26 (100.0) 0 ... 0 ...
Minnesota 125 15 (93.3) 3 (100.0) 47 (93.6) 50 (94.0) 0 ... 10 (100.0) 0 ... 0 ...
Mississippi 42 7 (100.0) 0 ... 3 (33.3) 24 (95.8) 0 ... 8 (87.5) 0 ... 0 ...
Missouri 84 — — — — — — — — — — — — — — — —
Montana 4 — — — — — — — — — — — — — — — —
Nebraska 20 9 (88.9) 0 ... 5 (100.0) 1 (100.0) 0 ... 3 (100.0) 1 (100.0) 1 (100.0)
Nevada 78 25 (96.0) 0 ... 28 (96.4) 12 (100.0) 0 ... 13 (92.3) 0 ... 0 ...
New Hampshire 12 3 (100.0) 0 ... 4 (75.0) 3 (66.7) 0 ... 2 (100.0) 0 ... 0 ...
New Jersey 252 88 (94.3) 0 ... 98 (89.8) 37 (86.5) 0 ... 29 (100.0) 0 ... 0 ...





















1Percentages shown only for reporting areas with information reported for >90% of cases, and indicate the percentage of those who completed therapy <1 year. 
2Most recent year for which data are available.
3Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy.  Excludes persons with initial isolate rifampin resistant, 
or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a 
blood specimen, and those who moved out of the country within one year of initiating treatment. 
4Persons of Hispanic origin may be of any race.
5Indicates two or more races reported for a person and does not include persons of Hispanic ethnicity.
6Excludes New York City.
7Not included in U.S. totals. 
Note: Case counts and percentage for race categories do not include persons of Hispanic ethnicity. See Technical Notes for description of completion of therapy calculation.
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
New Mexico 34 17 (100.0) 3 (100.0) 9 (88.9) 0 ... 0 ... 5 (80.0) 0 ... 0 ...
New York State6 172 45 (88.9) 2 (100.0) 57 (94.7) 39 (84.6) 0 ... 25 (84.0) 1 (100.0) 3 (66.7)
New York City 544 140 (92.9) 0 ... 247 (96.4) 110 (95.5) 1 (100.0) 37 (97.3) 8 (100.0) 1 (0)
North Carolina 178 33 (100.0) 8 (100.0) 39 (94.9) 70 (97.1) 0 ... 23 (100.0) 5 (100.0) 0 ...
North Dakota 8 1 (0) 3 (66.7) 0 ... 0 ... 0 ... 3 (100.0) 0 ... 1 (100.0)
Ohio 118 10 (100.0) 0 ... 34 (88.2) 36 (80.6) 0 ... 37 (78.4) 0 ... 1 (100.0)
Oklahoma 58 11 (100.0) 7 (85.7) 9 (100.0) 5 (80.0) 2 (100.0) 22 (90.9) 2 (100.0) 0 ...
Oregon 61 21 (95.2) 0 ... 22 (86.4) 6 (50.0) 0 ... 12 (91.7) 0 ... 0 ...
Pennsylvania 176 23 (82.6) 0 ... 82 (78.0) 49 (71.4) 0 ... 22 (72.7) 0 ... 0 ...
Rhode Island 23 5 (100.0) 0 ... 7 (85.7) 7 (100.0) 0 ... 4 (100.0) 0 ... 0 ...
South Carolina 92 10 (70.0) 0 ... 5 (60.0) 52 (88.5) 1 (100.0) 24 (87.5) 0 ... 0 ...
South Dakota 6 1 (100.0) 3 (66.7) 0 ... 2 (100.0) 0 ... 0 ... 0 ... 0 ...
Tennessee 118 15 (86.7) 0 ... 18 (94.4) 56 (98.2) 0 ... 28 (100.0) 1 (100.0) 0 ...
Texas 951 468 (87.2) 0 ... 158 (95.6) 186 (87.6) 0 ... 136 (83.8) 2 (100.0) 1 (100.0)
Utah 28 10 (100.0) 0 ... 7 (100.0) 5 (100.0) 2 (100.0) 4 (100.0) 0 ... 0 ...
Vermont 4 0 ... 0 ... 4 (100.0) 0 ... 0 ... 0 ... 0 ... 0 ...
Virginia 148 27 (100.0) 0 ... 56 (94.6) 50 (90.0) 0 ... 15 (100.0) 0 ... 0 ...
Washington 178 26 (80.8) 2 (100.0) 96 (81.3) 20 (95.0) 9 (77.8) 23 (95.7) 1 (100.0) 1 (100.0)
West Virginia 9 0 ... 0 ... 1 (100.0) 1 (100.0) 0 ... 6 (100.0) 1 (100.0) 0 ...
Wisconsin 42 5 (100.0) 0 ... 23 (91.3) 6 (83.3) 0 ... 8 (87.5) 0 ... 0 ...
Wyoming 0 — — — — — — — — — — — — — — — —
American Samoa7 2 0 ... 0 ... 0 ... 0 ... 1 (100.0) 0 ... 0 ... 1 (100.0)
Fed. States of Micronesia7 117 0 ... 0 ... 2 (0) 0 ... 111 (94.6) 0 ... 1 (100.0) 3 (100.0)
Guam7 44 0 ... 0 ... 16 (93.8) 0 ... 26 (96.2) 1 (100.0) 0 ... 1 (100.0)
Marshall Islands7 137 1 (100.0) 0 ... 0 ... 0 ... 134 (91.0) 0 ... 0 ... 2 (50.0)
N. Mariana Islands7 0 — — — — — — — — — — — — — — — —
Puerto Rico7 37 34 (91.2) 0 ... 1 (100.0) 2 (100.0) 0 ... 0 ... 0 ... 0 ...
Republic of Palau7 7 0 ... 0 ... 3 (100.0) 0 ... 3 (100.0) 0 ... 0 ... 1 (100.0)
U.S. Virgin Islands7 2 — — — — — — — — — — — — — — — —
Table 59. (Cont’d) Completion of Tuberculosis Therapy (COT) Cases and Percentages1, by Hispanic Ethnicity and Non-Hispanic 



















United States 9,550 7,774 (89.6) (95.9) 567 (92.8)
Alabama 108 94 (95.7) (98.9) 1 (100.0)
Alaska 71 67 (92.5) (98.5) 2 (100.0)
Arizona 184 131 (86.3) (95.4) 8 (100.0)
Arkansas 72 61 (72.1) (82.0) 3 (100.0)
California 2,164 1758 (88.5) (95.5) 102 (89.2)
Colorado 74 58 (94.8) (98.3) 4 (100.0)
Connecticut 62 49 (85.7) (91.8) 5 (100.0)
Delaware 18 17 — — 1 —
District of Columbia 37 27 (85.2) (100.0) 4 (100.0)
Florida 651 547 (93.6) (97.6) 33 (97.0)
Georgia 339 290 (88.6) (94.1) 17 (100.0)
Hawaii 115 102 (90.2) (100.0) 7 (100.0)
Idaho 11 9 (88.9) (100.0) 1 (100.0)
Illinois 327 267 (89.5) (97.0) 14 (100.0)
Indiana 94 77 (96.1) (100.0) 7 (85.7)
Iowa 47 41 (87.8) (97.6) 2 (100.0)
Kansas 36 30 (100.0) (100.0) 2 (50.0)
Kentucky 59 47 (91.5) (97.9) 3 (100.0)
Louisiana 139 120 (74.2) (87.5) 9 (77.8)
Maine 15 12 (91.7) (100.0) 0 ...
Maryland 175 149 (91.3) (100.0) 9 (100.0)
Massachusetts 201 149 (91.9) (93.3) 24 (87.5)
Michigan 141 107 (95.3) (98.1) 13 (100.0)
Minnesota 151 125 (94.4) (98.4) 18 (88.9)
Mississippi 65 42 (90.5) (97.6) 4 (100.0)
Missouri 104 84 — — 7 —
Montana 6 4 — — 0 ...
Nebraska 21 20 (95.0) (95.0) 0 ...
Nevada 91 78 (96.2) (100.0) 4 (100.0)
New Hampshire 15 12 (83.3) (91.7) 1 (100.0)
New Jersey 319 252 (92.1) (97.2) 30 (86.7)
New Mexico 50 34 (94.1) (97.1) 3 (100.0)
New York State6 215 172 (89.0) (97.1) 23 (91.3)
New York City 650 544 (95.2) (97.6) 55 (96.4)
North Carolina 216 178 (97.8) (99.4) 18 (100.0)
North Dakota 12 8 (75.0) (100.0) 1 (100.0)
Ohio 148 118 (83.9) (95.8) 10 (100.0)
Oklahoma 70 58 (93.1) (100.0) 2 (100.0)
Oregon 73 61 (86.9) (96.7) 5 (80.0)
Pennsylvania 214 176 (76.1) (93.2) 9 (100.0)
Rhode Island 27 23 (95.7) (95.7) 2 (100.0)
South Carolina 112 92 (84.8) (91.3) 8 (100.0)
South Dakota 9 6 (83.3) (100.0) 1 (0)
Tennessee 143 118 (96.6) (100.0) 4 (100.0)
Texas 1,209 951 (88.2) (94.4) 64 (93.8)
Utah 33 28 (100.0) (100.0) 1 (100.0)
Vermont 5 4 (100.0) (100.0) 1 (0)
Virginia 179 148 (94.6) (98.6) 10 (100.0)
Washington 210 178 (84.8) (93.8) 9 (77.8)
West Virginia 13 9 (100.0) (100.0) 1 (0)
Wisconsin 50 42 (90.5) (100.0) 5 (80.0)
Wyoming 0 0 — — 0 ...
American Samoa7 2 2 (100.0) (100.0) 0 ...
Fed. States of Micronesia7 128 117 (93.2) (94.0) 4 (100.0)
Guam7 48 44 (95.5) (100.0) 1 (100.0)
Marshall Islands7 153 137 (90.5) (93.4) 3 (100.0)
N. Mariana Islands7 31 0 — — 0 ...
Puerto Rico7 49 37 (91.9) (97.3) 1 (100.0)
Republic of Palau7 7 7 (100.0) (100.0) 0 ...
U.S. Virgin Islands7 2 2 — — 0 ...
Table 60. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy 
(COT): Reporting Areas, 20131
1Most recent year for which data are available.
2Initial isolate susceptible to rifampin (n = 5,755) or susceptibility unknown (n = 111); culture negative (n = 1,647); culture status unknown (n = 261).
3Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Colum-
bia). Percentages shown only for reporting areas with information reported for >90% of cases.
4Therapy <1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy.  Excludes persons with initial isolate 
rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive 
nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment. 
5Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood 
culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6Excludes New York City.
7Not included in U.S. totals. 
Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0. 
See Technical Notes for description of completion of therapy calculation.
Reporting area Total cases No. COT(%) No. COT(%)
Therapy <1 year indicated2,3,4
COT <1 year(%)
Therapy >1 year indicated3,5
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United States 9,510 (88.8) 9,122 (89.7) 8,492 (89.6) 8,113 (90.0) 7,774 (89.6)
Alabama 141 (94.3) 117 (91.5) 138 (93.5) 119 (90.8) 94 (95.7)
Alaska 32 (84.4) 49 (93.9) 54 (88.9) 61 (93.4) 67 (92.5)
Arizona 173 (83.2) 217 (86.2) 166 (87.3) 139 (94.2) 131 (86.3)
Arkansas 58 (86.2) 69 (87.0) 67 (83.6) 58 (81.0) 61 (72.1)
California 2,081 (84.3) 1,897 (88.0) 1,875 (87.6) 1,769 (89.0) 1,758 (88.5)
Colorado 65 (95.4) 53 (92.5) 59 (96.6) 47 (95.7) 58 (94.8)
Connecticut 79 (88.6) 67 (92.5) 68 (94.1) 60 (93.3) 49 (85.7)
Delaware 16 (81.3) 13 (100.0) 17 (94.1) 21 — 17 —
District of Columbia 32 (81.3) 31 (87.1) 48 (81.3) 27 (96.3) 27 (85.2)
Florida 689 (93.2) 706 (94.9) 607 (92.9) 562 (91.5) 547 (93.6)
Georgia 335 (85.4) 330 (90.0) 277 (89.5) 292 (91.1) 290 (88.6)
Hawaii 92 (83.7) 104 (95.2) 110 (90.0) 91 (92.3) 102 (90.2)
Idaho 16 (93.8) 14 (85.7) 11 (81.8) 13 (84.6) 9 (88.9)
Illinois 340 (90.3) 301 (87.4) 278 (92.1) 289 (91.7) 267 (89.5)
Indiana 100 (91.0) 80 (93.8) 87 (89.7) 85 (92.9) 77 (96.1)
Iowa 39 (87.2) 39 (94.9) 32 (87.5) 36 (80.6) 41 (87.8)
Kansas 56 (100.0) 36 (100.0) 27 (88.9) 31 (93.5) 30 (100.0)
Kentucky 59 (91.5) 72 (88.9) 56 (82.1) 68 (94.1) 47 (91.5)
Louisiana 162 (88.9) 171 (80.7) 140 (82.9) 119 (80.7) 120 (74.2)
Maine 7 (100.0) 6 (100.0) 8 (75.0) 17 (64.7) 12 (91.7)
Maryland 180 (90.0) 179 (91.6) 194 (94.8) 192 (90.1) 149 (91.3)
Massachusetts 212 (83.0) 187 (84.0) 155 (83.9) 172 (84.9) 149 (91.9)
Michigan 109 (89.9) 145 (89.7) 138 (90.6) 115 (87.8) 107 (95.3)
Minnesota 133 (93.2) 116 (90.5) 101 (95.0) 133 (95.5) 125 (94.4)
Mississippi 104 (88.5) 101 (93.1) 73 (91.8) 67 (89.6) 42 (90.5)
Missouri 72 (87.5) 95 (86.3) 81 (91.4) 71 — 84 —
Montana 7 (100.0) 6 (100.0) 7 (100.0) 5 (80.0) 4 —
Nebraska 28 (85.7) 24 (91.7) 20 (85.0) 17 — 20 (95.0)
Nevada 91 (89.0) 100 (94.0) 82 (95.1) 71 (90.1) 78 (96.2)
New Hampshire 13 (100.0) 8 (87.5) 10 (100.0) 7 (100.0) 12 (83.3)
New Jersey 337 (92.9) 325 (92.9) 252 (90.1) 232 (93.5) 252 (92.1)
New Mexico 31 (93.5) 29 (93.1) 38 (92.1) 27 (96.3) 34 (94.1)
New York State4 182 (87.9) 204 (91.7) 187 (94.1) 169 (94.1) 172 (89.0)
New York City 634 (92.4) 599 (92.8) 565 (92.0) 540 (93.7) 544 (95.2)
North Carolina 215 (93.5) 248 (96.0) 200 (95.5) 187 (97.9) 178 (97.8)
North Dakota 3 (66.7) 8 (75.0) 5 — 24 (54.2) 8 (75.0)
Ohio 142 (91.5) 150 (89.3) 118 (88.1) 129 (86.0) 118 (83.9)
Oklahoma 85 (87.1) 69 (94.2) 72 (91.7) 72 (87.5) 58 (93.1)
Oregon 75 (97.3) 71 (98.6) 64 (89.1) 53 (96.2) 61 (86.9)
Pennsylvania 195 (83.1) 181 (86.7) 202 (85.1) 181 (81.8) 176 (76.1)
Rhode Island 21 (90.5) 22 (68.2) 25 (80.0) 19 (89.5) 23 (95.7)
South Carolina 134 (92.5) 125 (93.6) 113 (95.6) 105 (90.5) 92 (84.8)
South Dakota 16 (93.8) 13 (84.6) 12 (83.3) 14 (92.9) 6 (83.3)
Tennessee 173 (94.2) 146 (93.2) 130 (94.6) 142 (95.8) 118 (96.6)
Texas 1,187 (89.4) 1,093 (85.2) 1,071 (87.9) 1,025 (90.0) 951 (88.2)
Utah 26 (100.0) 13 (100.0) 25 (100.0) 29 (96.6) 28 (100.0)
Vermont 5 (80.0) 5 (100.0) 6 (83.3) 4 (100.0) 4 (100.0)
Virginia 237 (88.2) 235 (88.9) 190 (88.9) 191 (84.8) 148 (94.6)
Washington 219 (94.1) 194 (88.7) 155 (85.2) 148 (85.1) 178 (84.8)
West Virginia 15 (73.3) 12 (100.0) 10 (90.0) 7 (100.0) 9 (100.0)
Wisconsin 55 (83.6) 41 (90.2) 62 (90.3) 58 (91.4) 42 (90.5)
Wyoming 2 (50.0) 6 — 4 — 3 — 0 —
American Samoa5 3 (66.7) 3 (33.3) 3 — 1 (100.0) 2 (100.0)
Fed. States of Micronesia5 176 (83.0) 160 (91.9) 130 (90.0) 161 (88.2) 117 (93.2)
Guam5 93 (96.8) 86 (95.3) 72 (94.4) 60 (86.7) 44 (95.5)
Marshall Islands5 109 (87.2) 189 — 143 ... 131 ... 137 (90.5)
N. Mariana Islands5 28 (96.4) 25 (96.0) 29 (75.9) 19 (84.2) 0 —
Puerto Rico5 51 (94.1) 70 (90.0) 34 (94.1) 49 (91.8) 37 (91.9)
Republic of Palau5 15 (86.7) 16 (100.0) 6 (83.3) 4 (100.0) 7 (100.0)
U.S. Virgin Islands5 0 — 0 — 0 — 3 — 2 —
Reporting area
2009 2010 2011 2012 2013
Year
No.2 No.2 No.2No.2(%)3 (%)3 (%)3 (%)3 (%)3
Table 61. Tuberculosis Cases and Percentages Among Persons Completing Therapy for 
Whom Therapy Was Indicated for ≤1 Year: Reporting Areas, 2009–20131
1Most recent year for which data are available.
2Total cases for which therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed who did not die within one 
year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the cen-
tral nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, 
and those who moved out of the country within one year of initiating treatment. 
3Percentage of total cases in persons who completed therapy within one year for whom therapy less than one year was indicated. Percentages shown only for 
reporting areas with information reported for >90% of cases.
4Excludes New York City.
5Not included in U.S. totals. 
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Table 62. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2015 and 2014
Metropolitan statistical area




Akron, OH 12 6 1.7 0.9 704,243
Albany-Schenectady-Troy, NY 6 13 0.7 1.5 881,830
Albuquerque, NM 14 15 1.5 1.7 907,301
Allentown-Bethlehem-Easton, PA-NJ 7 5 0.8 0.6 832,327
Atlanta-Sandy Springs-Roswell, GA 219 228 3.8 4.1 5,710,795
Augusta-Richmond County, GA-SC 14 12 2.4 2.1 590,146
Austin-Round Rock, TX 77 64 3.8 3.3 2,000,860
Bakersfield, CA 29 40 3.3 4.6 882,176
Baltimore-Columbia-Towson, MD 64 70 2.3 2.5 2,797,407
Baton Rouge, LA 23 19 2.8 2.3 830,480
Birmingham-Hoover, AL 30 47 2.6 4.1 1,145,647
Boise City, ID 8 6 1.2 0.9 676,909
Boston-Cambridge-Newton, MA-NH 149 159 3.1 3.4 4,774,321
Bridgeport-Stamford-Norwalk, CT 24 16 2.5 1.7 948,053
Buffalo-Cheektowaga-Niagara Falls, NY 17 19 1.5 1.7 1,135,230
Cape Coral-Fort Myers, FL 17 12 2.4 1.8 701,982
Charleston-North Charleston, SC 19 16 2.6 2.2 744,526
Charlotte-Concord-Gastonia, NC-SC 41 36 1.7 1.5 2,426,363
Chattanooga, TN-GA 10 7 1.8 1.3 547,776
Chicago-Naperville-Elgin, IL-IN-WI 304 280 3.2 2.9 9,551,031
Cincinnati, OH-KY-IN 21 27 1.0 1.3 2,157,719
Cleveland-Elyria, OH 39 40 1.9 1.9 2,060,810
Colorado Springs, CO 4 1 0.6 0.1 697,856
Columbia, SC 10 11 1.2 1.4 810,068
Columbus, OH 41 54 2.0 2.7 2,021,632
Dallas-Fort Worth-Arlington, TX 311 295 4.4 4.2 7,102,796
Dayton, OH 9 9 1.1 1.1 800,909
Deltona-Daytona Beach-Ormond Beach, FL 6 8 1.0 1.3 623,279
Denver-Aurora-Lakewood, CO 50 49 1.8 1.8 2,814,330
Des Moines-West Des Moines, IA 8 12 1.3 2.0 622,899
Detroit-Warren-Dearborn, MI 75 68 1.7 1.6 4,302,043
Durham-Chapel Hill, NC 9 14 1.6 2.6 552,493
El Paso, TX 38 43 4.5 5.1 838,972
Fayetteville-Springdale-Rogers, AR-MO 30 36 5.8 7.2 513,559
Fresno, CA 41 51 4.2 5.3 974,861
Grand Rapids-Wyoming, MI 20 10 1.9 1.0 1,038,583
Greensboro-High Point, NC 27 23 3.6 3.1 752,157
Greenville-Anderson-Maudlin, SC 11 10 1.3 1.2 874,869
Harrisburg-Carlisle, PA 11 12 1.9 2.1 565,006
Hartford-West Hartford-East Hartford, CT 25 21 2.1 1.7 1,211,324
Houston-The Woodlands-Sugar Land, TX 383 381 5.8 5.9 6,656,947
Indianapolis-Carmel-Anderson, IN 63 61 3.2 3.1 1,988,817
Jackson, MS 26 24 4.5 4.1 578,777
Jacksonville, FL 58 50 4.0 3.5 1,449,481
Kansas City, MO-KS 30 30 1.4 1.4 2,087,471
Knoxville, TN 8 9 0.9 1.1 861,424
Lakeland-Winter Haven, FL 26 15 4.0 2.4 650,092
Lancaster, PA 6 7 1.1 1.3 536,624
Las Vegas-Henderson-Paradise, NV 70 66 3.3 3.2 2,114,801
Lexington-Fayette, KY 17 ... 3.4 ... 500,535
Little Rock-North Little Rock-Conway, AR 21 12 2.9 1.6 731,612
Los Angeles-Long Beach-Anaheim, CA 805 807 6.0 6.1 13,340,068
Louisville-Jefferson County, KY-IN 31 36 2.4 2.8 1,278,413
Madison, WI 8 9 1.2 1.4 641,385
McAllen-Edinburg-Mission, TX 72 70 8.5 8.4 842,304
Memphis, TN-MS-AR 56 60 4.2 4.5 1,344,127
Miami-Fort Lauderdale-West Palm Beach, FL 250 235 4.2 4.0 6,012,331
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Milwaukee-Waukesha-West Allis, WI 31 18 2.0 1.1 1,575,747
Minneapolis-St. Paul-Bloomington, MN-WI 114 102 3.2 2.9 3,524,583
Modesto, CA 18 13 3.3 2.4 538,388
Nashville-Davidson-Murfreesboro-Franklin, TN 46 56 2.5 3.1 1,830,345
New Haven-Milford, CT 18 11 2.1 1.3 859,470
New Orleans-Metairie, LA 35 53 2.8 4.2 1,262,888
New York-Newark-Jersey City, NY-NJ-PA 943 965 4.7 4.8 20,182,305
Northport-Sarasota-Bradenton, FL 16 14 2.1 1.9 768,918
Ogden-Clearfield, UT 2 1 0.3 0.2 642,850
Oklahoma City, OK 25 18 1.8 1.3 1,358,452
Omaha-Council Bluffs, NE-IA 18 18 2.0 2.0 915,312
Orlando-Kissimmee-Sanford, FL 68 84 2.8 3.6 2,387,138
Oxnard-Thousand Oaks-Ventura, CA 24 46 2.8 5.4 850,536
Palm Bay-Melbourne-Titusville, FL 12 11 2.1 2.0 568,088
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 163 158 2.7 2.6 6,069,875
Phoenix-Mesa-Scottsdale, AZ 127 128 2.8 2.9 4,574,531
Pittsburgh, PA 15 23 0.6 1.0 2,353,045
Portland-South Portland, ME 9 8 1.7 1.5 526,295
Portland-Vancouver-Hillsboro, OR-WA 57 71 2.4 3.0 2,389,228
Providence-Warwick, RI-MA 36 24 2.2 1.5 1,613,070
Provo-Orem, UT 2 0 0.3 0.0 585,799
Raleigh, NC 30 22 2.4 1.8 1,273,568
Richmond, VA 14 17 1.1 1.3 1,271,334
Riverside-San Bernardino-Ontario, CA 121 115 2.7 2.6 4,489,159
Rochester, NY 19 21 1.8 1.9 1,081,954
Sacramento-Roseville-Arden-Arcade, CA 91 87 4.0 3.9 2,274,194
St. Louis, MO-IL 40 44 1.4 1.6 2,836,114
Salt Lake City, UT 31 24 2.6 2.1 1,170,266
San Antonio-New Braunfels, TX 89 91 3.7 3.9 2,384,075
San Diego-Carlsbad, CA 234 220 7.1 6.7 3,299,521
San Francisco-Oakland-Hayward, CA 353 356 7.6 7.7 4,656,132
San Jose-Sunnyvale-Santa Clara, CA 199 163 10.1 8.3 1,976,836
Santa Rosa, CA 9 12 1.8 2.4 502,146
Scranton-Wilkes-Barre-Hazleton, PA 6 4 1.1 0.7 558,166
Seattle-Tacoma-Bellevue, WA 143 132 3.8 3.6 3,733,580
Spokane-Spokane Valley, WA 2 5 0.4 0.9 547,824
Springfield, MA 8 11 1.3 1.7 631,982
Stockton-Lodi, CA 58 54 8.0 7.6 726,106
Syracuse, NY 10 11 1.5 1.7 660,458
Tampa-St. Petersburg-Clearwater, FL 63 81 2.1 2.8 2,975,225
Toledo, OH 9 2 1.5 0.3 605,956
Tucson, AZ 36 32 3.6 3.2 1,010,025
Tulsa, OK 17 22 1.7 2.3 981,005
Urban Honolulu, HI 98 112 9.8 11.3 998,714
Virginia Beach-Norfolk-Newport News, VA-NC 34 23 2.0 1.3 1,724,876
Washington-Arlington-Alexandria, DC-VA-MD-WV 271 270 4.4 4.5 6,097,684
Wichita, KS 14 12 2.2 1.9 644,610
Winston-Salem, NC 10 8 1.5 1.2 659,330
Worcester, MA-CT 28 24 3.0 2.6 935,536
Youngstown-Warren-Boardman, OH-PA 2 1 0.4 0.2 549,885
Total - 107 areas 7,618 7,547 3.5 3.5 218,373,901
San Juan-Caguas-Guaynabo, PR 35 34 1.6 1.5 2,196,538
Table 62. (Cont’d) Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2015 and 2014
Metropolitan statistical area
Cases Case rates Population 
estimates 2015
2015 20152014 2014
Note: 2015 and 2014 population case counts and rates updated using County Totals Dataset: Population, Population Change and Es-
timated Components of Population Change: April 1, 2010 to July 1, 2015 (http://www.census.gov/popest/data/counties/totals/2015/files/
CO-EST2015-alldata.csv); accessed July 27, 2016.
Ellipses (...) indicate metropolitan statistical area was not included for 2014 data because of <500,000 population.
See Technical Notes for definition of metropolitan statistical area.
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Table 63. Tuberculosis Cases, by Age Group: Metropolitan Statistical Areas                         
with >500,000 Population, 2015
Akron, OH 12 0 1 2 3 3 3
Albany-Schenectady-Troy, NY 6 0 0 0 3 0 3
Albuquerque, NM 14 0 0 0 3 6 5
Allentown-Bethlehem-Easton, PA-NJ 7 0 0 0 0 4 3
Atlanta-Sandy Springs-Roswell, GA 219 10 3 16 76 82 32
Augusta-Richmond County, GA-SC 14 0 0 1 6 7 0
Austin-Round Rock, TX 77 0 3 8 33 24 9
Bakersfield, CA 29 0 0 1 6 16 6
Baltimore-Columbia-Towson, MD 64 2 1 8 25 17 11
Baton Rouge, LA 23 0 0 1 7 11 4
Birmingham-Hoover, AL 30 0 0 1 6 17 6
Boise City, ID 8 1 1 0 3 0 3
Boston-Cambridge-Newton, MA-NH 149 1 3 12 45 45 43
Bridgeport-Stamford-Norwalk, CT 24 0 0 2 12 7 3
Buffalo-Cheektowaga-Niagara Falls, NY 17 1 1 2 4 8 1
Cape Coral-Fort Myers, FL 17 0 1 4 1 7 4
Charleston-North Charleston, SC 19 2 0 0 6 7 4
Charlotte-Concord-Gastonia, NC-SC 41 0 1 1 17 18 4
Chattanooga, TN-GA 10 1 0 0 3 1 5
Chicago-Naperville-Elgin, IL-IN-WI 304 8 4 22 90 94 86
Cincinnati, OH-KY-IN 21 0 0 2 8 9 2
Cleveland-Elyria, OH 39 2 0 4 8 13 12
Colorado Springs, CO 4 0 0 1 1 2 0
Columbia, SC 10 0 1 1 3 3 2
Columbus, OH 41 1 0 9 21 6 4
Dallas-Fort Worth-Arlington, TX 311 6 8 33 100 114 50
Dayton, OH 9 0 0 3 1 2 3
Deltona-Daytona Beach-Ormond Beach, FL 6 0 0 0 1 5 0
Denver-Aurora-Lakewood, CO 50 3 2 3 17 13 12
Des Moines-West Des Moines, IA 8 1 0 1 5 0 1
Detroit-Warren-Dearborn, MI 75 2 0 8 20 22 23
Durham-Chapel Hill, NC 9 0 0 1 4 1 3
El Paso, TX 38 1 2 5 5 10 15
Fayetteville-Springdale-Rogers, AR-MO 30 8 1 4 8 5 4
Fresno, CA 41 3 0 6 7 14 11
Grand Rapids-Wyoming, MI 20 0 1 1 9 5 4
Greensboro-High Point, NC 27 2 1 4 14 5 1
Greenville-Anderson-Maudlin, SC 11 0 0 3 2 3 3
Harrisburg-Carlisle, PA 11 0 1 2 4 3 1
Hartford-West Hartford-East Hartford, CT 25 0 0 4 11 6 4
Houston-The Woodlands-Sugar Land, TX 383 16 13 33 117 139 65
Indianapolis-Carmel-Anderson, IN 63 2 1 15 21 17 7
Jackson, MS 26 1 0 3 3 14 5
Jacksonville, FL 58 3 3 6 16 25 5
Kansas City, MO-KS 30 0 2 7 12 7 2
Knoxville, TN 8 0 0 2 1 1 4
Lakeland-Winter Haven, FL 26 0 0 0 5 17 4
Lancaster, PA 6 0 0 0 2 3 1
Las Vegas-Henderson-Paradise, NV 70 0 0 5 25 23 17
Lexington-Fayette, KY 17 0 1 1 5 7 3
Little Rock-North Little Rock-Conway, AR 21 0 0 2 7 8 4
Los Angeles-Long Beach-Anaheim, CA 805 6 8 57 168 303 263
Louisville-Jefferson County, KY-IN 31 1 1 5 8 13 3
Madison, WI 8 0 0 0 5 3 0
McAllen-Edinburg-Mission, TX 72 7 1 7 18 21 18
Memphis, TN-MS-AR 56 4 0 6 18 18 10
Metropolitan statistical area Totalcases Under 5 15–245–14 25–44 45–64 >65
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Miami-Fort Lauderdale-West Palm Beach, FL 250 5 5 28 79 94 39
Milwaukee-Waukesha-West Allis, WI 31 0 1 1 9 9 11
Minneapolis-St. Paul-Bloomington, MN-WI 114 1 9 5 53 28 18
Modesto, CA 18 1 1 1 3 4 8
Nashville-Davidson-Murfreesboro-Franklin, TN 46 2 0 4 16 12 12
New Haven-Milford, CT 18 0 0 0 8 8 2
New Orleans-Metairie, LA 35 1 0 5 13 11 5
New York-Newark-Jersey City, NY-NJ-PA 943 16 12 96 316 279 224
Northport-Sarasota-Bradenton, FL 16 0 0 1 3 8 4
Ogden-Clearfield, UT 2 0 0 0 1 0 1
Oklahoma City, OK 25 1 0 2 5 9 8
Omaha-Council Bluffs, NE-IA 18 1 0 2 9 3 3
Orlando-Kissimmee-Sanford, FL 68 0 0 4 26 28 10
Oxnard-Thousand Oaks-Ventura, CA 24 0 1 2 5 5 11
Palm Bay-Melbourne-Titusville, FL 12 0 0 1 0 4 7
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 163 3 1 8 49 63 39
Phoenix-Mesa-Scottsdale, AZ 127 5 5 20 40 31 26
Pittsburgh, PA 15 0 1 0 5 5 4
Portland-South Portland, ME 9 0 0 3 2 1 3
Portland-Vancouver-Hillsboro, OR-WA 57 1 2 8 20 13 13
Providence-Warwick, RI-MA 36 0 1 2 9 12 12
Provo-Orem, UT 2 0 0 1 1 0 0
Raleigh, NC 30 0 0 2 7 7 14
Richmond, VA 14 1 0 1 3 3 6
Riverside-San Bernardino-Ontario, CA 121 6 2 17 22 43 31
Rochester, NY 19 5 2 5 3 3 1
Sacramento-Roseville-Arden-Arcade, CA 91 0 4 10 23 17 37
St. Louis, MO-IL 40 2 2 2 12 12 10
Salt Lake City, UT 31 4 2 4 9 10 2
San Antonio-New Braunfels, TX 89 0 2 6 32 32 17
San Diego-Carlsbad, CA 234 5 6 29 60 66 68
San Francisco-Oakland-Hayward, CA 353 4 2 29 85 108 125
San Jose-Sunnyvale-Santa Clara, CA 199 1 0 9 66 59 64
Santa Rosa, CA 9 0 0 3 3 2 1
Scranton-Wilkes-Barre-Hazleton, PA 6 0 0 1 1 2 2
Seattle-Tacoma-Bellevue, WA 143 4 5 17 52 27 38
Spokane-Spokane Valley, WA 2 0 0 0 0 2 0
Springfield, MA 8 0 0 0 2 5 1
Stockton-Lodi, CA 58 3 1 5 17 18 14
Syracuse, NY 10 1 0 2 3 1 3
Tampa-St. Petersburg-Clearwater, FL 63 1 2 6 16 24 14
Toledo, OH 9 0 1 1 4 0 3
Tucson, AZ 36 3 1 3 8 13 8
Tulsa, OK 17 1 2 1 2 5 6
Urban Honolulu, HI 98 3 3 19 20 27 26
Virginia Beach-Norfolk-Newport News, VA-NC 34 1 2 5 9 11 6
Washington-Arlington-Alexandria, DC-VA-MD-WV 271 6 6 21 101 66 71
Wichita, KS 14 0 0 0 3 8 3
Winston-Salem, NC 10 2 0 2 2 3 1
Worcester, MA-CT 28 1 1 2 12 4 8
Youngstown-Warren-Boardman, OH-PA 2 0 0 0 0 1 1
Total - 107 areas 7,618 186 151 721 2,278 2,440 1,842
San Juan-Caguas-Guaynabo, PR 35 0 0 3 13 10 9
Table 63. (Cont’d) Tuberculosis Cases, by Age Group: Metropolitan Statistical Areas          
with >500,000 Population, 2015
Metropolitan statistical area Totalcases
Note: See Technical Notes for definition of metropolitan statistical area.
Under 5 15–245–14 25–44 45–64 >65
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Akron, OH 12 0 0 9 1 0 2 0 0
Albany-Schenectady-Troy, NY 6 0 0 3 1 0 1 0 1
Albuquerque, NM 14 7 1 1 0 0 5 0 0
Allentown-Bethlehem-Easton, PA-NJ 7 3 0 1 2 0 1 0 0
Atlanta-Sandy Springs-Roswell, GA 219 31 1 64 102 0 20 1 0
Augusta-Richmond County, GA-SC 14 2 0 5 5 0 2 0 0
Austin-Round Rock, TX 77 31 0 28 10 0 8 0 0
Bakersfield, CA 29 20 0 4 1 1 0 3 0
Baltimore-Columbia-Towson, MD 64 7 0 25 24 0 6 2 0
Baton Rouge, LA 23 3 0 4 7 0 6 2 1
Birmingham-Hoover, AL 30 3 0 1 18 0 7 1 0
Boise City, ID 8 1 0 2 1 0 2 0 2
Boston-Cambridge-Newton, MA-NH 149 26 0 69 31 0 14 6 3
Bridgeport-Stamford-Norwalk, CT 24 13 0 5 5 0 1 0 0
Buffalo-Cheektowaga-Niagara Falls, NY 17 0 0 8 2 0 3 0 4
Cape Coral-Fort Myers, FL 17 4 0 2 3 0 8 0 0
Charleston-North Charleston, SC 19 1 0 3 11 0 4 0 0
Charlotte-Concord-Gastonia, NC-SC 41 8 0 12 18 0 3 0 0
Chattanooga, TN-GA 10 1 0 1 1 0 7 0 0
Chicago-Naperville-Elgin, IL-IN-WI 304 87 0 129 48 1 39 0 0
Cincinnati, OH-KY-IN 21 3 0 11 0 0 7 0 0
Cleveland-Elyria, OH 39 2 0 9 15 0 13 0 0
Colorado Springs, CO 4 0 0 4 0 0 0 0 0
Columbia, SC 10 1 0 2 6 0 1 0 0
Columbus, OH 41 2 0 12 24 0 3 0 0
Dallas-Fort Worth-Arlington, TX 311 72 0 101 90 4 43 0 1
Dayton, OH 9 0 0 3 3 0 3 0 0
Deltona-Daytona Beach-Ormond Beach, FL 6 2 0 0 1 0 3 0 0
Denver-Aurora-Lakewood, CO 50 14 0 15 13 0 6 1 1
Des Moines-West Des Moines, IA 8 0 0 4 3 0 1 0 0
Detroit-Warren-Dearborn, MI 75 4 0 26 24 0 21 0 0
Durham-Chapel Hill, NC 9 0 0 3 5 0 1 0 0
El Paso, TX 38 34 0 0 1 0 3 0 0
Fayetteville-Springdale-Rogers, AR-MO 30 1 0 4 2 17 6 0 0
Fresno, CA 41 25 0 8 2 0 4 2 0
Grand Rapids-Wyoming, MI 20 3 0 11 5 0 1 0 0
Greensboro-High Point, NC 27 13 0 7 6 0 1 0 0
Greenville-Anderson-Maudlin, SC 11 1 0 1 3 1 5 0 0
Harrisburg-Carlisle, PA 11 2 0 4 1 0 3 1 0
Hartford-West Hartford-East Hartford, CT 25 3 0 12 5 0 5 0 0
Houston-The Woodlands-Sugar Land, TX 383 182 0 86 81 0 34 0 0
Indianapolis-Carmel-Anderson, IN 63 13 0 24 15 0 11 0 0
Jackson, MS 26 1 0 3 20 0 2 0 0
Jacksonville, FL 58 4 0 7 30 0 17 0 0
Kansas City, MO-KS 30 7 0 14 6 0 3 0 0
Knoxville, TN 8 1 0 1 0 0 5 1 0
Lakeland-Winter Haven, FL 26 7 0 3 3 0 13 0 0
Lancaster, PA 6 3 0 2 0 0 1 0 0
Las Vegas-Henderson-Paradise, NV 70 16 0 29 16 0 8 1 0
Lexington-Fayette, KY 17 4 0 0 3 0 10 0 0
Little Rock-North Little Rock-Conway, AR 21 5 0 5 7 0 4 0 0
Los Angeles-Long Beach-Anaheim, CA 805 298 0 391 45 3 44 22 2
Louisville-Jefferson County, KY-IN 31 5 0 7 10 1 8 0 0
Madison, WI 8 3 0 2 0 0 3 0 0
McAllen-Edinburg-Mission, TX 72 67 0 3 1 0 0 1 0
Memphis, TN-MS-AR 56 9 0 7 36 0 4 0 0
Miami-Fort Lauderdale-West Palm Beach, FL 250 97 0 30 102 0 20 1 0
Table 64. Tuberculosis Cases, by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2015





















Milwaukee-Waukesha-West Allis, WI 31 9 0 14 6 0 2 0 0
Minneapolis-St. Paul-Bloomington, MN-WI 114 9 2 30 67 0 6 0 0
Modesto, CA 18 9 0 5 0 0 2 2 0
Nashville-Davidson-Murfreesboro-Franklin, TN 46 4 0 10 16 0 16 0 0
New Haven-Milford, CT 18 4 0 7 6 0 1 0 0
New Orleans-Metairie, LA 35 9 0 8 9 0 8 1 0
New York-Newark-Jersey City, NY-NJ-PA 943 272 0 408 182 1 68 7 5
Northport-Sarasota-Bradenton, FL 16 5 0 2 3 0 6 0 0
Ogden-Clearfield, UT 2 1 0 1 0 0 0 0 0
Oklahoma City, OK 25 3 2 7 3 0 8 2 0
Omaha-Council Bluffs, NE-IA 18 4 0 5 4 0 3 2 0
Orlando-Kissimmee-Sanford, FL 68 17 0 12 26 0 13 0 0
Oxnard-Thousand Oaks-Ventura, CA 24 10 0 8 0 0 6 0 0
Palm Bay-Melbourne-Titusville, FL 12 1 0 1 5 0 5 0 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 163 19 0 71 56 0 15 2 0
Phoenix-Mesa-Scottsdale, AZ 127 63 4 30 15 1 14 0 0
Pittsburgh, PA 15 1 0 4 2 0 8 0 0
Portland-South Portland, ME 9 0 0 2 5 0 2 0 0
Portland-Vancouver-Hillsboro, OR-WA 57 10 1 30 4 1 11 0 0
Providence-Warwick, RI-MA 36 14 0 9 3 0 9 1 0
Provo-Orem, UT 2 1 0 0 0 1 0 0 0
Raleigh, NC 30 1 0 14 10 0 5 0 0
Richmond, VA 14 1 0 6 4 0 3 0 0
Riverside-San Bernardino-Ontario, CA 121 66 0 41 7 0 6 1 0
Rochester, NY 19 6 0 8 3 0 2 0 0
Sacramento-Roseville-Arden-Arcade, CA 91 11 0 60 4 0 5 11 0
St. Louis, MO-IL 40 1 0 15 12 1 11 0 0
Salt Lake City, UT 31 15 0 9 4 0 3 0 0
San Antonio-New Braunfels, TX 89 65 1 9 3 0 11 0 0
San Diego-Carlsbad, CA 234 124 0 84 4 2 17 3 0
San Francisco-Oakland-Hayward, CA 353 60 0 212 25 3 28 25 0
San Jose-Sunnyvale-Santa Clara, CA 199 21 0 127 4 1 6 40 0
Santa Rosa, CA 9 6 0 2 0 0 0 1 0
Scranton-Wilkes-Barre-Hazleton, PA 6 0 0 3 2 0 1 0 0
Seattle-Tacoma-Bellevue, WA 143 9 3 80 32 9 10 0 0
Spokane-Spokane Valley, WA 2 0 0 2 0 0 0 0 0
Springfield, MA 8 3 0 2 2 0 1 0 0
Stockton-Lodi, CA 58 22 0 26 2 0 5 3 0
Syracuse, NY 10 0 0 6 3 0 1 0 0
Tampa-St. Petersburg-Clearwater, FL 63 12 0 18 20 1 12 0 0
Toledo, OH 9 0 0 4 2 1 2 0 0
Tucson, AZ 36 12 1 10 4 0 9 0 0
Tulsa, OK 17 3 0 5 3 0 4 2 0
Urban Honolulu, HI 98 0 0 66 0 28 2 2 0
Virginia Beach-Norfolk-Newport News, VA-NC 34 7 0 17 8 0 2 0 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 271 65 0 89 95 1 21 0 0
Wichita, KS 14 3 0 4 2 1 4 0 0
Winston-Salem, NC 10 5 0 1 3 0 1 0 0
Worcester, MA-CT 28 5 0 9 12 0 1 1 0
Youngstown-Warren-Boardman, OH-PA 2 0 0 0 1 0 1 0 0
Total - 107 areas 7,618 2,140 16 2,820 1,558 80 833 151 20
San Juan-Caguas-Guaynabo, PR 35 34 0 1 0 0 0 0 0
Table 64. (Cont’d) Tuberculosis Cases, by Hispanic Ethnicity and Non-Hispanic Race: Metropoli-
tan Statistical Areas with >500,000 Population, 2015
1Persons of Hispanic/Latino origin may be of any or multiple race.
2Indicates two or more races reported for a person and does not include persons of Hispanic/Latino origin.
Note: Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and 
white) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. 
See Technical Notes for definition of metropolitan statistical area and Hispanic ethnicity and non-Hispanic race.





















Akron, OH 12 3 (25.0) 9 (75.0) 0 (0)
Albany-Schenectady-Troy, NY 6 1 (16.7) 5 (83.3) 0 (0)
Albuquerque, NM 14 6 (42.9) 8 (57.1) 0 (0)
Allentown-Bethlehem-Easton, PA-NJ 7 3 (42.9) 4 (57.1) 0 (0)
Atlanta-Sandy Springs-Roswell, GA 219 103 (47.0) 116 (53.0) 0 (0)
Augusta-Richmond County, GA-SC 14 8 (57.1) 6 (42.9) 0 (0)
Austin-Round Rock, TX 77 18 (23.4) 59 (76.6) 0 (0)
Bakersfield, CA 29 5 (17.2) 24 (82.8) 0 (0)
Baltimore-Columbia-Towson, MD 64 22 (34.4) 42 (65.6) 0 (0)
Baton Rouge, LA 23 16 (69.6) 7 (30.4) 0 (0)
Birmingham-Hoover, AL 30 25 (83.3) 5 (16.7) 0 (0)
Boise City, ID 8 0 (0) 7 (87.5) 1 (12.5)
Boston-Cambridge-Newton, MA-NH 149 16 (10.7) 129 (86.6) 4 (2.7)
Bridgeport-Stamford-Norwalk, CT 24 2 (8.3) 22 (91.7) 0 (0)
Buffalo-Cheektowaga-Niagara Falls, NY 17 6 (35.3) 11 (64.7) 0 (0)
Cape Coral-Fort Myers, FL 17 9 (52.9) 8 (47.1) 0 (0)
Charleston-North Charleston, SC 19 15 (78.9) 4 (21.1) 0 (0)
Charlotte-Concord-Gastonia, NC-SC 41 17 (41.5) 24 (58.5) 0 (0)
Chattanooga, TN-GA 10 8 (80.0) 2 (20.0) 0 (0)
Chicago-Naperville-Elgin, IL-IN-WI 304 80 (26.3) 224 (73.7) 0 (0)
Cincinnati, OH-KY-IN 21 7 (33.3) 14 (66.7) 0 (0)
Cleveland-Elyria, OH 39 27 (69.2) 12 (30.8) 0 (0)
Colorado Springs, CO 4 0 (0) 4 (100.0) 0 (0)
Columbia, SC 10 7 (70.0) 3 (30.0) 0 (0)
Columbus, OH 41 3 (7.3) 38 (92.7) 0 (0)
Dallas-Fort Worth-Arlington, TX 311 134 (43.1) 177 (56.9) 0 (0)
Dayton, OH 9 2 (22.2) 7 (77.8) 0 (0)
Deltona-Daytona Beach-Ormond Beach, FL 6 4 (66.7) 2 (33.3) 0 (0)
Denver-Aurora-Lakewood, CO 50 8 (16.0) 42 (84.0) 0 (0)
Des Moines-West Des Moines, IA 8 1 (12.5) 7 (87.5) 0 (0)
Detroit-Warren-Dearborn, MI 75 27 (36.0) 48 (64.0) 0 (0)
Durham-Chapel Hill, NC 9 4 (44.4) 5 (55.6) 0 (0)
El Paso, TX 38 14 (36.8) 24 (63.2) 0 (0)
Fayetteville-Springdale-Rogers, AR-MO 30 24 (80.0) 6 (20.0) 0 (0)
Fresno, CA 41 17 (41.5) 24 (58.5) 0 (0)
Grand Rapids-Wyoming, MI 20 4 (20.0) 16 (80.0) 0 (0)
Greensboro-High Point, NC 27 7 (25.9) 20 (74.1) 0 (0)
Greenville-Anderson-Maudlin, SC 11 9 (81.8) 2 (18.2) 0 (0)
Harrisburg-Carlisle, PA 11 4 (36.4) 7 (63.6) 0 (0)
Hartford-West Hartford-East Hartford, CT 25 7 (28.0) 18 (72.0) 0 (0)
Houston-The Woodlands-Sugar Land, TX 383 152 (39.7) 231 (60.3) 0 (0)
Indianapolis-Carmel-Anderson, IN 63 21 (33.3) 42 (66.7) 0 (0)
Jackson, MS 26 21 (80.8) 5 (19.2) 0 (0)
Jacksonville, FL 58 45 (77.6) 13 (22.4) 0 (0)
Kansas City, MO-KS 30 6 (20.0) 24 (80.0) 0 (0)
Knoxville, TN 8 5 (62.5) 3 (37.5) 0 (0)
Lakeland-Winter Haven, FL 26 14 (53.8) 12 (46.2) 0 (0)
Lancaster, PA 6 1 (16.7) 5 (83.3) 0 (0)
Las Vegas-Henderson-Paradise, NV 70 21 (30.0) 49 (70.0) 0 (0)
Lexington-Fayette, KY 17 11 (64.7) 6 (35.3) 0 (0)
Little Rock-North Little Rock-Conway, AR 21 12 (57.1) 9 (42.9) 0 (0)
Los Angeles-Long Beach-Anaheim, CA 805 134 (16.6) 667 (82.9) 4 (0.5)
Louisville-Jefferson County, KY-IN 31 14 (45.2) 17 (54.8) 0 (0)
Madison, WI 8 1 (12.5) 7 (87.5) 0 (0)
McAllen-Edinburg-Mission, TX 72 23 (31.9) 49 (68.1) 0 (0)
Memphis, TN-MS-AR 56 36 (64.3) 20 (35.7) 0 (0)
Miami-Fort Lauderdale-West Palm Beach, FL 250 63 (25.2) 187 (74.8) 0 (0)
Table 65. Tuberculosis Cases and Percentages, U.S.-Born Persons and Foreign-Born 
Persons1: Metropolitan Statistical Areas with >500,000 Population, 2015
Metropolitan statistical area







Milwaukee-Waukesha-West Allis, WI 31 7 (22.6) 24 (77.4) 0 (0)
Minneapolis-St. Paul-Bloomington, MN-WI 114 15 (13.2) 99 (86.8) 0 (0)
Modesto, CA 18 5 (27.8) 13 (72.2) 0 (0)
Nashville-Davidson-Murfreesboro-Franklin, TN 46 16 (34.8) 30 (65.2) 0 (0)
New Haven-Milford, CT 18 4 (22.2) 14 (77.8) 0 (0)
New Orleans-Metairie, LA 35 17 (48.6) 18 (51.4) 0 (0)
New York-Newark-Jersey City, NY-NJ-PA 943 165 (17.5) 777 (82.4) 1 (0.1)
Northport-Sarasota-Bradenton, FL 16 8 (50.0) 8 (50.0) 0 (0)
Ogden-Clearfield, UT 2 1 (50.0) 1 (50.0) 0 (0)
Oklahoma City, OK 25 15 (60.0) 10 (40.0) 0 (0)
Omaha-Council Bluffs, NE-IA 18 3 (16.7) 15 (83.3) 0 (0)
Orlando-Kissimmee-Sanford, FL 68 32 (47.1) 36 (52.9) 0 (0)
Oxnard-Thousand Oaks-Ventura, CA 24 9 (37.5) 15 (62.5) 0 (0)
Palm Bay-Melbourne-Titusville, FL 12 10 (83.3) 2 (16.7) 0 (0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 163 54 (33.1) 108 (66.3) 1 (0.6)
Phoenix-Mesa-Scottsdale, AZ 127 28 (22.0) 99 (78.0) 0 (0)
Pittsburgh, PA 15 7 (46.7) 8 (53.3) 0 (0)
Portland-South Portland, ME 9 2 (22.2) 7 (77.8) 0 (0)
Portland-Vancouver-Hillsboro, OR-WA 57 15 (26.3) 42 (73.7) 0 (0)
Providence-Warwick, RI-MA 36 6 (16.7) 30 (83.3) 0 (0)
Provo-Orem, UT 2 0 (0) 2 (100.0) 0 (0)
Raleigh, NC 30 10 (33.3) 20 (66.7) 0 (0)
Richmond, VA 14 7 (50.0) 7 (50.0) 0 (0)
Riverside-San Bernardino-Ontario, CA 121 28 (23.1) 91 (75.2) 2 (1.7)
Rochester, NY 19 6 (31.6) 13 (68.4) 0 (0)
Sacramento-Roseville-Arden-Arcade, CA 91 17 (18.7) 73 (80.2) 1 (1.1)
St. Louis, MO-IL 40 16 (40.0) 24 (60.0) 0 (0)
Salt Lake City, UT 31 6 (19.4) 25 (80.6) 0 (0)
San Antonio-New Braunfels, TX 89 42 (47.2) 47 (52.8) 0 (0)
San Diego-Carlsbad, CA 234 61 (26.1) 173 (73.9) 0 (0)
San Francisco-Oakland-Hayward, CA 353 51 (14.4) 302 (85.6) 0 (0)
San Jose-Sunnyvale-Santa Clara, CA 199 9 (4.5) 189 (95.0) 1 (0.5)
Santa Rosa, CA 9 2 (22.2) 7 (77.8) 0 (0)
Scranton--Wilkes-Barre-Hazleton, PA 6 3 (50.0) 3 (50.0) 0 (0)
Seattle-Tacoma-Bellevue, WA 143 29 (20.3) 114 (79.7) 0 (0)
Spokane-Spokane Valley, WA 2 0 (0) 2 (100.0) 0 (0)
Springfield, MA 8 4 (50.0) 4 (50.0) 0 (0)
Stockton-Lodi, CA 58 23 (39.7) 34 (58.6) 1 (1.7)
Syracuse, NY 10 2 (20.0) 8 (80.0) 0 (0)
Tampa-St. Petersburg-Clearwater, FL 63 29 (46.0) 34 (54.0) 0 (0)
Toledo, OH 9 2 (22.2) 7 (77.8) 0 (0)
Tucson, AZ 36 15 (41.7) 21 (58.3) 0 (0)
Tulsa, OK 17 9 (52.9) 8 (47.1) 0 (0)
Urban Honolulu, HI 98 37 (37.8) 61 (62.2) 0 (0)
Virginia Beach-Norfolk-Newport News, VA-NC 34 10 (29.4) 24 (70.6) 0 (0)
Washington-Arlington-Alexandria, DC-VA-MD-WV 271 41 (15.1) 230 (84.9) 0 (0)
Wichita, KS 14 6 (42.9) 8 (57.1) 0 (0)
Winston-Salem, NC 10 6 (60.0) 4 (40.0) 0 (0)
Worcester, MA-CT 28 2 (7.1) 26 (92.9) 0 (0)
Youngstown-Warren-Boardman, OH-PA 2 2 (100.0) 0 (0) 0 (0)
Total - 107 areas 7,618 2,147 (28.2) 5,455 (71.6) 16 (0.2)
San Juan-Caguas-Guaynabo, PR 35 29 (82.9) 6 (17.1) 0 (0)
Table 65. (Cont’d) Tuberculosis Cases and Percentages, U.S.-Born Persons and Foreign-Born 
Persons1: Metropolitan Statistical Areas with >500,000 Population, 2015
1Includes persons born outside of the United States (including the U.S. insular areas) and the sovereign freely associated states (the 
Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau).
Note: See Technical Notes for definition of metropolitan statistical area.
Metropolitan statistical area







Akron, OH 11 11 (100.0) 1 (9.1)
Albany-Schenectady-Troy, NY 6 6 (100.0) 1 (16.7)
Albuquerque, NM 14 14 (100.0) 2 (14.3)
Allentown-Bethlehem-Easton, PA-NJ 7 7 (100.0) 1 (14.3)
Atlanta-Sandy Springs-Roswell, GA 206 205 (99.5) 25 (12.1)
Augusta-Richmond County, GA-SC 14 14 (100.0) 0 (0)
Austin-Round Rock, TX 74 74 (100.0) 9 (12.2)
Bakersfield, CA 29 27 (93.1) 2 (6.9)
Baltimore-Columbia-Towson, MD 61 61 (100.0) 4 (6.6)
Baton Rouge, LA 23 23 (100.0) 3 (13.0)
Birmingham-Hoover, AL 30 30 (100.0) 3 (10.0)
Boise City, ID 6 6 (100.0) 0 (0)
Boston-Cambridge-Newton, MA-NH 145 144 (99.3) 3 (2.1)
Bridgeport-Stamford-Norwalk, CT 24 24 (100.0) 0 (0)
Buffalo-Cheektowaga-Niagara Falls, NY 15 15 (100.0) 0 (0)
Cape Coral-Fort Myers, FL 16 15 (93.8) 1 (6.3)
Charleston-North Charleston, SC 17 17 (100.0) 0 (0)
Charlotte-Concord-Gastonia, NC-SC 40 40 (100.0) 2 (5.0)
Chattanooga, TN-GA 9 9 (100.0) 0 (0)
Chicago-Naperville-Elgin, IL-IN-WI 292 290 (99.3) 10 (3.4)
Cincinnati, OH-KY-IN 21 21 (100.0) 1 (4.8)
Cleveland-Elyria, OH 37 37 (100.0) 2 (5.4)
Colorado Springs, CO 4 4 (100.0) 0 (0)
Columbia, SC 9 9 (100.0) 1 (11.1)
Columbus, OH 40 40 (100.0) 2 (5.0)
Dallas-Fort Worth-Arlington, TX 297 297 (100.0) 37 (12.5)
Dayton, OH 9 9 (100.0) 0 (0)
Deltona-Daytona Beach-Ormond Beach, FL 6 5 (83.3) 0 (0)
Denver-Aurora-Lakewood, CO 45 45 (100.0) 1 (2.2)
Des Moines-West Des Moines, IA 7 7 (100.0) 0 (0)
Detroit-Warren-Dearborn, MI 73 73 (100.0) 4 (5.5)
Durham-Chapel Hill, NC 9 9 (100.0) 0 (0)
El Paso, TX 35 35 (100.0) 0 (0)
Fayetteville-Springdale-Rogers, AR-MO 21 21 (100.0) 0 (0)
Fresno, CA 38 38 (100.0) 5 (13.2)
Grand Rapids-Wyoming, MI 19 19 (100.0) 1 (5.3)
Greensboro-High Point, NC 24 24 (100.0) 0 (0)
Greenville-Anderson-Maudlin, SC 11 11 (100.0) 0 (0)
Harrisburg-Carlisle, PA 10 10 (100.0) 0 (0)
Hartford-West Hartford-East Hartford, CT 25 25 (100.0) 1 (4.0)
Houston-The Woodlands-Sugar Land, TX 354 354 (100.0) 28 (7.9)
Indianapolis-Carmel-Anderson, IN 60 60 (100.0) 5 (8.3)
Jackson, MS 25 25 (100.0) 3 (12.0)
Jacksonville, FL 52 52 (100.0) 10 (19.2)
Kansas City, MO-KS 28 28 (100.0) 2 (7.1)
Knoxville, TN 8 8 (100.0) 1 (12.5)
Lakeland-Winter Haven, FL 26 26 (100.0) 1 (3.8)
Lancaster, PA 6 6 (100.0) 0 (0)
Las Vegas-Henderson-Paradise, NV 70 70 (100.0) 5 (7.1)
Lexington-Fayette, KY 16 16 (100.0) 4 (25.0)
Little Rock-North Little Rock-Conway, AR 21 21 (100.0) 4 (19.0)
Los Angeles-Long Beach-Anaheim, CA 791 787 (99.5) 50 (6.3)
Louisville-Jefferson County, KY-IN 29 29 (100.0) 1 (3.4)
Madison, WI 8 8 (100.0) 0 (0)
McAllen-Edinburg-Mission, TX 64 64 (100.0) 3 (4.7)
Memphis, TN-MS-AR 52 52 (100.0) 7 (13.5)
Miami-Fort Lauderdale-West Palm Beach, FL 240 240 (100.0) 15 (6.3)
Table 66. Tuberculosis Cases and Percentages, by Homeless Status,1 Ages >15 Years: 
Metropolitan Statistical Areas with >500,000 Population, 2015
Metropolitan statistical area





Cases reported as being 
homeless2
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Milwaukee-Waukesha-West Allis, WI 30 30 (100.0) 0 (0)
Minneapolis-St. Paul-Bloomington, MN-WI 104 104 (100.0) 5 (4.8)
Modesto, CA 16 16 (100.0) 0 (0)
Nashville-Davidson-Murfreesboro-Franklin, TN 44 44 (100.0) 1 (2.3)
New Haven-Milford, CT 18 18 (100.0) 0 (0)
New Orleans-Metairie, LA 34 33 (97.1) 1 (2.9)
New York-Newark-Jersey City, NY-NJ-PA 915 913 (99.8) 30 (3.3)
Northport-Sarasota-Bradenton, FL 16 14 (87.5) 0 (0)
Ogden-Clearfield, UT 2 2 (100.0) 1 (50.0)
Oklahoma City, OK 24 24 (100.0) 1 (4.2)
Omaha-Council Bluffs, NE-IA 17 16 (94.1) 0 (0)
Orlando-Kissimmee-Sanford, FL 68 68 (100.0) 7 (10.3)
Oxnard-Thousand Oaks-Ventura, CA 23 23 (100.0) 1 (4.3)
Palm Bay-Melbourne-Titusville, FL 12 12 (100.0) 0 (0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 159 158 (99.4) 4 (2.5)
Phoenix-Mesa-Scottsdale, AZ 117 107 (91.5) 6 (5.1)
Pittsburgh, PA 14 14 (100.0) 0 (0)
Portland-South Portland, ME 9 9 (100.0) 0 (0)
Portland-Vancouver-Hillsboro, OR-WA 54 54 (100.0) 4 (7.4)
Providence-Warwick, RI-MA 35 34 (97.1) 1 (2.9)
Provo-Orem, UT 2 2 (100.0) 0 (0)
Raleigh, NC 30 30 (100.0) 1 (3.3)
Richmond, VA 13 13 (100.0) 0 (0)
Riverside-San Bernardino-Ontario, CA 113 113 (100.0) 5 (4.4)
Rochester, NY 12 12 (100.0) 1 (8.3)
Sacramento-Roseville-Arden-Arcade, CA 87 87 (100.0) 0 (0)
St. Louis, MO-IL 36 35 (97.2) 2 (5.6)
Salt Lake City, UT 25 25 (100.0) 1 (4.0)
San Antonio-New Braunfels, TX 87 87 (100.0) 2 (2.3)
San Diego-Carlsbad, CA 223 223 (100.0) 18 (8.1)
San Francisco-Oakland-Hayward, CA 347 347 (100.0) 13 (3.7)
San Jose-Sunnyvale-Santa Clara, CA 198 197 (99.5) 2 (1.0)
Santa Rosa, CA 9 9 (100.0) 1 (11.1)
Scranton-Wilkes-Barre-Hazleton, PA 6 6 (100.0) 1 (16.7)
Seattle-Tacoma-Bellevue, WA 134 130 (97.0) 2 (1.5)
Spokane-Spokane Valley, WA 2 2 (100.0) 0 (0)
Springfield, MA 8 8 (100.0) 2 (25.0)
Stockton-Lodi, CA 54 54 (100.0) 4 (7.4)
Syracuse, NY 9 9 (100.0) 0 (0)
Tampa-St. Petersburg-Clearwater, FL 60 60 (100.0) 8 (13.3)
Toledo, OH 8 8 (100.0) 0 (0)
Tucson, AZ 32 31 (96.9) 1 (3.1)
Tulsa, OK 14 14 (100.0) 1 (7.1)
Urban Honolulu, HI 92 92 (100.0) 2 (2.2)
Virginia Beach-Norfolk-Newport News, VA-NC 31 31 (100.0) 1 (3.2)
Washington-Arlington-Alexandria, DC-VA-MD-WV 259 258 (99.6) 4 (1.5)
Wichita, KS 14 14 (100.0) 3 (21.4)
Winston-Salem, NC 8 8 (100.0) 0 (0)
Worcester, MA-CT 26 26 (100.0) 0 (0)
Youngstown-Warren-Boardman, OH-PA 2 2 (100.0) 0 (0)
Total - 107 areas 7,281 7,243 (99.5) 398 (5.5)
San Juan-Caguas-Guaynabo, PR 35 35 (100.0) 1 (2.9)
Table 66. (Cont’d) Tuberculosis Cases and Percentages, by Homeless Status,1 Ages >15 
Years: Metropolitan Statistical Areas with >500,000 Population, 2015
1Homeless within past 12 months of TB diagnosis. 
2Percent of those with known status. 
Note: See Technical Notes for definition of metropolitan statistical area.
Metropolitan statistical area No. No.(%) (%)
Total
cases
Cases with information on 
homeless status
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Tuberculosis in the United States
National Tuberculosis Surveillance System Highlights from 2015
Slide 1 (title slide). Tuberculosis in the United States—National Tuberculosis Surveillance System, High-
lights from 2015. This slide set was prepared by the Division of Tuberculosis Elimination, National Center 
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and 
Prevention (CDC), U.S. Department of Health and Human Services (HHS). It provides trends for the recent 
past and highlights data collected through the National Tuberculosis Surveillance System for 2015. Since 
1953, through the cooperation of state and local health departments, CDC has collected information on newly 
reported cases of tuberculosis (TB) disease in the United States. The data presented here were collected by the 
revised TB case report introduced in 2009. Each individual TB case report (Report of Verified Case of Tuber-
culosis, or RVCT) is submitted electronically to CDC. The data for this slide set are based on updates received 
by CDC as of June 9, 2016. All case counts and rates for years 1993–2015 have been updated.
Slide 2. Reported Tuberculosis (TB) Cases, United States, 1982–2015. The resurgence of TB in the mid-
1980s was marked by years of increasing case counts until its peak in 1992. Case counts decreased from 1993 
and 2014. However, in 2015, a slight increase occurred in the total number of TB cases reported in the United 
States. From 1992 until 2008, the total number of TB cases decreased 2%–7% annually. An unprecedented 
decrease occurred in 2009, when the total number of TB cases decreased by more than 10% from 2008 to 
2009. In 2015, a total of 9,557 cases were reported from the 50 states and the District of Columbia (DC). This 
represents an increase of 1.6% from 2014, but a 64.2% decrease from 1992.
Slide 3. TB Morbidity, United States, 2010–2015. This slide provides the total number of reported U.S. TB 
cases and the associated rates for each of the past 6 years. Rate is defined as the number of cases per 100,000 
population. The number of TB cases decreased from 11,159 in 2010 to 9,557 in 2015, and the TB rate de-
creased from 3.6 in 2010 to 3.0 in 2015.
Slide 4. TB Case Rates, United States, 2015. Forty-three states reported a rate ≤3.0 cases/100,000 popula-
tion, the 2015 national average. Seven states and DC reported a rate >3.0 cases/100,000 population; these 
accounted for 53% of the national total in 2015.
Slide 5. Map of U.S.-Affiliated Pacific Islands, by TB Case Rates, 2015. The Federated States of Mi-
cronesia, Republic of the Marshall Islands, Northern Mariana Islands and Palau had case rates at or above 
50/100,000 population. The lowest case rates were in Guam and American Samoa.
Slide 6. TB Case Rates, U.S.-Affiliated Pacific Islands, 2015. Case rates range from 7.4/100,000 population 
in American Samoa to 189.8/100,000 in the Republic of the Marshall Islands, compared with the substantially 
lower overall U.S. case rate (3.0/100,000).
Slide 7. TB Case Rates, by Age Group, United States, 1993–2015. During 2015, case rates in all age groups 
declined by >50% from their 1993 values: persons aged ≥65 years, from 17.7 cases/100,000 population in 
1993 to 4.8 in 2015; adults aged 45–64 years, from 12.5 to 3.6; adults aged 25–44 years, from 11.6 to 3.4; 
persons aged 15–24 years, from 5.0 to 2.1; children aged 5 to 14 years, from 1.7 to 0.5; and children aged ≤4 
years, from 5.2 to 1.2.
Slide 8. Reported TB Cases, by Age Group, United States, 2015. Three percent of TB cases were among 
children aged 0–4 years; 2% were among those aged 5–14 years; 10% were among persons aged 15–24 years; 
30% were among adults aged 25–44 years; 32% were among adults aged 45–64 years; and 24% were among 
adults aged ≥65 years.
Slide 9. TB Case Rates, by Age Group and Sex, United States, 2015. Case rates tended to increase with 
age, ranging from a low of <1 case/100,000 children aged 5–14 years to a high of 6.7 cases/100,000 men aged 
≥65 years. As age increased, the case rate among men increased faster than among women; the rates among 
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men aged ≥45 years were approximately twice those among women of the same age.
Slide 10. TB Case Rates, by Race/Ethnicity, United States, 2003–2015. By race/ethnicity, the rates indi-
cate a declining trend in TB since 2003. Asians consistently had the highest yearly TB rates, but their rates 
declined from 29.3 cases/100,000 population in 2003 to 18.2 in 2015, a 38% decrease. Rates also declined 
among the following racial/ethnic groups: non-Hispanic blacks/African Americans, from 11.7 in 2003 to 5.0 
in 2015 (–57%); Hispanics, from 10.2 to 4.8 (–54%); American Indians and Alaska Natives, from 8.3 to 6.1 
(–26%); and non-Hispanic whites, from 1.4 to 0.6 (–56%). Rates increased among Native Hawaiian/Other 
Pacific Islanders, from 15.7 to 18.2 (16%) from 2003 to 2015. Because of the low TB case counts and popu-
lation estimates for Native Hawaiians/Other Pacific Islanders in the United States, case rates for this group 
might appear high.
Certain key factors likely contribute to the disproportionate burden of TB among minority groups. For persons 
who were born in countries where TB is common, TB disease can result from infection acquired in their coun-
try of origin. Unequal distribution of TB risk factors (e.g., human immunodeficiency virus [HIV] infection) 
also might contribute to increased exposure to TB or to an increased risk for experiencing TB after becoming 
infected with Mycobacterium tuberculosis.
Slide 11. TB Case Rates, by Age Group and Race/Ethnicity, United States, 2015. After infancy (ages 0–4 
years), risk typically increased with age across all racial/ethnic groups, except among Native Hawaiians/Other 
Pacific Islanders, which did not indicate a trend. Rates were consistently higher among minority racial/ethnic 
groups than among non-Hispanic whites. Rates were the highest among Asians and Native Hawaiians/Other 
Pacific Islanders. Because of the low TB case counts and population estimates for Native Hawaiians/Other 
Pacific Islanders in the United States, case rates for this group might appear high.
Slide 12. Reported TB Cases, by Race/Ethnicity, United States, 2015. During 2015, approximately 85% of 
all reported TB cases occurred among racial/ethnic minorities: Asians, 33%; Hispanics, 28%; non-Hispanic 
blacks/African Americans, 21%; American Indians/Alaska Natives, 2%; and Native Hawaiians/Other Pacific 
Islanders, 1%. In contrast, 13% of cases occurred among non-Hispanic whites. Persons reporting two or more 
races, not including persons of Hispanic or Latino ethnicity, accounted for 2% of all cases.
Slide 13. Number of TB Cases Among U.S.-Born versus Foreign-Born Persons, United States, 1993–
2015. The graph illustrates the increase in the percentage of cases occurring among foreign-born persons 
during the study period, from 29% in 1993 to 66% in 2015. Overall, the number of cases among foreign-born 
persons remained stable before 2009, with approximately 7,400–8,000 cases/year. During 2009, the number 
decreased to 6,959, and that trend continued through 2013, with the number of cases among foreign-born 
persons decreasing to 6,186. However, since 2014, the number of cases among foreign-born persons has 
increased (6,350 cases during 2015). The number among U.S.-born persons decreased from >17,000 in 1993 
to 3,186 in 2015.
Slide 14. Trends in TB Cases Among Foreign-Born Persons, United States, 1993–2015. The percentage of 
TB cases accounted for among foreign-born persons increased from 29% in 1993 to 66% in 2015.
Slide 15. Reported TB Cases, by Origin and Race/Ethnicity, United States, 2015. Among U.S.-born 
persons with TB in 2015, 36% were non-Hispanic black/African American; 31% were non-Hispanic white, 
21% were Hispanic/Latino; 4% were Asian; 4% were American Indian/Alaska Native; and 3% were Native 
Hawaiian/Other Pacific Islander. Persons reporting two or more races totaled <1% of cases among U.S.-born 
persons. Among foreign-born persons with TB, 48% were Asian; 32% were Hispanic/Latino; 13% were non-
Hispanic black/African American; 4% were non-Hispanic white; and 2% were persons reporting two or more 
races, not including persons of Hispanic/Latino origin. Cases among American Indians/Alaska Natives and 
among Native Hawaiians/Other Pacific Islanders constituted 0.2% of the cases among foreign-born persons 
and are not included on the charts.
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Slide 16. Percentage of Foreign-Born Persons Among TB Cases, United States, 2005 and 2015. The 
number of states with <25% of their TB cases occurring among foreign-born persons decreased from 10 
states in 2005 to 6 states in 2015. The number of states with ≥25%–49% of cases among foreign-born persons 
decreased from 17 states and DC in 2005 to 8 states in 2015. However, the number of states that had ≥50% of 
their cases among foreign-born persons increased from 23 states in 2005 to 36 states and DC in 2015.
Slide 17. TB Case Rates Among U.S.-Born versus Foreign-Born Persons, United States, 1993–2015. TB 
rates among foreign-born persons remain higher than those among the U.S.-born population. During 1993–
2015, the rates among U.S.-born persons decreased from 7.4 cases/100,000 population to 1.2, whereas the 
rates among foreign-born persons decreased from 34.0 cases/100,000 population to 15.1.
Slide 18. TB Case Rates Among U.S.-Born versus Foreign-Born Persons, United States, 1993–2015. The 
chart presents the same data as on Slide 17, but uses a logarithmic scale to better illustrate the trends. The 
trend lines indicate a greater rate of decrease among U.S.-born, compared with foreign-born, persons during 
the study period.
Slide 19. Countries of Birth Among Foreign-Born Persons Reported with TB, United States, 2015. The 
top seven countries are displayed in the chart; those countries have remained relatively constant since 1986, 
when information regarding country of birth was first reported by all areas submitting reports to CDC. During 
2015, the top seven countries accounted for >60% of all cases among foreign-born persons, with Mexico ac-
counting for 20%; the Philippines, 13%; India, 9%; Vietnam, 8%; China, 7%; Guatemala, 3%; and Haiti, 2%. 
Persons from 136 other countries each accounted for ≤2% of the total, but altogether, accounted for 38% of 
foreign-born persons reported with TB.
Slide 20. Percentage of Foreign-Born Persons with TB, by Time of Residence in U.S. Before Diagnosis, 
2015. The chart indicates that the distribution for the top three countries of birth is Mexico, the Philippines, 
and India. Among persons born in Mexico, 9.2% had been in the United States for <1 year; 6.7%, 1–4 years; 
9.2%, 5–9 years; 23.9%, 10–19 years; and 38.9% for ≥20 years. Among persons born in the Philippines, 
13.4% had been in the United States for <1 year; 9.9%, 1–4 years; 12.2%, 5–9 years; 20.4%, 10–19 years; and 
33.8%, ≥20 years. Among persons born in India, 21.1% had been in the United States for <1 year; 21.6%, 1–4 
years; 14.9%, 5–9 years; 19.5%, 10–19 years; and 16.2%, ≥20 years. Values for unknown length of residence 
in the United States for these top three countries ranged from 6.7 to 12.1% for 2015. For all other foreign-
born persons, 19.3% had been in the United States for <1 year; 18.8%, 1–4 years; 12.8%, 5–9 years; 17.9%, 
10–19 years; 22.3%, ≥20 years; and 8.4%, unknown length of residence. Overall, 16.7% had been in the 
United States for <1 year; 15.8%, 1–4 years; 12.2%, 5–9 years; 19.5%, 10–19 years; 26.5%, ≥20 years; and 
9.2%, unknown length of residence.
Slide 21. Primary Anti-TB Drug Resistance, United States, 1993–2015. The graph starts in 1993, the 
year in which the individual TB case reports submitted to the national surveillance system began collecting 
information regarding initial susceptibility test results for patients with culture-positive TB. Data were avail-
able for >86.9% of culture-positive cases for each year. Primary resistance was calculated by using data from 
persons with no reported prior TB episode. Resistance to at least isoniazid was 8.2% in 1993; however, by 
2015, this had increased to 9.0%. Resistance to at least isoniazid and rifampin, known as multidrug-resistant 
TB (MDR TB), was 2.5% in 1993. The percent of primary MDR TB has remained approximately stable since 
it decreased to 1.0% in 1998. In 2015 the percent of primary MDR TB was 1.1%.
Slide 22. Primary MDR-TB, United States, 1993–2015. This graph focuses on trends in primary multidrug-
resistant TB (MDR-TB), which is based on initial isolates from persons with no prior history of TB. The num-
ber of primary MDR-TB cases, represented by the bars, decreased steadily from 407 in 1993 to 115 in 2001, 
with a slight increase to 132 in 2002. Since then, the total number of primary MDR-TB cases has fluctuated 
from 70 to 103 cases, with 73 cases reported for 2015. Primary MDR-TB, indicated by the trend line, de-
creased from 2.5% in 1993 to approximately 1.0% in 1998, and has fluctuated approximately 1.0% since then. 
During 2015, the percentage was 1.1%.
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Slide 23. Primary Isoniazid Resistance Among U.S.-Born versus Foreign-Born Persons, United States, 
1993–2015. On the basis of initial isolates from persons with no prior history of TB, the percentage of isonia-
zid resistance has remained higher among foreign-born persons than among U.S.-born persons for all years 
measured. Among foreign-born persons, the percentage declined from 12.1% in 1993 to 10.0% in 2015. In 
U.S.-born persons, the percentage decreased from 6.7% in 1993 to 4.2% in 2007, but has increased since then 
to 6.4% in 2015.
Slide 24. Primary MDR-TB Among U.S.-Born versus Foreign-Born Persons, United States, 1993–2015. 
The percentage of persons with primary MDR-TB has declined among both groups since 1993, although the 
decline among U.S.-born persons has been greater. Consequently, the proportion of primary MDR-TB cases 
in the United States that are attributed to foreign-born persons increased from approximately 25% in 1993 to 
86% in 2015 (not shown on slide). Among U.S.-born persons, the percentage with primary MDR-TB has been 
<1% since 1997 and was 0.5% in 2015. The percentage among foreign-born persons has fluctuated year to 
year, although it has remained from 1.2 to 1.8% since 1995. During 2015, the percentage of primary MDR-TB 
cases among foreign-born persons was 1.4%.
Slide 25. XDR-TB Case Count, Defined on Initial DST, United States, 1993–2015. Extensively drug-re-
sistant TB (XDR-TB) at first drug susceptibility test (DST) is defined as resistance to isoniazid and rifampin, 
plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs. One 
case of XDR-TB was reported in 2015, and the most reported in a single year was 10 in 1993. No cases were 
reported in 2003 and 2009, and no apparent trend exists in the number of cases over time.
Slide 26. Reporting of HIV Test Results Among Persons with TB, by Age Group, United States, 1993–
2015. The percentage of TB patients for whom HIV test results were reported increased from 29.9% among 
all ages in 1993 to 89.5% in 2015. Among adults aged 25–44 years, the percentage increased from 45.1% in 
1993 to 94.9% in 2015. California began reporting HIV test results to CDC in 2011, which accounts for the 
substantial percentage increase for that year.
Slide 27. Estimated HIV Coinfection Among Persons Reported with TB, United States, 1993–2015. 
Since the addition of HIV status to the individual TB case report in 1993, incomplete reporting has provided 
a challenge to calculating reliable estimates. However, reporting improved substantially beginning in 2011 
(see Slide 26). For all ages, the estimated percentage of coinfection among persons with TB who reported HIV 
testing (positive, negative, or indeterminate results) decreased from 48.2% to 5.5% overall during 1993–2015, 
and from 62.5% to 7.6% among persons aged 25–44 years during that period.
Slide 28. TB Cases Among Persons Aged ≥15 Years Residing in Correctional Facilities, United States, 
1993–2015. The number of cases among persons aged ≥15 years residing in a correctional facility has de-
creased from a high of 1,117 cases in 1994 to 330 cases in 2015. During 2000–2010, the number of TB cases 
reported from correctional facilities ranged from mid-to-high 400s to high 500s; 2011 was the first year cases 
decreased to <423 cases. Of total cases, the percentage of cases residing in a correctional facility has ranged 
from 5.0% in 1994 to 3.3% in 2002. The 1990s saw a decreasing trend in percentages until 2002. Since 2002, 
the trend has increased in percentages. However, during 2015, the percentage of total cases decreased to 3.6%.
Slide 29. TB Cases Reported Among Homeless Persons During the 12 Months Before Diagnosis, Ages 
≥15 Years, United States, 1993–2015. The number of cases among persons aged ≥15 years who were home-
less any time during the 12 months before the TB diagnosis has decreased from a high of 1,379 cases in 1994 
to 495 in 2015. This category has experienced an overall decrease since 1994, with the exception of slight 
increases during 2003, 2006, and 2010. Of total cases, the percentages among homeless persons have had an 
overall decrease from 7.5% in 1993 to 5.5% in 2015.
Slide 30. Mode of Treatment Administration Among Persons Reported with TB, United States, 1993–
2013. In 1993, the reporting areas began providing information regarding modes of treatment administra-
tion on the individual TB case report form. Treatment administered as only directly observed therapy (DOT) 
increased from 21.7% in 1993 to 63.2% in 2013, the latest year with available data. The proportion of patients 
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who received at least some portion of their treatment as DOT (on the basis of combining the percentage of pa-
tients who received only DOT and the percentage for whom some portion was self-administered) was 28.9% 
during 2013.
Slide 31. Completion of TB Treatment Therapy, United States, 1993–2013. Reporting areas began provid-
ing information regarding TB treatment therapy completion in 1993 through the individual TB case report 
form. The calculations include persons alive at diagnosis with an initial regimen of ≥1 drug prescribed, who 
did not die within 1 year of initiating therapy. The calculations exclude persons with an initial rifampin-
resistant isolate; patients with bone and joint disease, meningeal disease, or disease of the central nervous 
system; pediatric patients aged 0–14 years with miliary disease or a positive blood culture or a positive 
NAA from a blood specimen; and those who moved out of the country within 1 year of initiating treat-
ment. Overall completion of therapy had remained at approximately 92%–93% from 1998 through 2008, 
but increased to 95%–96% from 2009 to 2013. In 2013, the latest year with available data, completion of 
therapy was 95.9%. Completion in ≤1 year increased from 63.4% in 1993 to 89.6% in 2013. The Healthy 
People 2020 objective is completion of therapy in ≤1 year for 93% of patients (Objective IID-30, available at: 
https:// www. healthypeople.gov/ 2020/topics-objectives/objective/iid-30). CDC is working with state and local 
health departments to determine and evaluate reasons for apparent delayed therapy completion, which might 
vary by jurisdiction.
Slide 32. Definition for Mycobacterium tuberculosis Genotyping in the United States. The schematic 
shows the sequential assignment of unique spoligotype and 12-locus MIRU-VNTR combination (PCRType) 
or 24-locus MIRU-VNTR combination (GENType).
Slide 33. National Mycobacterium tuberculosis Genotyping Surveillance Coverage, by Year, United 
States, 2004–2015. During 2004, the proportion of positive cultures with ≥1 genotyped isolate was 52.6%; 
during 2015, it was 96.1%. The national indicator for genotyping surveillance coverage is 94.0%.
Slide 34. Number and Percentage of Unique and County-GENType Clustered Cases, United States, 
2013–2015. Unique cases are those with a spoligotype and 24-locus MIRU-VNTR (GENType) that does 
not match any other case in that county during the specified 3-year period. Clustered cases are ≥2 cases with 
matching spoligotype and 24-locus MIRU-VNTR (GENType) within a county during the specified 3-year 
period. During 2013–2015, 78% were unique cases, and 22% were clustered cases.
Slide 35. Number of County-Based Mycobacterium tuberculosis Genotype Clusters, by Cluster Size, 
United States, 2013–2015. A genotype cluster is defined as ≥2 cases with matching spoligotype and 24-locus 
MIRU-VNTR (GENType) within a county during the specified 3-year period. During 2013–2015, clusters 
occurred as follows: 958 2-case clusters; 233 3-case clusters; 115 4-case clusters; 48 5-case clusters; 31 6-case 
clusters; 14 7-case clusters; 17 8-case clusters; 10 9-case clusters; and 38 ≥10-case clusters.
Slide 36. Mycobacterium tuberculosis Genotype Clusters, by TB GIMS Alert Levels, United States, 
2013–2015. Alert levels are determined by the log likelihood ratio statistic (LLR) for a given cluster, identify-
ing higher than expected geospatial concentrations for a TB genotype cluster in a specific county, compared 
with the national distribution of that genotype. TB GIMS generates alert level notifications as follows: A “No 
alert” is indicated if LLRs are 0–<5; a “medium” is for LLRs of 5–<10; and a “high” alert is for clusters with 







Tuberculosis Case Definition for Public Health Surveillance
(Revised May 13, 2009)
Clinical Description
A chronic bacterial infection caused by Mycobacterium tuberculosis, usually characterized patho-
logically by the formation of granulomas. The most common site of infection is the lung, but other 
organs can be involved.
Clinical Case Definition
A case that meets all of the following criteria:
• A positive tuberculin skin test result or positive interferon gamma release assay for M. tuberculo-
sis.
• Other signs and symptoms compatible with tuberculosis (TB) (e.g., abnormal chest radiograph, 
abnormal chest computerized tomography scan or other chest imaging study, or clinical evidence 
of current disease).
• Treatment with two or more anti-TB medications.
• A completed diagnostic evaluation.
Laboratory Criteria for Diagnosis
• Isolation of M. tuberculosis complex from a clinical specimen,*
or
• Demonstration of M. tuberculosis complex from a clinical specimen by nucleic acid amplifica-
tion test,†
or
• Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be 
obtained or is falsely negative or contaminated.
Case Classification
Confirmed: A case that meets the clinical case definition or is laboratory-confirmed.
Comment: A case should not be counted twice within any consecutive 12-month period. However, 
a case occurring in a patient who had previously had verified TB disease should be reported and 
counted again if >12 months have elapsed since the patient completed therapy. A case should also 
be reported and counted again if the patient was lost to supervision for >12 months and TB disease 
can be verified again. Mycobacterial diseases other than those caused by M. tuberculosis complex 
should not be counted in tuberculosis morbidity statistics unless concurrent tuberculosis occurs.
                                                                                                                  
* Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid 
chromatography performed on a culture from a clinical specimen) are acceptable under this criterion.
† Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical pur-
poses. A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also 
genotyping. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the 
Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or 





Recommendations for Reporting and Counting Tuberculosis Cases
(Revised May 13, 2009)
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”1 in 
July 1997, substantial changes have occurred, and questions have been raised within the field of 
tuberculosis (TB) surveillance. This appendix updates and supersedes previous versions.
A distinction should be made between reporting TB cases to a health department and counting 
TB cases for determining disease incidence. Throughout each year, TB cases and suspected cases 
are reported to public health authorities by such sources as clinics, hospitals, laboratories, and 
health care providers. From these reports, the state or local TB control officer must determine 
which cases meet the surveillance definition for TB disease and whether the case is countable. 
These countable TB cases are then reported to the Centers for Disease Control and Prevention 
(CDC).
Beginning in 2009, state and local TB control officers may also report to CDC those TB cases 
that are verified but not countable for morbidity statistics, as a measure of programmatic and case 
management burden. The noncountable report can include persons with TB disease recurring 
within a consecutive 12-month period after the patient completed TB therapy.
I. Reporting TB Cases. CDC recommends that health care providers and laboratories be re-
quired to report all TB cases or suspected cases to state and local health departments on the 
basis of “Tuberculosis Case Definition for Public Health Surveillance” (Appendix A). This 
notification is essential for TB programs to
• ensure case supervision,
• ensure completion of recommended therapy,
• ensure completion of contact investigations,
• evaluate program effectiveness, and
• assess trends and characteristics of TB morbidity.
II. TB Surveillance. For purposes of surveillance, a case of TB is defined on the basis of labo-
ratory or clinical evidence of active disease caused by M. tuberculosis complex.*
________________________________
* Because the majority of laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis from closely related 
species, these laboratories report culture results as being positive or negative for “Mycobacterium tuberculosis complex.” Although 
in almost all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. tuberculosis, other species are possible. 
Other species in the M. tuberculosis complex include M. bovis, M. africanum, M. microti, M. canetii, M. caprae, M. pinnipedii, 
and M. mungi; the inclusion of these species in M. tuberculosis complex should not affect public health laboratories or programs 
because only a few laboratories identify to the species level. These seven species are approximately identical in DNA homology 
studies. In terms of their ability to cause clinical disease or be transmissible from person to person, M. bovis, M. africanum, M. mi-
croti, M. canetii, M. pinnipedii, and M. mungi behave like M. tuberculosis; therefore, disease caused by any of the organisms should 
be reported as TB, using the Report of Verified Case of Tuberculosis (RVCT). The only exception is the bacillus Calmette-Guérin 
(BCC) strain of M. bovis, which can be isolated from persons who have received the vaccine for protection against TB or as cancer 
immunotherapy; disease caused by the BCG strain of M. bovis should not be reported as TB.
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A. Laboratory Case Definition
Isolation of M. tuberculosis complex from a clinical specimen. The use of rapid identifi-
cation techniques for M. tuberculosis performed on a culture from a clinical specimen (e.g., 
DNA probes or high-pressure liquid chromatography) is acceptable under this criterion.
or
Demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplifica-
tion test. Nucleic acid amplification (NAA) tests must be accompanied by cultures of my-
cobacterial species. However, for surveillance purposes, CDC will accept results obtained 
from NAA tests approved by the Food and Drug Administration (FDA) and used accord-
ing to the approved product labeling on the package insert, or a test produced and validat-
ed in accordance with applicable FDA and Clinical Laboratory Improvement Amendments 
regulations.
or
Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not 
been or cannot be obtained or is falsely negative or contaminated. Historically, this crite-
rion has been most commonly used in diagnosing TB in the postmortem setting.
B. Clinical Case Definition. In the absence of laboratory confirmation of M. tuberculosis 
complex after a diagnostic process has been completed, persons must have all of the 
following criteria for a clinical TB diagnosis:
1. Evidence of TB infection based on a positive tuberculin skin test result or positive inter-
feron gamma release assay for M. tuberculosis, and
2. current treatment with two or more anti-TB medications.
and
One of the following:
1. Signs and symptoms compatible with current TB disease (e.g., an abnormal chest 
radiograph or abnormal chest computerized tomography scan or other chest imag-
ing study, 
or
2. Clinical evidence of current disease (e.g., fever, night sweats, cough, weight loss, 
hemoptysis).
NOTE: The software for TB surveillance developed by CDC includes a calculated variable 
called “Vercrit,” for which one of the values is Provider Diagnosis. Provider Diagnosis is se-
lected when the user chooses to override a Suspect default value in the case verification screen 
as Verified by Provider Diagnosis. Thus, Provider Diagnosis is not a component of the case 
definition for TB in the “Tuberculosis Case Definition for Public Health Surveillance” (Ap-
pendix A). CDC’s national morbidity reports have traditionally included all TB cases that are 
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considered verified by the reporting areas, without a requirement that cases meet the published 
case definition.
III. Counting TB Cases. Cases that meet the CDC surveillance case definition for verified TB 
are counted by 52 reporting areas with count authority (50 states, the District of Columbia 
[DC], and New York City) to determine annual incidence for the United States. The remain-
ing 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, Marshall 
Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) 
report cases to CDC but are not included in the annual incidence for the United States. The 
laboratory and clinical case definitions are the two diagnostic categories used in the CDC 
“Tuberculosis Case Definition for Public Health Surveillance” (Appendix A).
The majority of verified TB cases are accepted for counting on the basis of laboratory 
confirmation of M. tuberculosis complex from a clinical specimen.
A person might have more than one discrete (separate and distinct) episode of TB. If dis-
ease recurs within any 12-month consecutive period after the patient completed therapy, 
count only one episode as a case. However, if TB disease recurs in a person, and if >12 
months have elapsed since the person completed TB therapy or the person was lost to 
supervision, the TB case is considered a separate episode and should be counted as a new 
case.
Mycobacterial diseases other than those caused by M. tuberculosis complex should not be 
counted in TB morbidity statistics unless concurrent TB occurs.
A. Verified TB Cases
COUNT
Count only verified TB cases that meet the laboratory or clinical case definitions (see 
Section II). TB diagnosis must be verified by the TB control officer or designee. The 
CDC surveillance case definition for TB (Appendix A) describes and defines the crite-
ria to be used in the case definition for TB disease.
DO NOT COUNT
If diagnostic procedures have not been completed, do not count; wait for confirma-
tion of disease. Do not count as a case of illness in a patient for whom two or more 
anti-TB medications have been prescribed for preventive therapy for exposure to 
multidrug-resistant TB or while the diagnosis is still pending.
B. Nontuberculous Mycobacterial Disease
COUNT
An episode of TB disease diagnosed concurrently with another nontuberculous my-
cobacterial disease (NTM) should be counted as a TB case.
DO NOT COUNT
Disease attributed to or caused by NTM alone should not be counted as a TB case.
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C. TB Cases Reported at Death
COUNT
TB cases first reported to the health department at the time of a person’s death are 
counted as incident cases, provided the person had current disease at the time of 
death. The TB control officer should verify the TB diagnosis.
DO NOT COUNT
Do not count as a case of TB if no evidence exists of current disease at the time of 
death or at autopsy.
D. Immigrants, Refugees, Permanent Resident Aliens, Border Crossers,† and For-
eign Visitors2
COUNT
Immigrants and refugees who are examined after arriving in the United States and 
who receive a diagnosis of clinically active TB requiring anti-TB medications should 
be reported and counted by the locality of their residence at the time of diagnosis, 
regardless of citizenship status.
Border crossers† who receive a TB diagnosis and who plan to receive anti-TB therapy 
from a locality in the United States for ≥90 days should be reported and counted by 
the locality where they receive anti-TB therapy.
Foreign visitors (e.g., students, commercial representatives, and diplomatic person-
nel) who receive a diagnosis of TB, are receiving anti-TB therapy, and have been or 
plan to remain in the United States for ≥90 days should be reported and counted by 
the locality of current residence.
DO NOT COUNT
Any person who received a TB diagnosis and who started anti-TB drugs in another 
country should not be counted as a new case but should be reported as a person with a 
verified noncountable TB case.
Border crossers† and foreign visitors who receive a TB diagnosis and who receive 
anti-TB therapy from a locality in the United States for ≤89 days but who plan to 
return to their native country to continue therapy should not be reported or counted by 
the locality where they receive anti-TB therapy.
† Border crosser is defined by the U.S. Citizenship and Immigration Services3 as “an alien 
resident of the United States reentering the country after an absence of less than six months 
in Canada or Mexico, or a nonresident alien entering the United States across the Canadian 
border for stays of no more than six months, or across the Mexican border for stays of no 
more than 72 hours.” Border crossers might go back and forth across the border frequently in 
a short period.
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E. Out-of-State or Out-of-Area Residents
COUNT
A person’s TB case should be counted by the locality in which he or she resides at 
the time of diagnosis. TB in a person who has no address should be counted by the 
locality where TB is diagnosed and treated. The TB control officer should notify the 
out-of-state or out-of-area TB control officer of the person’s home locality to (1) de-
termine whether the case has been counted already to avoid double counting, and (2) 
agree on which TB control office should count the case if it has not yet been counted.
DO NOT COUNT
Do not count a case in a patient with newly diagnosed TB who is an out-of-area resi-
dent and whose TB has already been counted by the out-of-area TB control office.
F. Migrants and Other Transients
COUNT
Persons without any fixed U.S. residence are considered to be the public health re-
sponsibility of their present locality, and their TB case should be reported and counted 
where diagnosed.
DO NOT COUNT
Cases among transient TB patients should not be counted when evidence exists that 
they have already been counted by another locality.
G. Cases Occurring in Federal Facilities (e.g., Military and Veterans Administration 
Facilities)
COUNT
Cases among military personnel, their dependents, or veterans should be reported and 
counted by the locality where the persons are residing in the United States at the time 
of diagnosis and initiation of treatment.
However, if military personnel or dependents are discovered to have TB at a military 
base outside the United States but are referred elsewhere for treatment (e.g., a military 
base located within the United States), the TB case should be reported and counted 
where treated and not where the diagnosis was made.
DO NOT COUNT
Do not count if the case was already counted by another locality in the United States.
H. Cases Associated with the Indian Health Service
COUNT
TB should be reported to the local health authority (e.g., state or county) and counted 
where diagnosed and treatment is initiated. However, for specific groups (e.g., the Na-
vajo Nation) located in multiple states, health departments should discuss each case 
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and determine which locality should count the case.
DO NOT COUNT
Do not count if the case was already counted by another locality.
I. Cases Occurring in Correctional Facilities (e.g., Local, State, Federal, and Military)
COUNT
Frequently, persons who reside in local, state, federal, or military correctional facili-
ties are transferred or relocated within or between different correctional facilities. TB 
among these persons should be reported to the local health authority and counted by 
the locality where the diagnosis was made and treatment plans were initiated.
DO NOT COUNT
Do not count correctional facility residents’ TB cases that were counted elsewhere by 
another locality or correctional facility, even if treatment continues at another locale 
or correctional facility.
J. Peace Corps, Missionaries, and Other Citizens Residing Outside the United States
DO NOT COUNT
TB among persons who received their diagnosis outside the United States should not 
be counted. TB among these persons should be counted by the country in which they 
are residing, regardless of their plans to return to the United States for further evalua-
tion or treatment.
IV. Recommended Administrative Practices
To promote uniformity in TB case counting, the following administrative procedures are 
recommended:
A. All TB cases verified by the 52 reporting areas with count authority (50 states, DC, and 
New York City) during the calendar year (by December 31) will be included in the an-
nual U.S. incidence count for that year. All TB cases verified during the calendar year by a 
reporting area with count authority from one of the remaining eight reporting areas (Ameri-
can Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana 
Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) are also counted but are 
not included in the annual incidence for the United States. Cases for which bacteriologic re-
sults are pending or for which confirmation of disease is questionable for any other reason 
should not be counted until their status is clearly determined; they should be counted at the 
time they meet the criteria for counting. This means that a case reported in 1 calendar year 
might be included in the morbidity count for the following year. All reporting areas should 
ensure that agreement exists between final local and state TB figures reported to CDC. Re-
porting areas might not use this recommended protocol. They may wait until the beginning 
of the following year when they have received and processed all of the TB cases for inclu-
sion in the annual case count for the previous year. If reporting areas decide to revise their 
protocols, they should be aware that their TB trends might change.
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B. Occasionally, TB is reported to health departments by telephone, by letter or fax, or on 
forms other than the RVCT. Such information should be accepted as an official morbid-
ity report if sufficient details are provided; otherwise, the notification should be used as an 
indicator of a possible TB case (suspect) that should be investigated promptly for confirma-
tion.
V. TB Surveillance Definitions
Case: An episode of TB disease in a person meeting the laboratory or clinical criteria for 
TB as defined in “Tuberculosis Case Definition for Public Health Surveillance” (see Sec-
tion II for criteria).
Suspect: A case for which a high index of suspicion exists for active TB (e.g., in a known 
contact of a person with active TB or in a person with signs or symptoms consistent with 
TB) and that is currently under evaluation.
Verification of a TB case: The process whereby a TB case, after the diagnostic evalua-
tion is complete, is reviewed at the local level (e.g., state or county) by a TB control of-
ficial who is familiar with TB surveillance definitions; if all the criteria for a TB case are 
met, the TB case is then verified and eligible for counting.
Counting of a TB case: The process whereby a reporting area with count author-
ity evaluates verified TB cases against count criteria (e.g., assesses for case dupli-
cation). These cases are then counted for morbidity in that locality (e.g., state or 
county) and reported to CDC for national morbidity counting. Noncountable, veri-
fied cases may also be sent to CDC.
M. tuberculosis complex: Because the majority of laboratories use tests that do not rou-
tinely distinguish M. tuberculosis from closely related species, those laboratories report 
culture results as being positive or negative for M. tuberculosis complex. Although in 
approximately all cases of human disease, isolates in the M. tuberculosis complex are, in 
fact, M. tuberculosis, other species are possible. For example, one study in San Diego re-
ported that 6% of human tuberculosis was caused by M. bovis; cultures from these cases 
would be reported by the majority of laboratories as being positive for M. tuberculosis 
complex4. Other species in the M. tuberculosis complex include M. africanum, M. micro-
ti, M. canetii, M. caprae, and M. pinnipedii. Although M. microti, M. canetii, M. caprae, 
and M. pinnipedii are newly described species, their inclusion in M. tuberculosis complex 
should not affect public health laboratories or programs because only a few laboratories 
identify to the species level. These seven species are almost identical in DNA homology 
studies. In terms of their ability to cause clinical disease or be transmissible from person 
to person, M. bovis, M. africanum, M. microti, M. canetti, M. caprae, and M. pinnipe-
dii behave similar to M. tuberculosis; therefore, disease caused by any of the organisms 
should be reported as TB by using the RVCT form. The only exception is the BCG strain 
of M. bovis, which might be isolated from persons who have received the vaccine for 
protection against TB or as cancer immunotherapy; disease caused by the BCG strain of 
M. bovis should not be reported as TB.
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Nontuberculous mycobacteria: Mycobacteria other than M. tuberculosis complex that 
can cause human infection or disease. Common nontuberculous mycobacteria (NTM) 
include M. avium complex (also known as “MAC”) (M. avium, M. intracellulare), M. 
kansasii, M. marinum, M. scrofulaceum, M. chelonae, M. fortuitum, and M. simiae. Other 
terms have been used to represent NTM, including “MOTT” (mycobacteria other than 
TB) and “atypical” mycobacteria.
Reporting area: Areas responsible for counting and reporting verified TB cases to CDC. 
A total of 60 areas report cases to CDC: the 50 states, DC, New York City, American Sa-
moa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, 
Puerto Rico, Republic of Palau, and U.S. Virgin Islands. The annual incidence of tubercu-
losis for the United States is based on 52 of these reporting areas (the 50 states, DC, and 
New York City).
Alien: Defined by USCIS3 as “any person not a citizen or national of the United States.” 
The term alien is further defined as follows:
Border crosser: Defined by USCIS3 as “an alien resident of the United States reen-
tering the country after an absence of less than six months in Canada or Mexico, or a 
nonresident alien entering the United States across the Canadian border for stays of 
no more than six months, or across the Mexican border for stays of no more than 72 
hours.” Border crossers may go back and forth across the border frequently in a short 
period.
Class A TB with waiver2: All applicants who have tuberculosis disease and have 
been granted a waiver.
Class B1 TB, Pulmonary2:
No Treatment
Applicants who have medical history, physical exam, HIV, or chest radiographic 
findings indicative of pulmonary TB but have negative AFB sputum smears and 
cultures and have not received a diagnosis of TB or who can wait to have TB 
treatment started after immigration.
Completed Treatment
Applicants who received a diagnosis of pulmonary TB and successfully com-
pleted directly observed therapy before immigration. The report cover sheet 
should indicate if the initial sputum smears and cultures were positive and if 
drug susceptibility testing results are available.
Class B1 TB, Extrapulmonary2:
Applicants with evidence of extrapulmonary TB. Document the anatomic site of 
infection.
Class B2 TB, Latent TB Infection (LTBI) Evaluation2:
Applicants who have a tuberculin skin test (TST) of ≥10-mm induration but oth-
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erwise have a negative evaluation for TB. The size of the TST reaction, the appli-
cant’s status with respect to latent TB infection treatment, and the medications used 
should be documented. For applicants who have had >1 TST, if the applicant’s TST 
reaction converted, that should be documented (i.e., initial TST was ≤9-mm indura-
tion but subsequent TST was ≥10-mm induration).
Class B3 TB, Contact Evaluation2:
Applicants who are a recent contact of a known TB patient. The size of the appli-
cant’s TST reaction should be documented. Information about the source patient, 
including name, alien number, relationship to contact, and type of TB should also 
be documented.
Immigrant: Defined by the USCIS3 as “an alien admitted to the United States 
as a lawful permanent resident. Immigrants are those persons lawfully accorded 
the privilege of residing permanently in the United States. They may be issued 
immigrant visas by the [U.S.] Department of State overseas or adjusted to per-
manent resident status by the USCIS of the United States.”
Permanent Resident Alien: See Immigrant.
Waivers2: A provision allows applicants undergoing pulmonary or laryngeal TB 
treatment to petition for a Class A TB with waiver. Waivers should be pursued for 
any immigrant or refugee who has a complicated clinical course and would ben-
efit from receiving TB treatment in the United States. Applicants with diagnosed 
TB disease who are both smear- and culture-negative and will be traveling to the 
United States before start of treatment do not need to complete the waiver process.
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National Surveillance for Severe Adverse Events Associated with Treatment 
for Latent Tuberculosis Infection — Reporting Information
This information is included to alert our public health partners to the importance of reporting se-
vere (i.e., hospitalization or death) adverse events associated with treatment for latent TB infec-
tion (LTBI). Data regarding severe adverse events (SAEs) among persons receiving treatment for 
LTBI are needed to serve as a basis for periodic evaluation of LTBI treatment guidelines.
In April 2000, after the publication of updated Guidelines for Targeted Tuberculin Testing and Treat-
ment of Latent Tuberculosis Infection,1 CDC’s Division of Tuberculosis Elimination (DTBE) began 
receiving reports of SAEs related to use of a 2-month course of rifampin and pyrazinamide for LTBI 
treatment. In response, DTBE requested and received reports and conducted on-site investigations of 
liver injury among persons on LTBI treatment, and treatment guidelines were revised to recommend 
against the general use of rifampin and pyrazinamide for treating LTBI.2,3 In January 2004, DTBE 
implemented the National Surveillance System for Severe Adverse Events Associated with Treat-
ment for LTBI, which collects reports about SAEs associated with any LTBI treatment regimen, to 
quantify the frequency of SAEs and to characterize the clinical features of affected patients.4
Local medical providers should report possible LTBI treatment-associated SAEs to their respective 
local or state health departments. State health departments should report SAEs that occurred on or 
after January 1, 2004, to DTBE (e-mail: LTBIdrugevents@cdc.gov).
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Genotyping Background Information and Glossary
Tuberculosis (TB) genotyping is a laboratory-based analysis of the genetic material of the bac-
teria that cause TB disease, Mycobacterium tuberculosis complex. The total genetic content 
is referred to as the genome. Specific sections of the genome contain distinct genetic patterns 
that help distinguish different strains of M. tuberculosis. TB genotyping examines the location, 
number, and presence of different types of spacer or repetitive DNA patterns. The areas of the 
genome examined in TB genotyping are different from those related to drug resistance.
Applications of Genotyping
Persons with TB disease who are related by transmission should have matching genotype results. 
Conversely, persons with matching TB genotyping results are probably related by transmission in 
some way, although the connection might not be recent or direct.
Genotyping results, when combined with epidemiologic data, can help identify persons with TB 
disease involved in the same chain of transmission. This information adds value to conventional 
TB control activities in different ways. These applications are summarized as follows:
Patient-Level Applications of Genotyping
Complete Contact Investigations
• Confirm or refute patient connections (epidemiologic linkages) identified that might or 
might not be identified through routine contact investigations.
Cluster Investigations
• Find patient connections that were not identified through routine contact investigations.
• Detect, refute, or confirm potential false-positive culture results.
• Distinguish relapse TB disease from new TB infection among TB patients with recurrent 
TB disease.
Population-Level Applications of Genotyping
• Detect potential outbreaks by using geospatial or other analyses of genotype clusters.
• Refute outbreaks when cases believed to be part of the same outbreak have nonmatching 
genotype results.
• Define the scope of potential outbreaks by identifying all cases in an area with a matching 
genotype.
• Monitor known outbreaks over time by watching for new cases with the outbreak geno-
type that become added to existing clusters (outbreak surveillance).
History of TB Genotyping Surveillance in the United States
In 1996, CDC started the National Tuberculosis Genotyping Surveillance Network (NTGSN), a 
5-year initiative that established the utility of genotyping in TB control efforts.1 In 2004, based 
on the knowledge gained from NTGSN and associated studies,2 CDC established the National 
TB Genotyping Service (NTGS) and funded a national genotyping laboratory, located in Michi-
gan, to genotype at least one M. tuberculosis isolate from each culture-positive TB case reported 
in the United States.3 All TB control programs can use NTGS at no cost to the patients, health 
183
care providers, or health departments. NTGS participation is voluntary, with individual programs 
determining how genotyping data will be used for their TB control activities. Since 2004, ap-
proximately 115,000 M. tuberculosis isolates have been successfully genotyped through NTGS 
and its partnerships among CDC programs, national genotyping laboratories, and 58 states and 
jurisdictions.
In 2010, CDC launched the TB Genotyping Information Management System (TB GIMS), a se-
cure Internet-based database available to all 50 states, the District of Columbia, Puerto Rico, the 
U.S. Virgin Islands, and the U.S.-affiliated Pacific Islands. TB GIMS makes genotyping data eas-
ily available to users and links genotyping data to patient surveillance records. Key features in-
clude tools to link genotype results of isolate records from NTGS to patient surveillance records 
from the National TB Surveillance System (NTSS). Additional features include database queries 
regarding genotypes and clusters, data quality checks, aggregate reports, maps, and outbreak 
detection tools. TB GIMS has >500 users among local, state, federal, and territorial partners.
Genotyping-Based Outbreak Detection
CDC identifies genotype clusters that are most likely to represent TB outbreaks. Genotyping-
based outbreak detection involves using geospatial analysis to identify unusual groupings of TB 
cases with matching genotypes that might represent outbreaks. TB control programs can use 
outbreak detection information to help allocate and prioritize resources for investigation and 
intervention on specific TB genotype clusters.
CDC’s primary outbreak detection method is based on identifying higher than expected geospa-
tial concentrations of a TB genotype in a specific county, compared with the national distribu-
tion of that genotype. This method calculates a log-likelihood ratio (LLR) statistic; clusters with 
higher LLRs are more likely to represent greater geospatial concentrations than clusters with 
lower LLRs; higher LLRs might indicate recent transmission of TB. LLRs are then classified into 
alert levels within TB GIMS on the basis of established cut points. Clusters are classified as no 
alert (LLRs 0–<5), medium alert (LLRs 5–<10), or high alert (≥10). The alert level and changes 
in alert levels (e.g., from no to medium or high) can help TB programs identify outbreaks and 
prioritize TB genotype clusters for further investigation or intervention.
Genotyping Terminology
In NTGS, a genotype is defined as a unique combination of spacer oligonucleotide typing results 
(spoligotype) and 24-locus mycobacterial interspersed repetitive unit–variable number tandem 
repeat typing (MIRU–VNTR) results. Each unique combination of results is assigned a GEN-
Type designated as G followed by 5 digits, which are assigned sequentially to every genotype 
identified in the United States (e.g., G00162). This nomenclature is designed for convenience and 
ease of communication, but the specific numbers assigned have no additional importance outside 
NTGS. Genotyping data from NTGS should not be used for clinical decision making.
National TB Genotyping Surveillance Coverage in the United States
National TB genotyping surveillance coverage refers to the proportion of culture-positive TB 
cases with a genotyped M. tuberculosis isolate. High levels of coverage in the United States 
can provide a better understanding of the epidemiology of TB transmission within a specific 
geographic area, as well as nationally. Additionally, because outbreak detection algorithms are 
based on identifying unusual geospatial concentrations of genotypes, high coverage levels help 
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decrease the likelihood of false-negative alerts. The National Tuberculosis Indicator Project na-
tional genotyping surveillance coverage objective is 94%.4
GLOSSARY
Alert level: A mechanism used by TB GIMS to notify users of genotype clusters, possibly 
representing TB outbreaks, in a specific county. The alert level is determined by the LLR for a 
given cluster. This is calculated by TB GIMS and is updated whenever a new case is added to a 
genotype cluster. E-mail notifications are generated whenever an alert level changes from a no 
alert LLR (0–<5.0) to medium LLR (5.0–<10.0) or high LLR (≥10.0), or from a medium LLR to 
a high LLR.
Cluster investigation: A cluster investigation identifies epidemiologic links between TB patients 
whose isolates have matching genotypes. It might consist of reviewing information from public 
health and medical records and interviewing case managers and outreach workers. It can also 
involve re-interviewing TB patients.
Epidemiologic link (epi link): An epidemiologic link is a relationship that two TB patients 
share that explains where, when, and how M. tuberculosis might have been transmitted between 
them. Patients who name each other as contacts have an epidemiologic link. However, an epide-
miologic link can be a location where the two persons spent time together or an activity occurred 
that brought them together.
Genotype: The designation that represents one or more of the three genotyping techniques used 
for M. tuberculosis: spoligotyping, MIRU-VNTR analysis, and IS6110-based restriction frag-
ment length polymorphism (RFLP). These designations were developed to facilitate communica-
tion of genotyping information within and between TB programs. In the United States, we use 
GENType or PCRType to define a genotype.
Genotype surveillance coverage: Genotyping surveillance coverage is defined as the proportion 
of culture-positive TB cases with a genotype result.
GENType: A designation for each unique combination of spoligotype and 24-locus MIRU–
VNTR results. GENType is designated as G followed by five digits, which are assigned sequen-
tially to every genotype identified in the United States (e.g., G00017).
Genotyping cluster: A genotyping cluster consists of two or more cases in a jurisdiction dur-
ing a specified period with M. tuberculosis isolates that share matching genotypes. In the United 
States, all cases with matching GENType or PCRType are considered to be in a genotype cluster. 
The jurisdiction and period used vary on the basis of the specific application of the term cluster. 
Within TB GIMS, a single county and a 3-year period are used to define a cluster.
Geospatial concentration: Geospatial concentration is a measure of how concentrated a geno-
type is in time and space. It indicates that recent transmission has occurred because patients with 
infections with the same genotype in the same location are more likely to have come in contact 
with each other. TB GIMS uses the LLR to generate a numeric measure of geospatial concentra-
tion of a given TB genotype.
185
Linking: In TB GIMS, linking refers to the process of connecting genotyping results with a 
reported TB case from the National TB Surveillance System (NTSS). This step is essential for 
ensuring that demographic, risk factor, and geographic data can be viewed in TB GIMS for geno-
type clusters.
LLR (log-likelihood ratio): A measure of the geographic concentration of a specific genotype 
in a county, compared with the national distribution of that same genotype, throughout a 3-year 
period. The higher the LLR, the greater the evidence that the local genotype cluster within the 
county represents a greater geospatial concentration than the national average, which might indi-
cate recent transmission of M. tuberculosis.
MDR: Multidrug-resistant (MDR) tuberculosis strains are resistant to at least isoniazid and 
rifampin.
MIRU-VNTR: Mycobacterial interspersed repetitive unit–variable number tandem repeat typing 
analysis. MIRU-VTNR is a polymerase chain reaction (PCR)-based genotyping assay. The CDC 
genotyping program performs 24-locus MIRU-VNTR analysis on every isolate submitted for 
genotyping. Before 2009, only 12-locus MIRU-VNTR was performed.
Mycobacterium bovis: A member of the M. tuberculosis complex that is commonly associated 
with cattle, particularly in countries with a low socioeconomic status. In the United States, hu-
man cases of M. bovis TB typically have a foodborne origin (e.g., consumption of unpasteurized 
dairy products). M. bovis is typically resistant to pyrazinamide. Identification of TB isolates that 
are M. bovis can be performed through genotyping; however, this information should not be 
relied on for clinical decision making.
Mycobacterium tuberculosis complex: Often abbreviated MTC, a group of closely related 
mycobacterial species that can cause latent TB infection (LTBI) and TB disease (i.e., M. tubercu-
losis, M. bovis, M. bovis bacillus Calmette-Guérin, M. africanum, M. canetti, M. microti, M. pin-
nipedii, and M. mungi). Among humans, the majority of TB cases are caused by M. tuberculosis.
NTGS: The National TB Genotyping Service has provided TB genotyping services to local and 
state TB control programs since 2004. National genotyping laboratories are contracted by CDC 
to provide genotyping services at no cost to patients, health care providers, or health depart-
ments.
NTSS: National TB Surveillance System administered by CDC. NTSS collects surveillance data 
through an electronic reporting registry. Data collected include sociodemographic, clinical, and 
risk factor variables that are reported to CDC by states and local health departments.
PCRType: A designation for each unique combination of spoligotype and 12-locus MIRU–
VNTR results. PCRType is designated as PCR followed by five digits, which are assigned se-
quentially to every genotype identified in the United States (e.g., PCR01974).
Polymerase chain reaction (PCR): A laboratory method that can rapidly amplify limited quan-
tities of DNA, thereby enabling certain types of laboratory testing. The national genotyping 
laboratories routinely use two PCR-based techniques, spoligotyping and MIRU-VNTR analysis.
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Recent transmission: Although the precise time interval is not well-defined, recent transmis-
sion for TB is often considered to be TB disease that is attributable to exposure 2–3 years before 
disease onset. That is, the chain of transmission spanning from exposure to source case through 
onset of symptoms for secondary cases is <3 years. Immunocompromised patients (e.g., patients 
with human immunodeficiency virus infection or diabetes) might be at a higher risk for acquiring 
TB disease.
Relapse versus reinfection: A case of relapsed TB represents a worsening of signs and symp-
toms of disease after a period of improvement, caused by the same strain of M. tuberculosis. TB 
that represents a new infection (or reinfection) is disease caused by a second infection (often with 
a strain different from the strain that caused the initial infection). Genotyping the initial and the 
subsequent M. tuberculosis isolate might distinguish these two possibilities.
Report of a Verified Case of TB (RVCT): National surveillance data on patients with tuber-
culosis is recorded on this form and subsequently reported to CDC’s National TB Surveillance 
System.
Restriction fragment length polymorphism (RFLP): Also called IS6110-based, RFLP analysis 
was the first widely used method for genotyping M. tuberculosis isolates. A genotyping technique 
based on measuring the number and length of specific DNA fragments that are cut by using spe-
cific restriction enzymes.
Spoligotyping: Spacer oligonucleotide genotyping. A genotyping technique based on spacer se-
quences located in the direct repeat region in the chromosomes (genetic makeup) of the M. tubercu-
losis complex. The spoligotype is reported as a 15-digit number.
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